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v 
If you can keep your head when all about you 
    Are losing theirs and blaming it on you, 
If you can trust yourself when all men doubt you, 
    But make allowance for their doubting too; 
If you can wait and not be tired by waiting, 
    Or being lied about, don’t deal in lies, 
Or being hated, don’t give way to hating, 
    And yet don’t look too good, nor talk too wise: 
 
If you can dream—and not make dreams your master; 
    If you can think—and not make thoughts your aim; 
If you can meet with Triumph and Disaster 
    And treat those two impostors just the same; 
If you can bear to hear the truth you’ve spoken 
    Twisted by knaves to make a trap for fools, 
Or watch the things you gave your life to, broken, 
    And stoop and build ’em up with worn-out tools: 
 
If you can make one heap of all your winnings 
    And risk it on one turn of pitch-and-toss, 
And lose, and start again at your beginnings 
    And never breathe a word about your loss; 
If you can force your heart and nerve and sinew 
    To serve your turn long after they are gone, 
And so hold on when there is nothing in you 
    Except the Will which says to them: ‘Hold on!’ 
 
If you can talk with crowds and keep your virtue, 
    Or walk with Kings—nor lose the common touch, 
If neither foes nor loving friends can hurt you, 
    If all men count with you, but none too much; 
If you can fill the unforgiving minute 
    With sixty seconds’ worth of distance run, 
Yours is the Earth and everything that’s in it, 
    And—which is more—you’ll be a Man, my son! 
 
Rudyard Kipling, from “Rewards and Fairies” 
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ABSTRACT 
 
The blood-brain barrier (BBB) is the main interface of molecular exchange between the 
bloodstream and the central nervous system (CNS), where it plays an essential role on 
the control over the bi-directional passage of endogenous and exogenous compounds. At 
the BBB, P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) are the 
most important ABC drug efflux transporters preventing the entry into the brain of toxic 
compounds, drugs and xenobiotics circulating in the blood. There is increasing interest in 
understanding the molecular mechanisms underlying the modulation of P-gp and BCRP 
expression and function in order to control CNS accumulation of neurotoxicants and to 
overcome pharmacoresistance phenomena.  
Recent studies showed that morphine, itself a substrate of P-gp, is implicated in the up-
regulation of P-gp expression, which may contribute to its poor brain penetration and 
tolerance. However, it was unknown the mechanism underlying P-gp induction by 
morphine and its role on BCRP expression. Rats were used as an animal model for the 
study of the amplitude and the kinetics of the modulation of P-gp and Bcrp expressions at 
the BBB following a subchronic morphine treatment, in an escalating morphine dose 
regimen. Freshly isolated rat brain microvessels were used as BBB model to study P-gp 
and Bcrp contents following the in vivo treatment, while the hCMEC/D3 cell line was 
occasionally used for complementary studies. Our results demonstrated that a 5-day 
subchronic morphine regimen up-regulated both P-gp and Bcrp 12 to 24h after the last 
dose of morphine, which was not registered at earlier time-points of animal sacrifice, nor 
with a single dose of morphine. The animal treatment with a glutamatergic NMDA receptor 
antagonist, or a COX-2 inhibitor abolished the subchronic morphine-induced P-gp and 
Bcrp protein up-regulation, 24h after the last dose of morphine, suggesting that both are 
implicated in the morphine-dependent P-gp and Bcrp up-regulation. 
Since the registered up-regulation only occurred from 12h after the last dose of morphine-
onwards, we investigated whether it was a direct effect of continued exposure to 
morphine, or rather a consequence of the morphine withdrawal developed after 
discontinuation of treatment. Rats were treated either with a constant morphine infusion (5 
days), or two chronic morphine regimens where withdrawal was precipitated by naloxone 
administration: an escalating dose (5 days) or a constant dose morphine regimen followed 
by a withdrawal period (2 days) and resume of the treatment for 3 additional days. 
Continuous i.v. morphine did not change P-gp and Bcrp levels in rat brain microvessels, it 
does not have a direct consequence on the cascade of regulation of these transporters at 
the BBB. Naloxone-precipitated withdrawal after escalating or chronic morphine dose 
regimen increased Mdr1a and Bcrp mRNA levels, but protein expression and activity 
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remained unchanged after naloxone administration. This latter result discrepancy may be 
due to posttranslational regulation or naloxone action at non-opioid receptors hampering 
P-gp and Bcrp up-regulation. 
Subsequently, we did a large screening of the expression of several neurotransmitter 
receptors at the rat BBB, many of them implicated in the inflammatory cell-cell signaling, 
and which may have a role in the modulation of these ABC transporters. Also, we 
compared two different approaches of isolation of rat brain microvessels, mechanical 
dissection and enzymatic digestion, to assess which yield the purest microvessel fraction 
for the BBB study. The enzymatic digestion provided the highest enrichment of endothelial 
cells and pericytes, and the least contamination with astrocyte and neuron markers. 
Among the neurotransmitter receptors, rat brain microvessels have low expression of the 
adenosine receptor A1, the adrenoceptors α2A, β1, and cannabinoid receptors, while the 
ATP receptors P2Y1 and P2X7, and the adenosine receptor A2A assume a very significant 
expression, and so may play an important role in the cell signaling at the BBB. 
Additionally, newly synthetized thioxanthonic derivatives, which previously demonstrated 
to directly increase P-gp activity without necessarily increase its expression in Caco-2 
cells, were tested for P-gp activation in an in vitro BBB model, RBE4 cells, and it was 
evaluated whether they would afford protection against mitoxantrone-induced toxicity. 
Most of these compounds showed a prompt increase of Rho 123 efflux out of RBE4 cells, 
suggesting to be efficient P-gp activators in such model. However, when co-incubated 
with mitoxantrone, these compounds did not confer an increased protection against the 
mitoxantrone-induced cytotoxicity in RBE4 cells in culture for 24h. Still, thioxanthones 
remain as interesting drug candidates for an antidote strategy against the toxicity induced 
by harmful P-gp substrates, even though P-gp activation phenomenon should be 
interpreted carefully. 
In summary, the present work developed under this PhD dissertation explored important 
pathways of regulation of both the expression and activity of the two major ABC 
transporters present at the BBB, and thus can be valuable tools to either overcome 
pharmacoresistance in the treatment of neurological diseases or to revert the neurotoxicity 
of substrates. 
 
Keywords: Blood-brain barrier, P-glycoprotein, Breast Cancer Resistance Protein, 
Morphine, Regulation, Activation. 
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RESUMO 
 
A barreira hemato-encefálica (BHE) representa a principal interface entre a corrente 
sanguínea e o sistema nervoso central (SNC), desempenhando um papel essencial no 
controlo da passagem sangue-cérebro de diversos compostos endógenos e exógenos. A 
glicoproteina P (P-gp) e a proteína de resistência ao cancro da mama (BCRP) são os 
principais transportadores de efluxo da família ABC presentes ao nível da BHE, limitando 
a passagem cerebral de compostos tóxicos, fármacos e xenobióticos circulantes na 
corrente sanguínea. Actualmente, regista-se um crescente interesse na comunidade 
científica para a melhor compreensão dos mecanismos moleculares subjacentes à 
modulação quer da expressão quer da função da P-gp e BCRP, no sentido de 
desenvolver medidas mais eficazes quer para prevenção da acumulação de compostos 
neurotóxicos no SNC, quer para superar fenómenos de farmacorresistência associados à 
terapêutica. 
Estudos recentes evidenciam que a morfina, por si só um substrato da P-gp, está 
envolvida na indução da expressão da P-gp, o que poderá contribuir para a sua menor 
penetração cerebral, bem como para o desenvolvimento de tolerância. No entanto, não 
se conhece o mecanismo subjacente a  tal indução da P-gp pela morfina, nem o seu 
eventual papel na expressão da BCRP. Com efeito, na condução da presente 
dissertação, realizamos um estudo da amplitude e a cinética da regulação da expressão 
da P-gp e BCRP ao nível da BHE na sequência de um tratamento subcrónico com 
morfina, em regime de doses crescentes, usando o rato como modelo animal. Para o 
efeito, foram isolados os capilares cerebrais dos animais sujeitos a tratamento, in vivo, 
enquanto que a linha celular hCMEC/D3 foi ocasionalmente utilizada para estudos 
complementares. Os nossos resultados demonstraram que um tratamento subcrónico 
com morfina (5 dias) foi capaz de induzir tanto a P-gp como a Bcrp 12 a 24 horas após a 
última dose de morfina administrada, mas não para tempos de sacrifício anteriores, bem 
como tal indução não foi registada quando a morfina foi administrada de forma aguda. O 
tratamento animal com um antagonista do receptor glutamatérgico NMDA, ou com um 
inibidor da COX-2 anulou este efeito de indução da P-gp e Bcrp pela 
administraçãosubcrónica de morfina, o que sugere o envolvimento destes dois 
componentes na indução da P-gp e Bcrp dependente da morfina. 
Uma vez que este aumento da expressão só surgiu a partir de 12h após a última dose de 
morfina, decidimos investigar se tal seria um efeito direto da exposição continuada à 
morfina, ou por outro lado, uma consequência do síndrome de abstinência à morfina, 
desenvolvido após a descontinuação do tratamento. Desta forma, os animais foram 
tratados por um lado com uma infusão contínua de morfina (5 dias), ou sujeitos a dois 
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diferentes regimes de exposição crónica à morfina, após os quais o síndrome de 
abstinência foi provocado pela administração de naloxona. A administração de morfina 
em contínuo, via i.v., não alterou os níveis de P-gp e BCRP nos capilares cerebrais de 
rato, o que indica a ausência de uma consequência directa da morfina na cascata de 
regulação destes transportadores ao nível da BHE. O síndrome de abstinência opióide 
provocado pela naloxona aumentou os níveis de mRNA Mdr1a e Bcrp, mas tanto a 
expressão e atividade proteicas mantiveram-se inalteradas após a administração de 
naloxona. Esta discrepância de resultados pode-se dever ou a um regulamento pós-
translacional, ou a uma acção inespecífica da naloxona em receptores não opiáceos, 
impedindo a indução da P-gp e Bcrp. 
Num outro estudo, foi feito um screening da expressão de vários receptores de 
neurotransmissores na BHE de rato, muitos deles envolvidos na sinalização célula-célula 
em processos inflamatórios, e que podem ter um papel na modulação destes 
transportadores ABC. Além disso, foram ainda comparadas duas técnicas de isolamento 
de capilares cerebrais de rato, o método de dissecção mecânica e o método de digestão 
enzimática, de modo de apurar qual a metodologia que permite a obtenção da fracção 
capilar mais enriquecida para o estudo da BHE. A digestão enzimática gerou um maior 
enriquecimento em células endoteliais e pericitos, com mínima contaminação em 
astrócitos e neurónios. Quanto aos receptores de neurotransmissores, os capilares 
cerebrais de rato exibiram uma baixa expressão de receptores de adenosina A1, 
adrenérgicos α2A, β1, e canabinóides, enquanto que os receptores de ATP P2Y1 e P2X7, 
bem como o receptor A2A de adenosina assumem uma expressão muito significativa, pelo 
que poderão desempenhar um papel importante na sinalização celular ao nível da BHE. 
Por fim, um conjunto de compostos tioxantónicos, que anteriormente haviam 
demonstrado aumentar directamente a actividade da P-gp sem um aumento da sua 
expressão na linha celular Caco-2, foram testados com vista a activação da P-gp num 
modelo de BHE in vitro, células RBE4, e protecção celular contra a toxicidade induzida 
pela mitoxantrona. A maioria destes compostos mostrou aumentar rapidamente o efluxo 
da Rho 123 das células RBE4, sugerindo que tais compostos são activadores de P-gp 
igualmente eficientes neste modelo. No entanto, quando co-incubados com mitoxantrona, 
estes compostos não conferiram um aumento da protecção contra a citotoxicidade 
induzida pela mitoxantrona nas RBE4 em cultura durante 24h desde o início da 
exposição. Ainda assim, as tioxantonas permanecem como interessantes candidatos no 
desenvolvimento de estratégias antidotais contra a toxicidade de substratos da P-gp, 
embora este fenómeno de ativação da P-gp deva ser interpretado com cuidado. 
Em resumo, o presente trabalho desenvolvido no âmbito desta tese de doutoramento 
explorou importantes vias de regulação, quer ao nível da expressão como da actividade 
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dos dois principais transportadores ABC presentes na BHE, e que, portanto, poderão ser 
ferramentas úteis quer na tentativa de contornar fenómemos de farmacorresistência no 
tratamento de doenças neurológicas, como na reversão da neurotoxicidade de 
substratos. 
 
Palavras-chave: Barreira-hematoencefálica, Glicoproteína P, Proteína de Resistência ao 
Cancro da Mama, Morfina, Regulação, Activação. 
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RÉSUMÉ 
 
La barrière hémato-encéphalique (BHE) représente la principale interface d'échange 
moléculaire entre la circulation sanguine et le système nerveux central (SNC), où elle joue 
un rôle essentiel sur le contrôle du passage bidirectionnel de composés endogènes et 
exogènes. À la BHE, la P-glycoprotéine (P-gp) et Breast Cancer Resistance Protein 
(BCRP) sont les transporteurs d’efflux ABC les plus importants, empêchant l'entrée de 
composés toxiques, des médicaments et des xénobiotiques circulant dans le sang dans le 
cerveau. Il y a un intérêt croissant pour la compréhension des mécanismes moléculaires 
sous-jacents à la modulation de l’expression et de la fonction de la P-gp et BCRP, afin de 
pouvoir contrôler l'accumulation de substances neurotoxiques dans le SNC et de 
surmonter les phénomènes de pharmaco-résistance. 
Des études récentes ont montré que la morphine, elle-même un substrat de la P-gp, est 
impliquée dans l’augmentation de l'expression de la P-gp, qui peuvent contribuer à sa 
faible pénétration dans le cerveau et pour le développement de la tolérance. Cependant, 
le mécanisme sous-jacent  à l’induction de la P-gp par la morphine, bien comme son rôle 
sur l'expression de BCRP était inconnu. Des rats ont été utilisés comme modèle animal 
pour l'étude de l'amplitude et la cinétique de la modulation de la P-gp et Bcrp à la BHE, 
après un traitement morphinique subchronique, en utilisant un protocole d’escalade de 
doses. Des microvaisseaux cérébraux isolés ont été utilisés comme modèle pour étudier 
la BHE, et les contenus en P-gp et Bcrp après le traitement in vivo, tandis que la lignée 
cellulaire hCMEC/D3 a parfois été utilisé pour des études complémentaires. Nos résultats 
ont montré qu’un régime subchronique de traitement à la morphine pendant 5 jours a 
induit la P-gp et Bcrp 12 à 24 heures après la dernière dose de morphine, un effet qui n'a 
pas été enregistrée lors des précédentes temps de sacrifices des animaux, ni avec une 
traitement aigue à la morphine. Le traitement des animaux avec un antagoniste de du 
récepteur glutamatergique NMDA, ou avec un inhibiteur de la COX-2 a aboli l’induction 
protéique de la P-gp et Bcrp par la morphine-subchronique, ce qui suggère que les deux 
facteurs sont impliqués dans l’up-régulation morphine-dépendante de la P-gp et BCRP. 
Sachant que l’induction a été enregistrée seulement à partir de 12h après la dernière 
dose de morphine, nous avons examiné si elle était un effet direct de l'exposition continue 
à la morphine, ou plutôt une conséquence du sevrage à la morphine développé après 
l'arrêt du traitement. Les rats ont été traités soit avec une perfusion constante de 
morphine (5 jours), soit avec deux schémas chroniques de morphine lorsque le sevrage a 
été précipité par l'administration de naloxone: un régime de doses croissantes (5 jours) ou 
un régime de doses constantes de morphine. La perfusion en continue de morphine n'a 
pas changé les niveaux de P-gp et Bcrp dans les microvaisseaux cérébraux de rat, et du 
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coup n'a pas une conséquence directe sur la cascade de régulation de ces transporteurs 
à la BHE. Le sevrage provoqué par la naloxone a augmenté les niveaux d’ARNm pour le 
Mdr1a et Bcrp, mais l'expression et de l'activité protéiques sont restées inchangées après 
l'administration de naloxone. Cette disparité peut être dû soit à un effet de la régulation 
post-traductionnelle, soit à l’action de la naloxone dans des récepteurs non-opioïdes, qui 
peut entraver l’induction de la P-gp et Bcrp. 
Par la suite, on a fait un large screening de l'expression de plusieurs récepteurs de 
neurotransmetteurs chez la BHE de rat, beaucoup d'entre eux impliqués dans la 
signalisation inflammatoire, et qui peut jouer un rôle dans la modulation de ces 
transporteurs ABC. Aussi, nous avons comparé deux approches différentes de l'isolement 
des microvaisseaux cérébraux de rat, la dissection mécanique et la digestion 
enzymatique, pour évaluer ce qui donne la fraction la plus pure des microvaisseaux pour 
l'étude de la BHE. La digestion enzymatique a donné le plus haut enrichissement en 
cellules endothéliales et pericytes, et la moindre contamination avec des marqueurs 
d'astrocytes et des neurones. Parmi les récepteurs de neurotransmetteurs, les 
microvaisseaux rat ont montré une faible expression du récepteur d’adénosine A1, 
adrénergiques α 2a, β1 et cannabinoides, tandis que les récepteurs d’ATP P2Y1 et P2X7 et 
les récepteurs d’adénosine A2A assument une expression très significative, et peut donc 
jouer un rôle important dans la signalisation cellulaire au niveau de la BHE. 
Finalement, des nouvelles composés dérivés des thioxanthones, qui ont précédemment 
montré d’être capables d’augmenter directement l'activité P-gp, sans augmentation de 
l'expression dans les cellules Caco-2, ont été testés pour l'activation P-gp dans un modèle 
de BHE in vitro, les cellules RBE4, et ont été évalués dans le but de la protection 
cellulaire contre la toxicité induite par la mitoxantrone. La plupart de ces composés ont 
augmenté rapidement l’efflux de la Rho 123 des cellules RBE4, suggérant d'être 
activateurs de la P-gp efficaces dans ce modèle. Cependant, quand co-incubées avec la 
mitoxantrone, ces composés ne confèrent pas une protection contre la cytotoxicité induite 
par la mitoxantrone dans les cellules RBE4 en culture pendant 24h. Pourtant, les 
thioxanthones restent comme candidats intéressants dans une stratégie antidotal contre 
la toxicité induite par des substrats nocives de la P-gp, même si le phénomène 
d'activation de la P-gp doit être interprétée avec prudence. 
En résumé, le présent travail au sein de cette thèse de doctorat a exploré des voies 
importantes de régulation de l'expression et de l'activité des deux principaux transporteurs 
ABC présents à la BHE, et peuvent donc être des outils précieux soit dans la tentative de 
contourner des phenomènes de résistance aux médicaments dans le traitement des 
maladies neurologiques, soit dans le renversement de la neurotoxicité liée à des 
substrats. 
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OUTLINE OF THE DISSERTATION 
 
 Part I – General Introduction on the blood-brain barrier, ABC Transporters and 
Regulation 
In this section, a review on the existing literature on the blood-brain barrier, the main ABC 
transporters, and the known mechanisms of regulation of their expression at this barrier is 
presented, in order to provide a good basis for understanding the objectives and the 
obtained results of the experimental studies.  
 
 Part II – Objectives 
The general objectives set for the preparation of the present PhD dissertation are 
presented in this dedicated section. 
 
 Part III – Experimental section 
In part III, the manuscripts published or submitted for publication in the scope of this 
dissertation are presented.  
 
 Part IV – Discussion and Conclusions 
In this section, an integrated discussion of the results obtained in the scope of this 
dissertation is presented. The discussion of their potential relevance and their connection 
with existing scientific reports is also addressed here. Moreover, part III includes the main 
conclusions taken from the work of the present dissertation and the future perspectives of 
research. 
 
 Part V – References 
In this final part, all the literature references that were used in the introduction and 
discussion sections are listed. 
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I. GENERAL INTRODUCTION 
 
1. The Blood-Brain Barrier 
1.1. The Central Nervous System: a homeostatic need 
The central nervous system (CNS), which comprises the brain and the spinal cord, is 
generally considered as one of the most important and complex systems in the human 
body. Through its coordination with the peripheral nervous system, the CNS is vital to the 
control and function of all the other systems present in the organism. The CNS contains 
two distinctive liquid compartments, the interstitial fluid (ISF) and the cerebrospinal fluid 
(CSF). The brain ISF bathes the neurons and the neuroglia (i.e microglia, astrocytes, 
oligodendrocytes, ependymocytes), whereas the CSF fills the ventricles and surrounds 
the meninges that protect the external surface of the brain. In order to ensure the proper 
functioning of the CNS and its neuronal signaling and cell:cell communication, it is 
essential to closely regulate the extracellular microenvironment and the composition of 
these extravascular fluids, and thus maintain local homeostasis. Simultaneously, the body 
needs to guarantee a proficient supply of oxygen and nutrients to the brain, and on the 
other hand prevent the accumulation of metabolic waste products and toxins through an 
effective clearance system.  
In the human brain, the so-called CNS barriers represent barrier layers between the blood 
and the CNS and play an essential role in ensuring this constant supply of important 
nutritive elements, ions, amino acids and energy, and the removal of metabolic products, 
while at the same time, protect the brain against noxious substances (Daneman and Prat 
2015; Zlokovic 2008). 
 
1.2.  CNS barrier layers 
The first time there was evidence of the existence of a physical barrier between the CNS 
and the peripheral circulation was described by Paul Ehrlich in 1885, who noted that a dye 
injection into the blood circulation stained peripheral organs but not the brain and the 
spinal cord (Ehrlich 1885). Later in 1913, Ehrlich’s student Edwin Goldmann showed that 
an injection of trypan blue directly into the CSF stained cells within the CNS and not in the 
periphery (Goldmann 1913). Further support was later found by electron microscopy by 
Reese and Karnovsky, who demonstrated that when horseradish peroxidase was 
intravenously administrated it did not pass the capillary lumen, and thus evidencing the 
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existence of a solute exchange barrier between the blood and the brain (Reese and 
Karnovsky 1967). 
Three CNS barrier layers are described to be present in the human brain and spinal cord. 
A first interface is formed by the highly specialized endothelium of parenchymal 
microvessels comprising the blood-brain barrier (BBB), partitioning the blood and brain 
ISF. The combined surface area of these capillaries (between 150 and 200 cm2.g-1 tissue) 
represents the largest CNS interface for blood-brain exchange, resulting in a total area for 
exchange in the average human adult brain of between 12 and 18 m2 (Abbott et al. 2010; 
Nag et al. 2005). 
The second interface is provided by the epithelium of the choroid plexus (modified 
ependymal lining of the brain ventricles), which secretes the CSF into the brain ventricular 
system and forms the blood-CSF barrier (BCSFB) (Abbott et al. 2010; Brown et al. 2004). 
As a third interface present in the brain we have the arachnoid epithelium, which 
constitutes the middle layer of the meninges forming the outer covering of the CNS and 
separates the blood from the subarachnoid CSF. Due to its avascular nature and relatively 
small surface area, it does not represent a significant surface for exchange between the 
blood and the CNS (Abbott 2013; Abbott et al. 2010). 
In this dissertation, we will give special focus to the BBB and its ability to restrict the brain 
entry of xenobiotics and other blood-circulating harmful compounds into the CNS. 
 
1.3. Overview of the BBB and its function 
It is well established that the human brain consumes over 20% of total body oxygen and 
energy, while it only corresponds to approximately 2% of total body mass (Shulman et al. 
2003). Of the three mentioned CNS barriers, the BBB is distinguished as the most 
important interface for molecular exchanges between blood and the brain parenchyma, 
due to its dense network of microvessels throughout the brain and the proximity of their 
finest branches to individual neurons (Abbott et al. 2010). This network is composed of 
approximately 100 billion capillaries with diameters as small as 3 to 7 μm (Zlokovic and 
Apuzzo 1998), and the distance between capillaries is as short as 40 μm (Rodriguez-
Baeza et al. 2003). These characteristics ensure that almost every neuron is perfused by 
its own blood capillary and therefore guarantee an efficient oxygen and nutrient supply to 
such high brain demand. No brain cell is over 25 μm from a brain capillary, meaning that 
once the solute diffuses through the BBB, it is considerably close to the neurons or glial 
cells. Despite the huge number of capillaries, they occupy only 0.1% of the brain volume 
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(Pardridge 1991; Pardridge 2003). The BBB is present in all brain regions, except in 
specialized and very size-limited sites of physiological cross-talks between the brain and 
the periphery, i.e. the circumventricular organs, where blood vessels allow diffusion of 
blood-borne molecules across the vessel wall (Ballabh et al. 2004; Cardoso et al. 2010; 
McKinley et al. 2003; Weiss et al. 2009). 
BBB structure is formed by brain endothelial cells (BECs) composing the capillaries, which 
differ from endothelial cells present in the rest of the body due to the lack of fenestrations, 
and tight regulation of the movement of molecules, ions and cells across this barrier 
(Ballabh et al. 2004; Daneman 2012). The BBB exerts its barrier function at three different 
levels: (1) physical, through the extensive expression of tight junctions (TJs) along 
adjacent endothelial cells, reducing the paracellular pathway, (2) transporter-dependent 
passage, due to the existence of specific transport mechanisms mediating solute flux, and 
(3) metabolic, given the enzymes present in the BECs are capable of processing 
molecules in transit (Abbott et al. 2010). The resulting neurovascular coupling allows the 
maintenance of brain homeostasis by providing for the energy demands of neuronal 
activity, as well as it protects the CNS from toxins, pathogens, inflammation, injury, and 
disease, in association with various perivascular cells such as pericytes, microglia, 
astrocytes, and specialized cellular compartments such as the endothelial glycocalyx 
(Stanimirovic and Friedman 2012). In this way, the BBB plays a crucial role by exerting a 
bi-directional control over the passage of a large diversity of regulatory proteins, nutrients 
and electrolytes, as well as potential neurotoxins, and maintain a strict extracellular 
environment around synapses and axons. The BBB functions can be described as 
follows: 
1. Brain nutrition: the BBB expresses specific transport systems in the luminal and 
abluminal membranes of BECs in order to ensure the appropriate supply of 
essential water-soluble nutrients (Abbott et al. 2010); 
2. Regulation of ion homeostasis and preservation of neural signaling: the BBB 
provides a combination of specific ion channels and transporters to keep the 
optimal ionic composition for synaptic signaling function, as well as maintain the 
central and peripheral neurotransmitter pools separate, minimizing “cross-talk” 
(Abbott et al. 2010; Bernacki et al. 2008); 
3. Control molecular trafficking: the BBB functions as a shield preventing neurotoxins 
(endogenous metabolites or ingested/environmental xenobiotics) and many 
macromolecules in the blood circulation from entering in the brain. The protein 
content of the CSF is much lower and markedly different to that of plasma, and the 
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leakage of several serum macromolecules into the brain can result in serious 
pathological consequences (Abbott et al. 2010). In this way, the BBB minimizes 
neuronal cell death, and preserves neural connectivity and immune quiescence. 
Thus, the BBB guarantees that the CNS environment is not easily affected by peripheral 
changes under physiological conditions. However, the BBB remains a dynamic interface 
that acknowledges the necessity to meet the demands of the whole organism, which are 
not static. 
 
1.4. The Neurovascular Unit: the architecture of the BBB 
The properties of the BBB are mostly defined by the BECs, but these are regulated and 
maintained by crucial interactions with the basement membrane and neighboring cells, 
such as microglia and astrocytes, as well as neurons and perivascular pericytes (Cardoso 
et al. 2010; Zlokovic 2008). The close proximity of these cells results in an effective unit of 
paracrine regulation critical for normal CNS functioning, often called the neurovascular 
unit (NVU) (see Figure 1). 
 
1.4.1. Brain Endothelial Cells 
The brain microvascular endothelium constitutes the most critical element of the BBB. 
BECs have been identified as morphologically and metabolically distinct of those present 
in the peripheral circulation. In comparison to those cells, BECs are characterized by (1) 
the presence of a narrow junctional complex at their adjacent margins, eliminating gaps or 
spaces between cells and preventing any free paracellular diffusion of blood-borne 
substances into the brain parenchymal space, (2) lack of fenestrations typically present in 
peripheral capillaries, (3) fewer pinocytic vesicles, and (4) higher number of cytosolic 
mitochondria, suggesting important metabolic activity (Abbott 2005; Bearer and Orci 1985; 
Correale and Villa 2009; Dorovini-Zis et al. 1991; Lane et al. 1992; Villegas and Broadwell 
1993). In fact, BECs are said to be 50 to 100-fold tighter than those in peripheral 
microvessels (Abbott 2002) due to the expression of this elaborated junctional complex 
that includes mainly TJ and adherens junction (AJ) proteins (Hawkins and Davis 2005) 
[presented in more detail in section 1.4.1.1.]. Gap junctions have also been identified at 
the BBB, but their role in the barrier function is not clear (Zlokovic 2008). Additionally, the 
luminal surface of the BECs is covered by the so-called glycocalyx, which corresponds to 
a negatively charged mesh of proteoglycans, glycosaminoglycans, glycoproteins and 
glycolipids, making anionicity another determinant factor for BBB permeation (de Boer and 
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Gaillard 2006). Ultrastructural cytochemistry and immunocytochemistry revealed a 
functional polarity of the brain microvascular endothelium, characterized by an asymmetric 
distribution of the majority of the receptors and transporters present in the luminal and 
abluminal BECs plasma membranes, indicating that luminal and abluminal membranes of 
endothelial cells are functionally distinct (Correale and Villa 2009; Farrell and Pardridge 
1991). 
 
Figure 1. Representation of the BBB and the cells belonging to the NVU, an elaborate interplay of 
central and peripheral cells. 
The endothelium’s abluminal surface is covered by a basement membrane in which pericytes are embedded. 
Astrocyte-foot processes encircle the abluminal side of the vessel at great extent. Neurons and microglia are 
also members of the NVU as they interact with core elements of the BBB and influence barrier functions. 
Image taken from (Obermeier et al. 2013) 
 
More than an impermeable wall, the BECs express a particular pattern of receptors and 
specific transport systems [to be further characterized in section 1.5.], which on one hand 
facilitate the uptake of essential nutrients and hormones, and on the other hand help to 
regulate the concentrations of ions, metabolites and xenobiotics in the brain (Weksler et 
al. 2005; Zlokovic 2008). 
Lastly, the brain endothelium also forms a metabolic barrier once it expresses a 
specialized set of enzymes, such as alkaline phosphatase (AP), c-glutamyl 
transpeptidase, aromatic acid decarboxylase and several cytochrome P450 (CYP) 
isoenzymes and phase 2 conjugation enzymes that metabolize numerous xenobiotics, 
and whose expression is much higher than in non-neuronal capillaries (Decleves et al. 
2011; Persidsky et al. 2006; Shawahna et al. 2011). 
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BECs can be identified by several specific cell markers, including the von Willebrand 
factor VIII related antigen, which mediates platelet adhesion to injured vessel walls and 
serves as a carrier and stabilizer for coagulation factor VIII, and the glucose transporter-1 
(GLUT-1), which facilitates the transport of glucose across the brain endothelium into the 
CNS (Ballabh et al. 2004; Wilhelm et al. 2011).  
 
1.4.1.1. Intercellular Junctions 
The presence of intercellular junctions along the brain endothelium results in a physical 
barrier component to macromolecules and most polar solutes, significantly reducing the 
permeation through paracellular diffusion between endothelial cells from the blood plasma 
to the brain ECF. A junctional complex consists of all the transmembrane proteins and 
accessory cytoplasmic proteins located on the apical side of the endothelium (Stamatovic 
et al. 2008). The existent junctional complexes at the BBB include AJs and TJs. In 
peripheral endothelial cells, TJs are placed apically and separated from AJs (Staddon and 
Rubin 1996), but in the brain endothelium they are close to each other, forming the 
junction complex between adjacent endothelial cells (Stamatovic et al. 2008). TJs seal the 
BECs forming a continuous tubular structure, while AJs play a major role in the initiation 
and maintenance of BEC contact. TJ integrity depends highly on intact AJ, where cell-cell 
adhesion molecules are found (see Figure 2). 
 
 Tight Junctions 
TJs are responsible for the severe restriction of the paracellular diffusional pathway 
between the luminal and abluminal domains of the BECs, and effectively block penetration 
of macromolecules and polar solutes and ions by this route. Also, this enables the 
asymmetric distribution of membrane constituents, conferring cell polarity to the BECs 
(Cardoso et al. 2010; Hawkins and Davis 2005). This junctional system consists in a 
transmembrane protein complex spanning the intercellular cleft composed by occludin 
and claudins acting together with junctional adhesion molecules (JAMs). Occludin and 
claudins are linked to a number of cytoplasmic scaffolding and regulatory proteins zonula 
occludens protein 1 (ZO-1), ZO-2, ZO-3 and cingulin (Wolburg and Lippoldt 2002; 
Wolburg et al. 2009). The intracellular ZO-1, ZO-2 and ZO-3 regulate the effectiveness of 
TJs, which link claudin and occludin via cingulin to intracellular actin and the cytoskeleton 
(Wolburg and Lippoldt 2002; Wolburg et al. 2009). Selective loss of claudin-3 from the TJs 
has been shown to be associated with a loss of BBB integrity together with some 
functional barrier loss (Wolburg et al. 2003). Also, lack of claudin-5 severely compromises 
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the BBB in genetically modified mice (Nitta et al. 2003). The signaling at the TJs is bi-
directional, meaning that signals are transmitted from the cell interior to existing TJs to 
regulate its assembly and function, while TJs also receive and transfer information back to 
the cellular environment to regulate gene expression and subsequent cellular responses 
(Terry et al. 2010). 
The proper function of these TJs in not only related to the expression of these proteins 
spanning the intercellular cleft, but it is also influenced by how these proteins are 
organized and interact (Hamm et al. 2004), and by CNS-produced and circulating factors 
(Wolburg et al. 2003). Many of the cell types associated with brain microvessels, including 
pericytes, astrocytes, and nerve terminals adjacent to the endothelial ECM release 
several active factors that can modify tight junction assembly and barrier permeability 
(Abbott et al. 2010; Abbott et al. 2006). 
 
Figure 2. Schematic representation of the intercellular junctions present at the endothelial cells of the 
BBB. 
TJ proteins (occludin, claudins, JAMs) are anchored to the cell cytoplasm by ZO-1, ZO-2, ZO-3 and actin 
cytoskeleton. Cadherins of the AJs work to form adhesive contacts between cells, providing structural 
integrity, and are anchored to actin cytoskeleton via catenins. Actin cytoskeleton may be activated via an 
increase of intracellular calcium, which may change the claudins and occludin configuration, and thus modify 
the tight junctional properties. Image taken from (Abbott et al. 2010) 
 
 Adherens Junctions 
The AJs hold the cells together giving the tissue structural support, and are essential for 
contact inhibition during vascular growth and remodeling, initiation of cell polarity, and 
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formation of TJs (Hawkins and Davis 2005). Its disruption leads to barrier disruption itself 
(Wolburg and Lippoldt 2002). In these junctions, transmembrane cadherin proteins (in 
particular, VE-cadherin) span the intercellular cleft to form adhesive contacts between 
cells, and join the actin cytoskeleton via intermediary proteins, namely alpha-, beta- and 
gamma-catenin. In addition, studies have shown that human AJs express platelet 
endothelial cell adhesion molecule-1 (PECAM-1), which takes part in shaping AJs via 
interactions with beta-catenin (Matsumura et al. 1997). Although its function is still 
unclear, a new catenin termed p120ctn was recently discovered, presenting a high affinity 
binding to VE-cadherin, which might suggest it has relevance in BBB permeability and 
function (Bazzoni 2006). TJ and AJ components are known to interact and cooperate, 
particularly ZO-1 and catenins, once more suggesting the two intercellular junctions work 
in concert (Matter and Balda 2003). 
 
1.4.2. Basement membrane 
The basement membrane (BM) surrounds the brain endothelium and separates it from the 
neighboring cells, namely pericytes and astrocytes, and all these cells cooperate for its 
own production and maintenance (Persidsky et al. 2006; Weiss et al. 2009). It is 
composed of different extracellular matrix (ECM) structural and specialized proteins, such 
as type IV collagen, elastin, fibronectin and laminin, and proteoglycans (Erickson and 
Couchman 2000). The BM also includes matrix adhesion receptors, known as cell 
adhesion molecules (CAM), which are expressed on vascular cells, neurons and 
supporting glia (Del Zoppo et al. 2006). This BM provides an anchor for many signaling 
processes at the brain vasculature, and its disruption by matrix metalloproteinases can 
lead to BBB dysfunction and leukocyte infiltration, often observed in many different 
neurological disorders (Daneman and Prat 2015). 
 
1.4.3. Astrocytes 
Astrocytes are a major glial cell type, that closely interact with BECs, and whose end-feet 
processes cover almost completely the basolateral surface of the vascular tube, playing 
an essential role in the regulation and maintenance of specific BBB characteristics. 
Astrocytes release factors that modulate and maintain the BBB phenotype and a proper 
differentiation of BECs, such as the glial-derived neurotrophic factor (GDNF), transforming 
growth factor-β1 (TGF-β1), basic fibroblast growth factor (bFGF), interleukin-6 (IL-6) and 
angiopoietin 1 (Abbott et al. 2006; Bernacki et al. 2008; Bicker et al. 2014; Correale and 
Villa 2009). In fact, the close interaction between astrocytes and the brain endothelium up-
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regulates many BBB features, namely the expression of TJs, specialized enzyme systems 
and polarized transporter location (Abbott et al. 1992; Bicker et al. 2014; Hayashi et al. 
1997; Persidsky et al. 2006; Sobue et al. 1999) and helps control the cerebral blood flow 
(Koehler et al. 2009). This includes regulating the contraction/dilation of vascular smooth 
muscle cells surrounding arterioles as well as pericytes surrounding capillaries. 
 
Figure 3. Confocal microscopy image of a rat brain microvessel surrounded by astrocytic end-feet 
processes. 
Cell nuclei are stained in blue (TOPRO3), glial fibrillary acidic protein (GFAP), an astrocyte end-feet process 
marker, is stained in yellow (anti-Gfap), and P-glycoprotein, used as a marker of the luminal membrane of the 
brain microvascular endothelial cells, is stained in purple (anti-P-gp). Image provided by Dr. Bruno Saubaméa 
(Plateforme d’imagerie cellulaire, Faculté de Pharmacie, Université Paris Descartes). 
 
The astrocytical end-foot processes show high density of purinergic P2Y receptors, 
potassium channel Kir4.1, and water-channel protein aquaporin-4 (AQP4), indicating key 
roles in the gliovascular signaling and in the regulation of brain water and electrolyte 
metabolism under normal and pathological conditions (Abbott et al. 2006). In addition, the 
high density of AQP4 is also related to the expression of the dystroglycan-dystrophin 
complex in the end-feet processes, which helps link the cellular cytoskeleton to the BM by 
binding to agrin (Daneman and Prat 2015; Wolburg et al. 2011). Agrin, a heparin sulphate 
proteoglycan of the ECM, accumulates whenever there is BBB tightening (Abbott et al. 
2006; Bernacki et al. 2008), suggesting a vital role for the ECM in the cross-influence of 
astrocytes and endothelium. 
Astrocytes are in close contact with both neuronal cell bodies and brain capillaries, 
providing a cellular link between these elements, and underlining their importance for 
functional neuronal activity and NVU (Attwell et al. 2010; Daneman and Prat 2015; 
Persidsky et al. 2006).  
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1.4.4. Pericytes 
Pericytes are small vessel-associated cells sharing the BM with BECs, whose numerous 
cytoplasmic processes encircle capillaries, and existent gap junctions provide contact 
spots between the two cell types (Cuevas et al. 1984). Given such close relationship, 
pericytes are ideally suited to have many influences on brain microcirculation. Pericyte-to-
endothelia ratio in the brain is 30-fold higher compared to that of striated cells, and the 
endothelium coverage by pericytes, oscillating between 22 and 32% (Kim et al. 2006), 
varies considerably between different microvessel types (Allt and Lawrenson 2001). 
Pericytes show rich contents of α-smooth muscle actin, which is typical of a vascular 
smooth muscle cell, suggesting a contractile ability of pericytes (Cardoso et al. 2010; 
Peppiatt et al. 2006). The physical contact of pericytes' cellular processes over inter-
endothelial junctions, together with the α-smooth muscle actin contents, point to a 
functional role of pericytes in controlling cerebral blood flow (Peppiatt et al. 2006), but also 
in regulating junctional permeability (Edelman et al. 2006). 
In fact, it is believed that pericytes are linked to the regulation of BEC proliferation, 
migration and differentiation (Persidsky et al. 2006), and to the stabilization of small vessel 
architecture, neovascularization and angiogenesis (Bicker et al. 2014). The loss of such 
cell type leads to an abnormal vascular morphogenesis, endothelial hyperplasia and 
increased BBB permeability (Bicker et al. 2014; Hellstrom et al. 2001). Pericytes and 
BECs communicate through several apparatuses such as gap junctions, TJs, adhesion 
plaques (Allt and Lawrenson 2001) and soluble factors. Pericytes influence vessel stability 
as they synthesize most elements of the BM and activate signals that promote BECs 
differentiation and quiescence (Armulik et al. 2005; Dore-Duffy et al. 2006). In addition, 
pericytes release a great number of growth factors and angiogenic molecules which 
regulate microvascular permeability and angiogenesis (Dore-Duffy and LaManna 2007) 
and, therefore, play an important role in the maintenance of the BBB. 
 
1.4.5. Microglia 
The role of microglia in endowing BBB phenotype is still controversial. Microglia, which 
are CNS-resident parenchymal immune cells, occupy a strategic position in the BBB 
allowing control of innate and adaptive immune responses in the brain (Zenker et al. 
2003), surveying local microenvironment and changing the phenotype in response to 
homeostatic disturbance of the CNS. In the absence of pathology, the resting microglia 
have small bodies and long, thin processes; when activated, they assume a phagocytic 
morphology with short processes, accompanied by changes in surface antigen expression 
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and cytokine release (Zlokovic 2008). This way, these cells are fully competent in antigen 
recognition, antigen presentation and co-stimulation, supporting a possible role for these 
cells in perivascular inflammation regulation in the human CNS (Fabriek et al. 2005). As 
microglia are found in the perivascular space, it is thought that their interactions with 
BECs may contribute to the BBB properties (Choi and Kim 2008; Zenker et al. 2003). 
 
1.4.6. Neurons 
Although little is known on the effect of neurons on BBB properties, there is evidence that 
they can induce the expression of BECs regulatory enzymes (Persidsky et al. 2006), and 
also induce the stabilization of the endothelium TJs (Schiera et al. 2003). On the other 
hand, mature endothelium induces a stable brain microenvironment that enables proper 
neuronal activity (Cardoso et al. 2010; Choi and Kim 2008). 
 
 
 
 
 
 
1.5. Transport across the BBB 
In addition to structural elements assuring BBB tightness, metabolizing enzymes and 
transport systems constitute additional barriers. However, nutrients and some water-
soluble compounds like ions, amino acids, vitamins and proteins vital for proper brain 
function need to cross such barrier. Therefore, the BBB keeps various specific transport 
processes that allow entry into the brain to supply its needs. The different transport 
mechanisms existing in microvessel endothelial cells of the BBB are schematically 
presented in Figure 4. Depending on its intrinsic physicochemical properties (degree of 
ionization, water solubility, size, spatial conformation), the concentration gradient, its 
plasma protein binding and its affinity for a particular transporter, a particular molecule will 
be transported by one of these transport pathways to cross the BBB.  
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Figure 4. Major routes of molecular and cell trafficking across the endothelium of the BBB. 
Small lipophilic molecules and solutes may cross the BBB by passive diffusion. Various essential nutrients and 
ions are transported into the CNS through a carrier-mediated influx system, whereas several noxious 
substances, metabolites and xenobiotics are brain-to-blood pumped through a carrier-mediated efflux system. 
Macromolecules, such as peptides, can cross the endothelium through receptor-mediated transcytosis; in 
particular, positively charged macromolecules can non-specifically induce adsorptive-mediated transcytosis. 
Image taken from (Serlin et al. 2015). 
 
1.5.1. Paracellular pathway 
This transport mechanism relies on passive diffusion of molecules, and so it is limited to 
lipophilic or low molecular mass solutes, which are dependent on electrochemical, 
hydrostatic and osmotic gradients. This pathway is essentially determined due to the 
presence of TJs at the brain microvasculature, and is solute concentration-dependent 
hence not involving energy consumption. The transport of O2 and CO2 across the BBB is 
diffusive and blood-flow dependent, and move according to their concentration gradients. 
Also, a wide range of lipid-soluble molecules can diffuse through the BBB and enter the 
brain passively (Liu et al. 2004). However, these molecular and physicochemical 
properties are not always an absolute indication for CNS penetration, as well as there are 
a few effective CNS active molecules that do not comply with the general rules for BBB 
penetration. 
 
1.5.2. Carrier-mediated transport 
The carrier-mediated pathway is a saturable transport mechanism that can be energy-
dependent or independent, mediating the exchange of substrates between the systemic 
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circulation and the brain parenchyma, and it relies on the polarized expression of 
molecular carriers at both luminal and/or abluminal membranes of the BBB. Carrier-
mediated transport tend to be highly stereospecific in order to selectively vehicle nutrients 
and some small molecules, like amino acids, glucose, nucleoside amines and vitamins 
(Pardridge 2005). These transporters carry the influx (blood-to-brain) or efflux (brain-to-
blood) of molecules across the membrane of BECs by either facilitated diffusion (i.e. 
according to the concentration gradient) or by active transport (i.e. against the 
concentration gradient). For the latter, the energy required can be provided either by the 
hydrolysis of ATP (primary active transport) or by the co-transport of an ion or another 
molecule (secondary active transport). Membrane transport proteins can be classified into: 
1) water channels, 2) ion channels, 3) ATP pumps, 4) ATP-binding cassette transporters 
and 5) solute carrier transporters (Hediger et al. 2004).  
Ion transporters like the sodium-potassium-two chloride co-transporter and the sodium-
proton exchanger, predominantly expressed in the luminal side of the BBB (O'Donnell et 
al. 2006), and the chloride-bicarbonate exchanger, expressed at both sides, play critical 
roles in regulating the intracellular pH of the endothelium (Taylor et al. 2006). Influx 
transporters are grouped under two main families known as solute carrier (SLC), also 
known as solute linked carrier, and organic solute carrier (OST) transporters, whereas, the 
majority of the efflux transporters are grouped under a family known as ATP-binding 
cassette (ABC) transporters. 
 
1.5.2.1. Solute Carrier Transporters in the BBB 
The expression of SLCs in the cell membrane of BECs allows the transport of essential 
polar nutrients necessary for cell metabolism (Zhang et al. 2002). Some SLC transporters 
allow the entry of their substrates by facilitated diffusion, such as glucose and amino 
acids. Other SLCs operate as secondary active transporters: carrying their substrate 
against the concentration gradient, the energy required for transport is provided through 
co-transport of an ion or another molecule in the same direction (symport) or in the 
opposite direction (antiport). The main SLC transporters expressed at the BBB are GLUT-
1/SLC2A1 (Glucose Transporter), LAT-1/SLC7A5 (L-aminoacid transporter), 
OAT3/SLC22A8 (organic anion/cation transporter) and OATP1A4/SLC21A4 (organic 
anion transporting polypeptides) (Abbott et al. 2010; Kusuhara and Sugiyama 2005; 
Shawahna et al. 2011). Some significant SLCs expressed in the BBB are listed in Table 1 
(adapted from (Abbott et al. 2010). 
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Once the expression of some of these SLC transporters is polarized, and thus present in 
the luminal or abluminal membranes only, or in both, it results in preferential transport of 
substrates into or across the endothelial cell, and either blood-to-brain or brain-to-blood 
(Nag et al. 2005; Ohtsuki and Terasaki 2007). 
 
1.5.2.2. ATP-Binding Cassette Transporters in the BBB 
The ABC transporters present at the BBB function as active efflux pumps of a wide range 
of lipid-soluble compounds, and so are responsible for the removal of potentially 
neurotoxic endogenous or xenobiotic molecules from the brain (Dallas et al. 2006). The 
ABC transporters family will be described with further detail in a dedicated section [see 
section 2]. 
 
1.5.3. Transcytosis 
The majority of membrane transporters only carry small molecules (< 1000 Da). 
Therefore, the influx of large proteins into the brain, such as transferrin, low-density 
lipoprotein (LDL) and insulin occurs through a transport mechanism known as transcytosis 
(Pardridge 2005). Transcytosis can be a receptor-mediated (RMT) or an adsorptive-
mediated (AMT) phenomenon. 
In receptor-mediated process, a circulating ligand interacts with a specific receptor at the 
luminal side of the BECs, and once bound it promotes the formation of coated pits that 
eventually engulf to form an endocytic vesicle (Brown and Greene 1991; Scherrmann 
2002). These vesicles then travel to the abluminal side of the polarized endothelial cell, 
where they are released. Caveolae are these vesicular invaginations of the plasma 
membrane involved in molecular transport, cell adhesion and signal transduction, being 
caveolin the principal structural component (Frank et al. 2003; Parton and Richards 2003). 
BECs express several transport systems for neuroactive peptides such as arginine-
vasopressin, enkephalins, hormones, and some cytokines and chemokines. 
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Table 1. Non-exhaustive list of some SLC transporters expressed in the human BBB. 
Adapted from (Abbott et al. 2010) 
SLC Transporter 
(Gene Name/Abbreviation) 
BBB Location Orientation Endogenous Substrates/mechanism of transport 
SLC2A1/GLUT1 
Luminal 
Abluminal 
Blood to brain Glucose (facilitative, bi-directional) 
SLC5A1/SGLT1 Abluminal Brain to endothelium Glucose (sodium-dependent) 
SLC5A3/SMIT 
SLC2A13/GLUT13 
Luminal Blood to endothelium Myoinositol (sodium-dependent) 
SLC7A1/CAT1 
SLC7A3/CAT3 
Luminal Blood to endothelium 
Basic L-amino acids 
Lysine, arginine (sodium-dependent) 
SLC7A5/LAT1 
Luminal 
Abluminal 
Blood to brain 
Asparagine, glutamate, histidine, isoleucine, leucine, 
methionine, phenylalanine, threonine, tryptophan, 
tyrosine, valine (facilitative, bi-directional 
SLC7A6/LAT2 
Luminal 
Abluminal 
Blood to brain Arginine, lysine, ornithine (facilitative, bi-directional) 
SLC38A2/SNAT2 Abluminal Brain to endothelium 
Small neutral amino acids: alanine, asparagine, 
proline, serine, glycine (sodium-dependent) 
SLC38A3/SNAT3 
SLC38A5/SNAT5 
Abluminal Brain to endothelium 
Asparagine, glutamine, histidine, serine (sodium-
dependent) 
SLC1A4/ASCT1 
SLC1A5/ASCT2 
Abluminal Brain to endothelium 
Alanine, cysteine, glycine, isoleucine, leucine, 
methionine, serine, threonine, valine (sodium-
dependent) 
SLC1A3/EAAT1 
SLC1A2/EAAT2 
Abluminal Brain to endothelium 
Anionic amino acids: glutamate, aspartate (sodium-
dependent) 
SLC29A1/ENT1 
SLC29A2/ENT2 
Luminal Blood to endothelium 
Nucleosides, nucleotides, nucleobases (facilitative, 
equilibrative) 
SLC28A1/CNT1 
SLC28A2/CNT2 
Abluminal Endothelium to brain 
Nucleosides, nucleotides, nucleobases (sodium-
dependent) 
SLC16A1/MCT1 
SLC16A2/MCT8 
Luminal 
Abluminal 
Blood to brain Ketone bodies 
T3 thyroid hormone (facilitative) 
SLC22A7/OAT2 
SLC22A8/OAT3 
Luminal Blood to brain Dicarboxylate exchange with α-cetoglutarate, bicarbonate, Cl- 
SLC22A2/OCT2 
SLC22A3/OCT3 
Luminal Blood to endothelium Organic cation/proton exchange 
SLC22A5/OCTN2 
Luminal 
Abluminal 
Blood to 
endothelium Organic cation/proton exchange 
SLC29A44/PMAT Abluminal Brain to endothelium 
Organic cation/proton exchange, MPP+, serotonin, 
dopamine 
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While in RMT there is binding of a ligand to a specific receptor, in AMT excessive positive 
charged molecules bind to negatively charged sites on the plasma membrane. This 
process lacks specific targeting and may lead to widespread absorption (Bickel et al. 
2001; Correale and Villa 2009; Sauer et al. 2005). 
In both cases, to successfully achieve transcytosis of a molecule, the lysosomal 
compartment within the cell must be avoided. Routing away the formed endosome from 
the lysosome may be a specialized feature of the BBB endothelium, where the intact 
transcytosis of a significant number of macromolecules is needed, as it does not occur in 
many peripheral endothelia (Abbott et al. 2010; Nag et al. 2005). Once transcytosis is 
neither size-limited nor lipophilicity-dependent, and also safe and effective due to its high 
specificity, it has been proposed as a reference target pathway for CNS drug delivery. 
 
1.5.4. Cell passage across the BBB 
During the embryonic development, cells from the bone-marrow derived monocyte lineage 
enter into the brain, and after differentiation become resident immunologically-competent 
microglia (Glezer et al. 2007). However, in the adult brain and as a result of BBB 
maturation, leukocyte infiltration into the CNS is low compared to other tissues. Under 
normal healthy conditions, leukocyte traffic across the BBB is strictly regulated, with low 
expression of luminal adhesion molecules minimizing the first stages of leukocyte 
adhesion, in cooperation with other cells of the NVU (Engelhardt and Ransohoff 2012). 
Mononuclear cells are able to be recruited to the CNS and play roles complementary to 
those of microglia (Davoust et al. 2008), entering by diapedesis directly through the 
cytoplasm of BECs, and thus without TJ disruption (Wolburg et al. 2005). In pathological 
events such as inflammation, trauma or ischemia, TJs may be opened as a result of 
cytokines and other agents released by mononuclear cells, facilitating the entry by both 
transcellular and paracellular routes (Konsman et al. 2007; Scholz et al. 2007). In addition, 
during CNS inflammatory states, like multiple sclerosis, the brain endothelium exhibits an 
enhanced expression of adhesion molecules, such as ICAM-1 and VCAM-1, which are 
essential for T cell crawling on the BBB prior to diapedesis (Abadier et al. 2015; 
Engelhardt 2008). This leads to an increase in the leukocyte trafficking into the CNS, and 
consequently to enhanced central inflammation. 
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1.6. BBB study approaches 
It is undeniable that the BBB represents a unique interface in the human organism, 
resultant of a perfect and intimate connection of the brain endothelium with the 
neighboring brain parenchymal cells, playing a critical role in the regulation of brain 
microenvironment and functioning as a shield against neurotoxic agents. Considering its 
vital function, there is a considerable interest in the scientific and health community to 
study the BBB, which can be enumerated: 1) study of the BBB physiology (development, 
maintenance, regulation), 2) how does the BBB behave and its characteristics in 
pathological conditions, and 3) BBB permeability to compounds and CNS drug delivery. 
It is increasingly recognized that the BBB is not a static but a dynamic system, capable of 
responding to local changes and requirements, and able to be regulated and modified by 
different mechanisms and cell types, in both physiology and pathological conditions. This 
is crucial so the BBB can matches its activities to the requirements of the brain, whether 
for protection from circulating agents, adjustment of nutrient supply, or modification to 
facilitate local repair (Abbott et al. 2010). On the other hand, the BBB might be vulnerable 
to modification and see its role affected when a CNS disorder takes place. BBB 
dysfunction has been described in a variety of neurological diseases, not only as a late 
event but also as putatively involved in the early steps of disease progression (Weiss et 
al. 2009). It is estimated that approximately 1.5 billion people suffer from CNS disorders 
(Tosi et al. 2008), which corresponds to 6.3% of the global burden of disease, and this 
number is projected to rise in the coming years due to an aging population (Patel et al. 
2012). In addition, it is believed that 50% of the total worldwide population will show 
Alzheimer’s symptoms by the end of the 21st century (Tosi et al. 2008), leading to 
increasing concern by health organizations worldwide. In fact, recent studies have shown 
that BBB impairment is present in neurological diseases such as Alzheimer and 
Parkinson’s diseases, epilepsy, AIDS-provoked dementia or traumatic brain injury (van 
Vliet et al. 2007a; Zlokovic 2008), which can in turn contribute to progressive nerve cell 
dysfunction in such disorders. This is a matter that dramatically draws the attention of the 
pharmaceutical industry in search for novel therapeutic approaches to abrogate such 
disease processes. However, due to the referred outstanding properties of the BBB, it is 
estimated that only 2% of drug candidates are able to cross such barrier and reach the 
CNS to exert a therapeutic effect (Pardridge 2003), making this field of research one of 
the most stimulating challenges for the scientific world. 
Altogether, these facts have attracted great interest over the study of the BBB. In order to 
better understand the physiology and functioning of the BBB, different study approaches 
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were developed. It is generally accepted that the similarity of an experimental system to 
the in vivo situation is directly related to its degree of complexity (Cardoso et al. 2010). 
There are currently different animal or human models and experimental approaches 
available, and depending on the intended purpose, with their own advantages and 
disadvantages. These will be briefly described below. 
 
1.6.1. In vivo 
Considering in vivo studies are conducted in biological systems that preserve the whole 
brain microenvironment and perfectly functional biological processes, these provide the 
most reliable reference information for testing and validating other models. Due to ethical 
considerations and sensitivity of the CNS, all human molecular data concerning the BBB 
either came from patients or was generated from postmortem donors. To date, the effect 
of disease states and postmortem changes are still not fully understood, hence 
questioning the validity of the data. Taking this into account, the selection of animal 
experimental models that mimic as closely as possible the human BBB is important for 
studying BBB physiology and permeability to compounds and new agents of interest. 
Several animal models have been used to generate in vivo data including mice, rats, pigs, 
and upper primates. Such studies showed variable results and suggested essential 
interspecies differences (Alanne et al. 2009; Cutler et al. 2006; Syvanen et al. 2009). 
In vivo studies have been used to assess BBB-associated feature, such as TJ functioning 
(Yamamoto et al. 2008), activity of ABC transporters (Cisternino et al. 2004; Seleman et 
al. 2014; van Vliet et al. 2007b), permeability properties, as well as behavior patterns, in 
knockout animals for specific BBB proteins (Cardoso et al. 2010). Also, use of imaging 
techniques has been applied to this study, where large sample sizes and appropriate 
controls are needed to detect modest but clinically relevant BBB changes in early stages 
of cerebral microvascular disease and any subsequent progression (Farrall and Wardlaw 
2009). Positron emission tomography (PET) is an non-invasive imaging technique used to 
study the drug transport across the BBB. It requires the administration of a short half-life 
labeled compound containing a positron-emitting isotope, and it provides real time 
monitoring of the body distribution of the radiolabeled compound, including its brain 
distribution. In this way, it allows the study of the cerebral passage of radiolabeled 
products, and their possible brain efflux, and thus the activity of ABC transporters, by 
using known substrates and inhibitors. 
The in situ brain perfusion is an invasive technique suitable in rodents for measuring the 
BBB permeability of a compound. The perfusion of artificial saline via the heart or the 
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internal carotid, in a flow rate- and time-controlled manner, allows the measurement of the 
uptake into different brain regions and the accurate pharmacokinetic parameters of a 
compound that penetrates relatively fast. 
However since these studies can be highly demanding in technical and economic terms, 
other alternatives have been also used. 
 
1.6.2. Ex vivo 
Since ex vivo studies are performed on living tissue outside the organism with minimum 
alteration of natural conditions, experiments can be conducted under highly controlled 
conditions impossible in the intact organism. Ex vivo studies may also be performed on 
post-mortem collected tissues, which can be used to circumvent the limited availability of 
human brain tissue. This has been valuable for the study of BBB structure and function, 
namely for study of TJ (Ballabh et al. 2005), basement membrane assembly (Buttner et al. 
2005), and the expression of brain microvessel efflux transporters (Boer et al. 2008). 
Nevertheless, proteins may suffer rapid degradation if the collection of autopsy specimens 
doesn’t follow the right time and storage protocol, and such changes may render difficult 
the establishment of conclusive results. 
Isolated brain slices are one of the most common ex vivo methods for studying the 
structure of the BBB, where the interactions and the cell architecture of all components of 
the NVU are highly preserved. Its use allows the study of regional-dependent patterns 
associated with some brain diseases, as well as the exploration of molecular pathways, 
the study of their modulation with pharmacological agents, the screening of therapeutic 
molecules (Cardoso et al. 2010; Cho et al. 2007; Lossi et al. 2009), and specially the 
immunolocalization of many enzymes and transporters within the different cells 
composing the NVU by fluorescence immunohistochemistry. 
 
1.6.2.1. Isolation of brain capillaries 
A widely used technique consists in the isolation of brain microvessels from the cortical 
gray matter of the brain tissue. Different studies were carried out on isolated microvessels 
from different species like mouse, rat, monkey and human (Dauchy et al. 2008; Ito et al. 
2011; Shawahna et al. 2011; Uchida et al. 2011; Yousif et al. 2008). The characterization 
of gene and protein expression in isolated microvessels has gained considerable attention 
in molecular biology research. In order to isolate brain microvessels from fresh biopsies 
and/or post-mortem tissues, different techniques were developed, as here summarized. 
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 Mechanical dissection 
Mechanical dissection allows the isolation of brain microvessels through a mechanical 
disruption of the cortical gray matter followed by a gradient separation (dextran or 
albumin, typically), and filtration of the separated portion of the solution that contains the 
microvessels using a series of successive filters (Goldstein and Betz 1986; Yousif et al. 
2007). This protocol permits an important elimination of cell debris and contamination from 
other associated cell types in the NVU; however, pericytes, embedded in the basement 
membrane, and some astrocytic end-feet processes remain attached to the endothelium 
and cannot be eliminated. Inexpensive and quick to implement, this technique enables the 
study of gene and protein expressions of BBB microvessels. This method was broadly 
used in the development of the present thesis work to assess the effects of different 
exposure protocols conducted in vivo in rats, on the expression of BBB markers. 
 
Figure 5. Contrast-phase microscopic visualization of brain microvessels isolated by mechanical 
dissection of rat brain cortical grey matter. 
Image taken from (Yousif et al. 2007). 
 
 Enzymatic dissociation 
With enzymatic dissociation, the isolation of brain microvessels differs from the first as 
enzymatic digestion, usually with a cocktail of enzymes such as collagenase, dispase and 
DNase, replaces the mechanical disruption of the isolated brain gray cortical matter 
(Bowman et al. 1981; Ishikawa et al. 1999). 
 
 Laser microdissection 
Unlike the first two, this method involves a delicate cutting and isolation of brain 
microvessels under optical control with a laser, allowing a more precise isolation of 
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microvessels from a specific cerebral region (Emmert-Buck et al. 1996). Therefore, 
isolated microvessels are closer to those in in vivo condition and less variant to protein 
and mRNA transcript quantities. 
 
1.6.3. In silico 
The development of technology and of advanced algorithms gave rise to the creation of 
mathematical models using computer simulators to predict the BBB permeability of a 
particular molecule. Accurate in vivo measurements of BBB permeability have permitted 
testing of in silico predictive models based on understanding the role of physico-chemical 
properties of the compounds (solubility, lipophilicity, molecular weight, hydrogen bonding 
and electric charge) (Abbott 2013). This approach has drawn much attention in the 
development of new pharmaceutical compounds, since innovative molecules can be 
quickly and easily evaluated if they are likely good drug candidates for crossing the BBB 
in an early phase of development, even before synthesis (Naik and Cucullo 2012). It is 
also very useful in prediction of transporter properties (Demel et al. 2008), channels 
(Huber et al. 2009), protein activity (Maruszak et al. 2009) and toxicity evaluation 
(Piotrowski et al. 2007), among others. Still, in silico is a good prediction tool but currently 
insufficiently accurate to determine whether and how a compound crosses the BBB, as 
well as not providing quantitation of permeation. In addition, the complex nature of BBB is 
neglected, which leads to uncertain results and impairs the establishment of solid 
conclusions (Cardoso et al. 2010; Mehdipour and Hamidi 2009). 
 
1.6.4. In vitro 
In vitro modeling of the BBB results in a simplification of the in vivo situation, allowing the 
conduction of more controlled experimental system, often impossible to be carried out in 
vivo (Cecchelli et al. 2007), while also raising less ethical concerns and producing 
significant economical savings (Tajes et al. 2014). 
An ideal in vitro BBB model should be simple, reproducible, and mimic as closely as 
possible the in vivo human barrier either functionally or anatomically, in order to allow the 
drawing of proper conclusions concerning BBB-related issues in normal and pathological 
conditions. However, this is not fully achievable in practice, since cells are taken out from 
their natural brain microenvironment and grown in a simplified system, lacking many of the 
influences they would normally experience from both the CNS and the periphery. In 
particular, the in vitro cell model must reproduce functional and structural BBB properties, 
and therefore 1) preserve endothelial cell morphology with high expression of junctional 
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proteins, 2) present restrictive paracellular passage and selective permeability, 3) possess 
a realistic cell architecture, 4) display functional expression of transporter mechanisms, 
and 5) maintain a high transendothelial electrical resistance (TEER) as a marker of BBB 
maturity and integrity (Booth and Kim 2012; Naik and Cucullo 2012). Yet, in vitro 
approaches are somehow limited by the absence of in vivo signaling and intercellular 
contacts, and subjected to the in vitro differentiation and phenotypic modification that 
occurs when cells are isolated and kept in culture (Cardoso et al. 2010). Nevertheless, 
recent improvements in cell culture made available several models, which can provide 
very useful information concerning BBB basic physiology, BBB permeability to compounds 
and new therapeutics and permeation mechanisms, as well as for mimicking some 
aspects of the barrier in pathology (Abbott 2013; Ogunshola 2011; Shah et al. 2012). 
Furthermore, they may constitute the first approach in routine toxicity and pharmacological 
testing, thus reducing the number of animals used (Cardoso et al. 2010). Most in vitro 
BBB models derived from isolated brain capillary endothelial cells, considered to be the 
anatomic basis of the BBB, are used as primary cultures or as immortalized brain 
endothelial cell lines. Most models rely on brain tissue from rat, mouse, porcine, bovine 
and human. However, the obtained results must take into account interspecies 
differences, which should be considered when correlations between in vitro and in vivo 
approaches are done (Alanne et al. 2009; Cecchelli et al. 2007). 
 
 
 
 
 
 
 
Figure 6. Static VS Dynamic Models for the study of the BBB. 
In both static (A) and dynamic (B) BBB models, BECs (1), from either primary or immortalized cell lines, grow 
in the upper or inner compartment, respectively, of these culture systems. Other cell types composing the 
NVU, such as astrocytes, pericytes and microglia (2), can be co-cultured in the lower compartment of the 
static model, or in the surrounding compartment of the dynamic model. Images adapted from (Weiss et al. 
2009). 
 
Up to date, rat BEC monolayer culture is the simplest in vitro cell screening experiment 
and has proved to be useful in early stages of drug development (Garberg et al. 2005; 
Tajes et al. 2014). Different categories of BEC cultures can be used, comprising primary 
A) Static BBB Models B) Dynamic 3D flow BBB Models 
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cell cultures and immortalized cell lines: primary cultures more likely represent a simplified 
model of the in vivo condition but require considerable technical resources and are more 
time consuming; cell lines are less complex, but less resemble the in vivo condition 
(Cardoso et al. 2010). Also, both static and dynamic models are available, the latter 
consisting on subjecting endothelial luminal surface to a flowing fluid (Naik and Cucullo 
2012), and thus more closely mimicking the blood flow to which the cells are subjected in 
in vivo conditions (see Figure 6). They can range from simple monolayer of cells to co-
cultures of endothelial cells with other cell types belonging to the NVU. All together, these 
in vitro BBB models are a valuable tool for the screening of the permeability of new drugs, 
as well as to unravel the molecular mechanisms of BBB control in physiological and 
dysfunctional BBB in various CNS pathological states. 
 
 Primary culture of brain endothelial cells 
Even though technically challenging to isolate and maintain, primary cell cultures of BECs 
are the closest possible phenotype to the in vivo BBB, providing a convenient model and 
the optimal choice for BBB research (Smith et al. 2007). Although some cultures are 
conducted using human brain tissue (Bernas et al. 2010; Siddharthan et al. 2007), it is not 
a feasible option due to its limited availability, quality and uniformity. On the other hand, 
the yield of microvessels from small rodents commonly used for in vivo studies (mouse, 
rat) is low (Avdeef 2011). Subsequently, porcine and bovine tissues as a source of BECs 
are seen as a good alternative (Cecchelli et al. 2007). 
Primary cultures of BECs usually preserve well TJ proteins and transporter mechanisms, 
but it remains difficult to obtain a pure endothelial culture, as the basement membrane 
surrounding the microvascular endothelium also encloses pericytes (Calabria et al. 2006). 
They also quickly lose their specific characteristics in culture, undergoing dedifferentiation 
and senescence even upon limited passaging (Nakagawa et al. 2009), thus hampering 
usefulness as in vitro model of the BBB. 
 
 Immortalized cell lines 
Immortalization of brain microvessel endothelial cells are of great help for BBB study, as 
they achieve confluence in a very short time, allowing cell amplification and providing a 
large amount of cells per experience. Such cell lines are also available for many species, 
but are usually less tight than primary cultured cells, and may be deficient in some tight 
junctional proteins, enzymes and transport systems (Wilhelm et al. 2011). Cell lines have 
been generated mostly by SV40 T antigen (Stins et al. 1997), but also by human 
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papilloma E6E7 gene (Prudhomme et al. 1996), Rous sarcoma virus (Mooradian and 
Diglio 1991), as well as by incorporating human telomerase (Weksler et al. 2005). BBB 
studies profit from the existence of human cell lines, such as the hCMEC/D3 (human 
cerebral microvascular endothelial cell/D3 clone) cell line, which retains most of the 
morphological and functional features of BECs (Schreibelt et al. 2007; Weksler et al. 
2005). Despite their obvious advantages, immortalized cell lines have usually a poorly 
differentiated phenotype compared to the in vivo situation, as well as commonly present 
leaky intercellular junctions and lack paracellular barrier properties (Cardoso et al. 2010). 
Two of these immortalized cell lines, of human (hCMEC/D3 cells) and rat (RBE4 cells) 
origins, have been used in the development of the present thesis work. 
 
 Co-culture systems 
The interplay between different cellular components of the NVU on BBB structure and 
function has led to the establishment of more complex in vitro models, such as co-culture 
systems (de Boer and Gaillard 2006). Co-culture models have demonstrated to be more 
suitable than monocultures since their permeability is more selective (Tajes et al. 2014). 
Most co-culture systems are based on a BEC-astrocyte/pericytes/neuron/microglia two-
chamber cell culture system (Nakagawa et al. 2007), allowing a better understanding of 
the cross talk between the brain endothelium and the neighboring elements of the NVU 
and a closer reproduction of the in vivo condition (see Figure 7). Recently, there have also 
been studies with triple cultures of BEC, astrocytes and pericytes/neurons (Nakagawa et 
al. 2009; Nakagawa et al. 2007; Schiera et al. 2003), but its complexity is limiting the wide 
use of such in vitro models. 
 
 
Figure 7. Schematic representation of a static co-culture model for the BBB study. 
In A) it is exemplified a co-culture system with cultured endothelial cells on a plate insert and astrocytes at the 
bottom of the plate well; in B), a triple co-culture system is exemplified, where endothelial cells and pericytes 
are cultured on the top and bottom of the insert, respectively, and astrocytes grow on the bottom of the plate 
well. Image taken from (Cardoso et al. 2010). 
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 Dynamic models 
Given the shear stress provoked by the capillary blood flow influences the BECs and the 
tightness of the BBB, dynamic in vitro models more closely mimic the in vivo situation, 
than the static ones. It has been shown that the flow-induced forces as well as the 
presence of glial cells, or of factors released by them, improve the barrier properties and 
tightness of endothelial cells, thus rendering this approach a better model to study the 
BBB (Siddharthan et al. 2007). However, most screening tests are still done on static 
systems, considering that dynamic systems, even though reliable and promising, are 
technically demanding. 
 
1.6.4.1. hCMEC/D3 cell line 
The model was developed from cerebral microvessels obtained from a cortectomy 
performed on a patient with epilepsy. The immortalization was performed by double 
transfection with SV40 T antigen and human telomerase (hTERT) (Poller et al. 2008).  
The human immortalized hCMEC/D3 cell line retains most of the morphological and 
functional characteristics of BECs, namely the expression of TJs and the polarized 
expression of multiple active transporters, receptors and adhesion molecules, even if not 
co-cultured with glia or astrocytes (Schreibelt et al. 2007; Weksler et al. 2005). This cell 
line has shown consistent expression of a considerable number of BBB endothelial cell 
markers genes such as CD31, VE-cadherin, and von Willebrand factor (Poller et al. 2008; 
Weksler et al. 2005), as well as expresses fully functional drug efflux transporters (Dauchy 
et al. 2009; Weksler et al. 2005). Despite being an immortalized cell line, the paracellular 
pathway is considerably more restricted than in other cell lines, making it a promising 
candidate not only for microscopy, transcriptomic and proteomic studies, but also for 
measuring the passage of molecules from one compartment to another and, thus, drug 
transport. The model also permits the study of substrate affinity to a certain transporter 
with or without the presence of a specific inhibitor (Poller et al. 2008). 
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Figure 8. Phase-contrast microscopic view of the immortalized hCMEC/D3 and RBE4 cells. 
A) human hCMEC/D3 cell line (taken from (Weksler et al. 2005)) and B) rat RBE4 cell line (taken from 
(Wilhelm et al. 2011)). The highly similar morphology of these two brain microvascular endothelial cells is 
noteworthy. 
 
1.6.4.2. RBE4 cells 
The rat RBE4 cells are a rat immortalized cell line isolated and cultured for the first time 
using the Hughes and Lantos (Hughes and Lantos 1986) method with some modifications 
(Roux et al. 1989). The immortalization was obtained by transfection of the plasmid 
pE1A/neo carrying the E1A region of Adenovirus 2 (Roux et al. 1994). The rat RBE4 cell 
line has been extensively used in different types of studies, namely of transport (Faria et 
al. 2010; Vilas-Boas et al. 2013b) and subcellular localization of transporters 
(Babakhanian et al. 2007), signaling pathways (Zhang et al. 2009a) and inflammatory 
cascades (Pan et al. 2007b), toxicity (dos Santos et al. 2010) and toxicity modulation 
(Marreilha dos Santos et al. 2008), among others. According to the morphological and 
biochemical studies performed, the RBE4 cell line exhibit features that are representative 
of an in vivo BBB situation, namely the ability to form a confluent monolayer, polarized 
expression of BBB specific transporters, as well as the presence of BBB cell surface 
markers, such as TJ and AJ proteins (Bendayan et al. 2002; Friedrich et al. 2001; Huwyler 
et al. 1999; Regina et al. 1998; Regina et al. 1997; Roux et al. 1994). The major limitation 
of this model appears to be its relatively high paracellular permeability to small molecules, 
thus limiting their use for permeability studies (Bendayan et al. 2002; Roux and Couraud 
2005). 
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2. The ATP-binding cassette transporters in the BBB – 
Focus on P-glycoprotein and Breast Cancer 
Resistance Protein 
P-glycoprotein (P-gp, ABCB1, MDR1) and Breast Cancer Resistance Protein (ABCG2, 
BCRP) are the most critical efflux transporters, among the ABC transporters expressed in 
the BBB. These two transporters are present in the luminal, blood-facing side of the 
endothelial cells of brain capillaries, and thereby critical in the prevention of the entry of 
toxic molecules, drugs and other xenobiotics circulating in the blood into the brain (Cooray 
et al. 2002; Graff and Pollack 2004). On the other hand, P-gp and BCRP can also prevent 
the entry of CNS-acting drugs, and this barrier role may be even exacerbated in 
pathological conditions. In this section, the ABC transporter family will be explored in 
detail, and special focus will be given to the role of the expression and activity of P-gp and 
BCRP at the BBB. 
 
2.1. General Considerations on the ABC Transporter Family 
The cellular transport mechanisms, and particularly the membrane transporters, 
importantly contribute to cell homeostasis, and to the inter-individual variation in the 
bioavailability and vulnerability of a broad range of drugs, toxins, metabolic products and 
xenobiotics, playing a prominent role in their pharmacokinetics (i.e. absorption, 
distribution, metabolism and excretion) (Sai 2005). Within the human body, this is greatly 
determined by the balance of the uptake and efflux phenomena, along with metabolic 
activity. Among the efflux transporters, the ABC transporters are the most extensively 
studied.  
Multidrug resistance (MDR) was first described in the early seventies during the 
observation of treatment cross-resistance with different anticancer drugs and cytotoxic 
agents. Cells from these drug-resistant tumors were resistant to drugs with different 
structures and with different mechanisms of action (Biedler and Riehm 1970; Dano 1973). 
This phenotype of MDR was later associated with the overexpression of membrane 
proteins belonging to the family of ABC transporters. The term “ABC” standing for “ATP-
Binding Cassette” was introduced for the first time in 1992 following the discovery that 
these transporters used the energy of ATP hydrolysis to translocate solutes across 
cellular membranes, through the highly conserved ATP-binding cassette, the most 
characteristic feature of this superfamily of proteins (Higgins 1992). In the meantime, 
several proteins have been recognized to play a role in MDR, and of those, many 
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represent transporters belonging to this transporter superfamily. Thus, ABC transporters 
form one of the largest of all protein families, and are central, not only in the aforecited 
cancer resistance, but also in drug disposition and response (Gottesman and Ambudkar 
2001). In contrast to the above-mentioned SLC transporters, which essentially allow the 
entry of many endogenous compounds and xenobiotics within the cell, ABC transporters 
are able to efflux xenobiotics and, thus, act as key elements in the absorption, distribution 
and elimination of several molecules in the human organism. ABC transporters are 
selectively expressed in strategic tissues, such as the brain, intestine, kidney, liver, 
placenta and testis to determine drug absorption and disposition (DeGorter et al. 2012; 
Hagenbuch and Meier 2003; Sai 2005). 
At the absorption level, ABC transporters extrude drugs, xenobiotics and metabolites into 
the lumen of the intestine, thereby preventing their absorption into the blood or lymph 
circulation and protecting the body against acute and chronic toxicity (Ambudkar et al. 
1999; Schinkel and Jonker 2003). These transporters are also responsible for excretion of 
xenobiotics and metabolites via bile and urine, contributing to renal and biliary clearance 
(Hesselson et al. 2009; Schinkel et al. 1996). Yet, and not least important is their function 
as key determinants in drug and xenobiotic distribution, particularly in tissues protected by 
blood-tissue barriers, such as the placental barrier, the blood-testis barrier and, mostly 
important for the present subject, the BBB (DeGorter et al. 2012). The ABC transporter 
superfamily is responsible for the efflux of xenobiotics from the brain into the bloodstream, 
making some ABC transporters key elements in controlling the brain penetration of many 
drugs and, thus, their CNS effects (Abbott et al. 2010; Begley 2004; Scherrmann 2005). 
The great importance of the main ABC transporters expressed in the BBB relies on three 
critical characteristics that they all share: 1) localization in the luminal plasma membrane 
of brain capillary endothelial cells, at the blood-CNS interface, 2) highly effective and 
potent ATP-driven efflux transport against the concentration gradient of their substrates, 
and 3) a remarkably low substrate specificity that covers a wide range of structurally 
unrelated therapeutic drugs (Hartz and Bauer 2010). 
Therefore, the BBB not only acts as a physical barrier, but also actively eliminates a large 
number of molecules from the brain, protecting the brain from intoxicants but 
simultaneously restricting the entrance therapeutic drugs, and thus in some cases 
impairing effective CNS pharmacotherapy. 
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2.1.1. Nomenclature and Structure 
In the human genome, 49 genes encoding ABC transporters have been identified and 
divided into seven different subfamilies, A-G, based on their amino acid sequence 
similarities and evolutionary divergence (Miller 2015; Moitra and Dean 2011): ABCA (12 
members; previously ABC1), ABCB (11 members; previously MDR/TAP), ABCC (13 
members; previously MRP/CFTR), ABCD (4 members; previously ALD); ABCE (1 
member; previously OABP); ABCF (3 members; previously GCN20) and ABCG (6 
members; previously White) (see Table 2). The three ABCB, ABCC, ABCG subfamilies 
comprise the transporters involved in the efflux of xenobiotics. 
Investigation using topological models predicted the structure for most of the ABC family 
members. In general, ABC transporters display two hydrophobic transmembrane domains 
(TMDs), usually each containing multiple (typically six) membrane-spanning α-helices – 
which are involved in the recognition of substrates – and two hydrophilic cytoplasmic 
nucleotide-binding domains (NBDs) located in the cytoplasm – which in turn couple 
conformation changes induced by ATP binding and hydrolysis, and ADP release to the 
transport process (Higgins and Linton 2004; Jones and George 2004) (see Figure 9). 
Some members do not follow this typical structure as they display either fewer or 
additional TMDs and/or NBDs. In fact, ABC transporter proteins can be classified into 
either full transporters (when containing at least two TMDs and two NBDs) or half 
transporters (containing one of each domain), the latter being assembled into homodimers 
or heterodimers to form functional units (Hyde et al. 1990). Such is the case of ABCG2, 
which is a half transporter consisting in a singular TMD and NBD (Haimeur et al. 2004), 
while ABCC1, ABCC2, ABCC3, ABCC6 and ABCC10 have an extra amino terminal TMD 
(Couture et al. 2006). The NBD share three conserved domains: the Walker A and B 
domains, which are not ABC transporter-specific as they can be found in other nucleotide-
binding proteins, and the LSGGQ signature C motif, located upstream of the Walker B 
site, which, by being ABC transporter-specific, determines the affiliation of a protein to the 
ABC transporter family (Hyde et al. 1990). 
 
Table 2. Classification of the ABC transporter family transporters according to the Human Genome 
Organization nomenclature. 
Adapted from (Chaves et al. 2014) 
Subfamilies ABCA ABCB ABCC ABCD ABCE ABCF ABCG 
Alternative names ABC1 MDR/TAP MRP/CFTR ALD OABP GCN20 White 
Number of members 12 11 13 4 1 3 6 
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Figure 9. Topological models for the structure of most ABC transporters. 
A) Generally, ABC transporters display 2 TMDs and 2 NBDs located in the cytoplasm (e.g. P-gp, ABCC4, 
ABCC5). B) Some members display 3 TMDs and 2 NBDs (e.g. ABCC1, ABCC2, ABCC3, ABCC6), or 
alternatively, C) ABC transporters can constitute half transporters, with 1 TMD and 1 NBS (e.g. BCRP, 
ABCG1). Image taken from (ElAli and Hermann 2011) 
 
 
2.1.2. Mechanism of Action 
Every ABC transporter uses the energy released by ATP hydrolysis for the efflux of 
various endogenous compounds and xenobiotics against the concentration gradient. The 
transport involving these efflux carriers is considered a multistep process involving 
communication via conformational changes, in both directions, between the NBDs and 
TMDs. Within the membrane, the TMDs are organized to form an inverted “V” pocket, 
where substrates either in the cytoplasm or in the inner leaflet of the cytoplasmic 
membrane can bind and establish multiple interactions. The substrate binding to this 
pocket increases the affinity of NBDs for ATP (Ramachandra et al. 1998; Wang et al. 
1998). ATP binding to the NBDs and its hydrolysis induces a conformational change in the 
TMDs, leading to the opening of the inverted “V” to the opposite side, allowing substrate 
release into the extracellular space. Upon ATP hydrolysis, the transporter is then restored 
to its original inward facing orientation, able to begin a new cycle of transport (see Figure 
10) (Fukuda and Schuetz 2012; Martin et al. 2001). However, the exact mechanism 
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regarding the coupling of ATP hydrolysis to unidirectional substrate translocation is not yet 
completely clear. 
 
Figure 10. Schematic representation of the mechanism of ABC transporter function. 
Members of the ABC superfamily exert their transport function upon substrate binding, and subsequent ATP 
binding to the NBD. ATP hydrolysis induces a conformational change in the TMDs, which allows the transport 
of substrates to the extracellular space. Image taken from (ElAli and Hermann 2011) 
 
2.1.3. Physiological and pharmacological implications of the ABC Transporters 
ABC transporters are key elements in the maintenance of essential physiological functions 
in the human organism, including the extrusion of harmful compounds, transport of ions 
and peptides, and cell signalling (DeGorter et al. 2012; Gottesman and Ambudkar 2001; 
Gottesman et al. 2002). In fact, the improper functioning of these transporters may have 
severe clinical repercussions. As such, it has been shown that loss-of-function mutations 
in many genes coding for ABC transporters are linked to several human genetic diseases, 
including adrenoleukodystrophy (ABCD1) (Mosser et al. 1993), juvenile macular 
degeneration (ABCA4) (Allikmets et al. 1997), cystic fibrosis (ABCC7) (Teichgraber et al. 
2008), Tangier disease (ABCA1) (Bodzioch et al. 1999), among others (Gottesman and 
Ambudkar 2001). 
ABC transporters belonging to the subfamilies ABCB, ABCC, ABCG play a major role in 
protecting the body from xenobiotics – by opposing their intracellular accumulation, ABC 
transporters help reduce their potential harmful effects within the body. For example, the 
ABCB1 and ABCG2 provide the efflux of toxic compounds such as benzo[a]pyrene, a pro-
carcinogenic compound, and some of its metabolites and conjugates (Ebert et al. 2005; 
Yeh et al. 1992). 
Since a considerable number of therapeutic drugs fall as substrates of some ABC efflux 
transporters, the distribution and bioavailability of drugs can be compromised, and thus, 
the drug concentrations at the pharmacological target may be under the therapeutic level. 
Therefore, ABC transporters are often related to the development of a MDR phenotype, 
particularly evident in cancer or epilepsy treatment (Potschka 2010b; Qosa et al. 2015). 
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2.1.4. Role of ABC Transporters in the brain microvessels 
 
The localization and the oriented transport of ABC transporters present at the BBB 
provides support to its barrier function considering the CNS vulnerability to many 
stressors, such as ischemia, trauma or toxins, and the lack of self-renewal capacity and, 
therefore, cell replacement. Yet, experimental studies give no complete consensus 
regarding the distribution of the ABC transporters at the BBB. Whereas the use of isolated 
brain capillaries cannot ensure that the detected genes or proteins belong to the BECs, 
due to incomplete removal of pericytes and glial end-feet, BEC in culture do not suffer this 
contamination but the expression and activity of some genes are frequently influenced by 
culture conditions (Scherrmann 2005). In addition, the polarity exhibited by the brain 
microvessel endothelial cells is also critical inthe role of ABC transporters at the BBB 
level, since these are mostly expressed in the luminal side of the BECs. Some of the ABC 
transporters functions in the brain can be briefly described as 1) protection of cerebral 
microvessels through elimination of glutathionized organic molecules from endothelial 
cells, 2) brain protection through elimination of organic toxins and elimination of the β-
amyloid (Aβ) peptide from the brain, 3) regulate cell membrane composition by 
translocating lipids from the cytosolic to exoplasmic leaflet, and 4) control of neural 
precursor cell proliferation and differentiation into neurons and astrocytes (ElAli and 
Hermann 2011). 
 
Figure 11. Representation of the major ABC transporters expressed at the human BBB. 
ABC transporters are mainly present at the luminal side of the BECs, where P-gp and BCRP play the major 
role in the brain-to-blood efflux of neurotoxicants and xenobiotics. Image taken from (Chaves et al. 2014) 
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2.2. P-glycoprotein 
 
2.2.1. P-glycoprotein tissue distribution and main physiological roles 
P-glycoprotein was originally identified in 1976 as a membrane glycoprotein capable of 
altering membrane permeability of colchicine in drug-resistant ovary cells from Chinese 
hamsters (Juliano and Ling 1976). The presence of this efflux transporter was later 
identified in human (Thiebaut et al. 1987) and rodent (Croop et al. 1989) normal tissues, 
as well as in many cultured cells of mammalian and human origins, including 39 of 60 
tumor cell lines used by the United States National Cancer Institute in the discovery of 
new anti-cancer drugs (Alvarez et al. 1995). By the end of the 80’s, it was established that 
P-gp was expressed in several human tissues emphasizing its strong involvement in the 
pharmacokinetics and toxicology of xenobiotics. In fact, P-gp was found to be expressed 
at considerable high levels at the apical surface of epithelial cells of the intestine, liver bile 
and pancreatic ducts and kidney proximal tubules (Chin et al. 1989; Fojo et al. 1987; 
Thiebaut et al. 1987), suggesting its physiological role in the elimination of xenobiotics and 
endogenous metabolites. It is  also found in blood-tissue interfaces, such as the placenta, 
blood testis barrier and the BBB (Cordon-Cardo et al. 1990; Cordon-Cardo et al. 1989; 
Thiebaut et al. 1987), in turn suggesting its organ-protective role against toxic compounds 
circulating in the blood. The discovery of P-gp constitutes a major event since it brought, 
for the first time, a biological explanation for the frequently observed anticancer drug 
resistance phenomenon, in addition to clarifying its functions in the protection of 
susceptible organs like the brain, testis as well as the fetus from potential harmful 
compounds, and in the secretion of metabolic byproducts and xenobiotics to bile, urine 
and into the lumen of the gastrointestinal tract. To date, P-gp remains the most studied 
transporter of the ABC family. 
P-gp exists in different isoforms, which have more than 70% sequence homology and are 
encoded by a small number of closely related genes. In humans, P-gp is encoded by two 
ABCB genes, ABCB1/MDR1 and ABCB4/MDR2, which arose from a duplication event, 
and are located in the chromosome 7 (7q21) (Callen et al. 1987; Chin et al. 1989). The 
MDR phenotype is associated with the ABCB1 isoform, while ABCB4 encodes for a 
protein that carries out phosphatidylcholine transport into the bile (Hennessy and Spiers 
2007; Sharom 2006). In rodents, P-gp is encoded by three different genes: Abcb1a/Mdr1a 
and Abcb1b/Mdr1b, which both encode drug transporters and correspond to the ABCB1 
human analog, and Abcb4/Mdr2 which correspond to the ABCB4 human analog (Sharom 
2006). In the following sections of this dissertation, the term P-gp will be used to indicate 
the ABCB1 gene product (or Abcb1a/Abcb1b gene products in studies performed in 
rodents). 
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2.2.2. P-glycoprotein expression and function in the BBB 
P-gp was the first ABC transporter to be detected in the endothelial cells of the human 
BBB by immunochemistry (Cordon-Cardo et al. 1989). Over the course of time, genes 
encoding P-gp have been also identified in the cerebral endothelial cells of most living 
species, including rodents, rabbits, pigs, dogfish, cattle and monkeys, by several 
experimental approaches (Cisternino et al. 2001; Fricker et al. 2002; Jette et al. 1993; 
Miller et al. 2002; Thiebaut et al. 1987), suggesting that P-gp may serve as a general 
defense mechanism in the mammalian BBB, protecting the brain form potentially harmful 
lipophilic compounds from natural sources and other lipophilic xenobiotics that otherwise 
would penetrate the BBB by simple diffusion without any limitation (Schinkel 1999). The 
immunolocalization of P-gp in the human endothelial cells of the BBB has been 
extensively reported using brain sections, isolated brain microvessels and primary 
cultures of human brain endothelial cells. 
The localization of P-gp in capillary blood vessels of human brain tissue was evidenced by 
immunoelectron microscopy studies, being specifically expressed on the luminal surface 
of the endothelium whereas no staining was observed in neurons and glial cells (Tanaka 
et al. 1994). In the human cerebral microvascular endothelial cell line hCMEC/D3 the 
expression and functional activity of P-gp was clearly demonstrated (Dauchy et al. 2009; 
Poller et al. 2008; Weksler et al. 2005), as well as in primary cultures of human brain 
microvessel endothelial cells (HBEC), co-cultured or not with astrocytes (Lee et al. 2007; 
Megard et al. 2002), while P-gp expression was not found in primary human astrocytes 
cultured alone (Megard et al. 2002). Supporting these data, studies performed using 
human isolated microvessels and human brain sections evidenced strong 
immunocytochemical staining for P-gp, but no detection of this transporter was seen in 
neurons and glial cells (Seetharaman et al. 1998; Virgintino et al. 2002). In line with these 
results, two studies using isolated human brain microvessels showed high P-gp 
expression (Shawahna et al. 2011; Uchida et al. 2011), but given that during the isolation 
procedure there are still astrocyte foot-processes that remain attached to the 
microvessels, which cannot be removed, it is difficult to conclude that the expression of P-
gp is only due to brain endothelial cells and exclude its expression in astrocytes.   
However, P-gp does not seem to be exclusively expressed by the endothelial cells of the 
NVU. The research group of R. Bendayan has also identified P-gp at luminal and 
abluminal membranes of capillary endothelial cells, and likewise in adjacent pericytes and 
astrocytes of human and rat BBB, using immunogold cytochemistry at the electron 
microscope level (Bendayan et al. 2006). In agreement with this astrocytical presence, 
there is additional data suggesting that astrocyte foot processes are important sites of 
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microvascular localization for P-gp, and that it is present on the abluminal side of the 
human brain microvasculature (Golden and Pardridge 1999; Pardridge et al. 1997). Using 
human brain sections, immunodetection of P-gp was also possible in the microvascular 
pericytes that closely envelop the brain capillary endothelial cells (Virgintino et al. 2002). 
In another study using healthy human brains, P-gp was not detectable in neurons (Aronica 
et al. 2003; Tishler et al. 1995). 
In the rodent brain, both the Abcb1a and Abcb1b are present, but only Abcb1a is localized 
in brain capillaries of mice, while Abcb1b is only present in the brain parenchyma 
(Demeule et al. 2002). In the normal rat brain, a differential expression of the two codifying 
P-gp genes has been reported, with Abcb1a being expressed in all brain regions, whereas 
Abcb1b was predominantly expressed in the hippocampus (Kwan et al. 2003). 
These data are in agreement that P-gp is highly expressed on the luminal membrane of 
the endothelial cells of the BBB, and to a much lesser extent in the brain parenchyma, 
neuronal, and glial cells. Therefore, when a P-gp substrate enters in the BECs it is 
immediately pumped back into the bloodstream. The lack of concordant results evidencing 
the presence of P-gp in other brain cells than the endothelium suggests that P-gp 
expression in the brain parenchymal cells is nominal, although it may be significantly 
enhanced in pathologic conditions, such as amyotrophic lateral sclerosis (ALS) (Jablonski 
et al. 2012), epilepsia (Bauer et al. 2008), focal cortical dysplasia (Ak et al. 2007), and 
brain tumours (Haar et al. 2012). In fact, a cause-relationship may exist between brain 
pathologies as epilepsy, glioma and cortical dysplasia and the particular up-regulation of 
the expression of P-gp in astrocytes (Calatozzolo et al. 2005; Chengyun et al. 2006; 
Sisodiya et al. 2001; Tishler et al. 1995). 
The important role of P-gp in barrier function and brain protection is best highlighted when 
comparing brain drug distributions of wild-type and P-gp genetic knockout mice, as well as 
in studies in which transporter function is abolished by using P-gp selective inhibitors. In 
vivo dosing studies using P-gp knockout mice show 5 to 50-fold increased brain-to-plasma 
ratios of a large number of therapeutic drugs that are P-gp substrates and normally cannot 
cross the BBB and exert their pharmacologic effect (Decleves et al. 2011). For example, 
the brain penetration of ivermectin is increased up to 100-fold, and that of vinblastine up to 
3-fold in Abcb1a deficient mice when compared to wild-type mice (Schinkel et al. 1994). In 
line with this, the blockade of BBB P-gp through local application of P-gp inhibitors 
significantly increased the brain concentration of several drugs (Loscher and Potschka 
2005a). The selective inhibition of P-gp increased paclitaxel accumulation in the brain, 
substantially reducing tumour volume by 90% in nude mice with cerebrally implanted 
glioblastoma, while paclitaxel showed to be ineffective without the chemical knockout 
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(Fellner et al. 2002). Furthermore, the implementation of studies by positron emission 
tomography using P-gp substrates or inhibitors are powerful tools for studying the in vivo 
functionality of this transporter in the human BBB. Using 11C-verapamil and 11C-desmethyl 
loperamide, recent studies have shown that P-gp is functional to the BBB in humans 
(Kreisl et al. 2010; Muzi et al. 2009; Seneca et al. 2009; Wanek et al. 2013). 
All accounted, P-gp is nowadays considered the most prominent element of selective, 
active barrier function that limits xenobiotics from entering the brain. 
 
2.2.3. P-glycoprotein structure and mechanisms of drug efflux 
The human P-gp is a single polypeptide of 1280 amino acids weighing approximately 170 
kDa (Schinkel 1999). It contains two homologous but not identical TMDs each one 
containing six α-helices, linked by a highly charged extracellular portion, and two 
intracellular ATP-binding sites, the NBDs (Aller et al. 2009; Zhou 2008). The amino and 
carboxyl terminals of this polypeptide are also located intracellularly, while the first N-
glycosylated loop is extracellular (Zhou 2008). The 12 transmembrane (TM) segments fold 
together to form a barrel-like structure that traverses the plasma membrane, and the 
hydrolysis of ATP that follows the ATP binding to the NBDs provides the necessary 
energy for drug transport, as for all the ABC transporters (Schinkel 1999).  
 
 
Figure 12. Crystal structure of mouse P-gp. 
The N- and C-terminal halves of the molecule 
are colored yellow and blue, respectively. The 
TMDs and NBDs are also identified within the 
structure. The shaded area corresponds the 
approximate positioning of the lipid bilayer. 
Image taken from (Aller et al. 2009) 
 
 
 
 
The exact mechanism of drug transport has not been elucidated yet, but its structure 
rendering suggests that P-gp recognizes its substrates in the plasma membrane (Aller et 
al. 2009; Loo and Clarke 2005b). Considering the clinical relevance of this ABC 
transporter, the full structure characterization of mouse P-gp, which was reported to share 
87% sequence identity with human P-gp in a drug-binding competent state, brought 
important insights in this field of research (Aller et al. 2009). The characterized P-gp 
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structure presents a nucleotide-free inward-facing conformation arranged as two “halves” 
with pseudo two-fold molecular symmetry spanning  136 Å perpendicular to and  70 Å in 
the plane of the bilayer. The NBDs are separated by  30 Å. The inward facing 
conformation, formed from two bundles of six helices (TMs 1-3,6,10,11 and TMs 4,5,7-
9,12), results in a large internal cavity open to both the cytoplasm and the inner leaflet. 
Also, two portals - formed by transmembrane helices (TMHs) 4/6 and 10/12 – seem to 
allow the access for the entry of hydrophobic molecules directly from the membrane (Aller 
et al. 2009). The volume of the internal cavity within the lipid bilayer is substantial (  6,000 
Å3) and can accommodate at least two compounds simultaneously (Loo et al. 2003b). The 
inward-facing structure does not allow substrate access from the outer membrane leaflet 
nor the extracellular space. This conformation, in a pre-transport state, likely represents 
an active state where the binding of ATP, stimulated by a substrate, likely causes a 
dimerization in the NBDs and produces large structural changes, resulting in an outward 
facing conformation. Depending on the specific compound, substrates could either be 
released as a consequence of decreased binding affinity caused by changes in specific 
residue contacts between the protein and drug going from the inward to outward facing 
conformation or, alternatively, facilitated by ATP hydrolysis. In either case, ATP hydrolysis 
likely disrupts NBD dimerization and resets the system back to inward facing reinitiating 
the transport cycle (Aller et al. 2009; Tombline et al. 2005). 
 
Figure 13. Representation of a consensual model of P-gp substrate transport. 
A) P-gp is represented in its substrate-binding conformation, of two inward facing bundles of six TMHs, and its 
large internal cavity is open to both the cytoplasm and the inner leaflet of the lipid bilayer. Substrate-P-gp 
interactions facilitate ATP binding to the NBDs. B) ATP binding to the NBDs leads to a conformational change, 
resulting in an outward-facing conformation. This arrangement leads to the release of substrates into the 
extracellular space or to the outer leaflet of the lipid bilayer. Image taken from (O'Brien et al. 2012). C) 
General view of the substrate-binding cavity in the inward-facing conformation of a homology model of human 
P-gp. Image taken from (Pajeva et al. 2009). 
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This reported 3D structure for mouse P-gp was used to describe a model of human P-gp 
for the inward-facing conformation of the protein, which confirmed the role of TMDs 4, 6, 
10 and 12 as entrance gates to the internal cavity and describes differences in their 
functions (Pajeva et al. 2009). Furthermore, the analysis of human P-gp interactions with 
the QZ59 stereoisomers confirms the multi-specific binding of P-gp with its ligands 
(Pajeva et al. 2009). In fact, P-gp can distinguish between the stereoisomers of cyclic 
peptides, resulting in different binding locations, orientation and stoichiometry (Aller et al. 
2009; Pajeva et al. 2009). 
 
2.2.3.1. Mechanisms of drug efflux by P-glycoprotein 
The exact mechanism by which P-gp couples the ATP hydrolysis to allow the movement 
of drugs across the plasma membrane, as well as the exact site of substrate interaction 
with the transporter, are not clarified. However, several models have been proposed on 
the mechanism by which P-gp is able to efflux its substrates, namely the “hydrophobic 
vacuum cleaner”, “flippase” and “pore” models (Hennessy and Spiers 2007; Varma et al. 
2003). The first two models are the most widely accepted (Hennessy and Spiers 2007; 
Sharom 2011; Varma et al. 2003) and both models are consistent with the tertiary 
structural data for P-gp, indicating that substrates gain access to the pore from the lipid 
phase of the membrane (Rosenberg et al. 1997; Rosenberg et al. 2001). 
 
Figure 14. Proposed models of P-gp substrate efflux mechanisms. 
According to the “vacuum cleaner” model, P-gp recognizes hydrophobic substrates that previously partitioned 
into the lipid bilayer, and drives them out of the membrane directly to the external aqueous medium. In the 
“flippase” model, P-gp substrates are transported from the inner leaflet of the lipid bilayer, to either the outer 
leaflet of the plasma membrane or to the extracellular space. Image taken from (Sharom 2011). 
 
 “Hydrophobic vacuum cleaner” 
The compounds that interact with P-gp are relatively hydrophobic and readily soluble in 
lipid bilayers, and it is now widely accepted that they partition into the membrane before 
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interacting with the protein (Seelig and Landwojtowicz 2000). Moreover, P-gp substrate 
binding sites appear to be contained within its TMDs, and drugs gain access to these sites 
after partitioning into the lipid bilayer (Raviv et al. 1990). Thus, the idea that P-gp acts a 
"hydrophobic vacuum cleaner", that expels lipophilic molecules from the membrane into 
the extracellular medium, was firstly suggested by Higgins and Gottesman to account for 
the lipophilic nature of P-gp substrates (Higgins and Gottesman 1992) and has found 
widespread acceptance. The general consensus of the “hydrophobic vacuum cleaner” 
model relies on the principle that P-gp recognizes hydrophobic compounds embedded in 
the inner leaf of the plasma membrane (after they have partitioned into the bilayer), and 
pumps them out of the membrane directly to the external aqueous medium (Higgins and 
Gottesman 1992). This pumping action gives rise to a concentration gradient across the 
plasma membrane, with a higher drug concentration in the external aqueous phase. This 
way, the transporter is able to intercept substrates before they have an opportunity to 
enter the cytosol, and therefore protecting the cell from exposure to potentially toxic 
molecules (Sharom 2011). Additionally, P-gp 3D conformation changes upon nucleotide 
binding to the intracellular NBD have been reported (Rosenberg et al. 2003). In the 
absence of nucleotide, the two transmembrane domains form a single barrel with a central 
pore that is open to the extracellular surface and spans much of the membrane depth, 
while upon nucleotide binding the TMDs reorganize into three compact domains that open 
the central pore along its length in a manner that could allow access of hydrophobic drugs 
directly from the lipid bilayer to the central pore of the transporter (Rosenberg et al. 2003). 
The recent P-gp X-ray crystal structures also support this model, which demonstrated that 
two peptide stereoisomers are bound deep within the TMDs, suggesting they may gain 
access to P-gp from within the lipid bilayer (Aller et al. 2009). 
 
 The “flippase” model 
This model assumes that P-gp substrates are flipped from the inner leaflet of the lipid 
bilayer, to either the outer leaflet of the plasma membrane or directly to the extracellular 
space (Higgins and Gottesman 1992). This means that drug substrates should be located 
at the leaflet of the bilayer, rather than at the hydrophobic core of the membrane. 
According to this model, a low rate of spontaneous movement of substrates between the 
two bilayer leaflets is also necessary, to allow P-gp to generate a drug concentration 
gradient. Actually, P-gp has the ability to bind lipid-like drugs and platelet-activating 
factors (Eckford and Sharom 2006), apart from also translocating fluorescently-labeled 
phospholipids across the membrane in an ATP-dependent way (Romsicki and Sharom 
2001). Therefore, this transporter may function as a translocase or ‘flippase’ for lipophilic 
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molecules (Higgins and Gottesman 1992), moving them from the cytoplasm to the 
extracellular membrane leaflet. The rate of spontaneous transbilayer movement of many 
P-gp substrates is relatively low and, as they appear to be discretely localized in one 
membrane leaflet, the transporter would be able to maintain a higher substrate 
concentration in the outer leaflet (Sharom 2011). 
It should be noted that both these models described above assume that P-gp substrates 
partition into the lipid phase prior to interacting with the transporter. In fact, this may help 
to explain the P-gp unusually broad substrate specificity, since the primary determinant of 
specificity would be the ability of a substrate to appropriately intercalate into the lipid 
bilayer, with the subsequent substrate-binding site interaction being a secondary matter 
(Hennessy and Spiers 2007). Also, the P-gp substrate binding pocket is located within the 
TM regions that contact with the cytoplasmic membrane leaflet (Aller et al. 2009; Lugo 
and Sharom 2005b; Qu and Sharom 2002; Shapiro and Ling 1997a), which is consistent 
with both models. However, experimentally, it is difficult to distinguish between the 
“hydrophobic vacuum cleaner” and “flippase” models (Hennessy and Spiers 2007). 
 
2.2.4. P-glycoprotein substrates, substrate-binding sites and 
pharmacoresistance: clinical implication 
2.2.4.1. P-glycoprotein substrates 
As P-gp was the first ABC transporter to be described, it is also by far the best 
characterized, where a broad range of chemically diverse drugs have been identified as 
substrates. They are significantly different in size, structure, and function and include 
chemotherapeutic agents such as anthracyclines, vinca alkaloids, and tyrosine kinase 
inhibitors (TKIs), human immunodeficiency virus (HIV) protease inhibitors and HMG-CoA 
reductase inhibitors. Given the heterogeneity of P-gp substrates, the structural 
requirements for a substance to fall in a P-gp substrate category are difficult to define. 
However, a typical P-gp substrate is hydrophobic or amphipathic, presents a planar 
mainly aromatic ring system, and is usually positively charged at physiological pH 
(Sharom 1997). Still, P-gp is able to transport neutral compounds (digoxin, cyclosporine 
A), negatively charged molecules (fexofenadine, atorvastatin) and hydrophilic drugs 
(methotrexate, peptides) (Choong et al. 2010). Other xenobiotics recognized and 
transported by P-gp include opioid analgesics (Dagenais et al. 2004; King et al. 2001; 
Thompson et al. 2000), anti-psychotics and antidepressants (Uhr et al. 2003; Uhr et al. 
2000), anti-emetics (Schinkel et al. 1996), and an important number of chemotherapeutic, 
anti-retroviral and anti-epileptic drugs. A summary of these and other substrates of P-gp is 
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displayed in Table 3, and is evidence of the remarkable number of CNS and other drugs 
that can be transported by P-gp, and of its contribution to pharmacoresistance. 
 
 
2.2.4.2. P-glycoprotein role in pharmacoresistance 
While on one hand the presence of P-gp at the BBB plays a role in the protection of the 
brain parenchyma from the potentially toxic effects of blood-circulating xenobiotics, on the 
other hand, it may represent a real obstacle to drug brain penetration. This is of particular 
concern for therapeutic drugs targeting CNS diseases as it can lead to the emergence of 
pharmacoresistance. Here we focus on the implication of P-gp in the MDR phenotype in 
pathophysiological states where the brain is involved. 
 
 Brain tumors 
In general, brain tumours respond poorly to chemotherapy, and the development of a 
MDR phenotype is frequently observed. A great number of anti-cancer drugs have shown 
to be P-gp substrates: anthracyclines such as doxorubicine and daunorubicine (Kubota et 
al. 2001), etoposide (Lagas et al. 2010), tyrosine kinase inhibitors imatinib and gefitinib 
(Breedveld et al. 2005; Kawamura et al. 2009), taxanes (paclitaxel) (Fellner et al. 2002), 
and vinca alkaloids (vinblastine, vincristine) (Cisternino et al. 2003; Ushigome et al. 2000). 
This makes P-gp a serious cause in the resistance to anti-cancer treatment, particularly in 
brain tumours. Furthermore, P-gp is highly expressed in brain tumour cells, and especially 
in brain tumour microvessels (Calatozzolo et al. 2005; Demeule et al. 2001). 
 
 HIV-associated neurocognitive disorders 
P-gp at the BBB is also involved in the resistance of brain HIV to pharmacotherapy. The 
brain is known to be a site of viral replication for HIV and thus is an important target tissue 
for antiretroviral agents. HIV enters the brain early on in the course of infection, and 
infects brain parenchymal cells, causing the release of toxins and excitatory 
neurotransmitters, which, in turn, cause inflammation and cell death. The majority of HIV 
protease inhibitors (indinavir, saquinavir, nelfinavir), which brought considerable progress 
in the treatment of HIV infection, are also important P-gp substrates, as studies show that 
these drugs reach significantly higher brain levels in Abcb1a knockout mice when 
compared to wild-type mice (Kim et al. 1998; Washington et al. 2000). The remarkable 
increase in abacavir brain distribution showed in Abcb1a-deficient mutant mice over wild-
type mice suggests that P-gp may also play a significant role in restricting the reverse 
transcriptase inhibitor abacavir distribution to the CNS (Shaik et al. 2007). P-gp was also 
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demonstrated to be involved in the brain efflux of amprenavir and ritonavir (Edwards et al. 
2002; van der Sandt et al. 2001). Thus, P-gp-mediated efflux of several HIV protease 
inhibitors limits virus eradication from the brain, and is involved in the brain resistance to 
HIV pharmacotherapy. 
 
 Epilepsy 
It is believed that pharmacologic treatment fails to effectively control and prevent seizures 
in about a third of patients with epilepsy. This is a most likely multifactorial phenomenon, 
where different explanations are pointed to justify therapeutic failure (Potschka 2010b). In 
fact, there is considerable evidence that a large number of antiepileptic drugs are 
transported by P-gp: cell lines transfected with the human P-gp gene confirmed that P-gp 
transported the active metabolite of carbamazepine (carbamazepine-10,11-epoxide) as 
well as eslicarbazepine acetate and oxcarbazepine, transports that were blocked by P-gp 
inhibitors tariquidar and verapamil (Zhang et al. 2011a); a similar study was conducted to 
show that phenytoin and  phenobarbital are as well P-gp substrates (Zhang et al. 2010). 
Another hypothesis is linked to the overexpression of ABC transporters at the BBB, 
namely P-gp. Tishler and colleagues were the first to report that the expression of the 
gene encoding for P-gp in humans was markedly increased in the majority of patients with 
medically intractable temporal lobe epilepsy (Tishler et al. 1995). Moreover, the 
expression of P-gp seems to be increased in brain capillary endothelial cells and in glial 
end-feet covering the blood vessels of the epileptic foci (Dombrowski et al. 2001; Marchi 
et al. 2004; Sisodiya et al. 2002). Neuronal P-gp expression in epileptic patients has also 
been reported (Lazarowski et al. 2004a; Lazarowski et al. 2004b; Volk et al. 2004). Once 
more, these data point out the role that P-gp may play in drug resistance in refractory 
epilepsy, especially if epilepsy patients exhibit over-expression of P-gp at the BBB.  
 
 Psychiatric disorders 
A high percentage of patients with depression, psychosis and other psychiatric disorders 
respond inadequately to drug therapy, despite adequate choice of therapeutic drugs at 
maximum tolerated doses. The mechanisms underlying this resistance are still poorly 
understood, and as in epilepsy are most likely multifactorial. Still, some antidepressant 
and anti-psychotic drugs are known to be P-gp substrates, such as amitriptyline and 
paroxetine (Uhr et al. 2003; Uhr et al. 2000), and their penetration is enhanced in mice 
lacking P-gp. These data showing that brain penetration of anti-depressant drugs is 
dependent on the presence of P-gp have been proposed as an explanation for the 
observed resistance to treatment. Furthermore, several anti-epileptic drugs that are P-gp 
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substrates, such as carbamazepine or lamotrigine, are also used to treat psychiatric 
diseases like bipolar disorder (Rogawski and Loscher 2004). 
Given the implication of P-gp in the development of drug resistance, different strategies 
are being considered in order to circumvent this problem (Agarwal et al. 2011a). One 
strategy considers the inhibition of functional and active P-gp through the co-
administration of a P-gp inhibitor. A second strategy, of more recent debate, proposes the 
direct targeting of intracellular signalling pathways known to be involved in the regulation 
of P-gp expression. By targeting these pathways, the aim is to prevent a pathology-
associated overexpression of P-gp. Although P-gp targeting in order to decrease drug 
resistance seems to be a very promising approach, it must be taken into account that P-
gp is not the only ABC transporter expressed in the brain involved in MDR phenomena. 
Thus, especial attention should be also given to other major ABC transporters expressed 
at the BBB, in particular to BCRP, which is also known to be involved in drug resistance 
phenomenon. 
 
2.2.4.3. P-glycoprotein substrate-binding sites 
 
The presumptive drug-binding pocket comprises mostly hydrophobic and aromatic 
residues (Aller et al. 2009). Still, P-gp is able to recognize and transport an impressive 
broad range of substrates, ranging in size from approximately 250 Da (cimetidine) to more 
than 1850 Da (gramicidin D) (Schinkel 1999). While drug binding is known to occur within 
the TMD of P-gp, where and how substrates bind to this protein is not clear. The presence 
of multiple drug binding sites on P-gp could provide an explanation for the wide range of 
compounds known to interact with this protein. In fact, the existence of multiple drug 
binding sites that interact allosterically has been suggested, based on measurements of 
radiolabeled drug binding to P-gp (Martin et al. 2000). It was also proposed that both the 
N- and C-terminal halves of P-gp contain binding sites, and these two sites may generate 
a single region in the overall protein structure (Loo et al. 2003b; Morris et al. 1994), being 
this drug-binding pocket large enough to accommodate more than one substrate (Loo and 
Clarke 2001). Indeed, several research studies have demonstrated that two different 
substrates can bind to P-gp at the same time (Lugo and Sharom 2005a) (Loo et al. 
2003a). 
On the other hand, there is evidence for P-gp allosteric sites distinct from transport sites, 
as some compounds showed to confer allosteric control of the P-gp binding site for 
substrate transport (Martin et al. 1997). Therefore, binding sites can be classified as both 
transport and modulating sites (Martin et al. 2000; Shilling et al. 2006), and have the 
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ability to switch between high and low affinity states to accommodate substrates/inhibitors 
(Wang et al. 2003a).  
 
Table 3. List of some endogenous compounds and xenobiotics that are substrates of P-gp. 
Adapted from (Chaves et al. 2014; Loscher and Potschka 2005a; Nies 2007; Qosa et al. 2015; Robey et al. 
2011; Urquhart and Kim 2009). TKIs, Tyrosine kinase inhibitors 
P-glycoprotein substrates 
Therapeutic Class Compounds 
Anti-cancer drugs 
doxorubicine, daunorubicine, vinblastine, vincristine, etoposide, teniposide, 
paclitaxel, methotrexate, irinotecan, imatinib, gefitinib and other TKIs 
Anti-emetics domperidone, ondansetron 
Corticoids dexamethasone, hydrocortisone, corticosterone 
Anti-retroviral drugs amprenavir, indinavir, saquinavir, abacavir, nelfinavir, ritonavir, lopinavir 
Opioids and analgesics morphine, methadone, oxycodone, fentanyl, loperamide, norbuprenorphine 
Antidepressants and 
antipsychotics 
amitriptyline, nortryptiline, venlafaxine, fluoxetine, paroxetine, sertraline, 
amisulpride, risperidone 
Anti-epileptic drugs 
phenytoin, carbamazepine, lamotrigine, phenobarbital, felbamate, gabapentin, 
topiramate 
Antibiotics 
erythromycin, rifampicin, gramicidin A, valinomycin, tetracyclines, 
fluoroquinolines 
Immunosuppressants: Cyclosporine A, Tacrolimus, Sirolimus 
Anti-helminthic drugs ivermectin, abamectin 
Others: 
verapamil, colchicine, cimetidine, digoxin, fexofenadine, amiodarone, 
lovastatin, simvastatin 
Endogenous compounds: -Amyloid peptide, bilirubin, cortisol, aldosterone 
 
Thus, P-gp appears to bind multiple drugs by having a highly flexible binding cavity, which 
can accommodate several compounds in different locations by an induced fit mechanism. 
Biochemical cross-linking and fluorescence studies had already pointed to a substrate-
binding region with these properties (Loo and Clarke 2005a). The polyspecific nature of 
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the P-gp-binding pocket and its ability to bind more than one drug molecule 
simultaneously makes the rational design of specific high-affinity inhibitors a challenging 
problem. 
 
2.2.5. Modulation of P-glycoprotein at the BBB: inhibition, induction, and 
activation 
2.2.5.1. P-glycoprotein inhibition 
As previously mentioned, there is currently important evidence that ABC transporter-
mediated drug efflux, namely by P-gp at the BBB, is responsible for limiting brain drug 
delivery of several CNS drugs, thereby leading to treatment failure in brain disorders, 
including brain cancer, epilepsy and depression. 
Through the use of P-gp transporter inhibitors, one might overcome the function of the 
efflux transporter-mediated barrier and improve drug delivery to the brain. The importance 
of BBB P-gp was established when P-gp knockout mice exhibited up to 100-fold greater 
CNS exposure to ivermectin, resulting in serious CNS toxicity at dose levels safely used in 
wild-type animals (Schinkel et al. 1994). Since then, P-gp-mediated drug resistance has 
been considered a major clinical issue leading to a joint research effort, and as a result a 
large number of compounds have been screened for their ability to inhibit the major BBB 
ABC drug efflux transporters, particularly P-gp, and thus reverse MDR. Many of these P-
gp inhibitors are currently used in therapy for other clinical indications (see Table 4). Here 
we will present an overview of the different P-gp inhibitors and their corresponding 
mechanisms of action. 
 
Figure 15. Schematic representation of mechanisms of P-gp inhibition. 
P-gp may be inhibited through a) interference with the substrate-binding sites, b) alteration of the cell 
membrane integrity, c) interaction with the ATP-binding sites. Other mechanisms of limiting P-gp efflux activity 
may comprise ATP depletion and decrease P-gp expression. Image taken from (Akhtar et al. 2011) 
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Different mechanisms are said to be involved in P-gp inhibition: 1) competitive, non-
competitive or allosteric drug binding site blockage, 2) interference with ATP hydrolysis 
and 3) change in cell membrane lipids integrity (Akhtar et al. 2011). Verapamil and 
cyclosporine A are P-gp substrates that competitively inhibit the efflux pump by blocking 
the drug binding sites (Miller et al. 1991; Slater et al. 1986). Still, the presence of multiple 
binding sites hampers the development of conclusive structure-activity relation studies for 
substrates or inhibitors. On the other hand, compounds that inhibit ATP hydrolysis, such 
as quercetin, could perform better as P-gp inhibitors, since they are unlikely to be 
transported by P-gp, and will require a lower dose (Varma et al. 2003). Finally, commonly 
used pharmaceutical surfactants, such as sodium dodecyl sulphate and Tween-20, are 
emerging as a different class of P-gp inhibitors, which act by altering integrity of 
membrane lipids may contribute to modifications in P-gp secondary and tertiary structure 
and ultimately to its loss of function (Varma et al. 2003). 
 
2.2.5.2. P-glycoprotein inhibitors 
P-gp inhibitors can be classified into four generations according to their potency, 
selectivity and drug-drug interaction potential (see Table 4) (Palmeira et al. 2012a). 
 
 First generation P-gp inhibitors 
First-generation inhibitors include the classic P-gp inhibitors (verapamil or cyclosporine A) 
but also all pharmacological active compounds, already in clinical use or under 
investigation for other therapeutic indications, other than P-gp inhibition, irrespective of the 
date of discovery (Palmeira et al. 2012a; Varma et al. 2003). These include anti-
hypertensives, like reserpine, anti-arrhythmics, such as quinidine; and antidepressants, 
such as paroxetine. Many of these compounds are themselves P-gp substrates and, 
therefore, act through competition with another P-gp substrate for efflux (Varma et al. 
2003). The clinical use of these compounds is however limited since high serum 
concentrations, and thus toxic, are needed to achieve P-gp inhibition, given the low 
binding affinity for the transporter (Varma et al. 2003). Many of them are also substrates 
and inhibitors of other transporters and of drug-metabolizing CYP enzymes, which 
produce unpredictable pharmacokinetic interactions in the presence of other substrates 
(Breedveld et al. 2006). To overcome these limitations, several novel analogs were 
developed.  
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Table 4. List of some known P-gp inhibitors. 
Adapted from (Chaves et al. 2014; Loscher and Potschka 2005a; Nies 2007; Palmeira et al. 2012a; Qosa et 
al. 2015; Robey et al. 2011; Sharom 2011; Urquhart and Kim 2009; Zhou 2008) 
P-gp inhibitors Class Compounds 
1st Generation 
Anticancer drugs 
Tamoxifen, bicalutamide, fefitibin, lapatinib, erlotinib, 
tipifamib, vinblastine 
Anti-retroviral drugs Ritonavir, nelfinavir, saquinavir 
Antidepressant / antipsychotic 
drugs 
Amoxapine, loxapine, sertraline, paroxetine, 
fluoxetine, perphenazine, chlorpromazine, haloperidol 
Cardiovascular drugs 
Amiodarone, quinidine, verapamil, nifedipine, 
diltiazem, dipyridamole, reserpine, prazosin 
Immunosuppressant drugs Cyclosporin A, tacrolimus, sirolimus 
Others Methadone, disulfiram, pentoxifyline, midazolam 
2nd Generation  
Dexverapamil, 1,8-dibenzoyl-rifampicin (DiBenzRif)  
 dexniguildipine, valspodar (PSC-833), biricodar (VX-
710), timcodar (VX-853), toremifene, dofequidar (MS-
209) 
3rd Generation  
Zosuquidar (LY335979), tariquidar (XR9576), elacridar 
(GF120918), laniquidar (R101933), ontogen (OC144-
093) 
4th Generation 
Natural products 
Flavonoids (Quercetin, nobiletin), coumarins 
(conferone, cnidiadin, rivulobirin A), cannabinoids 
(cannabidiol), terpenes (portlanquinol, jolkinol B, 
uvaol, oleanolic acid, sipholenol A) 
Surfactants and lipids 
Pluronic P85, tween-20, triton X-100, crmophor EL, 
PEG-300, nonidet P40 
Dual ligands 
Dual inhibitors of P-gp and tumor cell growth 
[aminated thioxanthones such as 1-[2-(1H-
benzimidazol-2yl)ethanamine]-4-propoxy-9H-
thioxanthen-9-one] 
 
 Second generation P-gp inhibitors 
Second generation inhibitors are analogues of the initial agents to which structural 
modifications were applied in order to decrease their main therapeutic activity and 
increase P-gp inhibitory activity, resulting in less toxicity and greater potency, in 
comparison to the corresponding first-generation inhibitors (Palmeira et al. 2012a). 
Consequently, these compounds lack the pharmacological activity of the first-generation 
compounds, and usually, possess a higher P-gp affinity (Varma et al. 2003). Non-
immunosuppressive analogues of cyclosporin A, such as valspodar (PSC-833), the D-
isomer of verapamil, dexverapamil, and other compounds such as biricodar (VX-710), 
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timcodar (VX-853) and dofequidar (MS-209) are some of the second generation inhibitors. 
The synthetic rifampicin derivative, 1,8-dibenzoyl-rifampicin (DiBenzRif), has also recently 
showed to be a P-gp inhibitor, by depleting the ATP intracellular levels and increasing 
membrane fluidity (Vilas-Boas et al. 2013a). Nevertheless, they retain some first 
generation features that limit their clinical usefulness, since they lack P-gp selectivity and 
may, thus inhibit other ABC transporters, as well as may significantly inhibit the 
metabolism and excretion of cytotoxic agents, leading to unacceptable toxicity, complex 
and unpredictable drug-drug interactions (Fischer et al. 1998; Varma et al. 2003; Wandel 
et al. 1999). 
 
 Third generation P-gp inhibitors 
Several third-generation P-gp inhibitors were developed through quantitative structure-
activity relationship (QSAR) and combinatorial chemistry studies (Palmeira et al. 2012a), 
to overcome the limitations of previous P-gp inhibitor generations, and obtain the most 
selective and potent P-gp inhibitors known to date. In fact, the inhibitory effect of these 
compounds largely exceeds those of first and second generation in what concerns to 
potency and duration of action (Varma et al. 2003), and were primarily developed for MDR 
tumors treatment improvement. Another important feature of this third generation is that 
these compounds do not affect cytochrome P450 3A4 at relevant concentrations (Coley 
2010). Zosuquidar (LY335979), elacridar (GF120918), laniquidar (R101933) and 
tariquidar (XR9576) are among the most studied (Palmeira et al. 2012a; Varma et al. 
2003). 
Tariquidar inhibits P-gp by a non-competitive mechanism, particularly through ATPase 
activity inhibition, and binds to P-gp with a greater affinity than that of the transported 
substrates (Fox and Bates 2007), although it is not clear whether it binds directly to the 
ATP binding site or to an allosteric location (Martin et al. 1999).  
Elacridar acts by binding to the allosteric site of P-gp and reverses the drug resistance at 
the nanomolar range (Akhtar et al. 2011). However, tariquidar and elacridar were reported 
to also bind and inhibit the BCRP transporter (Kelly et al. 2011; Kruijtzer et al. 2002; 
Robey et al. 2004), thus increasing the potential for pharmacokinetic interactions. 
On the other hand, other third-generation agents, such as zosuquidar, demonstrated to be 
more specific for P-gp, rather than for other ABC transporters (Palmeira et al. 2012a). 
Zosuquidar, which is among the most potent P-gp modulators known to date, inhibits P-gp 
at nanomolar concentrations, both in vitro and in vivo (Dantzig et al. 2001; Green et al. 
2001), and there is no evidence that it may interact with MRPs or BCRP (Palmeira et al. 
2012a). Although a non-competitive inhibitory mechanism has already been suggested, as 
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this transporter cannot transport it (Dantzig et al. 1996), its mechanism of P-gp inhibition is 
still unclear. Despite the strong potency of third-generation P-gp inhibitors, there is still no 
commercial drug for use in MDR therapy, and this is due to disappointing results obtained 
in either preclinical or clinical trials. In what concerns targeting P-gp activity in the BBB, 
the existing differences in the sensitivity of P-gp located in different cells and blood–tissue 
barriers need to be considered. In fact, P-gp in the BBB proved to be more resistant to 
inhibition than P-gp in other tissues (Choo et al. 2006). This resistance can be overcome 
by a sufficiently high dose of an inhibitor, but this raises further concerns regarding 
tolerability of the approach. 
 
 Fourth generation P-gp inhibitors 
Given the several side effects and the pharmacokinetic interactions observed with 
previous generations, new strategies were employed to find new P-gp inhibitors, such as 
compounds extracted from natural origins and their derivatives, surfactants and lipids, 
peptidomimetics and agents with dual activity (Palmeira et al. 2012a), to give rise to the 
fourth generation of inhibitors. 
The knowledge that some food components interfere with the oral bioavailability of many 
drugs, which may involve P-gp, lead to the search of molecules obtained for the first time 
from natural sources, to which several chemical modifications have been performed to 
generate novel, selective, and high affinity P-gp inhibitors. Among these new natural 
products, several flavonoids, alkaloids, coumarins, cannabinoids, ginsenosides, terpenes, 
among others, have been identified and tested for P-gp inhibition, with very promising 
results (Coley 2010; Palmeira et al. 2012a). 
Many commonly used pharmaceutical surfactants are also emerging as a different class 
of P-gp inhibitors, which by altering the integrity of membrane lipids, seem to cause 
modifications in P-gp secondary and tertiary structure, resulting in the loss of P-gp 
functionality function due to interruption in hydrophobic environment by the surfactant 
molecule (Hugger et al. 2002). Furthermore, surfactants such as Pluronic P85, Tween-20, 
Triton X-100 and Cremophor EL can inhibit P-gp-mediated efflux, with no appreciable 
effect on the transbilayer movement of drugs (Palmeira et al. 2012a), and thus capable of 
a transporter-specific interaction rather than unspecific membrane permeabilization 
(Regev et al. 2007). 
Growing attention has also arisen in the development of multifunctional drugs, which have 
the ability to interact with multiple targets related to a specific pathological condition 
(Morphy and Rankovic 2009). For example, several aminated thioxanthones were 
reported as dual inhibitors of cell growth and P-gp (Palmeira et al. 2012b), setting a new 
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opportunity for MDR reversal. Additionally, other strategies have been adopted, such as 
the design of inhibitors of more than one transporter from the ABC superfamily (Palmeira 
et al. 2012a), as in some situations alternatively targeting multiple efflux transporters may 
possess a higher therapeutic efficacy than a specific drug (Roth et al. 2004). 
 
2.2.5.3. P-glycoprotein induction 
Since P-gp is one of the major drug efflux transporters expressed at the BBB, and with a 
wide range of substrates, a tight regulation of the expression of this transporter is crucial. 
The identification of the regulatory mechanisms of P-gp, how its expression can adapt to 
the changing environmental conditions, the elements that can trigger such adaptation, and 
the time and extent of such response are valuable, in order to be able to choose the best 
P-gp-modulating approach, as a new mechanism of enhancing the efficacy of drug 
therapy or to improve the clinical outcome of a disease progression state. 
 
 P-gp regulation in the periphery 
Disease processes, such as inflammation, can influence the expression of multiple 
hepatic ABC transporters, including P-gp (Ho and Piquette-Miller 2006; McRae et al. 
2003). Due to its role in multidrug resistance in cancer, the signals implicated on P-gp 
regulation in tumor cells have been widely explored. For the human ABCB1 gene, several 
promoter elements have been identified, such as GC-box, Y-box, p53, pregnane X 
receptor (PXR), inverse MED1, activator protein 1 (AP-1), NF-kB, and heat shock protein 
elements (Labialle et al. 2002; Scotto 2003). These promoter elements are binding sites 
for transcription factors that respond to environmental stimuli, such as oxidative stress, 
inflammation, hypoxia, xenobiotics and others. Furthermore, recent findings also suggest 
that P-gp is subject to microRNA (miRNA)-mediated gene regulation (Haenisch et al. 
2014). MiRNAs, small noncoding RNAs, which regulate the expression of their target 
genes post-transcriptionally by RNA interference, can directly or indirectly interfere with P-
gp expression, and are associated to both down-regulation (Feng et al. 2011; Zhu et al. 
2013) and up-regulation (Zhao et al. 2010; Zhu et al. 2008) phenomena. 
 
 P-gp regulation in the brain 
Since the BBB represents an interface between the periphery and the CNS, it is exposed 
to normal and pathological signals from both the blood and the CNS, which may likely 
influence transporter expression and overall BBB function. In fact, currently, there is 
convincing evidence that P-gp expression at the BBB can be altered during disease, such 
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as in epilepsy and stroke, and susceptible to a number of physiological and pathological 
signals (Miller et al. 2008). 
The expression of P-gp at the BBB has shown to be target of induction by many well-
known drugs, including dexamethasone, rifampicin and the herbal antidepressant St 
John’s wort (Bachmeier et al. 2011; Bauer et al. 2006; Narang et al. 2008; Zastre et al. 
2009). Also, some studies have indicated that anti-epileptic drugs might also induce P-gp 
(Potschka 2010a). Treatment with carbamazepine or valproic acid was associated with 
higher BBB P-gp expression rates when compared to treatment with lamotrigine or 
topiramate (Wang-Tilz et al. 2006), although these differences might be related to varying 
effects on seizure control. Also, carbamazepine, phenobarbital and phenytoin were 
reported to induce P-gp and other transporters in rat BEC lines via an interaction with the 
PXR and the constitutive androstane receptor (CAR) (Lombardo et al. 2008). 
Moreover, P-gp may not only be induced by several compounds, but also by other 
environmental factors, such as X-irradiation, UV-irradiation, cytokines, oxygen free 
radicals, tumor suppressor genes and heat shock (Chin et al. 1990b; Hu et al. 2000; Kioka 
et al. 1992b; Miyazaki et al. 1992; Ohga et al. 1998; Uchiumi et al. 1993; Wartenberg et al. 
2005; Zastawny et al. 1993; Zhou 2008). Some of these inducers are summarized in 
Table 5. 
 
Table 5. List of some known P-gp inducers at the BBB. 
Adapted from (Chaves et al. 2014; Silva et al. 2014f) 
P-glycoprotein Inducers 
Class Compounds 
Antibiotics and derivatives Reduced rifampicin derivative (RedRif), rifampicin 
Anti-retroviral drugs 
Abacavir, amprenavir, atazanavir, daurunavir, 
efavirenz, lopinavir, nevirapine, ritonavir 
Opioids Morphine, oxycodone 
Antiepileptic drugs Carbamazepine, phenytoin, phenobarbital 
Steroids 
1α,25-dihydroxyvitamin D4, pregnenolone-16α-
carbonitrile, retinoic acid 
Others 
Benzo[a]pyrene, venlafaxine, dexamethasone, 
hyperforin, insulin 
 
2.2.5.4. P-glycoprotein activation: an emerging P-gp-modulator class 
Very recently, a new class of compounds that interact with P-gp to increase its activity 
without increasing its protein expression has been denominated as P-gp activators (Silva 
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et al. 2014f; Sterz et al. 2009; Vilas-Boas et al. 2013b). A P-gp activator is a compound 
that binds to P-gp and induces a conformational change that stimulates the transport of a 
substrate bound on another binding site (Silva et al. 2014f), while a P-gp inducer acts by 
increasing the protein expression from which an associated increase in its activity is 
expected. This activation mechanism promotes P-gp transport function without interfering 
with protein expression levels, making it a more rapid process than P-gp induction (Silva 
et al. 2014f; Vilas-Boas et al. 2013b). Moreover, this is in line with the previous described 
functional P-gp model where, at least, two distinct sites for drug binding and transport are 
identified, which interact in a positively cooperative manner (Shapiro and Ling 1997b). 
In fact, it has long been known that there are compounds that bind to P-gp and stimulate 
the transport of a substrate on another binding site. Hoechst-33342 and Rhodamine (Rho) 
123 were shown to act by this cooperative mode of action (Shapiro and Ling 1998), and 
such was also suggested for prazosin and progesterone (Shapiro et al. 1999). 
Furthermore, a four-P-gp-binding site model was proposed, with three transport sites and 
a regulatory one, where the latter allows an allosteric change of conformation of the 
substrate-transport binding sites, altering its affinity, and thus increasing the rate of 
translocation (Martin et al. 2000). In line with this, it has long been suggested that the 
adaptation and survival mechanisms of living beings have allowed the binding of several 
xenobiotics at the same time to P-gp (Safa 1993; Safa 1998), increasing the transport of 
each other, not competing, but instead activating the transport cycle (Safa 2004). 
The most recently proposed models of P-gp drug binding suggest a large, flexible drug-
binding region, confirmed by the high-resolution crystal structure (Aller et al. 2009), 
containing a number of sub-sites where drugs can bind. The flexibility of the binding 
pocket would allow induced fit of multiple drugs via hydrophobic interactions, hydrogen 
bonding, and electrostatic interactions with residues lining the binding pocket. The number 
and strength of these interactions would dictate the affinity of drug binding to the protein. 
In another study, several small molecules, first designed as inhibitors of the p53 protein, 
were able to stimulate both doxorubicin and Rho 123 efflux in a P-gp-dependent manner 
(Kondratov et al. 2001). However, this dramatic stimulation of P-gp-mediated efflux of 
doxorubicin and Rho 123 by the identified compounds was accompanied by suppression 
of P-gp-mediated efflux of other substrates, such as paclitaxel or Hoechst 33342, 
indicating that they act as modulators of P-gp substrate specificity. Consistently, these P-
gp modulators altered the pattern of cross-resistance of P-gp-expressing cells to different 
P-gp substrates: an increase in resistance to doxorubicin, daunorubicin, and etoposide 
was accompanied by cell sensitization to vinca alkaloids, gramicidin D, and paclitaxel 
(Kondratov et al. 2001). The effect of these modulators seemed to depend at least 
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partially on the substrate-binding site postulated by Shapiro and Ling (Shapiro and Ling 
1997b).  
The P-gp modulating properties of 27 different imidazobenzothiazoles and 
imidazobenzimidazoles were also investigated (Sterz et al. 2009). Most of the compounds 
were able to stimulate P-gp-mediated efflux of daunorubicin and Rho 123 in a 
concentration-dependent manner, although some of the compounds also displayed weak 
inhibitory effects. These novel compounds seem to bind to the P-gp H site and activate 
the efflux of specific substrates of the R site in a positive cooperative manner, whereas 
binding of H-type substrates is competitively inhibited. This hypothesis was further 
confirmed by the observation that these modulators do not influence hydrolysis of ATP or 
its affinity towards P-gp (Sterz et al. 2009). 
Additionally, a synthetic derivative of rifampicin (a reduced derivative, RedRif), which 
showed to modulate P-gp expression and activity in a rat BBB model (RBE4 cells), also 
increased P-gp activity at time points when no increase in protein content had occurred 
yet, thus acting as a P-gp activator (Vilas-Boas et al. 2013b). In silico studies with this 
molecule consistently confirmed the previously described activation mechanism (Vilas-
Boas et al. 2013b). Furthermore, it was demonstrated that several thioxanthonic 
compounds were capable of rapidly and significantly increase P-gp activity, as assessed 
by the Rho 123 efflux assay performed in the presence of these thioxanthones (TXs) 
during a short 45 min efflux phase (Silva et al. 2014c). These results during such short cell 
exposure to TXs during the Rho 123 efflux phase cannot reflect a possible contribution of 
an increased P-gp protein expression, indicating the existence of a mechanism of P-gp 
activation. The registered increase in P-gp activity in the presence of TXs resulted in a 
significant protection against paraquat (PQ) cytotoxicity, an effect that was reversed upon 
incubation with a specific P-gp inhibitor (Silva et al. 2014c). Consequently, these 
thioxanthonic compounds may have protective effects against PQ intoxications, by 
favoring its P-gp-induced efflux. Similar results in terms of P-gp activation and protection 
against PQ cytotoxicity were obtained with dihydrolylated xanthones (Silva et al. 2014d). 
Therefore, P-gp activators that exert various effects on the intracellular accumulation of 
distinct P-gp substrates are useful tools for investigating the interactions between multiple 
drug binding sites of this transport protein (Sterz et al. 2009).  
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2.2.6. P-glycoprotein polymorphisms: implications in drug therapy and disease 
The human ABCB1 gene, located on the long arm of chromosome 7, is particularly 
characterized to be polymorphic, as well being a target of several mutations (Zhou 2008). 
To present date, more than 50 single nucleotide polymorphisms (SNPs) are known to 
occur in the ABCB1 gene (Sharom 2008; Sharom 2011). Some of these polymorphisms 
are known to change mRNA and protein expression, and P-gp function (Sharom 2008; 
Sharom 2011). Considering the important role of P-gp in the pharmacokinetics and 
bioavailability of many drugs, metabolites and xenobiotics, it is then predictable that P-gp 
polymorphisms can seriously contribute to the observed inter-individual variability to drug 
responses and vulnerability, and, consequently influence the outcome of drug treatment.  
This has raised a considerable interest in the study of P-gp polymorphisms in recent 
years. 
SNPs can result in a change in the amino acid coding sequence (non-synonymous) or not 
(synonymous; silent) (Sharom 2008). The first polymorphism to be reported in the human 
ABCB1 gene was the G2677T variant, a non-synonymous SNP that results in a change in 
the amino acid sequence, Ala893Ser (Ser893 polymorphism) (Marzolini et al. 2004). 
Among the most common and frequently described variants identified to date, the 
functional C3435T (exon 26, synonymous), G2677T (exon 21, non-synonymous) and 
C1236T (exon 12, synonymous) SNPs have been associated with an altered expression 
and function of P-gp in human tissues (Hitzl et al. 2001; Hoffmeyer et al. 2000). 
Unfortunately the results remain controversial: some studies show a relationship between 
a drug pharmacokinetics and an ABCB1 polymorphism, while others do not (Lee et al. 
2010). Most of the work was conducted at the intestinal barrier, and thus there are few 
data on the possible correlation between ABCB1 polymorphisms and activity of the 
transporter at the BBB. The synonymous C3435T polymorphism was reported to be linked 
with reduced P-gp mRNA expression in the duodenum and associated to increased oral 
absorption and higher plasmatic levels of digoxin (Hoffmeyer et al. 2000). This was later 
contradicted with subsequent studies with other P-gp substrates, such as tacrolimus, 
fexofenadine and cyclosporine A, which failed to confirm this association (Leschziner et al. 
2007). Another study demonstrated that C3435T polymorphism resulted in a slightly 
different P-gp tertiary structure, which altered interaction with drugs and modulators, 
despite of having the same amino acid sequence (Kimchi-Sarfaty et al. 2007). 
Furthermore, it was demonstrated that reduced fexofenadine uptake could be associated 
with the G2677T SNP, suggesting that this variant has increased activity in vivo (Kim et al. 
2001). Also, the non-synonymous mutations of G2677T/A/C, which result in the amino 
acid changes Ala893Ser, Ala893Thr, and Ala893Pro, resulted in changes in both 
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substrate specificity and ATPase kinetic properties, as evaluated with 41 different 
compounds (Sakurai et al. 2007). This suggests that the polymorphism at the amino acid 
893, located within the second intra-cellular loop in the C-terminal half of P-gp, is 
potentially implicated in the alteration of drug disposition and therapeutic efficacy. 
Recent research has focused on the association of protein expression level with 
haplotypes (a set of SNPs). The haplotype combination 3435C–2677G–1236T within the 
ABCB1 gene was found to be associated with a more severe depressive symptomatology, 
related to a poor response to antidepressants, and this may be due a higher expression of 
P-gp or to more active protein forms (Kato et al. 2008). Similarly, it was shown that the 
attention-deficit/hyperactivity disorder improvement caused by treatment with guanfacine 
was less evident in children with the T/T ABCB1 C3435T genotype, compared to either 
C/T or C/C genotypes (McCracken et al. 2010). Thus, a higher expression of P-gp would 
result in lower brain levels of CNS drugs that are P-gp substrates, and consequently in 
resistance to pharmacotherapy. In a recent study, the C3435T SNP, and the TT genotype 
(TT3435) linked to this SNP, were shown to be significantly more prevalent in Japanese 
patients with major depressive disorder than in the controls, suggesting that 
polymorphisms of ABCB1 may result in susceptibility to this disorder (Fujii et al. 2012). In 
addition, it was reported a higher frequency of the 1236C–2677G haplotype among 
individuals with Parkinson’s disease, where an altered P-gp expression might contribute to 
an accumulation of drugs and neurotoxins in harmful amounts (Westerlund et al. 2009). 
Therefore, this P-gp variant seems to be a susceptibility factor in Parkinson’s disease, 
particularly in such cases where there is an exposure to known risk factors for the 
development of this disease, such as exposure to pesticides. Three studies showed an 
increased risk of developing Parkinson’s disease after exposure to pesticides in 
individuals carrying certain ABCB1 alleles (Drozdzik et al. 2003; Dutheil et al. 2010; 
Zschiedrich et al. 2009). However, the association between haplotype and P-gp 
expression need to be further explored, in line with other factors, such as medication, diet, 
inter-individual differences in drug metabolism and disease, which may render results 
interpretation more difficult. 
Nevertheless, polymorphisms occurring in the ABCB1 gene are associated with increased 
susceptibility to several human diseases, and such knowledge, allied with substantial 
further investigation in this field, may help in the adoption of the appropriate interventions 
to reduce the likelihood of a particular disease. 
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2.3. Breast Cancer Resistance Protein 
2.3.1. BCRP tissue distribution and main physiological roles 
Three independent research teams conducted the discovery of this ABC transporter, 
almost simultaneously. BCRP was cloned for the first time in the breast carcinoma human 
cell line MCF-7 (Doyle et al. 1998). Shortly after, a new ABC transporter was identified in 
the placenta, which was then called ABCP for “placenta-specific ABC transporter” 
(Allikmets et al. 1998). Finally, a mitoxantrone resistance gene (MXR, mitoxantrone 
resistance protein) was also described in a colon carcinoma cell line (Miyake et al. 1999). 
Once BCRP/ABCP/MXR identified genes were sequenced, they have been found to be 
identical and to correspond to the exact same gene. This gene was then classified in the 
ABC transporter G subfamily, and the ABCG2 name was assigned. 
Such discovery arose the need to determine the location, expression and possible 
physiologic role of BCRP. Meanwhile, BCRP was reported to be expressed in many 
tissues at both gene and protein level. In humans, BCRP is expressed in the CNS, 
placenta, liver, adrenal gland, prostate, testis, endometrium, as well as in the small and 
large intestine, stomach, kidney, pancreas and lung (Fetsch et al. 2006; Maliepaard et al. 
2001a). In these tissues, BCRP was noted to be present at the venous and capillary 
endothelium (Maliepaard et al. 2001a). 
The tissue distribution of BCRP shows extensive overlap with that of P-gp, suggesting that 
both transporters should similarly confer protection from potentially harmful xenobiotics in 
various tissues (Schinkel and Jonker 2003). Indeed, similarly to P-gp, BCRP is also highly 
expressed in organs that determine absorption (small intestine), elimination (liver and 
kidney), and distribution (blood-brain and placental barriers), which increasingly 
recognizes its important role in drug disposition and tissue protection (Ni et al. 2010; 
Polgar et al. 2008; Robey et al. 2009). BCRP was identified to be present in hematopoietic 
stem cells of the human bone marrow (Scharenberg et al. 2002), where it is believed to 
exert a protective role against xenobiotics (Zhou et al. 2002). Importantly, BCRP 
expression was found to be strongly induced during lactation in the mammary gland of 
mice, cows and humans, and responsible for the secretion and concentration of clinically 
and toxicologically important substances such as the dietary carcinogen 2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and the chemotherapeutic agent topotecan 
into milk (Jonker et al. 2005). Also, BCRP is involved in the secretion of the B vitamin 
riboflavin, required for the metabolism of fats, into the milk, emphasizing its likely 
physiological role in lactation (van Herwaarden et al. 2007). In the placenta, BCRP 
expression was shown to play an important role in the protection of the developing fetus 
from possible toxins in the maternal space, as supported by studies carried out with 
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topotecan, nitrofurantoin and PhIP (Jonker et al. 2000; Myllynen et al. 2008; Zhang et al. 
2007). Thus, the physiological roles of BCRP are likely to provide tissue protection against 
endogenous toxins or xenobiotics, and to regulate cellular homeostasis of physiologically 
important endogenous compounds (Ni et al. 2010). 
The ABCG2 gene is highly conserved and has been found in all sequenced vertebrates to 
date (Robey et al. 2009). In most species there is only a single gene present, with the 
exception of rodents, which contain one or more copies of a closely related gene, Abcg3, 
and fish, which have 3 or more ABCG2 genes (Annilo et al. 2006; Robey et al. 2009). 
 
2.3.2. BCRP expression and function in the BBB 
P-gp and BCRP are the most extensively reported ABC transporters at the BBB. Shortly 
after BCRP discovery in human and rat brain capillaries, it became clear that this 
transporter also plays a crucial role in brain-to-blood efflux of xenobiotics, metabolites and 
endogenous compounds (Cooray et al. 2002; Hori et al. 2004). Several studies have used 
specific antibodies for BCRP to show that this transporter is abundant in vein and capillary 
endothelium cells of many normal tissues and organs, particularly those that express P-gp 
(Fetsch et al. 2006; Maliepaard et al. 2001a). BCRP was first identified at the BBB in 2003 
(Eisenblatter et al. 2003), and is now a well-recognized BBB component. Bcrp was shown 
to be much more abundant in the luminal membrane of mice cerebral endothelial cells 
than in the total cortex (Cisternino et al. 2004), and the same holds for rats (Lee et al. 
2007), pigs (Eisenblatter et al. 2003) and humans (Cooray et al. 2002). 
The presence of BCRP was showed in human brain tissue, which is consistently 
expressed in lysates of human temporal cortex and hippocampus (Aronica et al. 2005). 
ABCG2 gene transcripts were detected in several regions of the human brain (Dutheil et 
al. 2009). Expression and immunolocalization of BCRP was observed in human frozen 
brain sections, which strongly suggested that the fluorescent signals were limited to the 
microvessel endothelium (Cooray et al. 2002). Supporting evidence was obtained from 
human brain isolated microvessels, suggesting that BCRP is the major ABC transporter 
expressed at the BBB (Dauchy et al. 2008; Shawahna et al. 2011). The expression at 
mRNA and protein level and functional activity of BCRP have been confirmed in primary 
cultures of human brain endothelial cells (Lee et al. 2007), in the immortalized human 
brain endothelial cell line BB19 (Kusch-Poddar et al. 2005), and in hCMEC/D3 cells 
(Dauchy et al. 2009). Regarding the membrane localization within the endothelial cells, 
there is considerable proof that BCRP displays localization in the luminal side of the 
endothelium of the normal human brain (Aronica et al. 2005; Cooray et al. 2002; 
Maliepaard et al. 2001a). BCRP expression in the brain seems to be limited to the blood-
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brain vessels, as no neuronal or glial BCRP expression was detected (Aronica et al. 
2005). However, in a different study, the expression of BCRP was detected in both human 
brain microvessel endothelial cells and fetal human astrocytes, although in the latter in low 
levels (Zhang et al. 2003). A very limited expression of BCRP was demonstrated in the 
choroid plexus epithelial cells of the porcine and rat blood-cerebrospinal fluid, which may 
mean a similar but less significant function of this transporter in this brain barrier 
(Eisenblatter et al. 2003; Reichel et al. 2011). However, BCRP expression in the human 
BCSFB is currently unknown. 
For a long time, it was believed that P-gp was the major ABC transporter at the human 
BBB. This belief was substantiated by the findings that the P-gp was 3-fold more 
expressed than Bcrp in isolated mouse brain capillaries (Kamiie et al. 2008). However, 
porcine and human brain tissues evidenced that the expression of BCRP seemed higher 
compared to other ABC transporters, such as P-gp and ABCCs (Aronica et al. 2005; 
Cooray et al. 2002; Eisenblatter et al. 2003; Zhang et al. 2003). In contrast to previous 
studies in rodents, the expression profiles of ABC transporter genes on human cerebral 
microvessels showed that P-gp was about 7-fold less expressed than BCRP (Dauchy et 
al. 2008). These data were recently confirmed by quantitative proteomic analysis of 
isolated human cerebral capillaries, where BCRP expression was shown to be 1.6 times 
superior than that of P-gp in human brain microvessels (Shawahna et al. 2011; Uchida et 
al. 2011). In fact, the proteomics of ABC transporters present in microvessels isolated 
from frozen human brain samples were recently compared to the protein amounts of 
transporter homologues in mice (Uchida et al. 2011). Interestingly, their results showed 
that the human BCRP was 2-fold more than that of the mouse Bcrp, whereas the human 
P-gp were almost 2-fold less than the mouse Abcb1a (Uchida et al. 2011). This is 
indicative of the substantial interspecies differences, underlying the need to keep in mind 
that the expression of different ABC transporters at the BBB is variable among different 
species. In fact, P-gp seems to be the more abundant of the two transporters at the BBB 
of smaller species, like rat and mouse, whereas BCRP is more abundant than P-gp at the 
BBB of larger species, such as monkey and human (Ball et al. 2013). 
Mounting evidence suggests that BCRP helps in the restriction of brain penetration of 
substrate compounds. This was demonstrated by using P-gp knockout mice, in which 
Bcrp was inhibited by elacridar, resulting in enhanced brain uptake of prazosin and 
mitoxantrone (Cisternino et al. 2004). In addition, Bcrp (-/-) mice showed a 9.2-fold 
increase in brain penetration of genistein, a phytoestrogen, compared to wild-type mice 
(Enokizono et al. 2007). Another study using BCRP knockout mice showed an 
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augmentation of brain accumulation of the tyrosine kinase inhibitor imatinib up to 2.5-fold 
as compared to wild-type mice (Breedveld et al. 2005). 
Interestingly, P-gp knockout mice had approximately 3 times more BCRP in the brain 
microvessels than wild-type mice, suggesting an up-regulation of this transporter to 
compensate the lack of P-gp in the BBB (Cisternino et al. 2004). It also suggests that 
BCRP cooperates with P-gp at the BBB to restrict the passage of their common 
substrates into the brain. Another study using Mdr1a/b and Bcrp knockout mice clearly 
shows how the two drug transporters act in concert to limit the brain penetration of 
topotecan (de Vries et al. 2007). Indeed, the deficiency or inhibition of one of the two 
transporters is not always accompanied by an increase of the brain penetration of a 
common substrate: in Bcrp-deficient mice (but in which P-gp is present), P-gp alone is 
sufficient to prevent the brain penetration of the substrate; Similarly, mice deficient in P-gp 
(but in which the Bcrp is present), Bcrp alone is sufficient to limit the brain entry of the 
substrate (Kawamura et al. 2010). These data clearly show that these two ABC 
transporters compensate each other and act together to reduce the in vivo brain 
penetration of their common substrates. 
As with P-gp, studies have focused on the involvement of BCRP in the pathophysiology of 
neurodegenerative diseases. In what concerns Alzheimer’s disease, studies show that 
BCRP is implicated in the transport of the Aβ peptide, in human brain endothelial cells 
used as in vitro model (Tai et al. 2009). This is supported by an in vivo study, where the 
intracerebral accumulation of the Aβ peptide was lower in wild-type mice compared to the 
Abcg2 knockout mice (Xiong et al. 2009). These data suggest that the expression of 
BCRP is also an important factor contributing to the protection against the development of 
Alzheimer’s disease. 
 
2.3.3. BCRP structure and mechanisms of mechanisms of drug efflux 
BCRP is an approximately 72 kDa protein composed of 665 amino acids. BCRP structure 
differs from the common ABC transporters, like P-gp, as it is a half-transporter composed 
of a single N-terminal NBD, followed by a linker region and a single C-terminal TMD 
containing 6 TM α-helices (see Figure 16) (Ni et al. 2010). Its second unique feature is 
that BCRP, being composed by one NBD and TMB, requires dimerization o express 
activity. It may work as homo-oligomer or hetero-oligomer held together by disulfide bonds 
(Cucullo et al. 2007; Ni et al. 2010), and even as a homodimer, since the amplification of 
Abcg2 gene alone is sufficient to circumvent drug toxicity in drug-selected cell lines 
(Knutsen et al. 2000; Miyake et al. 1999). 
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The latest membrane topology of BCRP evidences that: Asp590, which is the only N-linked 
glycosylation site in BCRP (Diop and Hrycyna 2005; Mohrmann et al. 2005) is located in 
the extracellular loop connecting TM5 and TM6; Cys603, responsible for intermolecular 
disulfide bond formation is also in the extracellular loop; and Arg482, which is crucial for 
substrate specificity and overall transport activity of BCRP, is located in TM3 near the 
cytosolic membrane interface. Cys592 and Cys608, which are also in the extracellular loop, 
reportedly form intramolecular bonds and appear to have impact in the ability of the 
transporter to traffic and transport properly if mutated (Henriksen et al. 2005). Also, a 
GxxxG motif found in the BCRP protein structure, and shown to be involved in the 
dimerization of other membrane proteins (Russ and Engelman 2000), seems to be 
necessary for proper transport function, as the subsequent mutation of the glycines to 
leucines results in impaired function but not expression of BCRP (Polgar et al. 2004). 
 
Figure 16. Proposed membrane topology of P-gp and BCRP (ABCG2) transporters. 
It is noteworthy that BCRP is a half-transporter, composed by a single N-terminal NBD and a single C-terminal 
TMD containing 6 TM α-helices, while P-gp is composed by two NBDs (positioned on the C-terminal), and two 
TMDs. Image taken from (Sarkadi et al. 2004) (e.c. = extracellular, i.c. = intracellular) 
 
Despite the fact that BCRP shows low protein sequence identity in NBDs (~20%) and 
essentially no protein sequence identity in TMDs with P-gp or even MRP1, transfection of 
cells with BCRP cDNA confirmed its ability to confer resistance to a variety of 
chemotherapeutic agents such as mitoxantrone and topotecan (Doyle et al. 1998; Miyake 
et al. 1999). Like P-gp, BCRP performs ATP hydrolysis-dependent efflux transport of a 
large number of structurally and chemically unrelated compounds that also include non-
chemotherapy drugs and xenobiotics (Ni et al. 2010; Robey et al. 2009). 
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Three homology models of BCRP representing different conformational states have been 
generated. The first model, which used the MsbA structure as template (Ward et al. 2007), 
represents the substrate-unbound nucleotide-free inwardfacing open apo conformation. 
The second model, using the mouse P-gp structure as template (Aller et al. 2009), 
represents the substrate-bound nucleotide-free inward-facing closed apo conformation. 
The third model, which used the Sav1866 structure as template (Dawson and Locher 
2006), represents the nucleotide-bound outward-facing conformation. These authors 
proposed that substrate binding to the open apo form promotes the closure of TMs, which 
in turn, sends a signal to the NBDs, allowing the formation of the ATP sandwich in the 
outward-facing conformation upon nucleotide binding (Ni et al. 2010) (see Figure 17).  
 
Figure 17. Representation of the homology models of BCRP. 
A) Substrate-unbound nucleotide-free inward-facing open apo conformation, based on the MsbA structure; B) 
Substrate-bound nucleotide-free inward-facing closed apo conformation, based on the mouse P-gp structure; 
C) Nucleotide-bound outward-facing conformation, based on the Sav1866 structure. The two monomers of the 
BCRP dimer are represented in different colors. Image taken from (Ni et al. 2010) 
 
The development of these BCRP homology models lead to the identification of several 
unique features (Ni et al. 2010): 
I. The intracellular entry of the two inward-facing apo forms is large enough to allow 
access of a bulk of BCRP substrates from either the inner lipid leaflet of the plasma 
membrane or cytosol. 
II. The extracellular loop 1 connecting TM1 and TM2 forms intermolecular contacts with 
the extracellular loop 3 between TM5 and TM6, thus possibly stabilizing the dimeric 
structure. 
III. Comparing the open and closed inward-facing apo forms, there is a rotation of ~30° 
for TM4 and TM5 of BCRP, which forces TMs 1-3 and 6 to similarly change their 
positions, resulting in a more closed intracellular entry in the closed apo structure as 
compared with the open apo structure. Such a domain rearrangement would alter 
A C B 
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the shape of the substrate-binding cavity which is formed primarily by residues in the 
TMs by making it more compact in the presence of substrate binding. 
IV. In the outward-facing form of BCRP, there are even more drastic conformational 
changes, with the intracellular entry completely closed and the wide open V-shaped 
gap may allow the release of substrates from BCRP after ATP binding and 
hydrolysis. Once the intracellular entry in the outward-facing form is completely 
closed, the two NBDs of the BCRP dimer form the so-called ATP sandwich. 
V. When comparing the membrane topology of P-gp and BCRP, the extracellular loop 
between TM5 and TM6 in BCRP is much larger than the corresponding region in P-
gp (Rosenberg et al. 2010). Recent studies suggest that this extracellular loop may 
be critical in modulating substrate binding (Ozvegy-Laczka et al. 2008) as well as 
stability and ubiquitin-mediated degradation of BCRP (Wakabayashi et al. 2007). 
Still, further insights into the structure of BCRP will be of help to better understand the 
function of this transporter, providing tools towards the design of more potent and specific 
inhibitors. 
 
2.3.4. BCRP substrates and substrate-binding sites 
2.3.4.1. BCRP substrates 
A large number of chemotherapeutic and non-chemotherapeutic molecules have been 
shown to be substrates of BCRP, since its discovery as a drug efflux transporter 
contributing to the multidrug resistance phenotype of cancer cell lines. The BCRP 
substrate spectrum includes physiological compounds, common dietary xenobiotics, and 
several cancer and non-cancer drugs, a list of substrates that is progressively expanding. 
Particularly in the case of cancer medication, BCRP covers a spectrum of several 
structurally unrelated classes of anti-cancer agents, highlighting the importance of BCRP 
as multidrug resistance protein. Despite the broad range of BCRP substrates, several 
common characteristics can be found: 1) hydrophobic, lipophilic and hydrophilic 
compounds can be transported, but all of them contain hydrophobic regions, 2) the 
substrates usually range from 7-20 carbon atoms, 3) all substrates contain aromatic 
groups, 4) not all substrates have a planar structure but, all of them can assume a flat 
conformation, 5) most substrates contain charged groups, and both positively and 
negatively charged molecules are transported, 6) substrates have oxygen-containing, and 
often nitrogen-containing functional groups, and 7) most side functional groups can be 
donors and/or acceptors of hydrogen bonds (Szafraniec et al. 2014). 
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Table 6. List of some endogenous compounds and xenobiotics that are substrates of BCRP. 
Adapted from (Chaves et al. 2014; Loscher and Potschka 2005a; Nies 2007; Qosa et al. 2015; Robey et al. 
2011; Urquhart and Kim 2009) DHEA, dehydroepiandrosterone 
ABC 
Transporter Therapeutic Class Compounds 
BCRP 
Anti-cancer drugs 
Considerable overlap with P-gp; anthracylines, camptothecins, 
indolocarbazoles, mitoxantrone, methotrexate, imatinib, gefitinib, 
erlotinib 
HMG-CoA reductase 
inhibitors 
Rosuvastatin, pitavastatin, cerivastatin 
Anti-retroviral drugs Zidovudine, lamivudine, abacavir 
Antibiotics 
Ciprofloxacin, ofloxacin, norfloxacin, erythromycin, rifampicin, 
nitrofurantoin 
Immunosuppressants: Cyclosporine A, Tacrolimus, Sirolimus 
Others: Sulfasalazine, cimetidine, riboflavin, dipyridamole, prazosin 
Endogenous 
compounds: 
Estrone-3-sulfate, 17-oestradiol, DHEA sulfate 
Glucoronide, glutathione and sulphate conjugates 
 
Resistance to mitoxantrone is the hallmark of cells expressing BCRP, as well as 
resistance to camptothecin derivatives (9-aminocamptothecin, topotecan, irinotecan and 
SN-38, its active metabolite) (Doyle and Ross 2003; Maliepaard et al. 2001b; Yang et al. 
1995). Other chemotherapeutic substrates have been shown to be transported by BCRP, 
like the TKIs imatinib, gefitinib and nilotinib (Brendel et al. 2007; Burger et al. 2004; Elkind 
et al. 2005), and indolocarbazoles and antifolates such as methotrexate (Chen et al. 
2003). Several other substrate classes have been described, including antivirals (Pan et 
al. 2007a; Wang et al. 2003b; Wang et al. 2004), HMG-CoA reductase inhibitors (Hirano 
et al. 2005; Huang et al. 2006; Matsushima et al. 2005), carcinogens (Ebert et al. 2005; 
van Herwaarden et al. 2003; van Herwaarden et al. 2006) and antibiotics (Janvilisri et al. 
2005; Merino et al. 2006; Merino et al. 2005). A summary of some of the cancer and non-
cancer drugs transported by BCRP is given in Table 6. The expanding list of BCRP 
substrates highlights the fact that this transporter may play a significant role in brain 
pharmacology and protection. 
Furthermore, BCRP shows considerable overlapping substrate and inhibitor specificity 
with P-gp and ABCCs (Szakacs et al. 2006). For example, BCRP substrates such as 
glyburide, imatinib, methotrexate, mitoxantrone, and prazosin are also P-gp substrates, 
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although some of them such as methotrexate are poor substrates of P-gp (Dohse et al. 
2010; Ni et al. 2010; Schinkel and Jonker 2003). Furthermore, in addition to hydrophobic 
substrates such as mitoxantrone, BCRP can also transport hydrophilic conjugated organic 
anions, particularly the sulfated conjugates with high affinity, whereas P-gp generally 
transports hydrophobic compounds (Ni et al. 2010). 
Thus, this cross substrate specificity between BCRP and P-gp results in a synergistic 
effect of the transporters in limiting drug penetration across the BBB, but also renders 
difficult the estimation of the clinical implications of BCRP. 
 
2.3.4.2. BCRP substrate-binding sites 
Docking studies on the previously discussed BCRP homology models for various BCRP 
substrates suggest the existence of multiple substrate binding sites in the central cavity 
primarily formed by TM α-helices (Cai et al. 2010). In fact, it was demonstrated that 
different substrates, such as topotecan and daurorubicin did not reciprocally inhibit the 
efflux of each other (Nakanishi et al. 2003), suggesting that there are multiple drug binding 
sites in BCRP that are not, or are only partially, overlapping. To evidence drug binding in 
BCRP, direct drug binding interactions with BCRP has been investigated using photo-
affinity labeling (Alqawi et al. 2004; McDevitt et al. 2006; Shukla et al. 2006). Photo-affinity 
labeling of purified BCRP combined with trypsin digestion and mass spectrometry analysis 
of peptide fragments may provide valuable information for the drug-binding sites in BCRP 
(Ni et al. 2010). At present, the residues potentially involved in interactions of the 
photoactive substrates with BCRP have not been identified (Ni et al. 2010). Some other 
studies concordantly suggest that there are multiple drug binding sites in BCRP with 
doxorubicin, prazosin and daunomycin binding clustered in one region and Rho 123 and 
methotrexate binding in different regions (Clark et al. 2006; McDevitt et al. 2008; Pozza et 
al. 2006).  
In the BCRP protein structure, Arg482 has been extensively analyzed by site-directed 
mutagenesis and was found to be crucial for substrate specificity and transport activity 
(Miwa et al. 2003; Ozvegy-Laczka et al. 2005; Robey et al. 2003). In the homology 
models, Arg482 in TM3 is located in the central cavity close to the cytosolic membrane 
interface with the side chain pointing towards the drug translocation pathway (Ni et al. 
2010). Cells with a glycine or threonine instead of Arg482 were shown to readily transport 
doxorubicin and Rho 123 (Honjo et al. 2001; Lee et al. 1997; Rabindran et al. 1998). Also, 
docking studies indicated that mitoxantrone and Hoechst 33342, but not prazosin and SN-
38, may directly interact with Arg482, which is consistent with previous studies that show 
that a muation in this amino acid increases resistance to mitoxantrone but not to SN-38 or 
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prazosin (Miwa et al. 2003; Robey et al. 2003). Still, to date, it what really determines the 
substrate specificity of BCRP remains elusive. 
 
2.3.5. Modulation of BCRP transport: BCRP inhibitors and inducers 
2.3.5.1. BCRP inhibition 
Since BCRP was discovered to be present in brain endothelial cells, the long-standing 
opinion that P-gp is the only important transporter responsible for drug efflux at the BBB 
changed considerably.  
As with P-gp, BCRP has a considerable broad list of substrates, particularly a great 
number of chemotherapeutic drugs. Thus, it is expected that BCRP should also have a 
great impact on limiting brain drug delivery of such drugs, and consequently on treatment 
of brain disorders, namely brain tumors. However, BCRP expression at the BBB has not 
been unequivocally correlated to low brain penetration of all BCRP substrates. In fact, the 
brain penetration of several BCRP substrates, such as dehydroepiandrosterone (DHEA) 
sulfate, mitoxantrone, abacavir and zidovudine did not increase when using Bcrp knockout 
mice (Giri et al. 2008; Lee et al. 2005; Pan et al. 2007a). In contrast, and as mentioned 
before, it was promptly demonstrated that BCRP limits prazosin and mitoxantrone entry 
into the brain (Cisternino et al. 2004), as well as that the brain distribution of several 
drugs, such as sorafenib or imatinib, increased significantly in Bcrp1 knockout mice 
(Agarwal et al. 2011b; Breedveld et al. 2005; Enokizono et al. 2008). The controversy 
regarding the role of BCRP at the BBB was somewhat clarified with the use of P-gp/Bcrp 
knockout mice. This provided the opportunity to study the combined impact of these two 
drug efflux transporters on the CNS drug delivery. Indeed, the brain uptake of topotecan, 
a substrate for both P-gp and BCRP, was not increased in mice lacking BCRP, was 
slightly increased by 1.5-fold in P-gp knockout mice, but in mice lacking both transporters 
was increased by more than 12-fold (de Vries et al. 2007). Similar findings were obtained 
with lapatinib, dasatinib, gefitinib and sorafenib (Agarwal et al. 2010; Agarwal et al. 2011b; 
Chen et al. 2009; Polli et al. 2009). These data show that, even though these drugs are 
substrates of both transporters, the absence of only one of the transporters did not 
significantly increase brain drug delivery, unless both transporters were absent or inhibited 
at the BBB. This suggests that inhibition of either P-gp or BCRP can be compensated by 
the other respective transporter, and that both transporters cooperate in the prevention of 
drug entry into the brain (Agarwal et al. 2011a). 
Therefore, P-gp but also BCRP can significantly affect drug delivery to the brain, and 
thereby influence drug efficacy, as also their combined inhibition should be an attractive 
therapeutic strategy to improve delivery and efficacy of dual substrate drugs in the CNS. 
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Consequently, the use of combined inhibition for both P-gp and BCRP should have its 
greatest impact in the treatment of brain cancers, even though the overlap of P-gp and 
BCRP substrates is not limited to chemotherapeutic drugs. 
 
2.3.5.2. BCRP inhibitors 
In general, BCRP inhibitors can be classified according to their capacity to act specifically 
against BCRP, or with an overlap of activity against two transporters, usually P-gp and 
BCRP. When comparing specific P-gp and BCRP inhibitors, the former usually contains 
more nitrogen atoms and aromatic moieties (Szafraniec et al. 2014). 
There are several natural and synthetic compounds that have shown the ability to inhibit 
BCRP activity. Fumitremorgin C (FTC), a tremorgenic mycotoxin, was one of the first 
BCRP inhibitors to be discovered (Rabindran et al. 2000). FTC probably acts as 
competitive inhibitor, due to its structure resemblance to mitoxantrone and doxorubicin. 
However, its clinical application in vivo is limited due to neurotoxic side effects. This lead 
to the development of its tetracyclic analogs, Ko132, Ko134 and, the most potent, Ko143, 
which also show high, and even more potent inhibitory activity against both human and 
mouse BCRP/Bcrp1 (Allen et al. 2002), while being less toxic and suitable for use in vivo. 
Several steroids, such as 17β-estradiol, vitamin K3 and plumbagin showed to specifically 
block the BCRP-mediated efflux of mitoxantrone (Imai et al. 2002b; Shukla et al. 2007). 
Additional classes of BCRP inhibitors include pyridines and dihydropyridines, such as 
nimodipene and nicardipene; flavonoids such as quercetin, gensitein, chrysin and 
tectochrysin; taxane derivatives, bisindolylmaleimides and indolcarbazole kinase inhibitors 
(Polgar et al. 2008; Robey et al. 2009). 
Recent efforts have focused on TKIs such as imatinib, nilotinib, gefitinib, and erlotinib, 
which directly interact with BCRP at the substrate binding site and that block ATPase 
activity of the transporter, being both effective chemotherapeutics and potent BCRP 
inhibitors/substrates (Shukla et al. 2008). Even though some of these TKIs may show 
much higher influence on BCRP transport than on other ABC transporters, several studies 
showed that most of these TKIs, like erlotinib, gefitinib, lapatinib and sunitinib, are dual P-
gp/BCRP substrates that competitively inhibit both transporters (Agarwal et al. 2011a). On 
the other hand, and given the cooperation of P-gp and BCRP at the BBB, this suggests 
their potential use in combination therapy to improve drug pharmacokinetics and increase 
drug brain delivery for the treatment of CNS diseases. 
Elacridar has shown to be a dual P-gp/BCRP inhibitor, and it has been used in several 
pre-clinical studies to inhibit both transporters at the BBB with the purpose of enhancing 
brain distribution of simultaneously administered compounds (Cutler et al. 2006; Jin et al. 
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2011; Oostendorp et al. 2009). Indeed, similarly to what was demonstrated with double P-
gp/Bcrp1 knockout mice, elacridar showed to considerably increase dasatinib, gefitinb, 
sorafenib, and topotecan brain uptake (Agarwal et al. 2010; Agarwal et al. 2011b; Chen et 
al. 2009; de Vries et al. 2007). Thus, elacridar, which displays low toxicity in vivo, seems 
to be a promising candidate to increase brain delivery of drugs that are dual P-gp/BCRP 
substrates. 
 
Table 7. List of some inhibitors of BCRP. 
Adapted from (Agarwal et al. 2011a; Chaves et al. 2014; Cutler et al. 2006; Jin et al. 2011; Ni et al. 2010; 
Oostendorp et al. 2009; Szafraniec et al. 2014). TKIs, Tyrosine Kinase Inhibitors. 
 Specificity Compounds 
BCRP 
inhibitors 
BCRP-specific 
Fumitremorgin C and analogs (Ko132, Ko134), 17β-
estradiol, vitamin K3, plumbagin 
Dual P-gp/BCRP inhibitor Elacridar (GF12918), cyclosporine A, TKIs 
 
2.3.5.3. BCRP induction 
As with P-gp and other ABC transporters, the study of the regulatory mechanisms of 
BCRP is important to understand how the BBB responds to the changes in its 
environment, to identify the factors that urge a specific response, and the time and extent 
of such response. The identification of the regulatory mechanisms of this and other ABC 
transporters in health and pathological conditions can be of value in order to change 
disease progression or to enhance the efficacy of drug therapy. 
Most studies focusing on the regulation of BCRP are interested in the transcriptional 
mechanisms that regulate the expression of this transporter. 
 
 BCRP regulation in the periphery 
In the promoter region of the ABCG2 gene, response elements to hypoxia, estrogen, 
progesterone, xenobiotics, and to the transcription factor peroxisome proliferator-activated 
receptor (PPAR) γ have been identified (Robey et al. 2009; Tompkins et al. 2010). It was 
also proposed that Aryl hydrocarbon Receptor (AhR) up-regulates the expression of 
BCRP, and thus its regulation is associated with cellular defense, but the response 
element has not yet been identified in the promoter region (Robey et al. 2009). Treatment 
of Caco-2 cells with AhR agonists such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
benzo[a]pyrene, indolo[3,2-b]carbazole and benzo[k]fluoranthene resulted in increased 
BCRP mRNA and protein levels and a 180% increase of benzopyrene-3-sulfate efflux, a 
BCRP substrate (Ebert et al. 2005). Bcrp was reported to be up-regulated under hypoxic 
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conditions to reduce haem or porphyrin accumulation, thereby facilitating cell survival 
(Krishnamurthy et al. 2004). Likewise, Caco-2 cells continuously exposed to imatinib 
showed an up-regulation of BCRP expression, resulting in a decreased of imatinib 
accumulation into the cells (Burger et al. 2005). 
 
Table 8. List of some BCRP inducers. 
Adapted from (Robey et al. 2009; Xia et al. 2005) TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin 
 Class Compounds 
BCRP inducers 
AhR agonists 
TCDD, benzo[a]pyrene, indolo[3,2-b]carbazole, 
benzo[k]fluoranthene 
Steroids Progesterone, testosterone, 17β-estradiol 
Others Dexamethasone, imatinib 
 
 BCRP regulation in the brain 
Given its more recent discovery, the control of BCRP expression in the brain or at the 
BBB has been less studied than for P-gp. Nevertheless, there are a few studies that 
demonstrated induction or repression of expression of BCRP at the BBB. 
In rodents, exposure to dexamethasone, which acts at both PXR and GR nuclear 
receptors, has shown to increase Bcrp gene expression, protein expressions, as well as 
its functional activity in primary cultures of cerebral endothelial cells (Narang et al. 2008). 
On human cerebral endothelial cells, exposure to agonists of the nuclear receptor PPAR γ 
induced both genomic and protein expression of BCRP (Hoque et al. 2012). Also using 
human cerebral endothelial cells, exposure to pro-inflammatory cytokines (IL-1β, IL-6 and 
TNF-α) decreased the expression of BCRP and its transport activity (Poller et al. 2010). 
The role of sex hormones, such as testosterone, which showed to induce Bcrp1 
expression in the male mouse liver, and oestradiol, which showed to suppress Bcrp 
expression in rat kidneys, in the regulation of BCRP expression at the BBB still remains 
controversial, as it seems to be cell-dependent (Imai et al. 2005; Wang et al. 2006; 
Yasuda et al. 2006). Still, the ex vivo incubation of mice brain microvessels with 17β-
estradiol for 6 hours decreased BCRP protein expression and transport activity (Mahringer 
and Fricker 2010). 
Besides transcriptional regulation, BCRP is also susceptible to epigenetic regulation: 
depending on the cell lines, the BCRP promoter may be methylated and/or acetylated. 
Methylation of the BCRP promoter region has shown to repress BCRP expression, while 
its acetylation may result in an increase of BCRP expression (Robey et al. 2009; To et al. 
2006; Turner et al. 2006). In addition, as for P-gp, BCRP is also a target of miRNA-
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mediated gene regulation (Haenisch et al. 2014). Several miRNAs, such as miR-200c, 
miR-328, miR-519c, and miR-520h are linked to a decrease in BCRP expression, in 
human melanoma cell lines and in the human breast cancer cell line MCF-7 (Li et al. 
2011; Liu et al. 2012). 
 
 
2.3.6. BCRP polymorphisms: implications in drug therapy and disease 
The human ABCG2 gene is located on chromosome 4, and extends over 66 kb containing 
16 exons and 15 introns (Robey et al. 2009). It is highly polymorphic, given over 80 
naturally occurring SNPs have been reported in the ABCG2 gene (Tamura et al. 2007), 
which may have significant physiological and pharmacological relevance. Some of these 
genes polymorphisms can results in a change of the protein expression and/or function. 
Of these, the non-synonymous Q141K SNP, where a lysine replaces a glycine, and which 
affects the codon 421 (421C>A), is the most extensively studied, and has been found to 
be associated with inter-individual variations in the pharmacokinetics, response or toxicity 
of drugs (Keskitalo et al. 2009a; Keskitalo et al. 2009b; Sissung et al. 2010). This SNP 
has also been associated to genetic diseases, such as gout (Woodward et al. 2009). In 
particular, the Q141K SNP has been linked to decreased plasma membrane expression of 
BCRP, decreased drug transport or reduced ATPase activity (Imai et al. 2002a; Mizuarai 
et al. 2004; Morisaki et al. 2005; Tamura et al. 2006). Indeed, human subjects carrying the 
Q141 variant often had higher plasma levels of BCRP substrate drugs than the subjects 
carrying wild-type BCRP (Sparreboom et al. 2004; Sparreboom et al. 2005). 
Recently, research has developed interest in evaluating the clinical relevance of the 
Q141K SNP in patients undergoing chemotherapy. In these studies, elevated plasma 
concentration of gefitinib (Li et al. 2007), diflomotecan (Sparreboom et al. 2004), and 
increased bioavailability of oral topotecan (Sparreboom et al. 2005) were found. The Q141 
mutation has also been associated with increased adverse effects in response to gefitinib 
treatment (Cusatis et al. 2006). A recent study has revealed that Q141K undergoes 
increased lysosomal and proteasomal degradations compared to wild-type BCRP, which 
probably explains the lower level of protein expression of the variant (Furukawa et al. 
2009). This variant occurs in Japanese and Chinese populations at high allele frequencies 
(30-60%) and in Caucasians and African-American populations at relatively low allele 
frequencies (5-10%) (Lepper et al. 2005), which consequently leads to higher drug toxicity 
in some patient populations than in others. 
As previously mentioned, BCRP is involved in Aβ transport at the BBB, as well as it was 
found to be significantly up-regulated in patients with Alzheimer’s Disease (Xiong et al. 
2009). In fact, the C421A polymorphism has shown to be associated with an increased 
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susceptibility to the disease, since the wild type ABCG2 C/C genotype has shown to have 
higher transcription activity, and thus increased expression of BCRP, in Alzheimer’s 
Disease patients in comparison with the variant allele containing genotypes (CA and AA) 
(Feher et al. 2013). However, these results are contradictory, given the suggested 
protective role of BCRP in this neurodegenerative disorder. Considering the importance 
that BCRP at the BBB for the protection against unwanted substances including the Aβ 
peptides, it was expected that the variant A allele, with reduced transcription activity, 
should have shown better correlation with the development of this disorder. 
Furthermore, it was recently reported that diplotypes of two linked polymorphisms in the 
ABCG2 gene were associated with higher area under the curve (AUC) and Cmax of 
erlotinib (Rudin et al. 2008), but this remains to be confirmed in a larger cohort of patients. 
Nevertheless, these data underline the importance of the analysis of haplotypes as well as 
of individual polymorphisms in the prediction of drug pharmacokinetics, efficacy and 
toxicity. 
 
In conclusion, there is no doubt that P-gp and BCRP are the two main ABC transporters 
expressed at the human BBB, and the two main gatekeepers involved in the efflux 
transport of xenobiotics, endogenous molecules and metabolites. The high expression 
levels of these two drug efflux transporters has encouraged a deep exploration of their 
involvement at this brain-blood interface, and in particular, the signaling pathways 
involved in the regulation of their expression. 
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3. Transcriptional Regulation of ABC transporters: 
Focus on P-glycoprotein and BCRP induction 
mechanisms 
 
Given the drawbacks of direct transport inhibition, research has also focused on 
elucidating the intracellular signaling pathways that control ABC transporters, namely P-gp 
and BCRP, at the BBB. While most currently used inhibition mechanisms occur mainly at 
posttranslational level, resulting in a decrease of the functional activity of the transporter, 
the induction phenomena occur mainly at the transcriptional level. In what concerns 
specifically to the P-gp gene expression, it may be up-regulated either by an increase in 
the amount of ABCB1 mRNA through transcriptional regulation, or stabilization of the 
mRNA (Yague et al. 2003). Many studies have sought to identify the signaling pathways 
and regulatory networks that control the expression of ABC transporters, and several of 
them have been identified at the BBB, particularly for P-gp. ABC transporter expression 
and transport activity at the BBB can be altered by multiple factors, including disease, 
stress, diet, therapy and toxicant exposure (Miller 2010; Miller 2014). The up-regulation of 
ABC transporters at the BBB through the action of a number of ligand-activated receptors 
can lead to selective tightening of the barrier to both harmful neurotoxicants and 
therapeutic drugs, providing on one hand increased neuroprotection, but reduced drug 
delivery on the other hand (Miller 2010; Miller 2015). The full understanding of the 
molecular mechanisms underlying P-gp and BCRP regulation would allow the 
manipulation of their transcriptional activation to either increase or prevent it, and 
consequently reduce the intracellular accumulation of toxic xenobiotics and other 
compounds, or overcome the MDR phenomenon, respectively. Such an approach may 
have different advantages: 1) targeting transporter regulation allows subtler changes in 
transporter activity than direct transport inhibition, so transporters can be turned off for 
brief, controlled periods of time and, thus, reducing the risk of harmful toxicants entering 
the brain; 2) unlike direct inhibition, it can be used specifically to increase transporter 
expression and/or activity, and therefore increase barrier function for therapeutic 
purposes, and 3) knowing that BBB ABC efflux transporters are implicated in CNS 
disorders, targeting the signaling pathways that control these transporters could be a 
useful therapeutic strategy (Hartz and Bauer 2010). 
Here we will focus on the main P-gp and BCRP regulatory pathways that may occur in the 
brain, and/or in the BBB. 
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According to recent research we can define two signaling patterns that alter ABC 
transporter expression and/or activity at the BBB: 1) brain capillary endothelial cells 
express multiple nuclear receptors that can be activated by endogenous metabolites, 
nutrients, and xenobiotics, driving to increases in expression of multiple ABC transporters; 
2) upon ligand binding, certain receptors indirectly alter transporter expression through 
other downstream transcription factors (Miller 2015). 
 
3.1. Ligand-activated Receptors 
 
3.1.1. Direct action of ligand-activated nuclear receptors 
At the BBB, multiple ligand-activated receptors function as sensors for metabolites, drugs 
and toxicants. These receptors contain multiple functional domains, including ligand and 
DNA binding domains, and often activation function domains. They classically affect gene 
expression through translocation of the receptor-ligand complex to the nucleus, where it 
binds to the promoter regions of target genes. The conjugation of the receptor with its 
partner protein within the nucleus leads to binding of the heterodimer to the DNA, 
facilitating the assembly of the transcription complex (Novac and Heinzel 2004; Olefsky 
2001). Current data shows that several ligand-activated receptors are expressed in brain 
capillary endothelial cells, namely PXR, CAR, AhR, PPARα, vitamin D receptor (VDR), 
and glucocorticoid receptor (GR) (Miller 2014). Ligands for these receptors include a 
number of highly prescribed drugs, dietary constituents, and nutraceuticals (PXR, CAR, 
PPARα, VDR and GR) and persistent environmental contaminants (AhR) (Qosa et al. 
2015). This broad substrate specificity is in accordance with the function of these nuclear 
receptors in the activation of proteins that are involved in the detoxification of xenobiotics 
from the body, such as metabolizing enzymes and efflux transporters. There is currently 
evidence that the in vivo exposure to receptor ligands for PXR (Bauer et al. 2006; Chan et 
al. 2013), CAR (Wang et al. 2010), AhR (Wang et al. 2011), VDR (Durk et al. 2012) and 
GR (Narang et al. 2008) is able to increase P-gp expression at the BBB, and reduce drug 
delivery to the brain. 
Although the DNA-binding domain of PXR is highly conserved across species, the ligand-
binding domain is not, and consequently substantial species differences in ligand affinities 
for rodent versus human PXR can be found. In isolated rat brain capillaries, 16α-
carbonitrile (PCN), a specific rodent PXR ligand, was able to increase the P-gp protein 
expression and increase P-gp-mediated transport of a fluorescent cyclosporine A 
derivative (Bauer et al. 2004). Consistent with this finding, transgenic mice expressing 
human PXR, and treated with the human PXR activator rifampicin, showed an increase in 
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P-gp expression and transport activity in brain capillaries and a reduced central 
antinociception to the P-gp substrate methadone (Bauer et al. 2006). Isolated rat brain 
capillaries exposed to the CAR activators phenobarbital and [1,4-bis[2-(3,5-dichloro-
pyridyloxy)] benzene] also demonstrated an increased transport activity and protein 
expression of both P-gp and BCRP, which was corroborated by in vivo studies (Wang et 
al. 2010). Concerning the AhR receptor, isolated brain capillaries from rats exposed to 
TCDD showed increased P-gp and BCRP transport activity and protein expression (Wang 
et al. 2011). In accordance with increased P-gp expression in capillaries from TCDD-
dosed rats, in situ brain perfusion indicated significantly reduced brain accumulation of 
verapamil, a P-gp substrate (Wang et al. 2011). In opposition, a recent study conducted in 
in the hCMEC/D3 cell line demonstrated that exposure to TCDD had no effect on the 
protein expression or functional activity of P-gp nor BCRP (Jacob et al. 2015), which 
raises some controversy regarding the role of the AhR receptor in the regulation of P-gp 
and BCRP at the BBB. Treatment of primary rat brain microvascular endothelial cells with 
dexamethasone induced both P-gp and Bcrp expression and function, in a time- and 
dose-dependent manner, which was partially abolished by GR antagonist RU486 (Narang 
et al. 2008). One problem in assessing the mechanism of action of receptor ligands and 
receptors arises from the possibility that certain ligands could interact with more than one 
receptor (Miller 2015). 
 
 
Figure 18. Regulation of ABC transporters present at the BBB by direct action of ligand-activated 
nuclear receptors. 
Nuclear receptor activation by drugs, xenobiotics and endogenous compounds enhances the release of 
nuclear receptor from co-suppressors and translocation into the nucleus to stimulate ABC efflux transporter 
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expression. Short-term exposure to 17β-estradiol (E2 in the figure) reduces BCRP activity through activation 
of ERs, whereas long-term exposure to this molecule leads to BCRP degradation via ERβ and a PTEN/PI3-
K/Akt/GSK3 pathway. Image taken from (Qosa et al. 2015). 
 
 
3.1.1.1. Regulation of BCRP activity through estrogen signaling 
Although most nuclear receptors activate the expression of P-gp and BCRP at the BBB, 
short-term exposure of male or female rat and mouse brain capillaries to estradiol rapidly 
and reversibly reduces BCRP transport activity without altering protein expression, in a 
mechanism involving both estrogen receptor (ER) ERα and ERβ (Hartz et al. 2010b).  
Several studies show that BCRP transporter protein can undergo protein trafficking away 
from the plasma membrane, with subsequent degradation, and even reduced transporter 
transcription in both mouse and rat brain capillaries when exposed to 17β-estradiol (Hartz 
et al. 2010a; Hartz et al. 2010b; Mahringer and Fricker 2010). In fact, rodent brain 
capillaries have shown to express both ERα and ERβ, but the ERβ expression dominates 
at both the mRNA and protein levels (Hartz et al. 2010a; Hartz et al. 2010b; Miller 2015). 
When rat and mouse brain capillaries are exposed short-term to subnanomolar 
concentrations of 17β-estradiol, BCRP-mediated transport is reduced, with no alteration 
on its protein expression (Hartz et al. 2010a; Hartz et al. 2010b), occurring through 
intracellular vesicle trafficking. When either ERα-null mice or ERβ-null mice are exposed 
to this compound, none shows reduced BCRP transport, suggesting that both ER are 
involved. 
Extended exposure to 17β-estradiol for more than 6 hours decreases BCRP expression, 
which is mediated by ERβ but not ERα. In order to decrease BCRP expression, ERβ 
signals through phosphatase and tensin homolog (PTEN), phosphatidylinositide-3-kinase 
(PI3-K), protein kinase B (Akt), and glycogen synthase kinase-3β (GSK-3β) (Hartz et al. 
2010a; Mahringer and Fricker 2010). Such signaling increases ubiquitination of BCRP 
protein, which leads to transporter protein degradation at the proteasome (Mahringer and 
Fricker 2010). These studies suggest two estrogen-based strategies for reducing basal 
BCRP activity at the BBB, with ERα-specific agonists rapidly and reversibly reducing 
transport activity, while ERβ-specific agonists initially reducing transport activity and later 
sending BCRP protein to the proteasome for degradation (Miller 2015). 
 
Overall, these studies show that activation of most nuclear receptor at the BBB increases 
brain capillary localized ABC transporter and activity, resulting in barrier tightening. It is 
currently unknown whether changes in nuclear receptor–mediated transporter expression 
play a role at the BBB in humans, whether such changes could cause drug-drug side 
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effects in the brain capillaries in humans, or whether this approach could be used 
therapeutically (Hartz and Bauer 2010). Accumulating clinical data indicates, however, 
that nuclear receptors participate in the regulation of ABC transporters in the intestine, 
liver, and kidney. It is possible that this will also be the case at the human BBB. For 
example, transplant patients taking St. John’s wort, whose main constituent is hyperforin – 
a potent human PXR activator, in combination with the immunosuppressant cyclosporine 
A see an increase of the expression of metabolizing enzymes and drug efflux 
transporters, leading to altered pharmacokinetics of co-administered drugs (Karliova et al. 
2000; Moore et al. 2000). 
 
3.1.2. Increased expression by receptor-driven signaling 
Whereas direct ligand-activated nuclear receptor signaling is a relatively simple 
mechanism, the increase in ABC transporter expression can involve more complicated 
mechanisms through extended signaling from the plasma membrane or cytoplasm to 
transcription factors not directly activated by ligands. These transcription factors are often 
maintained in a cytoplasmic complex that facilitates poly-ubiquitination and guides the 
transcription factor to the proteasome for degradation. Upon activation, the transcription 
factor translocates to the nucleus, where it binds to specific sequences in target gene 
promoters. In fact, the transcription factor NF-κB appears to be such a factor, and a 
downstream point of convergence of stressed-induced signals (inflammation, epileptic 
seizures, oxidative stress) at the BBB, implicated in the regulation of ABC transporters 
(Miller 2015). 
 
3.1.2.1. Wnt/β-catenin signaling 
β-catenin is another modulator that has been noted to play a role in drug-induced 
alterations of the expression of ABC transporters at the BBB (Potschka 2010b). This 
protein acts as an adhesion molecule but also as a signaling factor in the Wnt-β-catenin 
pathway (McCarty 2009). The interaction of Wnt proteins with cell surface receptors leads 
to inactivation of GSK-3, and consequent cytosolic stabilization of β-catenin (Lim et al. 
2008). Consequently, β-catenin accumulates and translocates into the nucleus of the cell, 
where it will be able to modulate the effect of transcription factors. There is evidence that 
this signaling pathway can enhance P-gp and BCRP expressions (Lim et al. 2008). In fact, 
lithium chloride is a CNS active drug that is known to inhibit GSK-3, and proven to up-
regulate P-gp (Lim et al. 2008). 
 
 
Transcriptional Regulation of ABC transporters_________________________________________ 
78 
3.1.2.2. Inflammation 
Brain inflammation is involved in several CNS disorders, such as stroke, multiple 
sclerosis, Alzheimer’s and Parkinson’s diseases (Hartz and Bauer 2010). The resulting 
release of pro-inflammatory cytokines is known to influence gene expression in the BBB, 
including changes in the expression of ABC transporters. In fact, the administration of 
lipopolysaccharide (LPS) has shown to trigger cytokine-induced inflammation and reduce 
P-gp function in the brain, in both rats and mice (Goralski et al. 2003; Salkeni et al. 2009). 
However, the signaling can be complex, depending on the nature, the dose, and the time 
of exposure to the stimulus (Roberts and Goralski 2008). One of the most important 
inflammatory mediators that participate in the regulation of ABC transporters is the pro-
inflammatory cytokine, tumor necrosis factor-α (TNF-α). In rat brain capillaries, a long-
term (> 6h) TNF-α exposure activates TNF-R1 and induces release of big-endothelin-1 
(ET-1), which is in turn converted to ET-1 by extracellular ET converting enzyme (ECE). 
ET-1 signals through the endothelin receptor B (ETBR), which leads to the downstream 
activation of the inducible form of nitric oxide synthase (iNOS), protein kinase C isoform 
β2 (PKCβ2) and NF-κB, sequentially (see Figure 19, B) (Bauer et al. 2007; Rigor et al. 
2010). On the other hand, short-term exposure of isolated rat brain capillaries (1h) to TNF-
α decreased P-gp activity without affecting its expression, while expression and activity of 
BCRP was unchanged (see Figure 19, A) (Hartz et al. 2004; Hartz et al. 2006). Actually, 
TNF-α regulates both the induction and reduction of P-gp activity at the BBB, since 
signaling branches at the PKC isoforms: activating PKCβ1 initiates rapid loss of activity, 
with no change in expression, and activating PKCβ2 independently initiates a delayed 
increase in transporter expression (Hartz et al. 2006; Miller 2015). Thus, P-gp transport 
activity is reduced after short exposure to TNF-α but increased with longer exposure 
times, indicating a complex, time-dependent regulatory mechanism. 
Thus far, little is known about the regulation of other ABC drug efflux transporters at the 
BBB during inflammation. However, a recent study demonstrates that TNF-α and IL-1β 
both decrease BCRP protein expression and function in brain capillary endothelial cells 
(von Wedel-Parlow et al. 2009), which was previously demonstrated with ET-1 treatment 
(Bauer et al. 2007). The suppression of BCRP by IL-1β, IL-6, and TNF-α was also 
demonstrated in the human hCMEC/D3 BBB cell model (Poller et al. 2010). 
These studies are evidence that brain inflammation plays a role in the modulation of BBB 
ABC transporters in a complex, context-dependent way that will determine either the 
increase or decrease of the expression of these transporters. 
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Figure 19. Regulation of ABC transporters present at the BBB by inflammation and oxidative stress. 
A) Effect of a short-term and B) long-term exposure to TNF-α on the regulation of P-gp and the molecular 
mediators of each signaling pathway. C) Regulation of P-gp during oxidative stress through a signaling 
pathway that is triggered by ROS, such as H2O2. D) Regulation of P-gp through a signaling pathway that is 
triggered by diesel exhaust particles (DEP). Image taken from (Hartz and Bauer 2010) 
 
3.1.2.3. Oxidative Stress/Ischemia 
Brain inflammation is often accompanied by oxidative stress. Recent studies show that 
both microglia and brain capillary endothelial cells are able to produce reactive oxygen 
species (ROS) in response to cellular stress, and ultimately affect the expression of ABC 
transporters at the BBB (Hartz et al. 2008; Miller et al. 2008). Exposure of primary 
endothelial cells to H2O2 has shown to increase P-gp expression and function through 
extracellular signal-regulated kinase 1/2 (ERK 1/2), stress-activated protein kinase 
(SAPK), Akt and PKC (see Figure 19, C) (Felix and Barrand 2002; Nwaozuzu et al. 2003). 
Oxidative stress likely mediates P-gp induction through a receptor signaling mechanism, 
where the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) seems to be implicated (Copple 
2012). It was recently found that rats dosed with sulforaphane, a compound that was 
known to increase the expression of multiple ABC transporters in the live, also increased 
P-gp and BCRP expression in brain capillaries, and reduced the brain delivery of a P-gp 
substrate (Wang et al. 2014). Experiments with rat and mouse brain capillaries showed 
that Nrf2 acts indirectly, and thus requires p53, p38 and NF-κB to increase P-gp and 
BCRP expressions (Wang et al. 2014). Although these factors work in concert to increase 
transporter expression, to date it is unknown how this happens. 
In addition, oxidative stress induced by exposure to environmental toxins, such as diesel 
exhaust particles, seems to activate a signaling pathway involving NADPH oxidase and 
ROS production, which initiates TNF-α converting enzyme (TACE)-mediated TNF-α 
release. Here, TNF-α signals through TNF-R1, c-Jun N-terminal kinase (JNK), and 
nuclear translocation of another transcription factor, AP-1, resulting in increased P-gp 
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expression in isolated rat and mouse brain capillaries, in vitro (see Figure 19, D) (Hartz et 
al. 2008). This pathway and the pro-inflammatory pathway both involve signaling through 
TNF-R1, diverging at the level of the transcription factor, where in a pro-inflammatory 
context TNF-R1 signals through NF-κB and in an oxidative context it signals through AP-1 
(Miller 2014). Diesel exhaust particles exposure also increases BCRP expression, but it is 
not clear whether the identified signaling pathway is responsible for this increase or if 
other pathways may be involved (Hartz and Bauer 2010). Altogether, these findings point 
to the important role that oxidative stress have in the regulation of the expression of ABC 
transporters, resulting in BBB tightening and reduction of drug penetration into the brain. 
 
3.1.2.4. Signaling mechanisms for decreased P-gp activity 
Two signaling pathways that rapidly and reversibly reduce P-gp transport activity, without 
change of protein expression, have been described, in both rat and mouse brain 
microvessels. 
In isolated rat brain capillaries, vascular endothelial growth factor (VEGF) demonstrated to 
acutely and reversibly reduce P-gp transport activity, with no alteration of its protein 
expression or opening of TJs (Hawkins et al. 2010). VEGF seems to have such effect via 
activation of the VEGF receptor Flk-1 and Src kinase, considering the effect on P-gp 
activity was blocked when inhibitors of both the receptor and the kinase were used. 
Additionally, the Src-mediated phosphorylation of caveolin-1 may play a role in the down-
regulation of P-gp activity (Hawkins et al. 2010). These findings were confirmed in vivo by 
in situ brain perfusion, since an intracerebroventricular (i.c.v.) injection of low doses of 
VEGF resulted in an increased brain distribution of P-gp substrates, such as morphine 
and verapamil, without any effect on the tight junction marker, sucrose, and blocked by 
the systemic administration of a Src kinase inhibitor, PP2 (Hawkins et al. 2010). However, 
VEGF has multiple effects on the BBB at higher doses, including TJ disruption, and thus 
rendering its clinical use in P-gp activity modulation unlikely (Miller 2015). Still, the 
identification of the downstream elements of VEGF signaling is important for the 
development of possible targeting strategies for acute modulation of P-gp activity and 
brain drug delivery improvement.  
A second signaling pathway that has been described to decrease P-gp activity is a rather 
complex mechanism, and involves three signaling modules: pro-inflammatory, 
sphingolipid, and protein kinase (Miller 2015). Firstly, brain capillaries exposed to TNF-α 
release big-ET-1, which is later cleaved into active ET-1 by an extracellular ET converting 
enzyme and binds to the ETBR, as it is described in inflammatory conditions (Hartz et al. 
2006). The subsequent signaling leads to the activation of iNOS and PKCβ1. Secondly, 
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sphingosine is converted to sphingosine-1-phospate (S1P), which is transported out of the 
endothelial cells by MRP1, activating S1P receptor 1 (Cartwright et al. 2013), which then 
signals via PI3-K and Akt to activate mTOR, resulting in reduced P-gp activation (Miller 
2015). The activation of this pathway can transiently reduce P-gp activity at the rodent 
BBB, and thus is a promising approach to improve drug delivery to the brain. Still, it 
remains to be demonstrated whether this same signaling pathway occurs in the human 
BBB, and consequently if it would be practical in a clinical setting (Miller 2015). 
 
 
3.2. Epilepsy 
Epilepsy is one of the most common neurological disorders and affects more than sixty 
million people worldwide (Kotsopoulos et al. 2005). It is characterized by the recurrent 
manifestation of seizures, which can cause brain damage, and despite the advances in 
drug development and the introduction of novel antiepileptic drugs in the past years, about 
30-40% of the patients fail to respond to the treatment due to the development of 
pharmacoresistance (Loscher and Potschka 2005b), putting these patients in a life-
threatening situation. Patients with drug-resistant epilepsy have a seven-fold higher 
mortality compared to the general population or epileptic patients who respond to 
pharmacotherapy (Sperling et al. 1999). In general, nonresponsive patients experience a 
low quality of life; despite advances in pharmacotherapy and neurosurgery, drug-resistant 
epilepsy remains a major clinical problem (Piazzini et al. 2007). In fact, the cause for anti-
epileptic drug resistance in epilepsy is not yet fully understood, but several hypotheses for 
the underlying resistance are proposed. As already mentioned in a previous section, the 
expression of ABC transporters, such as P-gp and BCRP, seems to be increased in the 
brain of epileptic patients, and might contribute to anti-epileptic pharmacoresistance. The 
first time ABC transporters were suggested to contribute to anti-epileptic drug 
pharmacoresistance was in 1995, when a high expression of P-gp was detected in the 
capillary endothelial cells isolated from the brain tissue of refractory epileptic patients 
(Tishler et al. 1995). Since then, overexpression of P-gp, and other ABC efflux 
transporters such as BCRP have been confirmed either through in vitro, in vivo or clinical 
studies (Aronica et al. 2012; Potschka et al. 2004; Sisodiya et al. 2002). Furthermore, in 
vivo and in vitro studies showed that many anti-epileptic drugs are substrates of ABC 
transporters, namely of P-gp (Luna-Tortos et al. 2008). Consistent with these findings, the 
inhibition of these transporters increases the brain uptake and efficacy of several anti-
epileptic drugs in animal seizure models (van Vliet et al. 2006). Prevention of seizure-
induced transporter expression has also demonstrated to improve anti-epileptic drug 
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efficacy in drug-resistant epilepsy animal models (Schlichtiger et al. 2010). This body of 
evidence led to the conduction of numerous studies, over the past 10 years, to understand 
the regulatory mechanisms that stand behind the ABC transporter up-regulation at the 
BBB in epilepsy, and thus the development of pharmacoresistance to antiepileptic drugs. 
These studies were mainly focused on the mechanism driving the increases in P-gp 
expression. Recent in vitro and in vivo studies have suggested that overexpression of 
ABC transporters is complex and involves several elements of pathological alterations 
observed in epilepsy, such as inflammatory responses, oxidative stress, ligand-activated 
nuclear receptors and glutamate (Potschka 2010b). 
Glutamate is an excitatory neurotransmitter that contributes to excitotoxicity in several 
neurological diseases, like epilepsy, where its excessive release from neurons and glial 
cells occurs (Bankstahl et al. 2008). Glutamate signaling via ionotropic, N-Methyl-D-
aspartate (NMDA) receptors is major to the pathophysiology of such disorders (Barnes 
and Slevin 2003). In accordance with high glutamate levels in the epileptic brain, it has 
been shown that seizures induce overexpression of P-gp at the BBB in endothelial cells 
through glutamate by an NMDA receptor and cyclooxygenase-2 (COX-2)-dependent 
mechanism (Bauer et al. 2008). In fact, exposing isolated rodent brain capillaries to 
glutamate increased P-gp expression and transport activity, which were both abolished 
when blocking transcription or translation, substantiating that these effects depend on de-
novo protein synthesis (Bauer et al. 2008). As with inflammation, NF-κB appears to drive 
the increase in P-gp expression, but it is the excess of glutamate release that starts the 
signaling, through its binding to NMDA receptor, in a seizure-provoked situation. This 
presumably increases Ca2+ flow into the cell and activates phospholipase A2 (cPLA2), 
which produces arachidonic acid. This metabolite is then converted to prostaglandin-E2 
(PGE2) by COX-2, which is released to the extracellular space by efflux mediated by an 
MRP, likely MRP4 (Bauer et al. 2008). Extracellular PGE2 binds to a prostaglandin E 
receptor 1 (EP1R), which then signals NF-κB activation and increases P-gp expression 
(see Figure 20) (Bankstahl et al. 2008; Bauer et al. 2008; Pekcec et al. 2009; van Vliet et 
al. 2010; Zhu and Liu 2004). Consistent with this signaling pathway, seizure-induced P-gp 
up-regulation was blocked when rats were treated with celecoxib, a specific COX-2 
inhibitor (van Vliet et al. 2010; Zibell et al. 2009), and with SC-51089 (Fischborn et al. 
2010), a specific EP1R inhibitor. In line with this, COX-2 inhibition resulted in prevention of 
P-gp up-regulation and enhanced brain uptake of phenytoin in rats with recurrent seizures 
(van Vliet et al. 2010). Furthermore, seizure-induced P-gp expression in rats also showed 
to be NMDA receptor and COX-2 dependent, and the inhibition of these elements of the 
signaling pathway improved the efficacy of certain anti-epileptic drugs (Potschka and 
Luna-Munguia 2014). A recent publication shows that a similar signaling pathway (NMDA 
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receptor, COX-2) up-regulates P-gp activity in capillaries from the human brain (Avemary 
et al. 2013). 
 
 
Figure 20. Glutamatergic transmission as a trigger of transcriptional regulation of P-glycoprotein. 
Excessive extracellular glutamate signals Ca2+ intake, via endothelial NMDA receptors with consequent 
release of arachidonic acid from the plasmatic membrane, which is converted to PGE2 by COX-2. PGE2 acts 
through the EP1 receptor to have an effect on P-gp expression via NF-κB activation. Adapted from (Potschka 
2010b) 
 
In contrast to the amount of data concerning the effect of glutamate on P-gp expression, 
its role on BCRP expression at the BBB is not clear. A recent report showed that 
glutamate exposure decreased BCRP expression and activity in isolated porcine 
capillaries, and provided evidence that NMDA receptor/COX-2 contribute to the down-
regulation this transporter (Salvamoser et al. 2015). Similar results concerning BCRP 
down-regulation were obtained when using human capillaries isolated from surgical 
specimens of epileptic patients (Salvamoser et al. 2015). 
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4. Morphine and the Blood-Brain Barrier: Interplay with 
ABC transporters 
 
“…here was the secret of happiness, about which philosophers had disputed for so many 
ages, at once discovered; happiness might now be bought for a penny, and carried in the 
waistcoat-pocket; portable ecstasies might be had corked up in a pint-bottle; and peace of 
mind could be sent down by the mail.”  
― Thomas de Quincey, Confessions of an English Opium Eater 
 
4.1. Historical and general overview of Morphine 
Opiates, and morphine in particular, have been used by humans for millennia, either for 
their euphoric and recreational properties, or for their analgesic effect, which has made 
them an important part of current medical care (Brownstein 1993).  
Morphine is the principal active alkaloid, and the most abundant opiate found in opium, 
which is obtained from the seedpods of the opium poppy plant, Papaver Somniferum (see 
Figure 22, A). A first widespread use of opium was seen in the Ancient Era, since it was 
the most potent form of pain relief then available. Its widespread and worldwide 
recreational use began in the 15th century, as it became a powerful and valuable tool of 
international trade between major world empires, namely the Ottoman, Chinese and 
British Empires (Brownstein 1993). Morphine was extracted and isolated from the opium 
poppy plant for the first time in 1805, by Friedrich Sertürner, who named morphine after 
the god of sleep and dreams in Greek mythology, Morpheus (Brownstein 1993). Its 
commercial production began shortly after, in 1827 by the pharmaceutical company 
Merck. 
Morphine is considered a leader molecule among opioids and endowed with powerful 
analgesic properties. Despite the development of several powerful synthetic opioids, 
morphine occupies a prominent place in both severe acute and chronic pain management, 
particularly cancer-related pain. Unfortunately, morphine and its opioid derivatives, 
associated with a long-term use, have the potential to cause substance dependence. Due 
to its severe and harmful consequences, opiates are on the top of the list of problem 
drugs that cause the most burdens of disease and drug-related deaths worldwide. 
According to the latest World Drug Report (2014) by the United Nations Office against 
Drugs and Crime (UNODC), it is estimated that between 28.6 and 38 million people 
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worldwide are opioid users, including heroin and prescription painkillers. It is also 
estimated that approximately 69 thousand people die from opioid overdose each year. 
 
Figure 21. Global potential opium production since 1998 until 2013. 
Data obtained from the World Drug Report (2014) produced by the United Nations Office on Drugs and Crime. 
The present graph shows that, since 2001, Afghanistan is the world leader of opium production and supply. 
The potential production of opium in 2013 is estimated at 6.883 tons, which is a return to the levels observed 
in 2011 and 2008. The opium production in Afghanistan accounts for 80 per cent of the global opium 
production (5.500 tons). 
 
Morphine and codeine are the best-known opiate alkaloids, naturally occurring in opium, 
and their semi-synthetic derivatives, oxycodone and heroin, and full synthetic opioids, 
such as methadone, are also of valuable therapeutic use. The term opiate is refers to the 
natural opium alkaloids and their semi-synthetic derivatives, while the term opioid refers to 
the fully synthetic molecules. The endogenous opioid peptides, such as endorphins and 
enkephalins, have an opioid structural-related tyrosine terminal, as well as related 
morphine moieties, that account for their resembling biological effects of opioids.  
Morphine is a phenanthrene pentacyclic alkaloid with a piperidine ring (see Figure 22, B). 
Its molecular formula is C17H19NO3 and has a molecular weight of 285.35 g/mol. Since 
morphine is sparingly soluble in water, pharmaceutical companies produce mainly 
hydrochloride and sulfate salts for use in human medicine, both of which are about 300 
times more water-soluble than the parent molecule (Mazak et al. 2009). Therefore, 
morphine sulphate, in particular, is presented as a white crystalline powder or, in the case 
of morphine hydrochloride, it is presented as colorless silky needles of bitter taste. It 
presents an amphoteric character, due to its basic tertiary amino and phenol functional 
groups. In the blood plasma, at pH 7.4, a substantial portion (7.9%) of morphine is in the 
noncharged form, and thus can most likely penetrate biological membranes, including the 
BBB (Mazak et al. 2009). 
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Figure 22. Opium poppy plant and its principal active alkaloid, morphine. 
A) Opium poppy (Papaver somniferum) botanical drawing (University of Amsterdam, 20th century). B) 
Molecular structure of morphine, a phenanthrene pentacyclic molecule with a piperidine ring. 
 
It is generally accepted that oxygen, sunlight, UV radiation and metal ions can catalyze 
the degradation of morphine in aqueous solutions (Mazak et al. 2009), and once it 
contains a phenolic hydroxyl group, its stability in aqueous solution is pH-dependent. 
 
4.2. Pharmacokinetics and Pharmacological Considerations 
4.2.1. Morphine Pharmacokinetics in the human body 
Absorption. Morphine can be administered via several routes, including oral, intravenous 
(i.v.), subcutaneous (s.c.), intramuscular (i.m.), intrathecal and epidural. IV and 
subcutaneous continuous-infusion morphine are among the most common routes of 
administration, and are equally effective in producing analgesia. Its oral administration is 
not an especially effective pain-relieving drug when administered in a single dose, owing 
to its limited bioavailability (Brunk and Delle 1974). Conversely, the effectiveness of 
repeated doses seems to result from the presence of the enteropathic circulation, which 
allows a recirculation of morphine and its metabolites (Hanks et al. 1987). 
Peak plasma levels are achieved within 15-20 min of intramuscular and subcutaneous 
administration, and within 30-90 min after oral. Peak levels after oral administration are 
much lower than after parenteral routes, since oral morphine undergoes extensive first-
pass metabolism in the liver (Glare and Walsh 1991). 
Distribution. After absorption, morphine is rapidly and widely distributed and crosses 
barrier interfaces, such as the placenta and the BBB. At therapeutic doses, plasma protein 
binding is only 20-35%, predominantly to albumin and to a lesser extent to α1-acid 
A B 
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glycoprotein, and the volume of distribution is 1-6 L/kg (Glare and Walsh 1991). P-gp, 
which is expressed in the intestinal epithelial and at the BBB, as well as ABCCs are 
involved in brain efflux clearance of morphine (Tunblad et al. 2003; Xie et al. 1999). 
Metabolism. As previously stated, in humans, the mean bioavailability after oral 
administration of morphine is low (20-30%) due to extensive hepatic first-pass metabolism 
(Hanks et al. 2001). Morphine administered via the oral route results in higher metabolite 
production compared with other routes of administration that avoid first-pass metabolism 
(Faura et al. 1998). Experimental studies carried out in animal show that morphine is 
glucuronidated in the liver and intestinal mucosa (Dahlstrom and Paalzow 1975). 
Morphine has three major metabolites: morphine-3-glucoronide (M3G) morphine-6-
glucoronide (M6G), and normorphine (Glare and Walsh 1991; Labella et al. 1979; 
Osborne et al. 1986; Zaw-Tun and Bruera 1992). M3G is the main metabolite constituting 
45-55% of morphine’s metabolites, while 10-15% of morphine is converted into M6G 
(Christrup 1997). Uridine diphospho-glucuronosyltransferases (UGT) 2B7, involved in the 
formation of both metabolites but at different amounts (5 times more M3G than M6G), and 
UGT1A3, for the formation of M3G, are the major enzymes involved in the glucuronidation 
of morphine (Coffman et al. 1997). In addition to the liver, human brain homogenates have 
been shown to metabolize morphine at nanomolar concentrations to M3G and M6G 
(Yamada et al. 2003). Consequently, M6G can be formed directly in the CNS, and so it 
does not need to cross the BBB to exert a greater central effect than the M6G produced in 
the liver. Although analgesically inactive, M3G has been reported to mildly antagonize 
morphine and produce stimulatory effect, such as myoclonus, seizure and allodynia 
(Smith 2000). On the other hand, M6G has analgesic activity (Christrup 1997), and it 
greatly contributes to morphine analgesic effect. In fact, its higher potency and less 
marked respiratory depressive effects makes of M6G an attractive analgesic even when 
compared to the parent drug. However, its analgesic power following systemic 
administration is markedly lower than morphine, due to poor BBB permeability (De 
Gregori et al. 2012). Approximately 5% of morphine is N-demethylated into normorphine 
via CYP3A4 and CYP2C8 (Lalovic et al. 2006). 
Excretion. Morphine half-life is relatively short, which on a repeated dosing reaches a 
steady state level in 10-12 hours, while the duration of its action stands for approximately 
4 to 6 hours. Approximately 10% of a morphine dose is really excreted as unchanged 
morphine, while 45-55% is excreted as M3G, 10-15% as M6G, and 5% as minor 
metabolites (Christrup 1997). The elimination of morphine metabolites is mainly performed 
via urine (around 90% in 24 hours) in a combination of glomerular filtration and tubular 
secretion. Fecal elimination of these conjugates is relatively low (<10%) (Inturrisi 2002). 
Morphine clearance decreases in patients over 50 years old, which explains elderly 
________________________________________________ Morphine and the Blood-Brain Barrier 
89 
patients’ higher sensitivity to the drug (Kaiko 1980). This clinical observation implies that 
younger patients may need larger doses to achieve the same analgesic effect 
(Ventafridda et al. 1989).  
 
4.2.2. Therapeutic applications and Pharmacological Effects 
Morphine and other opioid derivatives are generally indicated to treat moderate to severe 
pain, either acute or chronic, and are among the most effective drugs available for pain 
management (Kalso et al. 2004). Neuropathic pain is particularly challenging to treat, and 
manifests as spontaneous pain (continuous or intermittent) and abnormally evoked pain 
(usually by touch or movement), typically characterized by numbness, tingling, burning 
and other unpleasant sensations (Dworkin et al. 2003; Ossipov and Porreca 2005). The 
abnormal pain syndromes that are most commonly associated with neuropathic pain are 
tactile or mechanical allodynia, meaning that touch is abnormally perceived as painful, 
and hyperalgesia, where perception of noxious stimuli is exaggerated. Neuropathic pain 
can arise from direct nerve damage due to trauma or surgery, or can be associated with 
viral infection, cancer, diabetes or chemotherapy (Dworkin et al. 2003; Ossipov and 
Porreca 2005). In such cases, sensory neurons within the pain pathway (e.g., in the spinal 
cord dorsal horn) become hyperexcitable, signaling pain despite the absence of painful 
stimuli (Millan 1999; Woolf and Salter 2000). The effective analgesic dose of morphine 
and other opioids varies considerably among patients, which is dependent on pain 
severity, pain perception by the patient, among other factors. 
However, the use of morphine is associated with a considerable number of side effects, 
which may be considered as desirable or undesirable. The development of some of these 
adverse effects markedly limits the use of opioids in pain management. The most 
common adverse effects are sedation, nausea and vomiting, constipation, and respiratory 
depression. Other adverse effects include confusion, hallucinations, nightmares, urinary 
retention, multifocal myoclonus, dizziness, and dysphoria (Bruera and Kim 2003). Here is 
a brief description of some of the most common adverse effects provoked by morphine: 
 Respiratory depression: morphine acts on brainstem respiratory centers to 
produce a dose-dependent respiratory depression. At the same time, as CO2 
accumulates, it stimulates central chemoreceptors, resulting in a compensatory 
increase in respiratory rate that masks the degree of respiratory depression. 
Tolerance develops rapidly to this effect with repeated drug administration. 
 Euphoria: morphine and other opioids can trigger feelings of euphoria and well-
being, which contributes to its addictive potential. 
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 Sedation: morphine produces sedation and drowsiness, which may be useful in 
certain clinical situations, like preanesthesia, but undesirable in ambulatory 
patients. Like with respiratory depression, this is particularly characteristic in an 
early phase of the treatment with morphine, and it tends to disappear with the 
development of tolerance. 
 Nausea and vomiting: such effects occur due to morphine’s action on the 
medullary chemoreceptor trigger zone. 
 Constipation: the most common adverse effect of morphine is constipation. It acts 
in multiple sites in the gastrointestinal tract and spinal cord to decrease intestinal 
secretions and peristalsis. Tolerance develops slowly to the smooth muscle effects 
of opioids, so constipation tends to persist when morphine is used for chronic pain. 
 Urinary retention: As opioids increase smooth muscle tone, they can cause 
bladder spasm and an increase in sphincter tone, leading to urinary retention. This 
is most common in elderly patients. 
 Inhibition of immune responses: morphine has shown to suppress a variety of 
immune responses that involve major cell types including natural killer cells, T 
cells, macrophages and polymorphonuclear leukocytes. This action is mediated by 
pharmacological activation of δ-receptors, which are present in immune cells 
(Lockwood et al. 1994), but possibly also through an in vivo neural-immune circuit 
through which morphine acts to depress the function of all cells in the immune 
system (Roy et al. 2011). 
 Tolerance and opioid-induced hyperalgesia: tolerance develops in most patients 
receiving opioid analgesics chronically, and it is characterized by a reduced effect 
of a given dose of morphine, and so a larger dose is required to produce the 
original effect (McQuay 1999). Preclinical studies suggest that apparent opioid 
tolerance may result from excitatory CNS changes that facilitate transmission of 
pain and increase sensitivity to pain (Angst and Clark 2006). This appears to result 
from the up-regulation of pro-nociceptive systems and this condition is termed 
opioid-induced hyperalgesia. 
In summary, opioid analgesics like morphine are widely used clinically for the 
management of acute to chronic pain, but their long-term use is compromised by the 
prevalence of undesirable side effects involving the CNS and gastrointestinal system. 
Furthermore, the prolonged use of morphine and related opioid drugs is linked to the 
development of analgesic tolerance, as well as with the development of physical 
dependence, which leads to severe withdrawal symptoms when opioid administration is 
suspended (Ballantyne and Mao 2003).  
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4.3. Mechanism of action 
The pain-relieving properties of morphine have been extensively studied. The 
pharmacological properties of morphine are a result of its interaction with endogenous 
opioid receptors, which were reported to be existent in the human body in 1973 (Pert and 
Snyder 1973; Simon 1973; Terenius 1973). The possibility of the existence of multiple 
subtypes of the opioid receptor through purely pharmacological studies was later 
proposed (Martin et al. 1976). Because the opioid receptors are widely distributed 
throughout the entire nervous system, opioids may exert their antinociceptive activity 
through different mechanisms. 
Opioid receptors are G-protein coupled receptors (GPCR), with seven TMDs, and are 
located in high levels in the brain and spinal cord (Ossipov et al. 2004). These receptors 
play a central role in basic physiological functions of the majority of known 
neurotransmitters and hormones, and can be activated by either endogenous or 
exogenous opioids, such as morphine. To date, four major opioid receptors families have 
been identified and cloned, and each has unique central pharmacological actions. The 
existence of genetic and physiological variations that influence the sensitivity of opioid 
receptors towards different opioid ligands, and the difference in their potency across 
various species and animal strains (Pasternak 2004), led to the proposal that receptors 
could be classified into subtypes: 
 μ (mu, MOR), which has three subtypes, μ1, μ2 and μ3 (Wang et al. 1994). 
Agonists of μ-opioid receptor generally produce analgesia, euphoria, respiratory 
depression, and are largely responsible for the physical dependence associated 
with opioids (Kieffer 1999). Activation of the μ receptors also leads to bradycardia, 
hypothermia and locomotor hyperactivity (Gourlay 2005). 
 κ (kappa, KOR), which has four subtypes, κ1a, κ1b, κ2 and κ3 (Mansson et al. 
1994). κ-opioid agonists provide analgesia and show little dependence liability; 
still, they are poor therapeutic targets, as they produce intense dysphoric reactions 
(Hasebe et al. 2004). Other resultant effects of the activation of these receptors 
are miosis, sedation, and dysphoria (Gourlay 2005).  
 δ (delta, DOR), with two subtypes, δ1 and δ2 (Kieffer et al. 1992). Agonists of the 
δ-opioid receptor also seem to be poor therapeutic targets, since their activation in 
rodents has shown to produce convulsions (Comer et al. 1993). 
 Nociceptin or orphanin (NOP) receptor, or the receptor-like orphan receptor (ORL), 
which was later added to the list of opioid receptors (Mollereau et al. 1994) (Feng 
et al. 2012). 
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Central μ-opioid receptors are those that are most responsible for the analgesic effects of 
morphine and with less severe side effects, and thus remain the primary choice in the 
clinical setting. In fact, morphine has an excellent affinity for the μ-opioid receptors, which 
is much superior compared to the affinities to the other opioid receptors. The 
pharmacological activity of morphine is mostly correlated with the anatomical distribution 
of these receptors, and indeed, it was showed that morphine had no effects on mice 
whose gene encoding for the μ-opioid receptor was abolished (Kieffer 1999). Yet, in 
another study, morphine was able to induce analgesic activity via stimulation of the κ-
opioid receptors, in MOR knockout mice (Yamada et al. 2006). 
The distribution and anatomical localization of the opioid receptors have been extensively 
explored throughout the preceding decades. Morphine sites of action can be basically 
classified in spinal and supraspinal sites of action. 
Opioid receptors, namely μ-opioid receptors, are concentrated in the outer laminae of the 
dorsal horns of the spinal cord, whereas δ-opioid receptors are diffusely distributed 
throughout the dorsal horn (Ossipov et al. 2004). The interaction of morphine with the 
opioids receptors at the spinal levels results in 1) closure of the calcium channels on the 
neuronal presynaptic terminal, resulting in a reduced release of neurotransmitters such as 
glutamate, acetylcholine, norepinephrine and serotonin, and 2) decreased activity of 
postsynaptic neurons due to an induced hyperpolarization by the opening of the 
potassium channels, which leads to a reduction in the nociceptive transmission (Goodsell 
2005).  
Descending inhibitory projections from supraspinal sites that are activated by opioid 
receptors also modulate nociceptive signals entering at the spinal cord level. Regions that 
were shown to express the opioid receptors include the frontal cortex, nucleus 
accumbens, hippocampus, thalamus, and hypothalamus (Ossipov et al. 2004). Two 
prominent regions in opioid-mediated antinociception, the periaqueductal gray (PAG) and 
the rostral ventromedial medulla (RVM) were identified as expressing opioid receptors. 
The PAG was found to be rich in μ-opioid receptors, whereas levels of δ- or κ-opioid 
receptors were low or undetectable (Mansour et al. 1995; Mansour et al. 1987). The RVM, 
which is defined as the region of the medulla including the nucleus raphe magnus, the 
nucleus gigantocellularis pars α, and surrounding reticular neurons, was found to express 
all three subtypes of the opioid receptors (Mansour et al. 1995; Mansour et al. 1987). 
Additionally, opioid receptors have also been identified in the locus coeruleus, which also 
plays a role in modulation of nociceptive inputs (Van Bockstaele et al. 1996). The action of 
morphine on the opioid receptors at the supraspinal level results in the activation of 
inhibitory bulbo-spinal pathways that project to the dorsal horn of the spinal cord, and are 
likely to reduce the level of transmission of the nociceptive message. 
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The efficacy of morphine is believed to be a result of a synergistic interaction between its 
activity at both spinal and supraspinal sites (Ossipov et al. 2004). 
 
4.4. Morphine Tolerance, Addiction and Withdrawal Syndrome 
4.4.1. Development of Tolerance to Morphine 
Frequent or chronic opioid intake leads to the development of the tolerance phenomenon 
in the CNS. Opioid tolerance is characterized by a reduced responsiveness to an opioid 
agonist such as morphine, and it usually reflects the need to use increasing doses of the 
drug to achieve the desired effect. Clinically, more than 10-fold dose escalations of opioid 
dose in chronic pain management are common (Buntin-Mushock et al. 2005), and illicit 
opioid addicts can consume daily doses tens to hundreds of fold higher than acutely 
effective doses (Christie 2008). Tolerance is a result of adaptive mechanisms not only at 
the level of the drug target (in this case the opioid receptors and the μ-opioid receptor, in 
particular), but also at the cellular, synaptic and network levels, where adaptations due to 
homeostatic mechanisms tend to restore normal function despite the continued 
perturbations produced by opioid agonists (Christie 2008). In general, opioid intake 
induces adaptive changes in opioid receptors that may differ if following acute 
(desensitization and/or internalization phenomena) or chronic (adaptive tolerance and 
receptor down-regulation) opioid administration (Harrison et al. 1998; Mayer and Hollt 
2006). Several intracellular molecules of signal transmission have been identified to be 
involved in opioid tolerance and dependence, including G proteins, cyclic AMP (cAMP), 
Mitogen-activated protein kinases (MAPK), and transcription factors, the latter responsible 
for the modification of gene expression, which may be responsible for the long-lasting 
neural plasticity induced by opioids (Christie 2008; Przewlocki 2004). 
 
4.4.2. Opioid Addiction 
Over the past 30 years, the clinical use of opioid has become widespread, with the 
development of different routes of administration to improve its safety, as well as through 
the development of extended-release, and immediate-release opioid formulations, which 
proved to be effective and with a leading role for the treatment of moderate to sever acute 
and chronic pain conditions. However, and despite its benefits and the widespread 
rational guidelines for their appropriate use, these opioid formulations are often 
inappropriately marketed and prescribed, which partially precipitates the current epidemic 
of recreational opioid use and addiction (Shurman et al. 2010). 
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Drug addiction, as in the case of morphine addiction, is a chronic relapsing disorder 
characterized by: 1) compulsive behavior to seek and take the drug, 2) loss of control in 
limiting intake, and 3) the emergence of a negative emotional state when the access to 
the drug is prevented (dependence) (Koob and Le Moal 2008). Drug addiction can be 
conceptualized as a disorder that progresses from impulsive drug use to uncontrollable, 
compulsive drug use in a cycle comprising three stages: 1) preoccupation/anticipation, 2) 
binge/intoxication, and 3) withdrawal/negative affect (Koob and Le Moal 1997). With the 
development of opioid addiction, a compulsive pattern of drug taking evolves, which is 
accompanied by the development of tolerance and its resulting escalation in drug intake to 
accomplish the original effect. The escalated drug use enhances the negative emotional 
symptoms of abstinence, which in turn results in profound dysphoria, irritability, sleep 
disturbances, anxiety, emotional pain, and craving. Craving often precedes somatic signs 
of withdrawal, and it relates with obtaining the drug and anticipation of its rewarding 
effects, as well as with anticipation of the aversive effects of withdrawal. Consequently, it 
is experienced as a need to obtain and take the drug to avoid the severe dysphoria, 
discomfort, and psychic stress experienced during withdrawal and abstinence (Shurman 
et al. 2010). 
The mechanisms underlying neurological disorder caused by opioid addiction are not 
currently clear. The neuronal basis of positive reinforcement relies on activation of 
dopaminergic neurons, resulting in an increased dopamine release in the mesolimbic 
brain structures. Certain aspects of opioid dependence and withdrawal syndrome are also 
related to noradrenergic and serotonergic systems, as well as to both excitatory and 
inhibitory amino acid systems (Feng et al. 2012).  
 
4.4.3. Opioid Withdrawal 
As so far discussed, opioid addiction is a complex disorder that progresses with the setup 
of tolerance, drug-seeking, physical dependence and development of withdrawal 
syndrome. The severity of opioid dependence and the somatic symptoms triggered by 
withdrawal are major contributors to the compulsive drug-taking behavior, short-term 
relapse, and thus the addictive potential of opioids (Ouyang et al. 2012). 
In humans, the typical opioid withdrawal syndrome is characterized by the manifestation 
of signs and symptoms like stomach cramps, diarrhea, rhinorrhea, sweating, elevated 
heart rate and increased blood pressure, irritability, dysphoria, hyperalgesia, and insomnia 
(Morgan and Christie 2011). After abrupt cessation of heroin or morphine use, the 
withdrawal syndrome develops within 24 hours and generally persists with declining 
severity for 1 week to 10 days (Morgan and Christie 2011). The withdrawal syndrome 
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contributes to opioid addiction presumably because repeated dosing is maintained or 
escalated to avoid the withdrawal symptoms, and thus leading to the development of more 
profound tolerance and dependence (Koob and Le Moal 1997; Morgan and Christie 
2011). The described signs and symptoms found in human opioid withdrawal can be 
promptly replicated in animal models of compulsive drug use (Morgan and Christie 2011; 
Ouyang et al. 2012), and therefore are valid instruments for prediction of opioid 
dependence in humans. Opioid withdrawal signs are readily observed and quantified 
following the administration of opioid antagonists, such as naloxone (termed “naloxone-
precipitated withdrawal”) or after abrupt cessation of treatment with relatively short-acting 
opioids (termed “spontaneous withdrawal”) (Morgan and Christie 2011). Opioid 
antagonist-precipitated withdrawal, through its peripheral administration, is the most 
common means of studying this phenomenon in animals. Upon opioid withdrawal in rats 
and mice, the manifested signs include “wet-dog” shakes, jumps, burrowing, hyperactivity, 
abnormal posture, teeth chatter, piloerection, ptosis, lacrimation, rhinorrhea, diarrhea, 
abrupt weight loss, and sweating (Laschka et al. 1976; Morgan and Christie 2011). As 
would be expected from the highly unpleasant nature of these symptoms, avoiding or 
relieving withdrawal is an important factor in continued drug use. In addition to its acute 
effect, learned associations between the withdrawal and environmental cues may be 
acquired upon opioid withdrawal (O'Brien 2008). In a phenomenon termed conditioned 
place aversion (CPA), animals will learn to spend less time in a previously neutral 
environment, which was later paired with aversive periods of an unconditional negative 
stimulus, such as naloxone-opioid withdrawal (Stinus et al. 2000). CPA can be produced 
with such low doses of naloxone that even physical withdrawal signs are not elicited 
(Gracy et al. 2001), which indicates that a negative affective state, rather than physical 
symptoms per se is an enough stimulus for learning (Schulteis et al. 1998). There is also 
evidence that withdrawal-associated stimuli can prime opioid self-administration in 
dependent animals, meaning that learned aversive cues may also impact drug taking 
behavior (Hellemans et al. 2006; Kenny et al. 2006). 
Opioid withdrawal is believed to result from multiple adaptations within the CNS, whose 
cellular and molecular mechanisms are still not fully understood. The PAG, in particular, 
seems to be implicated in the expression of many signs and symptoms of opioid 
withdrawal (Ouyang et al. 2012). Opioid receptor-effector uncoupling has been implicated 
in physical dependence, but it does not fully account for withdrawal signs and symptoms 
or rebound responses in neurons after the administration of opioid receptor antagonists 
(Ingram et al. 1998; Ouyang et al. 2012). Currently, there is evidence that glial activation 
occurs over repeated morphine administration in several brain regions and spinal cord, 
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and that it should importantly account for the development of tolerance, dependence and 
precipitation of opioid withdrawal (DeLeo et al. 2004; Watkins et al. 2005; Watkins et al. 
2007). In summary, chronic treatment with morphine has shown to activate glia in rodent 
models, evidenced by the up-regulation of glia-specific activation markers and release of 
pro-inflammatory cytokines, which may oppose the analgesic actions of opioids and 
contribute to opioid abuse liability and withdrawal symptoms upon cessation of opioid 
treatment (Song and Zhao 2001; Tawfik et al. 2005). Immunosuppressive treatments have 
shown to attenuate glial activation, and to reduce the precipitation of morphine 
dependence (Dougherty et al. 1986). Hence, treatments that reduce glial activation may 
be therapeutically useful to improve the efficacy of morphine, by reducing the 
development of tolerance, the abuse liability, and the potential withdrawal symptoms 
(Ledeboer et al. 2007). 
 
4.4.3.1. Cellular, molecular and neurotransmission adaptations during opioid 
addiction and withdrawal. The case of the glutamatergic transmission. 
Although the neurophysiology underlying these opioid-related phenomena is still not fully 
understood, recent progress has been made in the identification of molecular and cellular 
adaptations in opioid-sensitive neurons which can potentially lead to opioid tolerance, 
dependence and opioid-withdrawal behavior. It requires identification of adaptations that 
can drive cellular excitation or synaptic plasticity that are related to identifiable behavioral 
outputs including those involved in compulsive use of opioids. 
During chronic opioid exposure, excessive stimulation or inhibition of a signal downstream 
the μ-opioid receptor can result in a homeostatic adjustment of the signaling system. 
Tolerance, in particular, arises when the downstream signal of the μ-opioid receptor 
activation directly controls neural excitability, as it is the case of cAMP in some nerve 
terminals (Ingram et al. 1998). Both the cAMP/PKA and MAPK signaling cascades seem 
to be of interest, as they are directly downstream the μ-opioid receptor activation. 
Removal of the inhibitory stimulus on the hypertrophied cAMP signaling during withdrawal 
can lead to an overshoot in downstream signaling mechanisms and neural excitation, and 
thus lead to the opioid withdrawal manifestations (Christie 2008). Other kinase cascades 
may be implicated in tolerance and withdrawal at cellular level, including PKC (Bailey et 
al. 2006) and other signaling systems (Bailey and Connor 2005; Johnson et al. 2005). 
Furthermore, mechanisms of cellular tolerance can also develop as a general cellular 
homeostatic response to depression of neural excitation by opioid agonists, such as 
altered TM chloride gradients, calcium homeostasis and synaptic structure and strength 
(Christie 2008; Rich and Wenner 2007). 
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A great number of studies has also focused on the early and transient transcriptional 
activation and altered gene expression during morphine withdrawal, such as of members 
of the Fos, Jun and Krox families (Couceyro and Douglass 1995; Erdtmann-Vourliotis et 
al. 2000; Georges et al. 2000), components involved in receptor-coupled signaling, 
neuropeptides, and other genes associated with metabolic function, cell protection and 
synaptic plasticity (Ammon-Treiber and Hollt 2005). 
Several neurotransmitter systems, including the dopaminergic (Harris and Aston-Jones 
1994), cholinergic (Bristow et al. 1997), noradrenergic (Maldonado 1997; Van Bockstaele 
et al. 2001), and glutamatergic (Siggins et al. 2003; Zhu and Barr 2001) have been also 
shown to play an important role in opioid withdrawal. In fact, there is evidence that 
glutamate and the NMDA receptor in particular play a well-established role in opioid 
tolerance, dependence and withdrawal (Mao 1999; Mayer et al. 1999; Trujillo 2000; Zhu 
and Barr 2001). Functional NMDA receptors are required for the full development and 
expression of dependence. The NMDA receptor is a tetrameric heteromer composed of 
the essential NMDA-NR1 subunit (NR1) in combination with NMDA-NR2 subunits (NR2), 
of which there are four subtypes (NR2A–D), to form a glutamate-responsive NMDA 
receptor (Glass 2010). 
It has been shown that administration of NMDA receptor antagonists attenuates physical 
withdrawal symptoms in opioid-dependent mice (McLemore et al. 1997), guinea pigs 
(Tanganelli et al. 1991), rats (Trujillo and Akil 1991), and humans (Bisaga et al. 2001). 
Moreover, in rodent models, NMDA antagonists also suppress the above-mentioned CPA 
of naloxone-precipitated withdrawal (Glass 2010; Higgins et al. 1992). 
On the other hand, chronic treatment with opioids and its subsequent withdrawal also 
influences the glutamatergic transmission. An elevation of the extracellular glutamate 
levels has been demonstrated in the locus coeruleus after a naloxone-precipitated 
withdrawal from morphine (Zhang et al. 1994b). Studies have demonstrated that either the 
naloxone-precipitated withdrawal or the natural morphine withdrawal resulted in a 
significant increase in the concentrations of glutamate and aspartate (Sepúlveda et al. 
2004; Sepulveda et al. 1998). 
NMDA receptor activation has shown to modulate numerous intracellular signaling 
processes including protein kinase activity (Haddad 2005), protein transport (Shi et al. 
1999), transcription factor activity, and gene expression (Yoneda et al. 2001), as well as 
epigenetic events (Lubin et al. 2008). These properties of NMDA receptor activation may 
have profound effects on cellular and behavioral plasticity (Tsien 2000), such as long-term 
potentiation (LTP) and long-term depression (LTD) (Kullmann et al. 2000), in addition to 
whole-animal learning and memory (Shapiro and Eichenbaum 1999; Walker and Davis 
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2002), processes that play a role in opioid dependence. Furthermore, NMDA receptors 
and μ-opioid receptors are strategically co-positioned for postsynaptic modulation of 
glutamate signaling in several brain regions, such as the central nucleus amygdala (Glass 
2010). In addition, there is evidence of an elevation in extracellular fluid levels of 
glutamate and, to a lesser extent, aspartate within the locus coeruleus during naltrexone- 
or naloxone-precipitated withdrawal in morphine-dependent rats (Aghajanian et al. 1994; 
Zhang et al. 1994a). Glutamate i.c.v. injection was also able to dose-dependently 
precipitate withdrawal signs in morphine-dependent rats, but not in non-dependent 
animals (Tokuyama et al. 1996), suggesting that a rapid release of glutamate may be a 
trigger or key factor for the expression of withdrawal signs from opioids. 
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4.5. Morphine and the BBB 
4.5.1. Transport of morphine across the BBB – role of P-glycoprotein 
In order to exert its pharmacological properties, morphine must cross the BBB to reach 
the CNS and activate the central opioid receptors. Although morphine is a lipophilic 
molecule, the BBB does not seem to be as permissive to its passage as expected.  
Pharmacokinetic studies indicate that morphine reaches the brain through an active 
process (Bourasset and Scherrmann 2006). In addition, the co-administration of 
probenecid with morphine resulted in a 1.4-fold reduction in the brain-to-blood clearance 
of morphine in comparison to control animals, as well as it was seen an increase in the 
half-life of morphine in brain (Tunblad et al. 2003). Systemic clearance of morphine also 
decreased upon probenecid co-administration, suggesting morphine is a substrate for the 
probenecid-sensitive transporters at the BBB. 
Present evidence suggests that the ABC transporters expressed at the BBB, and 
specifically P-gp, may contribute to the active efflux of morphine from the brain, and thus, 
to the development of central tolerance to opioids. The interaction of P-gp with natural and 
synthetic opioids was first reported in 1993 (Callaghan and Riordan 1993). Since then, P-
gp mediated efflux of morphine at the BBB has been demonstrated using in vitro and in 
vivo approaches (Letrent et al. 1998; Letrent et al. 1999a; Letrent et al. 1999b; Mercer and 
Coop 2011; Schinkel et al. 1995; Xie et al. 1999; Zong and Pollack 2000). The first time 
morphine was identified to be a P-gp substrate was in vitro through the use of 
radiolabeled morphine across MDR cells (Callaghan and Riordan 1993; Huwyler et al. 
1998). It was later confirmed to be a P-gp substrate in vivo, using P-gp knockout mice 
(Schinkel et al. 1995). Subsequent in vivo studies in rats showed that the inhibition of P-gp 
with elacridar resulted in significantly elevated antinociceptive effects following morphine 
administration (Letrent et al. 1998). Similar results concerning the increase of 
antinociceptive effects of morphine were also later confirmed in mice pre-treated with the 
P-gp inhibitor verapamil (Shimizu et al. 2004). A microdialysis study performed using 
knockout and wild-type mice in order to assess the role of P-gp in the transport of 
morphine across the BBB also corroborated these data, showing that morphine is 
transported across the BBB by P-gp (Xie et al. 1999). In fact, they showed that morphine 
brain/plasma concentration ratio was significantly higher in P-gp knockout mice in 
comparison to wild-type mice. In line with these findings, using the tail flick and hot plate 
analyses, P-gp knockout mice showed a greater morphine antinociception effect than the 
wild-type mice, with an ED50 more than 2-fold lower in knockout mice in comparison to 
wild-type mice (Thompson et al. 2000; Zong and Pollack 2000).  
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Further studies were later conducted to determine the extent to which morphine is 
transported out of the brain by P-gp. Morphine was found to be a weak P-gp substrate in 
Caco-2 (Crowe 2002), HEK293 (Tournier et al. 2010) and L-MDR1 (Wandel et al. 2002) 
cells, which showed a efflux:influx ratio of 1.5, which was later confirmed in in situ animal 
studies (Dagenais et al. 2004). 
The assessment of morphine efflux transport at the BBB and its CNS effects has also 
been conducted in humans. A study conducted with healthy human volunteer subjects, 
pretreated with quinidine, a P-gp inhibitor, showed that when morphine was given 
intravenously they did not experience enhanced CNS opioid effects (Skarke et al. 2003), 
whereas when morphine was given orally, human volunteers showed sustained increased 
plasma concentrations (Kharasch et al. 2003). These results suggest that P-gp plays a 
role in orally administered morphine, probably by interfering with its intestinal disposition. 
However, a clinical study also conducted in humans demonstrated that P-gp inhibition by 
PSC-833 did not significantly alter the pharmacokinetic and pharmacodynamics profile of 
morphine (Drewe et al. 2000). 
More recently, it was demonstrated that the variability of P-gp expression in the brain 
cortex of mice and the analgesic effect of morphine were correlated (Hamabe et al. 2007). 
Furthermore, this study demonstrated a negative correlation between the expression of P-
gp or its ATPase activity and the antinociceptive effect of morphine, suggesting that the 
inter-individual variability of the morphine effect could be due to a difference in the 
expression and/or function of P-gp in the brain (Hamabe et al. 2007). 
The development of morphine pharmacokinetic modeling also helped to study the 
influence of P-gp on morphine brain distribution. One of these studies showed that 
morphine brain distribution is essentially determined by three factors: 1) limited passive 
diffusion across the BBB, 2) active efflux at the BBB, which is reduced by 42% when P-gp 
is inhibited, and 3) low active uptake capacity (Groenendaal et al. 2007). Such study 
clearly demonstrated that P-gp modulates the distribution of morphine within the biophase 
and so helps delay its CNS effect (Groenendaal et al. 2007). 
Moreover, inter-individual variability in the pain relief of patients with cancer has been 
associated with variants of the ABCB1 gene that alter the expression and/or activity of P-
gp (Campa et al. 2008; Lotsch et al. 2010). Not surprisingly, different studies suggest that 
the overexpression of P-gp at the BBB may contribute to the development of tolerance to 
morphine, by decreasing brain concentrations of morphine (Ambudkar et al. 2003; Mercer 
et al. 2007). 
 
  
________________________________________________ Morphine and the Blood-Brain Barrier 
101 
4.5.2. Morphine influence on the BBB 
The fact that morphine may exert an influence on the expression of protein specifically 
expressed at the BBB is of great interest, given there is data that suggest a possible 
correlation between the BBB modulation and the development of tolerance to morphine. 
Data concerning the influence of morphine on the BBB is still limited. However, some 
studies show that this compound is able to modify certain features of the BBB. Morphine 
has shown to affect BBB permeability.  
A significant increase of the brain concentration of sodium fluorescein, used as a 
permeability marker, was shown following an acute s.c. or i.c.v. morphine administration in 
mice (Baba et al. 1988). This increased permeability was inhibited by the administration of 
naloxone, suggesting that the μ-opioid receptors are involved in the regulation of the 
permeability of the BBB. More recently, the effect of a morphine chronic treatment, daily 
administered at a dose of 10mg/kg administered via intraperitoneal (i.p.), for 12 days, on 
the BBB permeability to large molecule tracers, such as Evans blue albumin and 
radioiodine, in several rat brain regions was investigated (Sharma and Ali 2006). They 
showed that morphine caused no significant BBB opening on the 12th day of morphine 
dependence. On the other hand, spontaneous withdrawal of morphine on day 1 resulted 
in profound stress symptoms, which were much more intense on the second day of 
morphine withdrawal. During morphine withdrawal, a marked increase in the BBB 
permeability to these protein tracers was seen in several regions of the brain, and this was 
most pronounced on the second day of morphine withdrawal (Sharma and Ali 2006). 
These findings suggested that morphine, its associated withdrawal syndrome, and 
subsequently provoked stress are capable to modify BBB function. 
Another study demonstrated that an acute morphine treatment (12 mg/kg i.p.) did not alter 
blood-to-brain transport of IL-1α, IL-2 or TNF-α, whereas both spontaneous and 
precipitated (injection of 1mg/kg of naltrexone) morphine withdrawal following a chronic 
morphine treatment had increased blood-to-brain transport of IL-2, with no change in 
blood-to-brain transport of IL-1α or TNF-α (Lynch and Banks 2008). The permeability of 
the BBB to IL-2 is usually dominated by brain-to-blood efflux, with only limited blood-to-
brain transport. With this study it was found that chronic morphine and withdrawal from 
morphine did not alter brain-to-blood efflux, but induced a novel saturable blood-to-brain 
transport system (Lynch and Banks 2008). 
Treatment of a primary culture of human brain microvessel endothelial cells with both 
morphine and the HIV-1 viral protein tat showed to induce the release of pro-inflammatory 
cytokines, which could trigger common intracellular pathways to regulate TJ protein 
expression, and, consequently, the structural and the functional integrity of the BBB 
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(Mahajan et al. 2008). Treatment of these cells with a combination of morphine and tat 
resulted in a significant decrease in ZO-1 and occludin gene expression in comparison to 
untreated control cells. Morphine alone and in combination with tat also increased JAM-2 
gene expression. 
The research group supporting the research of the present dissertation has also studied 
the effect of a chronic, 5-day protocol treatment with morphine in rats, a protocol that has 
previously demonstrated to induce opioid dependence (Noble et al. 2000), on the 
expression of several genes encoding for proteins critically involved in the maintenance of 
BBB properties, such as junction proteins, influx and efflux transporters (Yousif et al. 
2008). The expression of occludin registered a slight increase (1.23-fold induction) in 
isolated brain microvessels of morphine-treated rats in comparison to control rats (Yousif 
et al. 2008). However, the induction of this gene did not seem to have an effect on BBB 
tightness, as morphine-treated and saline-treated animals did not register any difference 
in terms of the brain accumulation of the radiolabeled sucrose, which was in situ brain 
perfused and used as a marker of BBB integrity (Yousif et al. 2008). These findings seem 
to be in agreement with the previous conducted study by Sharma and Ali (Sharma and Ali 
2006). 
 
4.5.2.1. Focus on the role of Morphine on the expression of ABC transporters 
Morphine is used in the control of pain in patients with cancer. Therefore, it is often co-
administered with several anticancer agents, and the majority of these agents are 
substrates for P-gp. The modulation of this ABC transporter at the BBB by the 
administration of morphine can modify the efflux, the distribution and efficacy of these 
chemotherapeutic agents and, thus, cancer therapy. 
There are a few studies that evidenced that morphine is also able to influence the 
expression and activity of the transport systems at the BBB, namely that of the ABC 
transporters. In 2000, a chronic administration of morphine in rats resulted in decreased 
antinociceptive response, which was accompanied by a 2-fold increase in P-gp protein 
expression in whole brain homogenates, determined by Western Blot (WB) (Aquilante et 
al. 2000). Rats were subjected to a 5-day treatment with morphine, where they received 
morphine at 10mg/kg in the first 2 days, and then 20mg/kg in the last 3 days of treatment, 
which resulted in a decrease of the antinociceptive effect of morphine. It was 
hypothesized that the registered P-gp up-regulation was an important cause for the 
enhanced morphine efflux from the brain, and, thus, reducing its pharmacological activity 
and contributing to the development of morphine tolerance (Aquilante et al. 2000). A 
similar study was later conducted in 2003 by Zong and Pollack, who demonstrated that 
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mice treated with morphine for 3 days showed an increase in the P-gp expression of 
about 1.4-fold in comparison to control mice (Zong and Pollack 2003). 
In 2004, a study explored the effect of short-term (72 h) morphine exposure on the P-gp 
expression of several human cancer cell lines and of the mouse fibroblast NIH-3T3 cell 
line, as well as its effects on cellular resistance to the known P-gp substrates, vinblastine 
and colchicine (Pajic et al. 2004). This study has shown that the P-gp regulation may be 
cell-type dependent, as the morphine treatment induced P-gp expression in the mouse 
fibroblast cell line, but not in any of the human cancer cell lines. 
ABCB1 gene expression was also reported to increase in human brain microvessel 
endothelial cells when exposed to either morphine (100 nM) or the HIV-1 protein tat, alone 
and in combination (Mahajan et al. 2008). 
The previously mentioned study, conducted by the research group supporting the 
research of the present dissertation, demonstrated that a chronic treatment with morphine 
for 5 days was able to induce the gene expression of several ABC efflux transporters, 
such as Abcb1a, Abcg2, and Abcc1, in rat brain microvessels (Yousif et al. 2008). 
However, no change was registered following this protocol on the P-gp protein expression 
or functional activity, assessed by WB and in situ brain perfusion, respectively. Still, 
chronic treatment with morphine showed to induce the expression of P-gp in two brain 
regions, the brain cortex and hippocampus, as evidenced at both mRNA level by 
quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), and protein level by in 
situ hybridization (Yousif et al. 2008). These findings are in agreement with the earlier 
results presented by Aquilante and her group (Aquilante et al. 2000). One should note, 
these results were obtained from morphine-treated rats that were sacrificed 12h after the 
last dose of morphine. Different studies have demonstrated that morphine withdrawal 
symptoms start to appear as early as 12h, and evolve for the following 24-72h after the 
last dose of morphine (Desjardins et al. 2008; Sharma et al. 2006). Therefore, such 
results on the modulation of P-gp and other BBB markers may be not only linked to the 
chronic morphine treatment applied, but can also be a result of the developing morphine 
withdrawal syndrome. 
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II. OBJECTIVES 
 
P-gp and BCRP are the main drug efflux transporters present at the rat and human BBB, 
having the most significant expression levels among all ABC transporters at the BBB, and 
also exhibiting the broadest list of substrates known at present time. Secondly, P-gp and 
BCRP share a considerable number of substrates, and so work in concert in the efflux of 
various drugs, neurotoxicants and xenobiotics out of the brain, cooperating in the task of 
brain protection and maintenance of CNS homeostasis. Therefore, a change on the 
expression of these two ABC transporters can have a dramatic impact on the brain levels 
of several compounds, and alter CNS vulnerability. The discovery of the exact 
mechanisms by which P-gp and BCRP are regulated enables the development of the best 
strategies 1) to either prevent disease-associated up-regulation and/or to down-regulate 
these efflux transporters, and thus improve the clinical prognosis and brain drug delivery 
and treatment efficacy of CNS disorders, or 2) to increase P-gp and BCRP activities as a 
mechanism of enhanced brain protection and antidote against harmful P-gp/BCRP 
substrates. 
Since morphine, as previously demonstrated, is be capable of inducing P-gp expression at 
the rat BBB, the first main objective of this dissertation is to evaluate if morphine 
exposure in the rat is also able to influence Bcrp expression at the BBB, as well as 
to study the mechanism behind morphine-induced P-gp and Bcrp up-regulation. For 
this purpose, the following specific objectives were set in order to accomplish the present 
aim: 
 To evaluate at what time and extent the expression of P-gp and Bcrp in the rat 
BBB is altered following a subchronic morphine treatment. 
 To explore the regulatory signaling mechanism underlying morphine 
treatment effects on the levels of P-gp and Bcrp at the rat BBB. For the 
matter, we focused on one of the mechanisms of P-gp transcriptional up-regulation 
described in the literature, namely the glutamatergic pathway, which is thought to 
be involved in the overexpression of P-gp in epilepsy. 
 To evaluate the role of the opioid withdrawal syndrome developed following a 
subchronic morphine treatment on the modulation of P-gp and Bcrp levels at 
the rat BBB. For this purpose, the animal study model was subjected to different 
morphine protocol treatments, following which the development of a spontaneous 
or naloxone-precipitated withdrawal syndrome was conditioned. 
One of the most widely used model and valuable tool for the study of BBB structure and 
function is the isolation of brain microvessels from the brain cortical gray matter. Another 
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main objective of the present dissertation consists in a methodological study, to compare 
two techniques of brain microvessel isolation, mechanical dissection and 
enzymatic dissociation, and evaluate which technique gives the purest and the 
most enriched brain capillary endothelial cell fraction. This methodological study is 
crucial regarding the choice of the best approach to isolate brain microvessels for 
subsequent molecular biology and functional studies on the BBB. The further 
characterization of this BBB model in terms of the expression of several 
neurotransmitter receptors is also attained, in order to better understand how the BBB 
is able to answer to the external stimuli. 
Considering the important physiological role of P-gp in the efflux and elimination of 
harmful compounds out of the brain, therefore providing significant protection to such a 
vital organ, and the already evidenced capacity of quickly increasing its transport activity 
in other study models, the second main objective of the present dissertation is to test 
promising drug candidates as P-gp activators in an in vitro rat BBB model, and thus 
as potential antidotes against neurotoxic P-gp substrates. For that purpose, the 
following specific objectives were set: 
 To evaluate the P-gp activation capacity of thioxanthonic derivatives in an in 
vitro rat BBB model (RBE4 cells). These compounds have shown in a previous 
study to be suitable P-gp activators in the human intestinal epithelial Caco-2 cells 
(colorectal adenocarcinoma). Therefore, our aim is to evaluate if these data can be 
extrapolated to other tissue barriers, such as the BBB. 
 To assess whether the tested compounds identified as potential P-gp 
activators are able to confer an effective protection against neurotoxic P-gp 
substrates in RBE4 cells.  For this matter, mitoxantrone was selected as the 
neurotoxic P-gp substrate, and the protection effectiveness of potential P-gp 
activators against its cytotoxicity was evaluated by simultaneous cell exposure to 
the potential antidote and the toxic P-gp substrate. 
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Rationale and Objectives: 
Our group had previously revealed that a subchronic morphine treatment was responsible 
for an increase of P-gp expression in rat brain cortex vessels, 12h after the last dose of 
morphine was administered (Yousif et al. 2008). Moreover, since several studies indicate 
that morphine is a substrate of P-gp in both rodents and humans (Hamabe et al. 2007; 
Letrent et al. 1999a; Zong and Pollack 2000), and thus play a role in its brain-to-blood 
active efflux at the BBB, P-gp induction following a chronic exposure to morphine may 
potentiate its poor brain penetration and the fast tolerance development. Yet, the 
mechanism by which chronic morphine treatment lead to the P-gp induction was not 
explored and remained unknown, as well as little was known about its effect on the 
expression of BCRP, another major ABC transporter present at the BBB. 
Therefore, in this study we proposed to explore the amplitude and the kinetics of the 
modulation of P-gp and Bcrp expressions following a subchronic morphine treatment, 
using a escalating morphine dose regimen (10-40 mg/kg, i.p.) in rats. For that purpose, 
animals were sacrificed at different times after the treatment suspension, and freshly 
isolated rat brain microvessels and large vessels were used to analyze P-gp and Bcrp 
contents, at both mRNA and protein level. We also proposed to analyze the role of 
glutamate, the glutamatergic NMDA receptor and COX-2 in the morphine-induced 
regulation of such ABC transporters as a hypothetical mechanism of regulation. Indeed, 
brain extracellular levels of glutamate have shown to be increased during morphine 
withdrawal (Sepulveda et al. 2004). Also, different studies showed that glutamate 
increased P-gp expression in rat brain microvessels through action on the NMDA 
receptor, and subsequent COX-2 activity (Bauer et al. 2008; Zhu and Liu 2004; Zibell et 
al. 2009). For this second purpose of this study, animals were also exposed to an NMDA 
receptor antagonist, MK-801, or to a COX-2 inhibitor, meloxicam, at the end of the 
subchronic morphine treatment. Subsequently, P-gp and Bcrp protein contents were 
assessed in rat brain microvessels and large vessels, once animals were sacrificed 24h 
after the last dose of morphine. 
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Abstract
Subchronic morphine treatment induces P-glycoprotein (P-
gp) up-regulation at the blood–brain barrier. This study
investigates the rate and extent to which P-gp and breast
cancer-resistance protein (Bcrp) increase at the rat blood–
brain barrier following subchronic morphine treatment. Rats
were given increasing doses of morphine (10–40 mg/kg) or
saline i.p. twice daily for 5 days. The brain cortex large
vessels and microvessels were then mechanical isolated 6,
9, 12, 24, and 36 h after the last injection. The gene and
protein expression of P-gp and Bcrp in morphine-treated and
control rats were compared by qRT-PCR and western
blotting. The levels of Mdr1a and Bcrp mRNAs were not
signiﬁcantly modiﬁed 6 h post morphine, but the Mdr1a
mRNA increased 1.4-fold and Bcrp mRNA 2.4-fold at 24 h.
P-gp and Bcrp protein expression in brain microvessels was
unchanged 6 h post morphine and increased 1.5-fold at
24 h. This effect was more pronounced in large vessels than
in microvessels. However, extracellular morphine concentra-
tions of 0.01–10 lM did not modify the expressions of the
MDR1 and BCRP genes in hCMEC/D3 human endothelial
brain cells in vitro. MK-801 (NMDA antagonist) and meloxi-
cam (cyclo-oxygenase-2 inhibitor) given after morphine
treatment completely blocked P-gp and Bcrp up-regulation.
Interestingly, misoprostol and iloprost, two well-known agon-
ists of prostaglandin E2 receptors induced both MDR1 and
BCRP mRNA levels in hCMEC/D3. Thus, morphine does not
directly stimulate P-gp and Bcrp expression by the brain
endothelium, but glutamate released during morphine with-
drawal may do so by activating the NMDA/cyclo-oxygenase-2
cascade.
Keywords: Bcrp, blood–brain barrier, glutamate, morphine,
P-glycoprotein.
J. Neurochem. (2012) 10.1111/j.1471-4159.2012.07890.x
Morphine, especially its subchronic and chronic use, is
associated with the development of phenomena such as
addiction, tolerance, and the appearance of withdrawal
symptoms when it is stopped. The mechanisms underlying
these events involve complex molecular pathways, most of
which have been attributed to regulation of the main
morphine target, the opioid receptors. However, there is
increasing evidence that the blood–brain barrier (BBB) is
also involved (Tournier et al. 2011). Morphine crosses the
BBB to reach the brain parenchyma, but it does so less
well than other opioid drugs like fentanyl and methadone
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(Dagenais et al. 2004). This relatively poor brain penetration
of morphine has been linked, in part, to its active efﬂux from
the brain to the blood by the P-glycoprotein (P-gp, MDR1,
ABCB1) at the BBB (Zong and Pollack 2000; Hamabe et al.
2006). P-gp is the best known of the many drug transporters
at the BBB (Scherrmann 2005). The breast cancer-resistance
protein [breast cancer-resistance protein (BCRP), ABCG2],
another drug efﬂux transporter, is also abundant at the BBBs
of monkeys and humans (Dauchy et al. 2008; Ito et al. 2011;
Shawahna et al. 2011) and has been shown to efﬂux some
substrates that it has in common with P-gp (Decleves et al.
2011). P-gp and BCRP belong to the ATP-binding cassette
(ABC) efﬂux transporter superfamily and they limit the
access of many drugs to the CNS (Urquhart and Kim 2009).
The effects of opioids on BCRP activity have been poorly
evaluated. Recently, we identiﬁed buprenorphine and its
metabolite norbuprenorphine as inhibitors of BCRP (Tour-
nier et al. 2010). However, the effect of exposure to
subchronic opioid treatment on the synthesis of BCRP at
the BBB has never been studied. In contrast, there have been
several studies on the P-gp-mediated transport of morphine
in rodents and humans (Callaghan and Riordan 1993; Letrent
et al. 1999b; King et al. 2001). Inhibiting P-gp increased
morphine-induced analgesia in rats (Letrent et al. 1999a),
and morphine has an increased anti-nociceptive effect in
P-gp-deﬁcient knockout mice (Thompson et al. 2000; Zong
and Pollack 2000). Moreover, variation in the pain relief in
patients with cancer has been associated with variants of the
ABCB1 gene which alter the expression and/or activity of
P-gp (Campa et al. 2008; Lotsch et al. 2009). The pharma-
cokinetic–pharmacodynamic relationships between the
plasma concentration of morphine and its CNS effect EEG
were clearly demonstrated by Groenendaal et al. 2007 who
showed that P-gp modulates the distribution of morphine
within the biophase and so helps delay its CNS effect by
(Groenendaal et al. 2007). Therefore, P-gp is a key element
in the regulation of the effect of morphine on the CNS. An
increase in P-gp expression during morphine treatment may
thus lead to a timely decrease in the brain uptake of
morphine, which may explain the tolerance frequently
observed in the CNS effects of morphine. Two studies have
shown that P-gp is induced in the brains of mice (Zong
and Pollack 2003) and rats (Aquilante et al. 2000) by chronic
exposure to morphine. Recently, we showed that subchronic
morphine treatment induced P-gp expression in rat brain
cortex vessels 12 h after the last morphine dose (Yousif
et al. 2008), but rate and amplitude of this stimulation and
the mechanism underlying it remain unknown. It may be
because of at least two mechanisms: (i) the direct induc-
tion of P-gp by morphine via increased transcription of
the gene encoding P-gp, increased translation, and/or
post-translational processing, (ii) an indirect effect of mor-
phine during the withdrawal syndrome occurring after
subchronic treatment. In this study, we have ﬁrstly investi-
gated the kinetics of P-gp and Bcrp mRNA and protein levels
in rat brain vessels at different times after the last dose of
subchronic morphine treatment and then evaluated the roles
of glutamate and cyclooxygenase-2 (COX-2) in this induc-
tion. During morphine withdrawal, there is an increase in the
excitatory amino acid neurotransmission in the CNS area,
particularly the glutamate and aspartate concentrations
(Sepúlveda et al. 2004). Glutamate acts at four receptor
subtypes: NMDA, AMPA, kainate, and metabotropic gluta-
mate receptors, and this neurotransmitter increases P-gp
expression in rat brain endothelial cells (Zhu and Liu 2004).
P-gp was found to be regulated by a pathway that involves
glutamate signaling through NMDA receptors and COX-2
activity, which have both been found in the brain capillary
endothelial cells (Bauer et al. 2008; Zibell et al. 2009). In
this way, a glutamate–NMDA receptor–COX-2 pathway
could be involved in this morphine-mediated induction.
Materials and methods
Animals
The adult male 8-week-old Sprague–Dawley rats weighing 200–
240 g used in this study were purchased from Charles River
laboratory (L’arbresle, France). They were housed in groups of four
animals per cage in a temperature- and humidity-controlled room
with 12 : 12 h light/dark conditions (light from 8:00 AM to 8 PM)
and access to food and water ad libitum. They were acclimated for at
least 3 days prior to experimentation. The care and treatment of
animals conformed to the standards and guidelines promulgated by
the European Union Council Directive (2010/63/EU).
Drug treatment
Acute and subchronic morphine dosing
We used two treatment protocols. For acute treatment, rats were
given a single dose (10 mg/kg or 40 mg/kg, ip) of morphine (or
saline) and killed 3, 6, and 24 h later to study the levels of Mdr1a
and Bcrp mRNAs in cerebral vessels. For subchronic treatment,
animals were given several doses of morphine (or saline) over
5 days. The test rats were given morphine i.p. twice daily: 10 mg/kg
on day 1, 20 mg/kg on day 2, 30 mg/kg on day 3, and 40 mg/kg on
days 4 and 5. The increasing doses of morphine were used to
overcome any tolerance developed and to better simulate addiction
to morphine. Control rats were given physiological saline (1 mL/kg
i.p.) twice daily. Rats in both groups were killed at 6, 9, 12, 24, and
36 h post-treatment (day 5).
Treatment with MK-801
We measured the levels of P-gp and Bcrp by western blotting in rats
conditioned by subchronic morphine treatment and then given
dizocilpine maleate (MK-801, Sigma-Aldrich, Lyon, France), an
NMDA antagonist, to determine the inﬂuence of glutamate on the
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morphine-induced increases in P-gp and Bcrp. The rats were given
two injections of 1 mg/kg MK-801 i.p. one 1 h and the other 4 h post
morphine or saline treatment, because its half-life of elimination is only
2 h. They were killed 24 h after the last morphine or saline injection.
Treatment with Meloxicam
We studied the inﬂuence of COX-2 on the increases in P-gp and
Bcrp induced by morphine treatment by giving them each a single
i.p. injection of meloxicam (10 mg/kg), a COX-2 inhibitor,
immediately after the last morphine or physiological saline injection.
They were killed 24 h after the last morphine or saline injection.
Isolation of large vessels and microvessels from rat brain cortex
The brain cortex vessels were isolated from treated rats according to
Yousif et al. 2007. Brieﬂy, rats were anesthetized with isoﬂurane
and decapitated. Their brains were immediately removed and placed
in ice-cold Hank’s buffered salt solution (HBSS). The cerebella,
meninges, brainstems, and large superﬁcial blood vessels were
removed from the brains and the remaining cortices were minced in
ice-cold HBSS (4 mL per gram of tissue). The minced samples were
then homogenized in a Potter–Thomas homogenizer (Kontes Glass,
Vineland, NJ, USA) (0.25 mm clearance), using 15–20 up-and-
down strokes at 400 rpm. The resulting homogenates were centri-
fuged at 1000 g for 10 min. Each pellet was suspended in 17.5%
dextran (64–76 kDa, Sigma-Aldrich, Lyon, France) and centrifuged
for 15 min at 4400 g at 4°C in a swinging-bucket rotor. The
resulting pellets were suspended in Hank’s Buffered Salt Solution
containing 1% bovine serum albumin (BSA), while the supernatants
containing a layer of myelin were centrifuged once more for 15 min
at 4400 g. The two pellets from each sample were pooled,
suspended in HBSS with 1% BSA, and this suspension passed
through a 100 lm nylon mesh. Large vessels (mainly 20–30 lm)
were collected from the fraction retained on the 100 lm nylon
mesh. The ﬁltrate was passed through a 20 lm nylon mesh which
retained the microvessels (mainly 4–6 lm).
Measurement of transcript levels
Extraction of RNA from brain tissues
Total RNA was obtained from the isolated large vessels and
microvessels by lysing the surrounding basal lamina with proteinase
K and then extracting the RNA using the RNeasy Micro-Fibrous
Tissue micro-kit (Qiagen GmbH, Hilden, Germany) according to the
manufacturer’s instructions. The isolated RNA samples were puriﬁed
from contaminating genomic DNA by treatment with DNase (RNase-
Free DNase Set, Qiagen, SA). The concentration and purity of
the RNA samples obtained were assessed spectrophotometrically
using a Nanodrop spectrophotometer (Nanodrop ND-1000; Nano-
Drop Technologies, Wilmington, DE, USA), and the integrity of the
RNA was checked by electrophoresis through 0.8% agarose gels.
Reverse transcription
Total RNA samples (1 lg) from brain vessels or cultured hCMEC/D3
cells were reverse transcribed into cDNA in a ﬁnal volume of 20 lL.
The mixture consisted of 1 lg total RNA, 500 lM of each
deoxyribonucleotide triphosphate, 10 mM dithiothreitol, 1.5 lM
random hexa-nucleotide primers, 20 U RNAsin ribonuclease inhib-
itor, and 100 U Superscript II Rnase reverse transcriptase. Reagents
were purchased from Invitrogen (Cergy-Pontoise, France). Reverse
transcription was performed on a programmable thermal cycler
(PTC-100 programmable thermal controller; MJ Research Inc.,
Waltham, MA, USA). Hexamers were annealed at 25°C for 10 min,
the productswere extended at 42°Cfor30 min, the reaction terminated
by heating at 99°C for 5 min, and samples were quick-chilled to 4°C.
Real-time quantitative PCR
The effect of morphine on the transcripts levels was investigated by
qRT-PCR as previously described (Yousif et al. 2007). Speciﬁc
primer sequences were designed using OLIGO 6.42 software
(Medprobe, Oslo, Norway) (Table 1) and these primers were
synthesized by Invitrogen Life Technologies (Invitrogen). Fluores-
cent PCR reactions were performed on a Light Cycler thermal cycler
(Light-Cycler® instrument; Roche Diagnostics) using the LC-
FastStart DNA Master SYBR Green I kit (Roche Diagnostics,
Meylan, France). The PCR reaction mixture contained 1 lL LC-
FastStart DNA Master SYBR Green 1 mix, 1.2 lL of 10 mM
MgCl2, 0.5 lL of each upper and lower primer (ﬁnal concentration
0.5 lM), and 1.8 lL water. The cDNAs were diluted 50-fold and
5 lL aliquots were mixed with an equal volume of PCR mixture to
give a ﬁnal volume of 10 lL. The thermal cycling conditions were
8 min at 95°C, followed by 40 ampliﬁcation cycles at 95°C for 5 s,
64°C for 5 s, and 72°C for 5 s. Gene expression in each sample was
normalized on the basis of its b-actin gene expression (rat samples)
or TATA box-binding protein (TBP) gene expression (human
samples). The change was calculated from the ratio of the
expression of the gene of interest to that of the housekeeping gene
(b-actin or TBP) in morphine-treated and control samples.
Western blotting
Immunoblots were performed on protein extracted from both
large vessels and microvessels isolated at different times after the
Table 1 Sequences of primers used for qRT-PCR
Gene Forward primer (5′–3′) Reverse primer (5′–3′) Length (bp)
Rat b-actin CTGGCCCGGACCTGACAGA GCGGCAGTGGCCATCTCTC 132
Mdr1a CAACCAGCATTCTCCATAATA CCCAAGGATCAGGAACAATA 97
Bcrp CAGCAGGTTACCACTGTGAG TTCCCCTCTGTTTAACATTACA 75
Human TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 132
MDR1 CACCCGACTTACAGATGATG GTTGCCATTGACTGAAAGAA 81
NR1 TCGGACAAGAGCATCCA GACACGCATCATCTCAAACC 87
BCRP TGACGGTGAGAGAAAACTTAC TGCCACTTTATCCAGACCT 122
© 2012 The Authors
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last dose of morphine or saline to measure, semi-quantitatively,
the amounts of P-gp and Bcrp. b-actin was the reference protein.
After its extraction, the protein content from samples of large or
microvessels was determined with the Bradford reagent
(Sigma-Aldrich, Lyon, France) and a BSA calibration curve.
Equal amounts of proteins were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis on 8% acrylamide/
bisacrylamide gels and the separated proteins were transferred
electrophoretically to a nitrocellulose membrane (2 h at 80 V).
Free sites on the membrane were blocked by incubation overnight
at 4°C with 5% non-fat milk in Tris-buffered saline containing
0.1% Tween 20. The membranes were immunoblotted by
incubation overnight at 4°C with mouse monoclonal antibody
C219 against rat P-gp (diluted 1 : 100) (Abcam, Cambridge,
UK), or rat monoclonal anti-rat Bcrp antibody BXP-53 (diluted
1 : 150) (Abcam) The membranes were then washed and
incubated for 1 h at 25°C with horseradish peroxidase-conjugated
anti-mouse IgG (diluted 1 : 20 000) or anti-rat IgG (1 : 10 000)
(GE healthcare, Buckinghamshire, UK). The membranes were
washed again and exposed to Amersham ECL blotting detection
reagent (ECL, Amersham Biosciences Europe GmbH, Orsay,
France). Signals were revealed using the Bio-Rad ChemiDoc®
XRS imaging device (Marnes La Coquette, France). The blots
were then stripped and reprobed with monoclonal mouse anti-b-
actin antibody AC-74 (Sigma-Aldrich, Lyon, France) (diluted
1 : 10 000). Proteins were quantiﬁed using the Quantity One data
analyser software v. 4. 6. 1 (Bio-Rad) and normalized to b-actin.
Effect of morphine, glutamate, iloprost, and misoprostol
on the expression of P-gp and BCRP in the hCMEC/D3 cells
The hCMEC/D3 cells were kindly donated by Dr. P.O. Couraud
of the Institut Cochin, University Paris Descartes, Paris, France.
The immortalized hCMEC/D3 cells were cultured as previously
described (Dauchy et al. 2009). Cells were grown on plates
coated with rat-tail collagen type I in EBM-2 medium supple-
mented with 1 ng/mL bFGF, 2.5% FCS, ascorbate acid, 10 mM
HEPES, penicillin–streptomycin at 37°C in a saturated atmo-
sphere of 5% CO2, 95% air. The culture medium was changed
every 3–4 days.
Cells were cultured for 24 h in medium alone (controls) or in
medium containing morphine (0.01, 0.1, 1, or 10 lM), glutamate
(10 or 100 lM), iloprost (1 or 10 lM), or misoprostol (1 or 10 lM).
Total RNA was extracted from the hCMEC/D3 cells using the
RNeasy mini kit (Qiagen GmbH, Hilden, Germany) according to the
manufacturer’s instructions, including DNAse I treatment to remove
genomic DNA. The concentrations and purity of the RNA samples
were assessed. The expressions of the MDR1 and BCRP genes were
evaluated by qRT-PCR using the procedure outlined above. The
reference genes were TBP and b-actin.
Statistical analysis
Data were analyzed using GraphPad Prism® 4.0 software (San
Diego, CA, USA). The results are expressed as means ± SD.
Student’s unpaired t-test was used to identify signiﬁcant differences
between in vivo morphine and saline groups. The effect of morphine
on hCMEC/D3 cells was analyzed by one-way ANOVA and a post hoc
Tukey’s test. All the tests were two-tailed and statistical signiﬁcance
was set at p < 0.05.
Results
Expression of Mdr1a and Bcrp gene in the
cortex vessels of morphine-treated rats
The levels of Mdr1a and Bcrp mRNAs were determined in
cortex large vessels and microvessels of rats 3, 6, and 24 h
after a single dose of saline or morphine (n = 4 per group).
The levels of neither the Mdr1a nor the Bcrp gene were
signiﬁcantly altered by morphine at any of the times tested
(data not shown).
We also determined the effect of a 5-day morphine
treatment on the levels and kinetics of Mdr1a and Bcrp
mRNAs in cortex microvessels (Fig. 1a and 2a) and large
vessels (Fig. 1b and 2b). The amounts of Mdr1a and Bcrp
transcripts in both microvessels and large vessels were
unchanged 6 h after the last dose of morphine. But, the
levels of bothMdr1a and Bcrp genes increased starting at 9 h
after the last morphine dose. The amounts of Mdr1a
transcripts in microvessels were signiﬁcantly increased by
22% at 12 h and by 36% at 24 h after the last dose of
morphine (Fig. 1a). Mdr1a mRNA levels increased more in
large vessels than in microvessels. The levels of Mdr1a
transcripts 12 h after the last morphine dose were increased
by 60% in large vessels and by 22% in microvessels (Fig. 1a
and b). However, levels of Mdr1a transcripts in both types of
vessels returned to baseline 36 h after the last dose of
morphine (Fig. 1a and b).
The levels of Bcrp transcripts in both the microvessels and
large vessels of morphine-treated rats were roughly double
those of controls, with the increase occurring earlier in large
vessels (Fig. 2a and b). Thus, the amount of Bcrp transcript
was 120% greater than that of controls 12 h after the last
morphine injection in large vessels, whereas it was only 40%
greater in microvessels. Bcrp gene expression was still
signiﬁcantly greater than in controls 36 h after the last dose
of morphine, in both the large vessels and microvessels,
unlike Mdr1a expression (Fig. 2b). These data indicate that
the levels of both Mdr1a and Bcrp transcripts were increased
in rat brain vessels from 12 h after the last dose of a
subchronic morphine treatment.
P-gp and Bcrp in the cortex vessels of
subchronic morphine-treated rats
Western blot experiments with the anti-P-gp C-219 antibody
revealed an immunoreactive protein of about 170 kDa,
corresponding to P-gp, in isolated large vessels and micro-
vessels, as previously reported (Yousif et al. 2007). The
levels of P-gp were no higher than those of controls 6 h after
the last dose of morphine. But, its level in both microvessels
and large vessels was 1.5-times that of controls 24 h after the
last dose of morphine. Like mRNA levels, morphine
increased the expression of P-gp more in large vessels than
in microvessels. The P-gp expression in microvessels
decreased back to baseline at 36 h (Fig. 3).
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We also determined the kinetics of Bcrp expression in the
samples that were used for P-gp analysis. Just like its mRNA,
the amount of Bcrp protein was unaltered 6 h after the last
dose of morphine, but had increased 1.45-fold in large
vessels and 1.6-fold in microvessels by 24 h post treatment
(Fig. 4) and the amount of Bcrp in morphine-treated rats was
still higher than in controls 36 h post treatment.
Thus, the levels of P-gp and Bcrp proteins were increased
in brain vessels of morphine-treated rats from 24 h post
treatment, as were the levels of Mdr1a and Bcrp transcripts
from 12 h after the last morphine dose.
Effect of morphine on the levels of MDR1 and BCRP
transcripts in human hCMEC/D3 cells
We tested the effect of morphine on immortalized human
brain capillary endothelial (hCMEC/D3) cells to determine
whether the up-regulation of P-gp and Bcrp in brain vessels
by morphine involved only the vascular endothelial cells or
the complete neurovascular unit (Weksler et al. 2005). Cells
were exposed to concentrations of morphine from 0.01 to
10 lM for 24 h and the amounts of MDR1 and BCRP gene
transcripts were determined by qRT-PCR. Morphine did not
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Fig. 1 Changes in Mdr1a gene expression over time in morphine-
treated rats after the last dose of morphine compared to control rats
(baseline ﬁxed at 100%) in small cerebral vessels (a) and large
cerebral vessels (b). All data have been normalized to b-actin mRNA
in the same sample and are expressed as means ± SD (n = 4 rats
per time point). *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test).
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Fig. 2 Changes in breast cancer-resistance protein (Bcrp) gene
expression over time in morphine-treated rats after the last dose of
morphine compared to control rats (baseline ﬁxed at 100%) in small
cerebral vessels (a) and large cerebral vessels (b). All data have
been normalized to b-actin mRNA in the same sample and are
expressed as means ± SD (n = 4 rats per time point). *p < 0.05,
**p < 0.01 (Student’s t-test).
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alter the levels of either MDR1 or BCRP gene transcripts in
hCMEC/D3 cells at any of the concentrations used (Fig. 5).
Effect of MK-801 and meloxicam on the expression of
P-gp and Bcrp in cortex vessels
As endothelial cells may not be the direct target of morphine
to increase P-gp and BCRP expression, we looked for the
pathway by which it might act in rat cortex vessels. It was
recently shown that exposure of isolated rat brainmicrovessels
to glutamate ex vivo signiﬁcantly increased P-gp expression by
activation of the NMDA/COX-2 pathway (Bauer et al. 2008).
We therefore treated rats with morphine with or without the
NMDAantagonistMK-801 to determinewhether activation of
NMDA receptors by glutamate was involved in the up-
regulation of P-gp and Bcrp. The amounts of P-gp and Bcrp
measured by western blotting indicated that MK-801 totally
blocked the morphine-dependent up-regulation of P-gp and
Bcrp in large vessels and microvessels 24 h after the last
morphine dose; their expressions in rats given morphine plus
MK-801 were comparable to those in control rats (Fig. 6 and
7).MK-801 had a less pronounced effect onBcrp expression in
large vessels than in microvessels. Similarly, meloxicam, a
COX-2 inhibitor, totally blocked the morphine-dependent up-
regulation of P-gp and Bcrp in large vessels as well as in
microvessels 24 h after the last morphine dose (Fig. 6 and 7).
Neither MK-801 nor meloxicam given alone changed the
expression of Mdr1a and Bcrp; their activities were the same
as in saline-treated rats (data not shown). Taken together,
these results suggest that NMDA/COX-2 pathway is impli-
cated in morphine-dependent Bcrp and P-gp induction.
Effect of glutamate, iloprost, and misoprostol on the levels
of MDR1 and BCRP transcripts in human hCMEC/D3 cells
We tested the effect of glutamate on MDR1 and BCRP
transcripts in hCMEC/D3 cells to determine whether gluta-
mate was directly involved in the regulation of P-gp and
BCRP. Cells were exposed to 10 and 100 lM of glutamate
for 40 min, washed, and then incubated in glutamate-free
medium for 5.3 h before the amounts of MDR1 and BCRP
gene transcripts were analyzed by qRT-PCR. The relative
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expressions of MDR1 and BCRP were not signiﬁcantly
different from those in non-treated cells (Fig. 8a and b). We
also measured the transcript levels of the NR1 gene of the
NMDA receptor in hCMEC/D3 cells. NR1 transcript levels
were very low in hCMEC/D3 cells (cycle threshold > 32 for
a dilution 1 : 20 of the cDNA reversed transcribed from 1 lg
of total RNA), that may explain the absence of effect of
glutamate on hCMEC/D3 cells.
As prostaglandin E2 (PGE2) is the major product of COX-
2, we also tested the effect of two PGE2 analogs, iloprost and
misoprostol, on hCMEC/D3 cells to determine whether
COX-2 activity is involved in the regulation of P-gp and
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BCRP expression. Cells were exposed to 1 lM or 10 lM of
iloprost or misoprostol for 6 h and the amounts ofMDR1 and
BCRP gene transcripts were also determined by qRT-PCR.
Both concentrations of iloprost signiﬁcantly increased the
concentrations of MDR1 and BCRP gene transcripts. Thus,
10 lM iloprost increased MDR1 transcripts three-fold over
controls and BCRP transcripts two-fold (Fig. 8c and d).
Misoprostol had weaker effects on the levels of MDR1 and
BCRP transcripts; 10 lM misoprostol produced just a
signiﬁcant increase in MDR1 expression over the control
and a weaker increase in BCRP expression.
Discussion
Opioids, particularly morphine, are the standard analgesics
used in the clinical management of chronic and severe pain.
However, patients require greater and greater doses to
maintain the same level of analgesia as they become tolerant
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Fig. 8 Effects of glutamate, iloprost, and misoprostol on MDR1 and
BCRP gene expression. hCMEC/D3 cells were incubated with
medium containing 0, 10 lM, or 100 lM of glutamate at 37°C for
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Journal of Neurochemistry © 2012 International Society for Neurochemistry, J. Neurochem. (2012) 10.1111/j.1471-4159.2012.07890.x
© 2012 The Authors
8 S. Yousif et al.
to their central effects, a phenomenon known as central
tolerance. The animal treatment protocol, with frequent
increasing doses reﬂects the typical pattern of opioid abuse.
The subchronic morphine treatment, twice daily for 5 days,
allows the serum concentration of morphine to ﬂuctuate, with
peaks and troughs of morphine. These ﬂuctuations generate
withdrawal after the last dose of morphine as already
reported in our laboratory (Desjardins et al. 2008). This
proﬁle of drug administration is also responsible for the
development of tolerance to morphine (Way et al. 1969;
Kalivas and Duffy 1987). P-gp, a key-element in the control
of the brain distribution of several opioids at the BBB,
including morphine, may be responsible for this tolerance, as
its expression is also increased by morphine. There have
been two reports of P-gp induction in the whole brains of
mice (Zong and Pollack 2003) and rats (Aquilante et al.
2000) after subchronic exposure to morphine. Aquilante
et al. 2000 measured the amount of P-gp the day after the
last dose of morphine, while Zong and Pollack 2003 did so
24 h after the last morphine dose. But, neither of these
studies distinguished the effect of morphine during treatment
from that occurring during withdrawal. We have previously
used isolated rat brain microvessels to show that the amount
of P-gp at the BBB increased as early as 12 h after a 5-day
morphine treatment; this treatment was similar to that used in
the studies cited above (Yousif et al. 2008). The subchronic
morphine treatment used in this study is widely used for
behavioral and neurobiological studies in our laboratory. We
showed, recently, that it triggers withdrawal that started as
early as 9 h after the last dose of morphine (Desjardins et al.
2008). The working hypothesis for this study was that the
induction of P-gp and Bcrp in the rat BBB was because of
the withdrawal syndrome following subchronic morphine
treatment rather than from the direct effect of morphine at the
BBB during the morphine treatment. A single dose of
morphine (10 or 40 mg/kg, i.p.) did not increase the levels of
P-gp mRNA in either type of rat brain vessels at 3, 6, and
24 h. Similarly, the levels of P-gp transcripts and protein
were not modiﬁed 6 h after a 5-day morphine treatment,
suggesting that morphine itself does not stimulate P-gp
synthesis during this treatment. Conversely, the levels of
Mdr1a transcripts and P-gp protein increased between 9 h
and 24 h after this morphine treatment. Therefore, these
in vivo experiments suggest that morphine does not directly
induce P-gp up-regulation at the brain endothelial, but
triggers other mechanisms during withdrawal that follows its
chronic administration which then induce P-gp synthesis.
This is supported by our in vitro experiments showing that
morphine did not stimulate the synthesis ofMDR1 transcripts
in hCMEC/D3 human endothelial cells, although P-gp
synthesis by these cells is increased by rifampin (Zastre
et al. 2009). Our data are also supported by other in vitro
experiments demonstrating the absence of P-gp induction in
several cancer cell lines exposed to morphine (Pajic et al.
2004). In contrast, Pal et al. 2011 have shown that prolonged
exposure (15 days) of caco-2 cells to 3 lM morphine
increased their MDR1 mRNA contents, suggesting that
effect of morphine on P-gp expression may depend on tissue
of origin and length of exposure (Pal et al. 2011).
We therefore postulate that morphine-mediated stimulation
of P-gp synthesis occurs during the spontaneous withdrawal
syndrome that follows the end of a 5-day morphine treatment
rather than to a direct effect of morphine on P-gp expression.
Guo et al. (2005) found that the extracellular concentration
of glutamate in the hippocampus of mice determined
by microdialysis was decreased after acute or subchronic
morphine treatment. But, they also showed that the extra-
cellular glutamate concentration was signiﬁcantly increased
in an artiﬁcial morphine withdrawal situation induced by the
opioid antagonist naloxone (Guo et al. 2005). There is also
good evidence from studies on rodents with experimental
epilepsy that the massive release of glutamate or intracere-
broventricular injection of kainate results in the activation of
glutamate receptors in the hippocampus and the increase in
P-gp expression (Zhu and Liu 2004; Potschka 2010).
Glutamate also increases P-gp expression in primary cultures
of brain endothelial cells (Zhu and Liu 2004). It has also been
shown recently that exposure of isolated rat brain microves-
sels to glutamate ex vivo signiﬁcantly increases P-gp
synthesis through the activation of NMDA receptors, which
increases the activity of COX-2, which, in turn produces
prostaglandin E2. It is believed that the effect of COX-2 on
P-gp expression is mediated by PGE2 acting on E-type
prostanoid receptor (EP) 1 receptors. PGE2 is a major
product of COX-2 signaling in the brain. MRP4, a member
of the multidrug-resistance proteins (MRPs) belonging to the
ABC protein superfamily, takes part in the brain-to-blood
efﬂux transport of PGE2 at the BBB. It is thus likely to be
involved in the release of PGE2 from the endothelial cells
and so to act as a signaling molecule (Reid et al. 2003;
Akanuma et al. 2010). It acts on four different G protein-
coupled receptors (EP1, EP2, EP3, and EP4), which mediate
diverse effects (Hata and Breyer 2004). EP1 receptor
expression has already been found in isolated rat brain
capillaries by (Pekcec et al. 2009), and its blockade by SC-
51089, a speciﬁc antagonist of EP1 receptor, abolished the
glutamate-induced increase of P-gp expression in brain
capillaries, suggesting that the EP1 receptor plays a key role
in the signaling events that regulate P-gp expression via
glutamate.
The regulation of P-gp gene transcription at the BBB is
rather complex and is far from being completely understood
(Miller 2010). Several factors that are known to be involved in
the regulation of the MDR1 promoter. NF-kB is a ubiquitous
transcription factor that has been shown to up-regulate P-gp
expression and function in several cancer cells (Bentires-Alj
et al. 2003). Upon activation of NF-kB, PI3K/Akt are
upstream signals which lead to the phophorylation of IkB
© 2012 The Authors
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proteins by IkB kinase. The phosphorylated IkB allows the
release of NF-kB, which is translocated to the nucleus, where it
activates its target genes (Karin 1999). EP1 receptor signaling
is coupled to the phospholipase C/inositol triphosphate
pathway, leading to activation of PI3K/Akt and mobilization
of intracellular calcium (Asbóth et al. 1996). PGE2 also
activates NF-kB through EP1 receptors in colonocytes and
strongly induces IkB phophorylation, (Kim et al. 2007).
Hence, we postulate that these mechanisms might be present
at the BBB and the downstream effect of COX-2 on the
regulation of P-gp and BCRP expression may be through
a PGE2-EP1-PI3K/Akt-NF-kB signaling pathway. The
b-catenin signaling pathway might also be behind the effect
of NMDAr/COX-2 on the regulation of P-gp and BCRP
expression. Lim et al. 2008. showed that stabilizing and
activating b-catenin signaling increases P-gp expression and
that this was functionally signiﬁcant (Lim et al. 2008).
Moreover, manipulating b-catenin signaling also affects the
expression of other ABC transporters, such as BCRP (Scotto
2003). The EP1 receptor contributes signiﬁcantly to the PGE2-
mediated stabilization of b-catenin by activating phospholi-
pase C and PI3K, and thus strongly increases the amount of
b-catenin in the nucleus (Lee et al. 2004). The stabilization
and subsequent translocation of b-catenin leads to the activa-
tion of the Tcf-/Lef-1 transcription factor, which alters the
expression of several genes, including theMDR1 gene (Fujino
et al. 2002).
Thus, these data on the release of glutamate and its effect
on P-gp support our hypothesis that the induction of P-gp
synthesis in brain large vessels and microvessels of rats
treated with morphine for 5 days involves the glutamatergic
system and is because of the glutamate released during
spontaneous morphine withdrawal. This induction driven by
morphine withdrawal may occur through activation of the
NMDA receptor by glutamate and COX-2 activity. We tested
the direct effect of glutamate on MDR1 and BCRP transcript
production by incubating hCMEC/D3 cells with two con-
centrations of glutamate (10 and 100 lM). Glutamate had no
inﬂuence on MDR1 and BCRP expression, the transcript
levels were the same as in the control (Fig. 8). We also
checked the mRNA levels encoding for the NR1 subunit of
the NMDA receptor by qRT-PCR on cDNA from hCMEC/
D3 cells. There was very low expression of the NR1 subunit
of the NMDA receptor in these cells, which agrees well with
the ﬁnding that glutamate had no effect on MDR1 and BCRP
mRNA levels in hCMEC/D3.
As we observed the greatest expression of P-gp in brain
vessels 24 h after the last morphine dose, we dosed morphine-
treated rats with two injections of 1 mg/kgMK-801 or a single
injection of meloxicam after the last dose of morphine to see
whether the NMDA/COX-2 pathway could be involved.
Both MK-801 and meloxicam completely blocked the over-
expression of P-gp in both microvessels and large vessels.
Althoughmeloxicam is not a very speciﬁc inhibitor of COX-2,
it consistently proved to be a preferential inhibitor of COX-2
rather than of COX-1, in contrast to a group of standard
NSAIDs (Engelhardt 1996; Degner et al. 1998). COX-1 has
not been shown to be constitutively expressed in the endothe-
lial cells of the human BBB (Tomimoto et al. 2002), whereas
there is evidence that COX-2 is (Zibell et al. 2009). This
indicates that the observed effect of meloxicam is more likely
to be because of inhibition of COX-2 than of COX-1. As
hCMEC/D3 cells express no NMDA receptor, exposing this
human cell line toMK-801 ormeloxicam should have no effect
on the expression of MDR1 and BCRP genes. We incubated
hCMEC/D3 cells with PGE2 analogs, iloprost and misopros-
tol, to determine the involvement of COX-2 in the regulation of
P-gp and BCRP in these cells and to study the downstream
cascade. Iloprost is a structural analog of prostacyclin whose
afﬁnity for EP1 receptors is similar to that of PGE2, whereas
misoprostol is a PGE1 analog whose agonist activity is
mediated by EP2, EP3, and EP4 receptors (Abramovitz et al.
2000). Iloprost increased the amounts of both MDR1 and
BCRP gene transcripts, whereas the highest concentration
tested of misoprostol increased MDR1 transcription but had
little effect on BCRP expression (Fig. 8c to 8f). These ﬁndings
also point to COX-2 activity mediated by PGE2 should act via
EP1 receptor rather than via EP2–EP4 receptors. We believe
this is clear evidence that the glutamate release and COX-2
activity after the last morphine dose are involved in the
induction of P-gp up-regulation. We therefore suggest that
repeated doses of morphine without the withdrawal syndrome
may not affect P-gp synthesis during exposure to morphine.
However, the glutamate released during the spontaneous
morphine withdrawal syndrome does affect P-gp expression
and may be part of the mechanism underlying morphine
tolerance, even though the small increase in Mdr1a mRNA
expression found here cannot be themajor cause of tolerance as
morphine is a poor substrate of P-gp. Schinkel et al. 1995
showed that the concentration of morphine in the brains of
Mdr1a ‘knockout’ mice was only 1.7-fold greater than that in
the brains of normal mice (Schinkel et al. 1995). These
pre-clinical datamay have clinical relevance as patients treated
with opiates for pain relief (oxycodone, morphine, hydromor-
phone) or heroin maintenance (methadone) suffer from
withdrawal syndrome. This could increase P-gp expression
and thus decrease the pharmacological effect of opiates that are
P-gp substrates, but most importantly decrease the efﬁcacy of
anti-cancer drugs that are frequently given with morphine, and
of methadone for heroin addiction, as these drugs are better
substrates of P-gp than morphine.
We have also measured the kinetics of P-gp induction in
large vessels and microvessels. P-gp synthesis is not
uniform throughout the rat brain vasculature, as there is
less P-gp in small arteries than in microvessels and small
veins of the brain cortex (Saubamea et al. 2012). Our
results show that the increase in P-gp expression was more
pronounced in large vessels than in microvessels, suggest-
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ing that small arteries and veins are more sensitive to the
released glutamate. We also ﬁnd that the expression of
Bcrp, like that of P-gp, is increased following subchronic
morphine treatment. There is a lack of information on the
effects of opioids on BCRP activity despite increasing
evidence that BCRP at the BBB modulates the brain
distribution of drug substrates. We showed recently that
buprenorphine and its main metabolite in human, norbupr-
enorphine, are inhibitors of BCRP, whereas opioids
appeared to be poor substrates of BCRP (Tournier et al.
2010). However, we clearly showed that the concentration
of Bcrp in rat brain vessels was doubled 36 h after the last
dose of a 5-day morphine treatment. The increase in Bcrp
synthesis was higher than that of P-gp and more
prolonged. The concentration of Bcrp did not return to
baseline 36 h after the last dose of morphine, unlike that of
P-gp. This difference in Bcrp and P-gp induction might
mean that there is a distinct transcriptional mechanism or
post-transcriptional regulation during the activation of the
Mdr1a and Bcrp genes, although they both involve NMDA
receptor activation and COX-2 activity. These higher
concentrations of Bcrp protein are positively correlated
with greater Bcrp gene expression 36 h after the last dose
of morphine, in contrast to the ﬁndings for Mdr1a and
P-gp. These distinct results could also be related to the
difference in the half-lives of these two transporters: P-gp
has a half-life of 14–17 h (Muller et al. 1995), whereas the
estimated half-life of BCRP is longer around 60 h (Peng
et al. 2010). Thus, de novo synthesized P-gp might be
eliminated faster than BCRP. This is, to our knowledge,
the ﬁrst time that Bcrp expression has shown to be
regulated via glutamate-NMDA-COX-2 activation. The
increase in BCRP expression that follows morphine
treatment may thus decrease the penetration of drugs that
are BCRP substrates into the brain. The substrates of
BCRP that are used to treat humans are mainly anti-cancer
drugs like cytotoxic drugs and tyrosine kinase inhibitors.
Erlotinib and geﬁtinib, two tyrosine kinase inhibitors used
to treat several solid cancers, are well-known substrates of
BCRP and their brain distributions are restricted because
of the high concentration of BCRP at the BBB (Chen et al.
2011; de Vries et al. 2012). This low brain penetration is a
major issue in the treatment of brain metastasis that is
often observed in patients suffering lung cancer and
metastatic renal cancer. There is also evidence that the
expression of BCRP in isolated human brain microvessels
is higher than that of P-gp (Shawahna et al. 2011), making
BCRP a key element in controlling the access of its
substrates to the brain. As morphine is widely prescribed to
manage severe pain in patients with cancer, the up-
regulation of BCRP following intermittent morphine
treatment and withdrawal syndromes may increase the
expression of BCRP in the human BBB, which could
restrict the distribution within the CNS of any anti-cancer
drugs that are substrates of BCRP.
In conclusion, we have clearly shown that the expression
of P-gp and Bcrp at the rat BBB is not increased at the end of
a subchronic morphine treatment that triggers tolerance to the
analgesic effects of morphine. Thus, our data do not support
the concept that P-gp auto-induction is involved in the
mechanism of tolerance often observed with morphine.
Conversely, the expression of P-gp and Bcrp begins to
increase 9 h after the last dose of a subchronic morphine
treatment, which coincides with the appearance of the
morphine withdrawal syndrome. We suggest that morphine
withdrawal syndrome occurring after a subchronic morphine
treatment leads to the activation of the NMDA/COX-2
pathway whose consequences are increases in P-gp and Bcrp
expression at the rat BBB.
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General outcome: 
The results obtained in the present publication demonstrated, for the first time, that 
subchronic morphine exposure was able to up-regulate P-gp but also Bcrp expression at 
the rat BBB. Furthermore, it was also the first time that a glutamate-NMDA receptor-COX-
2-PGE2 signaling pathway was pointed and demonstrated as being implicated in the 
morphine-induced up-regulation of both ABC transporters.  
In fact, a 5-day subchronic morphine regimen was able to up-regulate both P-gp and Bcrp 
12-24h after the last dose of morphine, an effect that was not registered at earlier time-
points of animal sacrifice (6h, 9h). This was confirmed at both mRNA and protein level. 
The peak of Abcb1a and Abcg2 mRNA induction was registered at 24h, with a 1.4-fold 
and a 2.4-fold increase, respectively. Similarly, P-gp and Bcrp protein levels were 1.5-fold 
and 1.6-fold increased 24h after the last dose of morphine. Such effects were more 
pronounced in rat brain large vessels than in microvessels. 
On the other hand, neither a single dose administration of morphine in rats, nor the direct 
exposure of the hCMEC/D3 endothelial cell line to morphine were able to modify the 
mRNA levels of Abcb1a/ABCB1a and Abcg2/ABCG2. This suggests that changes in the 
expression of these ABC transporters are more likely linked to a prolonged exposure to 
morphine, and that it must involve other cells of the NVU other than only endothelial cells, 
in a cell-cell interaction complex mechanism. 
The NMDA receptor antagonism, as well as COX-2 inhibition resulted in the abolition of 
the subchronic morphine-induced P-gp and Bcrp protein up-regulation, 24h after the last 
dose of morphine. These results suggest that the NMDA receptor, and thus its ligand, 
glutamate, and COX-2 are implicated in the morphine-dependent P-gp and Bcrp up-
regulation. 
Since the induction of P-gp and Bcrp was only registered from 12h after the last dose of 
morphine-onwards, which is timely-coincident with the development of opioid withdrawal 
following a similar subchronic morphine regimen (Desjardins et al. 2008), together with the 
fact that some studies showed that brain extracellular glutamate levels are considerably 
increased during morphine withdrawal (Guo et al. 2005; Sepulveda et al. 2004), lead us to 
consider that the development of the morphine withdrawal could drive the modulation of 
the expression of P-gp and Bcrp at the rat BBB, rather than the direct effect of morphine 
exposure. The following presented study has focused on the research of this particular 
subject. 
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Rationale and Objectives: 
The results obtained in vivo evidenced that P-gp and Bcrp expressions in rat brain 
microvessels were increased following a 5-day, twice daily, subchronic morphine 
administration. However, this up-regulation was not registered during the treatment or 
once it was interrupted, but only several hours after the last administration of morphine, at 
a timely coincident point with the development of a spontaneous morphine withdrawal 
syndrome. These results strongly encouraged us in the pursuit of a better understanding 
of the mechanism involved in the modulation of P-gp and Bcrp by morphine, namely by 
trying to understand whether it is a direct consequence of continued exposure to 
morphine, or rather a result of the morphine withdrawal which is further developed after 
discontinuation of treatment, such as the previous results seem to point to. 
Thus, the aim of the present study was to evaluate the effects, on one hand, of a 
subchronic continuous morphine infusion, and on the other hand, of naloxone-precipitated 
morphine withdrawal on the expression and activity of P-gp and Bcrp at the rat BBB. For 
this purpose, rats were subjected to three different protocols: 
i. a continuous i.v. infusion of morphine for 120h (5 days), to attain a theoretical 
plasmatic concentration of morphine of 100 ng/mL (study 1). Animals were 
sacrificed immediately, once the morphine infusion was interrupted; 
ii. Triggering of a precipitated morphine withdrawal with an injection of a single dose 
of naloxone (1 mg/kg, s.c.), a strong μ-opioid receptor antagonist, 1h after an 
escalating morphine dosing regimen (10-40 mg/kg, i.p., twice daily for 5 days) 
(study 2). Rats were sacrificed 12h after naloxone administration; 
iii. a chronic morphine regimen (10 mg/kg s.c., twice daily for 5 days), followed by a 
withdrawal period (2 days), and treatment was resumed for 3 additional days. 
Similarly, a single administration of naloxone (1 mg/kg, s.c.) was given in order to 
trigger an intense precipitated opioid withdrawal (study 3). Rats were sacrificed at 
two different time points: 4h and 24h after naloxone administration. 
The administration of naloxone provokes an intense precipitated withdrawal in morphine-
dependent rats, which was measured through the observation of a set of behavioral signs. 
Control rats were given physiological saline in an equal protocol of administration in the 3 
studies. Once more, animals were sacrificed to obtain freshly isolated brain microvessels, 
which were subsequently used to analyze P-gp and Bcrp expressions, at both mRNA and 
protein level, following each of the described treatment protocols. 
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Abstract: 
Rationale: Chronic morphine regimen increases P-glycoprotein (P-gp) and breast cancer 
resistance protein (Bcrp) expressions at the rat blood-brain barrier (BBB) but what drives 
this effect is poorly understood. 
Objectives: Assess subchronic continuous morphine infusion and naloxone-precipitated 
morphine withdrawal effects on P-gp/Bcrp contents and activities at the rat BBB. 
Methods: Rats were treated either with (i) a continuous i.v. morphine for 120h, (ii) 
escalating morphine dosing (10-40 mg/kg, i.p., 5 days), (iii) a chronic morphine regimen 
(10 mg/kg s.c., 5 days) followed by a withdrawal period (2 days) and treatment for 3 
additional days. Animal behavior was assessed after naloxone-precipitated withdrawal 
(1mg/kg, s.c.). P-gp/Bcrp expressions and activities were determined in brain 
microvessels by qRT-PCR, WB, UHPLC-MS/MS, and in situ brain perfusion of P-gp or 
Bcrp substrates. 
Results: Continuous i.v. morphine did not change P-gp/Bcrp protein levels in rat brain 
microvessels, whereas naloxone-precipitated withdrawal after escalating or chronic 
morphine dose regimen increased Mdr1a and Bcrp mRNA levels by 1.4-fold and 2.4-fold, 
respectively. Conversely, P-gp/Bcrp protein expressions remained unchanged after 
naloxone administration, and brain uptake of [3H]-verapamil (P-gp) and [3H]-mitoxantrone 
(Bcrp) was not altered. 
Conclusions: Subchronic morphine infusion and naloxone-precipitated morphine 
withdrawal have poor effect on P-gp/Bcrp levels at the rat BBB. 
 
Keywords: Blood-brain barrier, Morphine, Opioid withdrawal, P-glycoprotein, Breast 
Cancer Resistance Protein 
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1. INTRODUCTION 
Opioids represent one of the most powerful analgesics used for the treatment of moderate 
to severe chronic pain.1,2 On the other hand, opioids such as morphine and heroin, due to 
their euphoria and pleasure inducing properties, are also well-known substances of 
abuse. Their misuse is a major public health concern as it leads to the development of 
phenomena like physical dependence, opioid tolerance, and ultimately to severe 
withdrawal syndrome when the consumption is abruptly suspended.3 Central nervous 
system (CNS) effects of morphine depend on both pharmacokinetic and 
pharmacodynamic parameters. From a pharmacokinetic point of view, it is well 
demonstrated that morphine CNS effects are linked to its ability to cross the blood-brain 
barrier (BBB) that is partially embedded by its brain-to-blood efflux mediated by the ATP-
binding cassette (ABC) transporter P-glycoprotein (P-gp, Abcb1a, Mdr1a).4,5 Thus, 
modulation of P-gp at the BBB may enhance or decrease CNS distribution of P-gp 
substrates such as morphine, respectively. There is considerably increasing evidence that 
chronic exposure to morphine induces adaptive modifications including those of gene 
regulation and brain plasticity.6-8 Interestingly, twice daily subchronic morphine exposure 
has been shown to increase P-gp content in rat,9-11 and mouse whole brain.5 Actually, we 
previously showed that P-gp expression in rat brain microvessels was only up-regulated 
several hours after, and not immediately after, treatment suspension, following a twice 
daily subchronic morphine administration, which timely coincided with the beginning of a 
spontaneous morphine withdrawal.11 Breast cancer-resistance protein (BCRP, ABCG2), 
another drug efflux transporter, has been shown to share a significant number of 
substrates with P-gp, and it is more expressed than P-gp at the human BBB, unlike in 
rodents.12 Like P-gp, Bcrp was induced in rat brain microvessels following a subchronic 
morphine treatment.11 However, it remains unknown if P-gp and Bcrp induction at the rat 
BBB is directly triggered by morphine, or indirectly through its subsequent morphine 
withdrawal. To answer this question, we either intravenously and continuously infused rats 
with morphine for 5 days, or provoked a strong morphine withdrawal with naloxone, an 
opioid receptor antagonist, after two different subchronic morphine regimens. P-gp and 
Bcrp expression in rat brain microvessels and functional activities at the BBB were 
evaluated in the different animal treatment protocols.   
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2. EXPERIMENTAL PROCEDURES 
2.1. Animals  
Adult male Sprague–Dawley rats weighing 200 to 250g (5 to 7 weeks old) were purchased 
from Janvier laboratory (Le Genest-Saint-Isle, France). They were housed in groups of 
three animals per cage under standard 12h light/dark conditions (light from 8:00 a.m. to 8 
p.m.) in a temperature- and humidity-controlled room. The animals had access to food 
and water ad libitum and were acclimated for a minimum of 7 days prior to conducting 
experiments.  All animal experiments complied with the standards and guidelines 
promulgated by the latest European Union Council Directive (2010/63/EU) and were 
approved by the local ethics review committee (Paris Descartes University n°12-186). 
 
2.2. Animal treatments: 
(±)-Morphine hydrochloride was obtained from Francopia (Paris, France). (±)-Naloxone 
hydrochloride was purchased from Sigma (St Quentin-Fallavier, France). All drugs were 
diluted in isotonic and sterile sodium chloride. Animals were treated using a volume of 0.1 
mL/100 g of body weight (b.w.) when injected either subcutaneously (s.c.) or 
intraperitoneally (i.p.). We used three treatment protocols of chronic exposure to morphine 
(Fig. 1).  
Study 1: Rats were infused with either morphine (15.6 mg/kg/day) or saline for 120h (5 
days), at a constant flow rate of 1 mL/kg/h, via the jugular vein cannula (i.v.). Considering 
a total plasma clearance of morphine in the rat as 108 ± 32 mL/min/kg,13 the concentration 
of the infused morphine solution – 0.65 mg/mL – and the rate of infusion, it is expected to 
attain a theoretical morphine concentration in the plasma of 100 ng/mL, at steady-state, 
Study 2: Rats were treated with either saline (control group) or escalating doses of 
morphine (test group) over a period of 5 days. The test group was given morphine i.p. 
twice daily: 10 mg/kg on day 1, 20 mg/kg on day 2, 30 mg/kg on day 3 and 40 mg/kg on 
day 4 and 5, as previously described.11 Rodents chronically exposed to morphine have 
shown to develop a conditioned-place preference.14 To provoke an intense morphine 
withdrawal, a single dose of naloxone (1mg/kg, s.c.) was given 1h after the administration 
of the last dose of morphine (day 5), and animals were sacrificed 12h after naloxone 
injection. Opioid withdrawal signs were visible as soon as naloxone was injected.  
Study 3: Animals were given s.c. morphine 10 mg/kg twice daily, over the course of 5 
plus 3 additional days, with a two-day spontaneous withdrawal of morphine between the 
two periods of administration. To cause an acute and strong morphine withdrawal, rats 
received a single injection of naloxone 1 mg/kg (s.c.) 1h after the last dose of morphine 
(day 10). Rats were sacrificed 4h or 24h after naloxone injection.  
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Control rats were given physiological saline in an equal protocol of administration in the 3 
studies. 
 
2.3. Behavioral Studies 
Spontaneous (18h and 36h after the last dose of morphine of the first period of 
administration – study 3) and naloxone-precipitated (30s after the administration of s.c. 
naloxone 1 mg/kg – study 2 and study 3) withdrawal syndromes were observed for 25 min 
in circular Plexiglas observation boxes (30 cm wide; 40 cm high). Two classes of 
withdrawal signs were measured: counted signs and observed signs. The number of teeth 
chattering, jumps and wet dog shakes were counted and the sum is a score for each 
counted signs. Ptosis, defecation, mastication, salivation and abnormal posture were 
observed over periods of 5 min, with one point being given for the presence of each sign 
during each period. The number of periods showing the sign was then counted (maximum 
score 5). Global withdrawal score was calculated as the sum of scores for all signs. B.w. 
was measured during the treatment and before observation period. 
 
2.4. Quantification of morphine concentrations in rat plasma 
Plasma samples collected during the 5-day morphine infusion (study 1) were used to 
determine the concentrations of morphine after solid-phase extraction procedure by high 
performance liquid chromatography tandem mass spectrometry (LC/MS-MS) (TSQ 
Quantum Ultra®, Fisher). Separation was carried out on a Hypersil Gold aQ® column (100 
mm x 2.1 mm, 3 µm) (Fisher Scientific, Illkirch, France) maintained at 40°C. The mobile 
phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in 
acetonitrile (solvent B) with gradient program. Briefly, morphine was extracted using Oasis 
HLB® solid-phase extraction cartridges (1 cc, 30 mg, Millipore-Waters, Guyancourt, 
France). Aliquots of rat plasma (100 µL) were added to 800 µL of human plasma and 100 
µL of internal standard (morphine-d3, 200 ng/mL, Cerilliant, LGC, Molsheim, France) and 
100 µL ammonium sulfate (0.5 M, pH 9.3), and loaded onto extraction columns that had 
been preconditioned with methanol LC-MS grade, followed by H2O LC-MS grade, under 
gentle vacuum. The extraction columns were then washed with H2O LC-MS grade and 
dried under vacuum for 10 min. Morphine and the internal standard were then eluted in an 
acetonitrile/H2O (1:4) mix with 0.1% formic acid. After evaporation under nitrogen flow at 
30°C, the residue was dissolved in 70 µL of H2O LC-MS grade with 0.1% formic acid, 
centrifuged at 13 000 rpm for 10 min and 10 µL were used for injection. Detection in triple 
quadrupole mass spectrometer used an electrospray ionization (ESI) probe and operated 
in the positive ion mode. The multiple reaction monitoring transitions used for 
quantification were 286.08/201.04 for morphine and 289.10/164.97 for morphine-d3. The 
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retention times of morphine and internal standard were approximately 2.4 and 2.5 min, 
respectively. The linear calibration ranges were 0.15 ng/mL-200 ng/mL in plasma (r² 
>0.999). 
 
2.5. Isolation of microvessels from rat brain cortex 
All steps were carried out at 4°C. The brain cortex vessels were isolated from rat brain 
cortices as previously described.15 Rats were euthanized by CO2 inhalation and 
decapitated. Brain microvessels were obtained after mechanical dissection, centrifugation 
in a dextran (64–76 kDa, Sigma) gradient buffer and filtered through two successive 100-
µm and a 20-µm nylon meshes.  
 
2.6. RNA extraction and reverse transcription (RT) 
Total RNA was isolated through homogenization and cell lysis in a TissueLyser system 
(Qiagen, Courtaboeuf, France), extraction using the RNeasyQiagen Micro kit according to 
the manufacturer’s instructions (Qiagen), and treatment with DNase (RNase-Free DNase 
Set, Qiagen). The concentration and purity of the RNA samples obtained were assessed 
spectrophotometrically using a Nanodrop spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). 
Total RNA samples were reverse transcribed into cDNA in a final volume of 20 µL. RT 
reagents were purchased from Invitrogen (Cergy-Pontoise, France). RT was performed on 
a programmable thermal cycler (PTC-100 programmable thermal controller; MJ Research, 
Waltham, MA, USA). 
 
2.7. Quantitative Real-Time PCR 
Specific nucleotide primer sequences (Table 1) were designed using OLIGO 7 software 
(Medprobe, Oslo, Norway) and synthesized by Eurogentec (Angers, France). 
Amplification was detected by SYBR® Green fluorescence on an ABI PRISM® 7900HT 
sequence detection system (Applied Biosystems, Courtaboeuf, France). The thermal 
cycling conditions were 2 min at 50°C then 10 min at 95°C followed by 40 amplification 
cycles at 95°C for 15s, at 60 or 65°C for 45s and at 95°C for 15s. Results were expressed 
as the ratio between the expression of the gene of interest to that of the housekeeping 
gene (β-actin) in treated and saline groups, as previously described.11 
 
2.8. Western blot (WB) 
Immunoblots were performed on protein extracted from isolated microvessels to measure, 
semi-quantitatively, the amounts of P-gp and Bcrp as previously described.11 P-gp, Bcrp 
and β-actin expressions were revealed using the following primary antibodies: mouse 
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monoclonal antibody C219 against rat P-gp (Abcam, Cambridge, UK), rat monoclonal 
anti-rat Bcrp antibody BXP-53 and mouse monoclonal anti-β-actin (AC-15) antibody 
(HRP) (Abcam).  
 
2.9. Protein Quantification by UHPLC MS/MS 
The protein quantification of P-gp and Bcrp was performed using a QTAP approach, as 
previously described16 and is detailed in supplementary methods. The denatured and 
alkylated proteins were precipitated with a methanol-chloroform-water mixture before 
digestion). The standard isotope-labeled (SIL) peptide mixture was added and samples 
were analyzed with an ACQUITY UPLC H-Class® System coupled to a Waters Xevo® TQ-
S mass spectrometer (Waters, Manchester, UK) operated in MRM mode. Data was 
analyzed using Skyline software and the QuaSAR plugin17 was used to evaluate 
performance and obtain linear regression equations from calibration points. Finally, a 
home-developed R script allowed the calculation of the peptide amounts from the light to 
heavy ratios from these equations. 
We take into account the microvascular endothelial cell (EC) enrichment of each sample 
by analyzing the relative amount of the EC marker Pecam-1. A list of specific peptides for 
Pecam-1 were selected, according to the previously defined in silico criteria.18 A 
preliminary UPLC-MS/MS sample analysis allowed us to select the three peptides with the 
highest signal from this list, and include them in the MRM analysis method. P-gp and Bcrp 
levels in each sample were normalized by dividing the calculated expression values by the 
sum of the areas of the three Pecam-1 peptides. Indeed, previous studies have shown 
that the concentration of a protein is directly proportional to the sum of the peak-areas of 
the three most intense peptides. 19,20 
 
2.10. In situ Rat Brain Perfusion 
2.10.1. Surgery and Perfusion 
The brain transport of [3H]-verapamil (Perkin Elmer, Courtaboeuf, France) and [3H]-
mitoxantrone (Moravek, Brea, CA, USA), P-gp and Bcrp substrates respectively, was 
measured by in situ brain perfusion as previously described.23 Rats were anaesthetized 
18h after naloxone administration in rats receiving saline or morphine according to study 
3. Animals were initially perfused with tracer-free Krebs-carbonate buffer for 30s and then 
with [3H]-verapamil or [3H]-mitoxantrone (0.5 µCi/mL) and [14C]-sucrose (0.1 µCi/mL) for 
90s at 10 mL/min. Perfusion was finished by decapitating the rat. Samples were digested 
in 2 mL of Solvable (Perkin Elmer) and mixed with 9 mL of Ultima gold XR (Perkin Elmer). 
Dual label counting was performed in a Tri-Carb counter (Perkin Elmer). 
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2.10.2. Calculation of the luminal BBB transport parameters 
All calculations have been previously described.23 The brain vascular volume (Vv; µL/g) 
was estimated from the tissue distribution of [14C]-sucrose using the following equation:  
 
where X* (dpm/g) is the amount of [14C]-sucrose in the right brain hemisphere and C*perf 
(dpm/µL) is the concentration of [14C]-sucrose in the perfusion fluid. 
The apparent brain volume of distribution (Vbrain; µL/g) was calculated from: 
where Xbrain (dpm/g) is the calculated amount of the [3H]-compound in the 
right cerebral hemisphere and Cperf (dpm/µL) is the concentration of [3H]-compound in the 
perfusion fluid. 
Brain tissue radioactivity of the [3H]-compound was corrected for vascular contamination 
with the following equation: 
where Xtot (dpm/g) is the total quantity of [3H]-compound measured 
in the brain tissue (vascular + extravascular). 
Initial brain transport rate is expressed as a Kin (µL/g/s) and was calculated from: 
 
where T is the perfusion time (s). 
 
2.11. Pharmacokinetic calculations and statistical analysis 
Morphine plasma total clearance (mL/min/kg) was calculated for each rat as the rate of 
morphine infusion (mg/min/kg) divided by the mean of morphine plasma concentrations 
(ng/mL) determined at each time point, assuming that steady-state plasma concentrations 
of morphine were achieved from 24h after the start of morphine infusion. Mean ± SD of 
morphine plasma clearance was thus calculated for all rats of the study 1. Data were 
analyzed with GraphPad Prism® 4.0 software (San Diego, CA, USA). The results are 
expressed as means ± SEM. Student’s unpaired t-test was used to identify significant 
differences between in vivo morphine and saline groups. All the tests were two-tailed and 
statistical significance was set at p < 0.05. 
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3. RESULTS 
3.1. STUDY 1 – Effect of constant morphine i.v. infusion on brain 
microvessel P-gp and Bcrp expressions 
In the study 1, rats were infused via i.v. for 5 days at a constant infusion rate (1 mL/kg/h) 
with a morphine solution of a known concentration (0.65 mg/mL). Steady-state morphine 
plasma levels were achieved from 24h after the beginning of the infusion and remain 
reasonably stable until the 5th day of infusion (Fig. 2). The mean steady-state of morphine 
plasma levels was 182 ± 27 ng/mL, given a mean systemic plasma morphine clearance of 
61 ± 6 mL/min/kg. UHPLC-MS/MS and WB results showed no significant modification of 
either P-gp or Bcrp contents in brain microvessels from rats infused by morphine, when 
compared to the saline-infused group (Fig. 3, Study 1, A and B) (Table 3). This clearly 
showed that morphine at such a constant plasma concentration for 5 days does not 
modulate the expression of P-gp and Bcrp in the rat BBB. This raises the question of 
whether or not a strong naloxone-precipitated morphine withdrawal could be responsible 
of P-gp and Bcrp modulation in the rat BBB. 
 
3.2. STUDY 2 – 5-day protocol treatment with naloxone-precipitated opioid 
withdrawal 
3.2.1. Validation of withdrawal syndrome development – behavioral studies 
The development of a spontaneous withdrawal syndrome in study 2 was previously 
described by our research team.24 Here, we described behavioral signs using the same 
morphine protocol after the precipitation of opioid withdrawal with the injection of the µ-
receptor antagonist naloxone. Animals showed typical opioid withdrawal behavioral signs, 
including abnormal posture, diarrhea, mastication, wet-dog shakes, ptosis, salivation and 
jumping. The global withdrawal score (Fig. 4) was highly significant in morphine-
pretreated rats (34.4 ± 2.2) as compared to saline-pretreated rats (1.6 ± 0.4) (p < 0.001). 
 
3.2.2. Effect of naloxone-precipitated opioid withdrawal on Mdr1a/P-gp and 
Bcrp/Bcrp contents in rat cortical microvessels 
Rats were sacrificed 12h after the administration of a single injection of naloxone (1 
mg/kg) following the last morphine dose (day 5). In the morphine-treated rats Mdr1a and 
Bcrp transcript levels increased by 1.4-fold and 2.5-fold, respectively (Table 2). However, 
in opposition to the qPCR data, UHPLC-MS/MS and WB analyses did not evidence the 
expected up-regulation of P-gp and Bcrp proteins in brain microvessels of morphine-
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pretreated animals as compared to saline-pretreated animals (Fig. 3, Study 2, A and B) 
(Table 3). 
 
3.3. STUDY 3 – 10-day protocol treatment with both spontaneous and 
precipitated opioid withdrawal 
3.3.1. Validation of withdrawal syndrome development – behavioral studies 
Since study 3 has never been validated before as being capable of implementing an 
opioid dependent-state and the subsequent withdrawal – neither a spontaneous nor a 
precipitated one –, we conducted a set of behavioral studies similar to the ones conducted 
previously for study 2. Physical dependence to opioids was induced in rats by 
administration of morphine 10 mg/kg s.c. twice daily. The b.w. gain was measured every 
12h during the course of the treatment (Fig. 5a). By the end of the first 5 days of 
treatment, control rats receiving physiological saline s.c. showed a 12% gain in b.w. while 
rats receiving morphine gained as little as 6% in b.w. (p < 0.001). After the first period of 
spontaneous withdrawal and just before starting re-dosing rats with morphine (day 8), it 
was clear that the weight gain during this period in the morphine-treated group was 
considerably weaker to that of the saline-treated group (14% in the morphine group vs 
27% in the control group, p < 0.001); b.w. gain remained lower in the rats treated with 
morphine until the end of the treatment protocol. 
Withdrawal signs were monitored at the two time-points when morphine was withdrawn. 
The calculated scores for the spontaneous and precipitated withdrawals are presented in 
Fig. 5b and Fig. 5c, respectively. Animals in spontaneous morphine withdrawal manifested 
typical behavioral signs, including diarrhea, teeth chattering, mastication, wet-dog shakes 
and ptosis. Withdrawal signs were observed 18h and 36h from the last injection of 
morphine after the first 5 days of treatment, and global withdrawal scores of morphine-
treated rats were significantly higher than those of saline-treated rats at both 18h (9.4 ± 
2.0 vs 2.5 ± 0.4) and 36h (5.9 ± 0.8 vs 1.8 ± 0.3) (p < 0.05 and p < 0.001, respectively) 
(Fig. 5b). However, these manifestations became fewer and less intense at the 36h-time 
point of assessment of spontaneous morphine withdrawal. Animals in a naloxone-
precipitated withdrawal at the end of the treatment protocol (day 10) showed a very similar 
behavior to that observed in study 2 once the withdrawal was precipitated: they exhibited 
the previously mentioned spontaneous signs of opioid withdrawal plus abnormal posture, 
salivation and jumping. It is clear that the naloxone-precipitated withdrawal induced a 
much stronger abnormal behavior (Fig. 5c) than the opioid spontaneous one (Fig. 5b). As 
shown in Fig. 5c, the global withdrawal score is 14-times higher in morphine-treated rats 
(27.0 ± 2.9) than in saline-treated rats (1.9 ± 0.2) (p < 0.001). 
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3.3.2. Effect of naloxone-precipitated opioid withdrawal on Mdr1a/P-gp and 
Bcrp/Bcrp contents in rat cortical microvessels 
In order to evaluate the impact of the precipitated opioid withdrawal on the expression of 
P-gp and Bcrp in brain microvessels in study 3, qRT-PCR were performed on brain 
microvessels from treated rats sacrificed 4h (t=4h) and 24h (t=24h) after the 
administration of naloxone (1 mg/kg) (day 10). Morphine-treated group registered a 
significant 1.4- and 2.3-fold increase in the levels of Mdr1a and Bcrp transcript levels, 
respectively (Table 2). 24h after the naloxone-precipitated opioid withdrawal, Mdr1a 
mRNA levels in brain microvessels were no longer significantly different between saline- 
and morphine-treated rats in contrast to those of Bcrp which remained significantly higher 
in the morphine-treated group (Table 2). However, in contrast to the results obtained by 
qPCR at t=4h (for P-gp and Bcrp) and at t=24h (for Bcrp), UHPLC-MS/MS and WB 
experiments did not evidence any significant change in P-gp and Bcrp protein contents in 
the morphine plus naloxone-treated group compared to the saline plus naloxone-treated 
group (Fig. 3, Study 3, A and B) (Table 3). 
 
3.3.3. Effect of naloxone-precipitated opioid withdrawal on the activity of P-gp 
and Bcrp at the rat BBB 
The brain transport rate (Kin) of [3H]-verapamil, a P-gp substrate, did not show any 
statistical difference 18h after naloxone dosing between saline- (1.61 ± 0.15 µL/g/s; n=5) 
and morphine-treated (1.81 ± 0.23 µL/g/s; n=4) animals. Any significant modification 
between the two groups was neither observed for the brain transport of [3H]-mitoxantrone, 
a Bcrp substrate, (0.56 ± 0.02 µL/g/s; n=5, for saline plus naloxone-treated rats vs 0.56 ± 
0.02 µL/g/s; n=4, for morphine plus naloxone-treated rats). These results showed that P-
gp and Bcrp transport activities in brain microvessels were not modified by the 
implemented treatment.  
Low molecular weight sucrose is commonly used as a marker of vascular space and BBB 
integrity once it does not significantly cross plasma membranes in a short time and its 
paracellular diffusion is hampered by existing tight junctions between ECs in the BBB. The 
sucrose whole brain volumes (Vv) in the saline plus naloxone- (16.1 ± 1.2 µL/g; n=10) and 
morphine plus naloxone-treated (16.9 ± 1.2 µL/g; n=9) rats were not significantly different. 
These sucrose spaces also agreed with the physiological vascular space,23 showing that 
the physical integrity of the BBB in both groups of rats was maintained. 
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4. DISCUSSION 
Among the described effects of morphine at the BBB, it has been shown that P-gp and 
Bcrp were transiently up-regulated following an exposure to morphine during 5 days, with 
an escalating dose regimen (10-40 mg/kg, i.p).11,25 The aim of this new work was to know 
whether morphine itself or its subsequent precipitated withdrawal syndrome was 
responsible for P-gp and Bcrp up-regulation in the rat BBB.  
First, we maintained morphine plasma levels stable at 182 ± 27 ng/mL for 4 days in rats. 
These plasma concentrations are close to those reached in patients continuously exposed 
to morphine (112 ± 50 ng/mL) for pain control.26 The calculated plasma clearance for 
morphine in this study (61 ± 6 mL/min.kg) also approaches the ones found in the 
literature.27 Despite a continuous morphine exposure, P-gp and Bcrp expressions were 
not modified in brain microvessels, which clearly demonstrates that morphine exposure by 
itself has no effect on these transporters in the BBB. Therefore, the increase in P-gp and 
Bcrp brain contents after subchronic morphine exposure reported in the literature5,9-11 was 
more likely due to morphine withdrawal than to morphine itself. Since the elimination half-
life of morphine is roughly 1h in both plasma and brain in the rat,28,29 it is completely 
eliminated from the body in the rat 6h after morphine dosing. Therefore, induction of P-gp 
and Bcrp that starts 24h after the last morphine dose of a subchronic treatment5,9 could be 
due to the morphine withdrawal.  
In opposition to the morphine continuous infusion protocol, studies 2 and 3 consisted on a 
subchronic exposure to morphine that triggers a series of plasma morphine peaks and 
troughs of undetectable plasma concentrations of morphine. This peak and trough plasma 
morphine alternation is favourable to the installation of physical dependence and 
withdrawal once morphine treatment is suspended.24 To test the effect of a strong 
precipitated morphine withdrawal on P-gp and Bcrp expressions, we applied study 2 and 
dosed rats with naloxone, a strong inducer of morphine withdrawal, after the last morphine 
injection. The protocol adopted for study 3 contrasts with study 2 by having an additional 
spontaneous withdrawal over a 2-day period, which increased the naloxone-precipitated 
withdrawal syndrome. In both studies 2 and 3, Mdr1a and Bcrp mRNA levels in brain 
microvessels were increased with similar folds to the ones found in the previous work 
during a spontaneous morphine withdrawal.11 Protein expression of P-gp and Bcrp were 
studied by WB and further validated by UHPLC-MS/MS using a QTAP approach.16 The 
expression levels in all samples (Supplementary Table 2) are within the same magnitude, 
in line with previously reported values for rat brain microvessels,16,22 hence validating our 
analysis. Three specific peptides for Pecam-1 were included in the MRM method for the 
MS analysis in order to evaluate the EC enrichment of each sample. We observed a 
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heterogeneous level of the EC marker Pecam-1 across the samples (data not shown), 
which indicate differences on EC enrichment. The expression levels of P-gp and Bcrp 
were, thus, normalized by dividing the expression values by the sum of the areas of the 
three Pecam-1 peptides in each sample (Fig. 3 A1 and B1),19,20 The analysis of the 
resulting data showed that the induction of P-gp and Bcrp was not confirmed at protein 
level. This difference could be explained by posttranslational regulation, as has been 
previously suggested.30 The absence of enhanced P-gp or Bcrp activities in brain 
microvessels was yet confirmed by in situ brain perfusion. We previously showed that P-
gp and Bcrp were up-regulated in brain microvessels not before 12h after the suspension 
of the morphine treatment (day 5).11 Interestingly, the onset of the registered induction 
coincided with the initial development of an opioid withdrawal syndrome in the rat,24 
suggesting that these two phenomena could be mechanistically related. Furthermore, we 
showed that morphine-mediated P-gp and Bcrp up-regulation depended on the activation 
of the NMDA glutamatergic receptor and COX-2 activity.11 In fact, naloxone-precipitated 
morphine withdrawal showed to provoke a 2-fold increase (from 10 μM to 21 μM, 
approximately) on the extracellular glutamate levels in the locus coeruleus in rats.31 
Similar extracellular glutamate levels and fold increase were observed in the hippocampus 
of morphine-dependent mice treated with naloxone, while no significant change was 
observed in saline-treated mice.32 Corroborating these results, Sepulveda et al have 
demonstrated that both naloxone-precipitated withdrawal and spontaneous morphine 
withdrawal in the rat resulted in a significant increase in the concentrations of glutamate 
and aspartate in the nucleus accumbens.33 Glutamate has been shown to increase both 
P-gp expression and activity in rodent brain microvessels, when exposed to relatively high 
concentrations (50-100 μM).34-36 Conversely, when glutamate was used at concentrations 
higher than 150 μM it resulted in a reduction on P-gp expression and activity, likely due to 
cell toxicity.34 Even though naloxone-precipitated withdrawal did not seem to drive such an 
augmentation on brain extracellular levels of glutamate, these studies evidence a potential 
contribute of morphine withdrawal and the subsequent glutamate release on the up-
regulation of P-gp at the BBB. Still, we did not observe such P-gp and Bcrp induction in 
brain cortex microvessels once a strong precipitated morphine withdrawal has been 
triggered. It is known that there are several signaling pathways implicated in the cellular 
regulation of P-gp and BCRP at the BBB.37 Thus, even though naloxone is a selective 
antagonist of the µ-opioid receptors, the absence of P-gp and Bcrp up-regulation in brain 
microvessels following the naloxone-precipitated opioid withdrawal may be explained by 
its effect on other non-opioid receptors,38,39 which may also be involved in the regulation of 
these ABC transporters following a morphine chronic treatment. For example, naloxone 
showed to have a low-affinity for the NMDA receptor in a Xenopus oocytes model.40 
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However, to efficiently block NMDA receptors, naloxone had to be used in high (300 µM) 
concentrations,40 while plasma naloxone concentrations only reached low micromolar 
values in in vivo studies similar to our experimental settings.41 Moreover, it is unlikely that 
naloxone may have a direct effect on the NMDA receptor at the currently administered 
dose, as NMDA receptor antagonism is related to anti-nociception and prevention of 
withdrawal,42,43 which are opposite to the naloxone-precipitated effects. Naloxone also 
proved to reverse neuropathic pain in rats via inhibition of toll-like receptor 4 (TLR4) 
signaling.44,45 Activation of TLR4 leads to downstream production and release of pro-
inflammatory cytokines like TNF-α and Il-1β, which are signaling factors known to play a 
role in the regulation of P-gp and Bcrp at the BBB.46,47 However, naloxone only showed to 
inhibit TLR4 at doses 100-fold superior (100 mg/kg) to the ones used in the present study 
(1 mg/kg), while 1 mg/kg and 10 mg/kg doses failed to produce such effect.45 Thus, P-gp 
and Bcrp up-regulation following a subchronic morphine treatment11 may result from a 
sum of multiple mechanisms and signaling pathways implicated in the modulation of both 
transporters at the BBB, and naloxone may act at non-opioid receptors, linked for instance 
to an inflammatory component of morphine withdrawal, to partially hamper P-gp and Bcrp 
up-regulation.  
Conclusion: In summary, we showed that P-gp and Bcrp protein contents and activity 
were not up-regulated in the rat when morphine is intravenously and continuously infused 
for several days nor when a strong morphine withdrawal is pharmacologically precipitated 
by naloxone. Thus, although we have registered an induction which temporally coincided 
with the development of the withdrawal syndrome following a subchronic morphine 
treatment in the rat,11 our present results show that a strong precipitated morphine 
withdrawal has poor effects on P-gp and Bcrp at the rat BBB, suggesting that brain 
distribution of P-gp and Bcrp substrates may not be altered following this treatment. Still, 
further studies are needed in order to understand the signalling mechanisms differentially 
activated upon triggering spontaneous or precipitated opioid withdrawal that may regulate 
P-gp and BCRP at the BBB.  
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6. FIGURES 
Figure 1  
 
Fig. 1. Schematic representation of morphine treatment protocols. a) Study 1: animals 
received a constant i.v. morphine infusion of 0.65 mg/kg/h for 120h, and were immediately 
sacrificed. b) Study 2: animals were treated with morphine on a regimen of twice daily 
injections with escalating doses over a period of 5 days, and morphine withdrawal was 
precipitated by naloxone (1mg/kg, s.c.) 1h following the last morphine injection. Rats were 
sacrificed 12h after the injection of naloxone. c) Study 3: animals were treated with 10 
mg/kg of morphine twice daily over a period of 5 plus 3 days, with a two-day interval 
between the two periods of administration. Morphine withdrawal was precipitated by 
naloxone (1mg/kg, s.c.) 1h following the last morphine injection, and rats were sacrificed 
4h and 24h after. 
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Figure 2 
 
Fig. 2. Plasma concentrations of morphine versus time (mean ± SEM) during constant 
rate infusion of a morphine solution at 0.65 mg/kg/hr (n=4). The total infusion time was 
120h. 
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Figure 3 
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Fig. 3. Effect of continuous i.v. infusion of morphine (study 1), naloxone-precipitated 
opioid withdrawal following a 5 day escalating-dose morphine regimen (study 2), or 
naloxone-precipitated opioid withdrawal following a 5 plus 2 day fixed-dose morphine 
regimen (study 3) on the protein expression of P-gp (A1, A2) and Bcrp (B1, B2) in cortical 
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microvessels. On study 1, rats were treated over a period of 5 days and immediately 
sacrificed upon cessation of treatment, whereas on study 2 and study 3, rats were 
sacrificed 12h and 4h, respectively, after the administration of naloxone. A1 and B1 show 
quantification of P-gp and Bcrp specific tryptic peptides analyzed by UHPLC-MS/MS 
(MRM mode); protein expression values (fmol/µg) have been normalized to Pecam-1. A2 
and B2 show P-gp and Bcrp expression levels analyzed by WB, where protein expression 
data have been normalized to β-actin protein. All generated data are compared to control 
group (baseline fixed at 1) and are expressed as mean ± SEM (n = 4-6 rats per group). 
Unpaired t-student test with Welch’s correction. NS: non-significant. 
 
Figure 4 
 
Fig. 4. Global withdrawal score in naloxone-precipitated opioid withdrawal in saline- or 
morphine-treated rats (study 2). Rats were subjected to observation immediately after the 
administration of naloxone. Two independent experiments were achieved. Results are 
expressed as mean ± SEM (n=6 rats per treatment). Unpaired t-student test with Welch’s 
correction (***p < 0.001). 
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Figure 5 
 
 
  
Fig. 5. (a) Evolution of weight variation as compared to weight before the first injection of 
morphine (study 3). Body weight of each rat was measured before the injection of 
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morphine in a constant dose-regimen, twice daily for 5 plus 3 days. Three independent 
experiments were achieved. Results are expressed as mean ± SEM. (n=12 rats per 
treatment) two-way repeated measure ANOVA (**p < 0.01, ***p < 0.001); (b) Global opioid 
withdrawal score in the developed spontaneous opioid withdrawal (study 3). Rats were 
subjected to observation at 18h and 36h after the last injection of morphine over 5 days of 
treatment. Results are expressed as mean ± SEM (n=8 rats per treatment). Unpaired t-
student test (*p < 0.05; ***p < 0.001); (c) Evolution of global withdrawal score in naloxone-
precipitated opioid withdrawal. Rats were subjected to observation during 5 periods of 5 
min, immediately after the administration of naloxone. Results are expressed as mean ± 
SEM (n=8 rats per treatment). Unpaired t-student test with Welch’s correction (***p < 
0.001). 
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7. TABLES 
Table 1. Primer sequences used for SYBR Green-based qRT-PCR 
Gene Forward Primer (sense) (5’-3’) Reverse Primer (antisense) (5’-3’) Length (bp) 
β-actin CTGGCCCGGACCTGACAGA GCGGCAGTGGCCATCTCTC 132 
Abcb1a 
(Mdr1a) CAACCAGCATTCTCCATAATA CCCAAGGATCAGGAACAATA 97 
Abcg2 
(Bcrp) CAGCAGGTTACCACTGTGAG TTCCCCTCTGTTTAACATTACA 75 
 
 
Table 2. Effect of naloxone-precipitated opioid withdrawal after subchronic treatment with 
morphine on the mRNA levels of the selected genes in cortical microvessels (studies 2 
and 3). Rats were treated over the course of 5 days and sacrificed 12h after the 
administration of naloxone (study 2), or over a period of 5 plus 3 days and sacrificed 4h or 
24h after the administration of naloxone (study 3). P-gp and Bcrp mRNA levels were 
analyzed by qRT-PCR and presented as fold expression towards saline group. All data 
have been normalized to β-actin mRNA and are expressed as mean ± SEM. Unpaired t 
test with Welch’s correction (n=6 rats per group) (*p < 0.05, **p < 0.01, ***p < 0.001 vs 
saline-treated group). 
 Gene Saline + Naloxone     (Mean ± SEM) 
Morphine + Naloxone 
(Mean ± SEM) 
Study 2 
Time point: 12h 
Abcb1a (Mdr1a) 1.00 ± 0.10 1.40 ± 0.08* 
Abcg2 (Bcrp) 1.00 ± 0.19 2.51 ± 0.30** 
Study 3 
Time point: 4h 
Abcb1a (Mdr1a) 1.00 ± 0.05 1.35 ± 0.06** 
Abcg2 (Bcrp) 1.00 ± 0.11 2.26 ± 0.14*** 
Time point: 24h 
Abcb1a (Mdr1a) 1.00 ± 0.07 1.18 ± 0.07 
Abcg2 (Bcrp) 1.00 ± 0.11 1.87 ± 0.33* 
Manuscript 2____________________________________________________________________	
158 
Table 3. Protein Expression in cortical microvessels of rats treated with morphine or 
saline solution according to the studies 1, 2 and 3 (see Experimental Section). Protein 
levels were obtained by QTAP quantification by UHPLC-MS/MS. 
 Proteins 
Expression (fmol / µg of total protein) 
Saline 
 (Mean ± sd) 
Morphine 
(Mean ± sd) 
Study 1 
P-gp (Abcb1a) 16.3 ± 1.64 22.4 ± 4.40 
Bcrp (Abcg2) 0.99 ± 0.17 1.64 ± 0.06 
Study 2 
(+ Naloxone) 
P-gp (Abcb1a) 13.2 ± 3.15 15.8 ± 1.38 
Bcrp (Abcg2) 0.98 ±0.59 1.2 ± 0.66 
Study 3 
(+ Naloxone) 
P-gp (Abcb1a) 26.3 ± 3.00 28.2 ± 1.93 
Bcrp (Abcg2) 3.6 ± 0.52 4.24 ± 2.29 
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SUPLEMMENTARY DATA 
 
EXPERIMENTAL PROCEDURES 
1. Study 1: Animal surgery, treatment and blood sampling 
This study was conducted in the laboratory of Bertin Pharma Company (Orléans, France). 
Rats underwent jugular and femoral vein cannulation while under general anesthesia with 
4% isoflurane: 96% oxygen. Following surgery, the animals were allowed to recover 
overnight before starting the experiments. Groups of rats received an infusion for 120h (5 
days), at a constant flow rate of 1 mL/kg/h, via the jugular vein cannula (i.v.) of either 
morphine (15.6 mg/kg/day) or saline. If we consider a total plasma clearance of morphine 
in the rat as 108 ± 32 mL/min/kg,1 the concentration of the infused morphine solution – 
0.65 mg/mL – and the rate of infusion were chosen to obtain, at steady-state, a theoretical 
morphine concentration in the plasma of 100 ng/mL. 
Blood samples (200 µL) were collected twice daily during 5 days of morphine infusion, via 
the femoral vein cannula, in order to prevent possible contamination from the morphine 
infusion. Blood samples were subsequently centrifuged, and plasma was collected and 
stored at -20°C, before they were used for quantification of morphine concentration by 
LC/MS-MS. 
 
2.  Protein Quantification by UHPLC MS/MS  
2.1. Quantitative targeted proteomics (QTAP) method 
P-gp and Bcrp were quantified using a QTAP approach, as previously described 2. The 
protein expression is calculated according to the measured concentration of surrogate 
tryptic peptides determined by using UHPLC MS/MS in multiplexed reaction monitoring 
(MRM) mode. These target peptides were previously reported 3 (for further information, 
consult Supplementary Table 1). The standard isotope-labeled (SIL) peptides were added 
to samples prior to analysis. The UHPLC-MS/MS parameters optimization was performed 
with the assistance of Skyline® software 4. The standard solutions of peptides were either 
provided by Pepscan (Lelystad, The Netherlands), or synthetized by Pr. M. Vidal and Dr. 
W. Q. Liu (UMR 8638, Paris, France). The former standard solution concentrations were 
determined after acid hydrolysis and amino-acid analysis (Dr. E. Thioulouse, Hôpital 
Trousseau, Paris, France). 
Enzymes and ProteaseMAX detergent were purchased from Promega (Charbonnières-
les-Bains, France), solvents were obtained from VWR (Strasbourg, France) and all other 
reagents were from Sigma Aldrich (Saint Quentin Fallavier, France). 
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2.2. Protein digestion 
Protein samples were digested as previously described 2,5. Briefly, protein extracts were 
diluted in denaturing buffer (7 mol.L-1 guanidine hydrochloride, 10 mmol.L-1 EDTA, 500 
mmol.L-1 Tris pH 8.5), reduced by DTT and alkylated by iodoacetamide. The resulting 
denatured and alkylated proteins were precipitated with a methanol-chloroform-water 
mixture. The protein pellets were then ressuspended in an urea solution at 8 mol.L-1 and 
further diluted to 1.2 mol.L-1 by using 0.1 mol.L-1 Tris pH 8.5. Samples were first pre-
digested for 3h at RT with rLysC endoprotease (enzyme:protein ratio = 1:50). Proteins 
were further digested overnight at 37°C using trypsin (enzyme:protein ratio = 1:100) with 
0.05% (W/W) ProteaseMAX detergent. The SIL peptide mixture was added and digestion 
was stopped by adding formic acid to a final concentration of 2.5% (V/V). 
 
2.3. Protein quantification 
Samples were analyzed with an ACQUITY UPLC H-Class® System (Waters, Manchester, 
UK) coupled to a Waters Xevo® TQ-S mass spectrometer (Waters, Manchester, UK). The 
column was an Acquity Peptide BEH® C18 Column (300Å, 1.7 µm, 2.1 mm X 100 mm) 
supplied by Waters (Guyancourt, France). Peptides were separated in a 24 min gradient 
going from 100 % aqueous mobile phase (water and 0.1% formic acid (V/V)) to 35% of 
apolar mobile phase (ACN with 0.1% formic acid (V/V)), at a flow-rate of 0.5 mL/min, at 
30°C. The Xevo TQ-S was operated in positive electrospray ionization (ESI+) mode using 
a capillary voltage of 2.80 kV, desolvation gas at a flow-rate of 800 L/h, at 650°C. 
Peptides were detected by a multiplexed MRM-mode method using three to four 
transitions per native- or heavy-labeled peptide (Supplementary table 1). The peak areas 
were integrated using the Skyline software. The resulting calibration curves were analyzed 
with the Skyline’s QuaSAR plugin 6 to evaluate performance and obtain the linear 
regression equations. Finally, a home-developed R script allowed the calculation of the 
peptide amounts from the light to heavy ratios from these equations. 
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Supplementary table 1. Target peptides and selected ions used in the UHPLC-MS/MS 
multiplexed SRM method analysis. 
Protein Peptide Sequence 
Isotope 
Type 
Precursor 
M/z 
Precursor 
Charge 
Product 
M/z 
Product 
Charge 
Fragment 
Ion Type 
Bcrp 
SSLLDVLAAR light 522.8 2 
757.5 1 y7 
644.4 1 y6 
529.3 1 y5 
430.3 1 y4 
SSLLDVLA[+4]AR heavy 524.8 2 
761.5 1 y7 
648.4 1 y6 
533.4 1 y5 
434.3 1 y4 
P-gp 
NTTGALTTR light 467.8 2 
719.4 1 y7 
618.4 1 y6 
561.3 1 y5 
490.3 1 y4 
NTTGALTTR[+10] heavy 472.8 2 
729.4 1 y7 
628.4 1 y6 
571.3 1 y5 
500.3 1 y4 
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General outcome: 
Study 1 was conducted with the purpose of maintaining a continuous, uninterrupted 
exposure to morphine, and thus evaluate if morphine itself has a direct effect on the 
expression of P-gp and Bcrp at the rat BBB. The results obtained with such study 
demonstrated that, even though animals were continuously exposed to morphine and had 
attained significant plasmatic concentrations of morphine throughout the treatment, P-gp 
and Bcrp protein expressions did not change in rat brain microvessels. This suggests that 
the observed up-regulation of both ABC transporters in the previous study (Yousif et al. 
2012) was not a direct consequence of morphine on the cascade of regulation of P-gp and 
Bcrp at the BBB. 
Since the induction of P-gp and Bcrp has been reported to appear 12h to 24h after the last 
morphine dose of a subchronic dosing regimen (Aquilante et al. 2000; Yousif et al. 2012; 
Zong and Pollack 2003), it seems likely that morphine withdrawal can be responsible for 
this modulation. Therefore, studies 2 and 3 are two different protocols that favor the 
installation of morphine physical dependence, and were developed in order to induce an 
intense opioid withdrawal, precipitated by naloxone. The considerable high global 
withdrawal scores observed confirm the success of the implemented protocols to attain 
the development of morphine dependence and the subsequent precipitated withdrawal. 
Naloxone-precipitated withdrawal after escalating or chronic morphine dose regimens 
increased Mdr1a and Bcrp mRNA levels by 1.4-fold and 2.4-fold, respectively. Such 
results are of similar magnitude to the previously obtained during a spontaneous morphine 
withdrawal (Yousif et al. 2012). However, induction of P-gp and Bcrp was not confirmed at 
protein level, neither by WB nor by UHPLC-MS/MS. P-gp or Bcrp transport activities at the 
rat BBB, analyzed by in situ brain perfusion, also remained unchanged, which 
corroborated such findings. 
The P-gp and Bcrp modulation discrepancy found at mRNA and protein levels following 
naloxone-precipitated withdrawal protocols could be due to posttranslational regulation, 
like it has been previously suggested (Vogel and Marcotte 2012), as well as it could mean 
that naloxone may act at non-opioid receptors and hamper P-gp and Bcrp up-regulation, 
such as receptors linked to an inflammatory component of morphine withdrawal. The 
following presented study does a large screening of several neurotransmitter receptors, 
many of them implicated in inflammatory cell-cell signaling, as potential receptors 
expressed at the rat BBB, and which may have a role in the modulation of these ABC 
transporters.
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Rationale and Objectives: 
The regulation and maintenance of the BBB structure and properties is a product of the 
close interaction between cells constituting the NVU, particularly the BECs, astrocytes, 
pericytes, and microglia, and the presence of multiple modulating factors in both the brain 
ISF and the bloodstream, such as neurotransmitters, hormones, ions and cytokines. 
Currently, there is little data on the expression of major neurotransmitter receptors in the 
different cell types composing the BBB. The exploration of the expression of 
neurotransmitter receptors present at the BBB would allow a better understanding of 
some of the active cell:cell communication mechanisms at the BBB, which are most likely 
implicated in neurovascular signaling and in the modulation of BBB structure and function. 
Furthermore, this can bring further insight into some of the already partially known 
mechanisms of regulation of ABC transporters, such as the one that morphine is 
implicated in. For such study, it is crucial to select the most appropriate BBB model that 
more closely preserves the original BBB structure and features. 
Therefore, the subsequently presented study had two main aims: 
 To compare two different approaches of isolation of rat brain microvessels, 
mechanical dissection and enzymatic digestion, for the yield of the purest 
microvessel fraction for the study of the BBB. For this purpose, the expression of 
several specific cell markers for the different cell constituents of the NVU was 
compared between samples obtained by either mechanical dissection or 
enzymatic digestion. The expression of such markers in isolated microvessels was 
also compared against the expression in rat brain cortex as a measure of 
enrichment on the BBB cell markers. 
 To assess the expression of 11 neurotransmitter receptors in both rat brain cortex 
samples and in isolated rat brain microvessels: adrenergic receptors α2A, β1 and β2 
(Adra2a, Adrb1, Adrb2), adenosine receptors A1, A2A and A3 (Adora1, Adora2a, 
Adora3), ATP receptors P2X7 and P2Y1 (P2rx7, P2ry1), cannabinoid receptors CB1 
and CB2 (Cnr1, Cnr2), and the glutamate receptor subunit NMDAr1. 
The expression of different genes of interest was evaluated using the qRT-PCR 
technique. 
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Abstract: 
The blood-brain barrier (BBB) is crucial to the maintenance of the correct neural 
homeostasis and microenvironment. The dynamic interplay between the cells composing 
the neurovascular unit (NVU), as well as the input of neurotransmitters, hormones, ions 
and cytokines, coming from both the nervous tissue and the bloodstream, allows the 
regulation of the proper BBB structure and function. In this study, we performed the 
isolation of rat brain microvessels, a powerful tool for the BBB study, through two different 
approaches, mechanic and enzymatic, and compared the resulting mRNA levels of each 
specific brain cell markers in microvessels obtained by each technique and to rat brain 
cortex, by qRT-PCR. In addition, also by qRT-PCR, the expression of 11 neurotransmitter 
receptors (adrenergic receptors α2A, β1 and β2, adenosine receptors A1, A2A and A3, ATP 
receptors P2X7 and P2Y1, cannabinoid receptors CB1 and CB2, and glutamate receptor 
subunit NMDAr1) was analyzed in both rat brain cortex samples and in isolated rat brain 
microvessels obtained by these two techniques. 
An enrichment of EC (2-fold for glut-1) and pericyte (4.8-fold and 1.2-fold for ng-2 and 
pdgfrb, respectively) markers was observed in microvessels isolated enzymatically in 
comparison to the mechanic isolation. Also, a general reduction of the expression of the 
selective markers for the other brain cell types (gfap, s100b 5-fold, mbp 1.6-fold, syp 10-
fold reduction) was registered from microvessels isolated mechanically to enzymatically, 
suggesting that the enzymatic approach yield a more pure fraction of brain capillaries than 
the mechanic approach. According to the obtained mRNA levels, the NMDA receptor 
subunit NR1, and the ATP receptors P2Y1 and P2X7 are the most expressed genes in 
cortex samples, being 257-, 156- and 85-fold more expressed than the least expressed 
gene tested in cortex, which is the adrenoceptor β2, followed by the CB2 and the 
adrenoceptor α2A as the least expressed receptors in the rat cortex. Among the analyzed 
neurotransmitter receptors, rat brain microvessels demonstrate to poorly express the 
adenosine receptor A1, the adrenoceptors α2A and β1, as well as both CB receptors, while 
the ATP receptors P2Y1 and P2X7, and the adenosine receptor A2A assume a very 
important expression among the tested genes. These results suggest that purinergic 
receptors P2Y1 and P2X7 and adenosine A2A are highly express at the rat BBB, and so 
may play an important role in the cell signaling between the bloodstream and the CNS, 
and in the regulation of BBB function. 
 
Keywords: Blood-brain barrier, isolated microvessels, neurotransmitter, receptors, RT-
PCR  
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1. INTRODUCTION AND OBJECTIVES 
The blood-brain barrier (BBB) is an essential element required for the maintenance of the 
adult central nervous system (CNS) proper homeostasis and function. Communication 
between the CNS and the vasculature is mediated through the constitutive components of 
the BBB, microvessel endothelial cells (ECs) closely connected by tight junctions, 
surrounded by pericytes that share the same basal membrane with ECs, and astrocyte 
end-feet processes. The dynamic interplay between these cells within the neurovascular 
unit (NVU) allows the regulation of the BBB homeostasis, CNS blood flow, entry and 
clearance of compounds into/out of the CNS. The brain access of many compounds, 
including many drugs used in therapy, is amply limited by ATP-binding cassette (ABC) 
efflux transporters present at the luminal membrane of the brain microvessel ECs (Chaves 
et al. 2014; Coureuil et al. 2014). 
The neural microenvironment is crucial for the neurovascular development and 
maintenance of BBB function and properties. The overall exact mechanisms underlying 
the preservation of normal function of the NVU, and how cells of the NVU are involved in 
these mechanisms are still unknown, but are without doubt a result of the 
neurotransmitter, hormone, ionic and cytokine input coming from both the nervous tissue 
and the bloodstream (del Zoppo 2008; Iadecola and Nedergaard 2007; Paemeleire 2002). 
Recent studies have uncovered critical insights about neural and vascular communication 
within the NVU, particularly related to extracellular matrix-mediated signaling, as well as 
through calcium-mediated signaling (McCarty 2009). At present time, little is known about 
the role of major neurotransmitter receptors in the neurovascular signaling, and 
particularly on the expression of these receptors in the different cell-types composing the 
BBB, namely in brain ECs, astrocytes, pericytes, and microglia. While the presence of 
some neurotransmitter receptors in cerebral vessels, such as the adrenergic receptors, 
which serve to regulate vasoconstriction and vasodilation as in the systemic vasculature, 
is consensual (Durieu-Trautmann et al. 1991), the expression and role of neurotransmitter 
receptors such as the purine, cannabinoid and glutamate receptors remain controversial. 
Furthermore, cerebral vessels of different size and nature (arteries, veins, and capillaries) 
may considerably differ regarding the presence/absence and level of expression of such 
receptors. 
In the present study, we used isolated grey cortical matter of rat brain, and isolated rat 
brain cortical microvessels in order to check and compare the expression of specific cell 
markers for each constituent of the NVU in these samples, and therefore evaluate the 
purity of the obtained isolated microvessels by quantitative real time-polymerase chain 
reaction (RT-PCR). Furthermore, the expression of 11 neurotransmitter receptors in either 
rat brain cortex samples and in isolated rat brain microvessels was assessed: adrenergic 
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receptors α2A, β1 and β2 (Adra2a, Adrb1, Adrb2), adenosine receptors A1, A2A and A3 
(Adora1, Adora2a, Adora3), ATP receptors P2X7 and P2Y1 (P2rx7, P2ry1), cannabinoid 
receptors CB1 and CB2 (Cnr1, Cnr2), and the glutamate receptor subunit NMDAr1. 
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2. MATERIALS AND METHODS 
2.1. Animals  
Adult male Sprague–Dawley rats weighing 150 to 200g (4-5 weeks old) were purchased 
from Janvier laboratory (Le Genest-Saint-Isle, France). They were housed under standard 
12h light/dark conditions (light from 8:00 a.m. to 8 p.m.) in a temperature- and humidity-
controlled room, and had access to food and water ad libitum. All animal experiments 
complied with the standards and guidelines promulgated by the latest European Union 
Council Directive (2010/63/EU) and were approved by the local ethics review committee 
(Paris Descartes University n°12-186). 
 
2.2. Isolation of rat brain cortex samples and of microvessels from rat brain 
cortex 
All steps were carried out at 4°C. Rat brain cortex vessels were isolated according to 
(Yousif et al. 2008), which minimizes contamination from astrocyte and neuron mRNA. 
Rats were euthanized by CO2 inhalation and decapitated. Brains were immediately 
removed and placed in ice-cold Hank’s buffered salt solution (HBSS) supplemented with 
10 mM HEPES. Brain cortices were isolated and either collected for homogenization and 
RNA extraction (< 30 mg), or used to isolate brain microvessels. To obtain brain 
microvessels, two different approaches, an enzymatic and a mechanic method, were 
adopted. 
Mechanic method: Total isolated cortices were minced in HBSS, and homogenized in a 
Potter-Thomas homogenizer (0.25 mm clearance). The resulting homogenates were 
centrifuged at 2000g for 10 min at 4°C, and each pellet was suspended in 17.5% dextran 
(64–76 kDa, Sigma) and centrifuged at 4400g for 15 min at 4°C. The resulting pellets 
were suspended in HBSS containing 1% bovine serum albumin (BSA), and passed 
through a 100-µm nylon mesh. The filtrate was then passed through a 20 µm nylon mesh 
where microvessels (mainly 4–6 µm) were retained and immediately collected. 
Enzymatic method: Brain cortices were isolated and minced as described in the mechanic 
method, and centrifuged at 600g for 5 min at 4°C. The remaining pellets were 
enzymatically digested and homogenized in a buffer solution containing Liberase DL 
(0.195 Wunsch U/mL) and Dnase I (20 Kunitz U/mL) for 45 min at 37°C. The resulting 
homogenates were re-centrifuged and each pellet was then suspended in HBSS 
containing 18% BSA and centrifuged at 1500g for 15 min at 4°C. The resulting pellets 
were suspended in HBSS containing 1% BSA and passed through a 10 µm nylon mesh. 
Manuscript 3____________________________________________________________________	
178 
The fraction retained in the mesh was subsequently collected and used for further 
analysis. 
 
2.3. Extraction and dosage of total RNA from rat brain cortex and rat brain 
microvessels 
Total RNA was isolated through tissue homogenization and lysis in a TissueLyser system 
(Qiagen, Courtaboeuf, France) and extraction using the RNeasyQiagen Micro kit (for rat 
brain microvessel samples) and MiniPlus kit (for rat brain cortex samples) according to the 
manufacturer’s instructions (Qiagen). The concentration and purity of the RNA samples 
obtained were assessed spectrophotometrically using a Nanodrop spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA). 
 
2.4. Reverse Transcription and Quantitative Real-Time PCR 
cDNA synthesis: All RNA samples were reverse transcribed in the same Reverse 
Transcription (RT) from 1 μg of total RNA into cDNA in a final volume of 20 µL. Reverse 
transcription reagents were purchased from Invitrogen (Cergy-Pontoise, France). RT was 
performed on a programmable thermal cycler (PTC-100 programmable thermal controller; 
MJ Research, Waltham, MA, USA). 
RT-PCR theoretical principles: The transcript levels for each target gene were 
investigated by qRT-PCR as previously described (Coureuil et al. 2010; Di Tullio et al. 
2004). Relative expressions of target genes were determined for samples with a gene 
Cycle Threshold (CT) lower than 33. Target genes were considered to be unquantifiable 
when CT values were above 33. To ensure the validity of the comparison between the 11 
neurotransmitter mRNA expressions, efficiency of PCR (E) was checked and it was 
greater than 95% for all the tested genes. 
The ΔΔCT method was used to compare the expression of a gene of interest in rat brain 
microvessels and cortex, which were normalized to that of the housekeeping gene TATA 
box-binding protein (TBP). This comparison was possible because the expression of the 
TBP gene in cortex and microvessels was not statistically different in any of the tested 
samples. 
PCR amplification: Specific nucleotide primer sequences (see Table 1) were designed 
using OLIGO 7 software (Medprobe, Oslo, Norway) and synthesized by Eurogentec 
(Angers, France). Amplification was detected by SYBR® Green fluorescence on an ABI 
PRISM® 7900HT sequence detection system (Applied Biosystems, Courtaboeuf, France). 
Thermocycling was carried out in a final volume of 20 µL. The thermal cycling conditions 
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were 2 min at 50°C then 10 min at 95°C followed by 40 amplification cycles at 95°C for 
15s, at 60 or 65°C for 45s and at 95°C for 15s. 
 
2.5. Statistical Analysis 
Data were analyzed with GraphPad Prism® 6.0 software (San Diego, CA, USA). The 
results are expressed as means ± SEM. One-way and two-way ANOVA comparisons with 
the Bonferroni’s post-test adjustment were used to compare the expression of genes in 
different analyzed tissues. Statistical significance was set at p < 0.05 for all the tests.
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3. RESULTS 
 
3.1. Expression profiles of cell markers for endothelial cells (glut1), pericytes 
(ng2, pdgfrb), astrocytes (gfap, s100b), microglia (cd11b), 
oligodendrocytes (mbp) and neurons (syp) 
The mRNA expression of several genes considered as CNS cell markers for ECs (glut1), 
pericytes (ng2, pdgfrb), astrocytes (gfap, s100b), microglia (cd11b), oligodendrocytes 
(mbp) and neurons (syp) was evaluated by qRT-PCR, and their relative abundances 
between samples  – brain cortex homogenates, rat brain microvessels isolated by an 
enzymatic method and by a mechanic method – were compared (Table 2). The marker 
used for ECs, glut1, was significantly enriched in isolated microvessels when compared to 
brain cortex, registering 8.5-fold and 15.6-fold enrichment in microvessels isolated 
mechanically and enzymatically, respectively (p < 0.05). Similar results were found for ng-
2 and pdgfrb, both selective markers used for pericytes, which are in strict contact with the 
BBB endothelium: ng-2 was 15.2-fold (p < 0.01) and pdgfrb 12-fold (p < 0.001) more 
expressed in brain microvessels isolated enzymatically than in the cortex. In contrast, the 
relative amounts of gfap and s100b (representing contamination by astrocytes) were 
significantly reduced in isolated microvessels when compared to their presence in brain 
homogenates: when we compare microvessels isolated enzymatically to brain 
homogenates, gfap expression was reduced 25.6-fold while s100b was reduced 67.7-fold 
(p < 0.001). As expected, syp mRNAs, tracing contamination by neurons, were massively 
lowered in microvessels isolated enzymatically. In brain microvessels obtained 
enzymatically, a reduction of 4.3-fold (p < 0.05) in the expression of mbp, a selective 
marker used to detect oligodendrocytes, was also registered, when compared to the brain 
cortex. 
Comparing the two methods of isolation of rat brain microvessels, there is an enrichment 
of EC and pericyte cell markers when the enzymatic method is used – glut1 is 
approximately 2-fold, ng-2 4.8-fold (p < 0.01) and pdgfrb 1.2-fold higher in microvessels 
isolated enzymatically than in the ones isolated mechanically. This suggests that 
microvessels isolated with an enzymatic approach yield a more pure fraction of brain 
capillaries than microvessels isolated with a mechanic approach. In agreement with these 
data, a general reduction of the expression of the selective markers for the other cell types 
(gfap, s100b 5-fold, mbp 1.6-fold, syp 10-fold reduction) was registered from microvessels 
isolated mechanically to enzymatically, evidencing a clear reduction on the contamination 
coming from other cell elements surrounding the brain capillaries in these microvessel 
isolates. 
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3.2. Expression profiles of genes encoding neurotransmitter receptors: 
Adra2a, Adrb1, Adrb2, Adora1, Adora2a, Adora3, P2rx7, P2ry1, Cnr1, 
Cnr2, NMDAr1 
The expression of 11 neurotransmitter receptor genes – adrenergic (Adra2a, Adrb1, 
Adrb2), adenosine (Adora1, Adora2a, Adora3), ATP (P2rx7, P2ry1), cannabinoid (Cnr1, 
Cnr2), and glutamate receptor NMDAr1 – was investigated by qRT-PCR in samples from 
rat brain cortex homogenates and rat brain microvessels isolated mechanically and 
enzymatically. The expression of all the tested genes was detectable and quantifiable in 
all samples. The amount of each transcript in the three types of samples was normalized 
to the smallest amount of mRNA of one target gene detectable and quantifiable in the 
same kind of sample (to the target gene the least expressed is given the arbitrary 
expression of 1). 
Among the tested, NMDAr1, P2ry1 and P2rx7 are the most expressed genes in cortex 
samples, being 257-, 156- and 85-fold more expressed than the least expressed gene 
tested in cortex, which is Adrb2 (Fig. 1, a). Adrb2 together with Adrb1, Cnr2 and Adra2a 
are the least expressed receptors in the rat cortex. 
The least expressed gene in rat brain microvessels isolated enzymatically was found to be 
Adora1, followed by Cnr1 (2.1-fold), Adrb1 (6.4-fold), Cnr2 (6.8-fold) and Adra2a (7.2-
fold). In microvessels isolated enzymatically, it was also found that P2ry1 (788-fold of the 
least expressed gene, Adora1), Adora2a (454-fold), P2rx7 (264-fold) and Adrb2 (21-fold) 
assume a very important expression among the tested genes (Fig. 1, b). 
In rat brain microvessels isolated mechanically, while Adora1 and Adra2a are the least 
expressed genes, followed by Adora3 (1.1-fold), Cnr2 (1.6-fold), Adrb1 (3.2-fold) and Cnr1 
(5-fold), and similarly to what was found in microvessels isolated enzymatically, P2rx7 
(150-fold), Adora2a (126-fold) and P2ry1 (80-fold) are also among the most expressed 
genes (Fig. 1 c). 
 
 
3.3. Comparison of expressions of studied neurotransmitter receptors genes 
between rat brain isolated microvessels and rat brain cortex  
Once the expression of the selected neurotransmitter receptors was determined in rat 
brain cortex homogenates and in rat brain microvessels, their expression among tissues 
was compared (Table 3). Comparisons subsequently described will mainly focus on the 
expression levels found in rat brain cortex and in rat brain microvessels isolated using the 
enzymatic approach, since this technique yielded the purest capillary fraction, and thus 
should best reflect the expression of neurotransmitter receptors at the BBB. The transcript 
levels found for Adora1, Cnr1 and NMDAr1 in rat brain microvessels are approximately 
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50-fold lower (p < 0.001) to those found in brain cortex samples (Table 3, Fig. 2), 
suggesting that these genes are barely expressed in rat brain capillaries, or even that they 
might come from neuronal contamination. In rat brain microvessels isolated mechanically 
the lower expression for these genes is less substantial, being Adora1 25-fold, Cnr1 8.5-
fold and NMDAr1 4.2-fold less expressed than in brain cortex (p < 0.001). The higher 
expression of Adora1, Cnr1 and NMDAr1 in rat brain microvessels isolated mechanically 
than in the capillaries isolated enzymatically may suggest that cells which closely 
surround the capillaries, such as astrocytes and pericytes, may express these receptors. 
The expressions of Adrb1 and Adora3 in rat brain microvessels isolated enzymatically 
were found to be approximately 3.5-fold (p < 0.01) and 8.5-fold (p < 0.001) inferior to ones 
found in brain cortex samples, respectively. The adrenergic receptor Adrb2 and the 
adenosine receptor Adora2a are the only neurotransmitter receptors studied seeing their 
expression to be increased from rat brain cortex samples to rat brain microvessels, being 
7-fold and 5-fold higher, respectively (Table 3, Fig. 2). In turn, the adrenergic receptors 
Adra2a, ATP receptors P2rx7, P2ry1 and the cannabinoid receptor Cnr2 do not see their 
expressions considerably altered from brain cortex to brain microvessel samples. 
However, we should note that Adra2a and Cnr2 are among the least expressed genes in 
the brain cortex, whereas P2rx7 and P2ry1 are among the most expressed, meaning that 
the expression of these latter genes in the microvessels is very significant, as shown in 
Fig. 1 b, c, and in Fig. 2. This suggests that these receptors are present in the NVU, and 
so may play a role in the cell signaling between the bloodstream and the CNS. 
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4. DISCUSSION 
 
Purine receptors are membrane-bound receptors that have extracellular nucleosides (P1 
receptors) or nucleotides, such as ATP (P2 receptors) as receptor ligands, and are 
thought to be important signaling intervenients for the normal function of the NVU 
(Iadecola and Nedergaard 2007). Such receptors are involved in regulation of 
vasodilatation and of BBB permeability (Peterson et al. 2010; Sipos et al. 2000). 
Adenosine (P1) receptors consist of four known subtypes (A1, A2A, A2B, A3), and their 
activation leads to modification of adenylyl cyclase signaling, by regulating the intracellular 
levels of cAMP (Fredholm et al. 1994) (Fredholm et al. 2001). Even though the expression 
of A1 and A3 receptors has been detected in astrocyte preparations (Alloisio et al. 2004; 
Verkhratsky et al. 2009), their expression in the cerebrovasculature remains controversial 
(Di Tullio et al. 2004; Ngai et al. 2001). On the other hand, A2A receptors seem to be 
reasonably well expressed in the blood-brain vessels (Koehler et al. 2006; Ngai et al. 
2001). In the present study, we demonstrated that among the three adenosine receptors 
tested, A1, A2A and A3, A3 has the lowest expression in the rat brain cortex. This is in 
agreement with a previous study, which showed that adenosine receptors A3 have low 
expression in the brain (Rebola et al. 2005). Focusing on their expression in the brain 
microvasculature, whereas the expression of the adenosine receptors A1 and A3 assume 
a less important relative expression, the A2A receptors see their relative expression greatly 
increased in comparison to that of brain cortex (Table 3, Fig. 1 and 2). This suggests that 
the A2A adenosine receptor in particular may play a role in the BBB signaling system, 
which can be stimulated by either the adenosine signaling coming from astrocytes and 
other neighboring cells of the CNS, or alternatively by agonists circulating in the blood. In 
a study using bovine brain capillary ECs, the presence of A2A and A3 adenosine receptors 
was demonstrated by RT-PCR and radioligand binding assays, while A1 was absent and 
the presence of the A2B receptor remained uncertain (Schaddelee et al. 2003). The protein 
expression of both A1 and A2A adenosine receptors was evidenced by Western Blot (WB) 
on primary ECs isolated from mice brains and on the human brain endothelial cell line 
hCMEC/D3 (Carman et al. 2011; Mills et al. 2011), supporting that the BBB is able to 
directly respond to extracellular adenosine. In fact, it was also demonstrated that the 
activation of the adenosine receptors A1 and A2A at the brain ECs facilitated the entry of 
intravenously administered macromolecules, such as dextrans and anti-β-amyloid 
antibody, into the murine brain (Carman et al. 2011). 
 
The P2 receptors are subdivided into ligand-gated ion channels P2X receptors, and G-
protein-coupled P2Y receptors (von Kugelgen 2006), and so far little is known about their 
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expression at the BBB and their hypothetical role for the maintenance of the BBB 
properties. Two different RT-PCR experiments evidenced the expression of mRNA for 
P2Y1, P2Y2, P2Y4 and P2Y6 in primary rat BBB ECs (Anwar et al. 1999), and the 
expression of the G protein-coupled receptors P2Y2, P2Y6, P2Y11 as well as the ionotropic 
P2X4, P2X5 and P2X7 receptors in the hCMEC/D3 cells (Bintig et al. 2012). Our present 
study demonstrates that P2X7 and P2Y1 receptors are among the most expressed 
neurotransmitter receptors of all tested genes, either in the rat brain cortex or in isolated 
microvessels. Interestingly, both purinergic receptors do not see their expression 
considerably altered from samples of brain cortex to isolated brain microvessels (Table 3), 
indicating that these receptors may play an important signaling role at the BBB. 
In the brain, P2X7 receptor is predominantly expressed in the microglia (Harry 2013), and 
it is known that its activation promotes the release of IL-1α and IL-1β (Bernardino et al. 
2008; Ferrari et al. 1997; Mingam et al. 2008), TNF-α (Hide et al. 2000), superoxide 
(Parvathenani et al. 2003), and plasminogen (Inoue et al. 1998). Microglial P2X7 receptor 
activation also seems to be involved in the protection of neurons against glutamate-
induced neurotoxicity (Suzuki et al. 2004). P2X7 receptor is also expressed in other brain 
cell types, such as astrocytes, and thus it may play a role in the modulation of glutamate 
release from astrocytes and in neuroexcitability, since astrocytes react with 
neurotransmitters released from the synapse (Duan et al. 2003). However, to date, little is 
known about the role of ATP and of the P2X7 receptors expressed in the ECs of the BBB. 
Nevertheless, microglial P2X7 receptor has shown to regulate BBB properties. It was 
recently demonstrated that the selective blockade of the activation of microglial P2X7 
receptors was able to prevent basal lamina degradation and BBB leakage provoked by 
3,4-methylenedioxymethamphetamine (MDMA, ecstasy) via P2X7 receptor-microglial 
activation (Rubio-Araiz et al. 2014). 
 
P2Y1 receptor is widely expressed in the different regions of the mammalian brain, and in 
different brain cell types, including Purkinje cells, oligodendrocytes, astrocytes, microglia 
and neurons (Weisman et al. 2012). This purinergic receptor has shown to be implicated 
in the regulation of glial cell functions (Moran-Jimenez and Matute 2000), providing 
neuroprotection against oxidative stress, and contributing to brain development and repair 
(Fujita et al. 2009; Mishra et al. 2006). P2Y1 receptor activation in microglia has shown to 
promote the down-regulation of pro-inflammatory response, as its activation increases the 
release of the anti-inflammatory cytokine, IL-10 (Seo et al. 2008). Similarly to P2X7 
receptor, little data is available concerning the role of P2Y1 receptor at the brain 
microvasculature. Still, recent studies indicate that activation of P2Y2 receptors in the 
brain vascular endothelium can increase the transendothelial permeability of leukocytes 
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(Kukulski et al. 2010; Seye et al. 2002; Seye et al. 2003), suggesting that the activation of 
P2Y2 receptors, and possibly of P2Y1, in brain microvessels may function as a novel 
target for increasing drug delivery into the brain. 
 
The adrenoceptors are a class of G protein-coupled receptors, targets of catecholamines, 
such as norepinephrine and epinephrine, comprising α (α1A, α1B, α1D, and α2A, α2B, α2C) and 
β (β1, β2, and β3) receptor subtypes. Our present results evidence that the adrenoceptors 
α2A, β1 and β2 are poorly expressed in either the rat brain cortex or in isolated rat brain 
microvessels (Fig.1 and 2). Nevertheless, we demonstrate that even though the 
expression of the β2 adrenoceptor is low in brain microvessels, it sees its expression being 
enriched up to 7-fold when microvessels are purified from total brain cortex (Table 3, Fig. 
2), whereas the expression of the other two adrenoceptor sub-types tested remain 
unchanged or are even lower than in brain cortex. The β adrenoceptors in the ECs are 
responsible for controlling vascular homeostasis and regulation of receptor 
desensitization, internalization and signaling via β-arrestins (DeWire et al. 2007). The 
expression of β1 and β2 adrenergic receptors was firstly demonstrated in a bovine primary 
culture of brain ECs (Durieu-Trautmann et al. 1991). The expression of the β2 
adrenoceptor in the BBB was also evidenced to mediate the interaction of the Neisseria 
meningitidis pathogen with the brain endothelium and to facilitate its crossing through the 
BBB (Coureuil et al. 2010). These data are in line with the present results obtained in this 
study. 
 
Cannabinoid receptors essentially mediate distinct effects: type 1 cannabinoid receptors 
(CB1) mediate the psychoactive effects of cannabinoids and are mainly expressed in the 
CNS, whereas type 2 cannabinoid receptors (CB2) mostly mediate anti-inflammatory 
effects and are predominantly expressed in cells of the immune system and hematopoietic 
cells (Cabral et al. 2008; Miller and Stella 2008). In the brain, the expression of CB2 
receptors was found in brain microvascular ECs. The endocannabinoid system is 
implicated in neuroprotection, modulation of the inflammatory response, reduction of brain 
edema and induction of neuroprotective hypothermia (Cabral and Griffin-Thomas 2009). 
Activation of CB1 receptors can protect against excitotoxicity, by control of the release of 
excitatory neurotransmitters from neurons (Marsicano et al. 2003), and promote 
neurogenesis (Aguado et al. 2007). On the other hand, activation of CB2 receptors 
reduces oxidative stress and neuroinflammation by attenuating microglial activation and 
production of proinflammatory mediators (Campbell and Gowran 2007; Horvath et al. 
2012). It is generally accepted that CB2 receptors are predominantly expressed by 
immune cells and resident microglia, whereas the presence of CB2 receptors in neurons 
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remains controversial (Atwood and Mackie 2010; Van Sickle et al. 2005; Walter et al. 
2003). Our study shows that CB receptors are expressed at very low levels in either rat 
brain cortex or rat brain microvasculature. In a study conducted using human 
cerebromicrovascular ECs, the mRNA and protein expression of both CB1, CB2 receptors 
was demonstrated (Golech et al. 2004).  Little CB2 receptor immunoreactivity in healthy 
brain endothelium or in human brain microvascular ECs has also been evidenced 
(Ramirez et al. 2012), and seem to be up-regulated in pathologies and in response to 
inﬂammation and stress (Schley et al. 2009; Zhang et al. 2011b). A recent study showed 
that CB1 receptor mRNA levels are found in both human brain microvessel ECs and 
human astrocytes, but CB2 receptor are only found in astrocytes (Hind et al. 2015). 
Furthermore, this study demonstrates that several endocannabinoids are able to regulate 
the BBB permeability in vitro via CB2 receptors. Considering the low expression of these 
receptors at the mammalian BBB, and their overall role in the CNS, it is expected that CB 
receptors present in the ECs have a small role in the regulation of BBB permeability and 
control of neuroinflammation, by working in concert with the other cell types and 
modulators that constitute the NVU. 
 
Concerning the presence of the NMDA receptor in brain ECs, its expression has been a 
matter of study over the past decade, but the resulting data has generated controversy 
regarding its actual expression at the BBB and its role. The gene expression of several 
subunits of the NMDA receptor was first demonstrated in cultured rat brain ECs in 1998 
(Krizbai et al. 1998). Since then, several studies using molecular-biology techniques for 
direct localization of this glutamate receptor have brought little consensual results. Gene 
expression and functional activity of main NMDA receptor subunits failed to be 
demonstrated in rat and human cortical microvessels and in cultured cerebrovascular ECs 
(Morley et al. 1998). Furthermore, NMDAr1 subunit expression was not detected in a rat 
brain microvascular EC culture by WB (Domoki et al. 2008). However, in 2003, a research 
group was able to demonstrate by RT-PCR, WB and immunoprecipitation that 
immortalized human ECs expressed the NMDAr1 subunit (Sharp et al. 2003). The 
expression of NMDAr1 and NMDAr2 subunits were also evidenced by WB, in primary 
cultures of rat brain ECs (Andras et al. 2007); similarly, in mouse brain microvessel ECs, 
the expression of NMDAr1 was evidenced by RT-PCR, immunostaining, and WB (Legros 
et al. 2009). The presence of the NMDAr1 subunit was also reported by 
immunofluorescence, WB and qPCR, in the hCMEC/D3 cell line (Reijerkerk et al. 2010). 
In our current study, the NMDAr1 expression in the enzymatic isolation of microvessels, 
which is the technique that yields a purest fraction of brain ECs, is relatively poor in 
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comparison to the other tested genes. However, its mRNA levels are still fairly identified, 
and thus supporting that this receptor is expressed at the rat brain BBB. 
The presence of the NMDA receptor in the brain microvasculature has been recently 
indicated as an element for the regulation of the expression of the ABC drug efflux 
transporters (Bauer et al. 2008; Salvamoser et al. 2015; Zibell et al. 2009), namely P-
glycoprotein and Breast Cancer Resistance Protein (BCRP). Additionally, it was also 
evidenced that in a murine BBB model, the NMDA receptor mediates the 
hyperhomocysteinemia effect on the increase of the BBB permeability, by regulating the 
expression of adherens and tight junctions present at the brain ECs (Beard et al. 2011). 
Using the same murine BBB model, this receptor also showed to mediate the up-
regulation of the glucose uptake transporter (glut-1) during oxygen/glucose deprivation 
and subsequent reoxygenation in brain ECs (Neuhaus et al. 2012). 
 
Conclusion: the analysis of the mRNA levels of markers for the different cell types of the 
CNS present in brain microvessels isolated using a mechanic and an enzymatic approach 
allow us to conclude that the enzymatic approach is the method which yields the purest 
fraction of brain capillary ECs. This method renders a capillary cellular fraction more 
highly enriched in pericyte and endothelial cell markers, and with less other cell 
contaminants than what is obtained with the mechanic isolation from the rat brain cortex, 
and thus should be preferentially used for the study of the BBB physiopathology and 
properties. In addition, the current study gives an original look over the expression of 
several neurotransmitter receptors in both rat brain cortex and in rat brain isolated 
microvessels, as well as providing a comparative analysis of their relative amounts among 
these tissues. Therefore, the present study allows us to understand which 
neurotransmitter receptors are more specifically expressed along the BBB, such as the 
ATP receptors P2X7 and P2Y1, as well as the adenosine receptor A2A, suggesting their 
important role in the signalling system for the normal functioning of the NVU.  
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6. TABLES 
 
Table 1. Primer sequences used for SYBR Green-based real-time quantitative polymerase chain 
reaction. 
Gene (name) Forward Primer (5’-3’) Reverse Primer (5’-3’) Length (bp) 
TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 132 
Adra2A (ADr α2A) CGGCAATAGCAGCTGGAACGG GCCAAACACGGTGAACAGCAT 127 
Adrb1 (ADr β1) CTGCTACAACGACCCCAAGTG AACACCCGGAGGTACACGAA 120 
Adrb2 (ADr β2) CCTTGGCGTGTGCTGATCTA GTCCAGAACTCGCACCAGAA 109 
Adora1 (Ar A1) AAGATCCCTCTCCGGTACAAG ACTCAGGTTGTTCCAGCCAA 123 
Adora2a (Ar A2A) GCCTGTTTTGTCCTGGTCCT ACCAAGCCATTGTACCGGAG 107 
Adora3 (AR A3) TGTCCTGTGTGCTTCTGGTC AGTGGTAACCGTTCTATATCTGACT 113 
Grin1 (NMDAr1) GCAGGTGGAGTTGAGTACCATGTAC CAGCTTGTTGTCCCGCACA 94 
Cnr1 (CB1) CGCACAGCCTCTAGACAACAG TGCTCTTGATGCAGCTCTCC 104 
Cnr2 (CB2) GCCACCCAGCAAACATCTATGC CATGGACAGACAGGCTTTGGCT 89 
P2rx7 (ATPr P2X7) ATCGGTGTGCTTTCTTCGG CAGGCTCACTCTGTTTCGGC 96 
P2ry1 (ATPr P2Y1) CAAGCAGAACGGAGACACAAG GTGCATCAGGTCATCTCAGGG 96 
gfap AGGCAGAAGCTCCAAGATGAAAC TCTCCAGATCCACACGAGCCAA 109 
s100b CACCGAAGCCAGAGAGGACT TGGAAGACATCAATGAGGGCAAC 99 
glut-1 CCCAGGTGTTCGGCTTAGAC CTCTCAGGGCAGAAGGGCAAC 118 
ng-2 ACCAGCTAGAGGTAGTCCAGG GACACCATCACCAAGTAGCCAG 94 
pdgfrb ACCCAGCCACTTGAACCTGA ATCTACAGATTCATCCTTGCTCA 73 
cd11b AGGCTCAGACAGAGACCAAAG TGATGAGAGCCAAGAGCACCAG 102 
mbp CTCCCTGCCCCAGAAGTCG GGGGTGTACGAGGTGTCACAAT 86 
syp GCCACGGACCCAGAGAACATTA TTCAGGAAGCCAAACACCACT 125 
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Table 3. Relative expression (mRNA) of several neurotransmitter receptors in samples from 
rat microvessels isolated enzymatically or mechanically in comparison expression levels in 
the rat brain cortex (receptor expression in brain cortex was given an arbitrary expression 
value of 1).  All data have been normalized to TBP mRNA and are expressed as means ± SEM of 
3 independent experiments. One-way ANOVA with Bonferroni’s Multiple Comparison post-test 
adjustment *p< 0.05, **p< 0.01, ***p<0.001. 
 Cortex Microvessels enzymatic 
Microvessels 
mechanic 
Adrenergic receptors 
Adra2A 1.00 ± 0.07 1.08 ± 0.10 0.40 ± 0.17* 
Adrb1 1.00 ± 0.02 0.29 ± 0.04** 0.40 ± 0.13** 
Adrb2 1.00 ± 0.10 6.99 ± 1.34** 7.03 ± 0.52** 
Adenosine receptors 
Adora1 1.00 ± 0.09 0.02 ± 0.01*** 0.04 ± 0.01*** 
Adora2A 1.00 ± 0.05 5.32 ± 0.79** 4.02 ± 0.67* 
Adora3 1.00 ± 0.05 0.12 ± 0.04*** 0.13 ± 0.04*** 
ATP receptors 
P2rx7 1.00 ± 0.09 1.48 ± 0.20 2.24 ± 0.77 
P2ry1 1.00 ± 0.07 1.68 ± 0.31 0.47 ± 0.13 
Cannabinoid receptors 
Cnr1 1.00 ± 0.08 0.02 ± 0.01*** 0.12 ± 0.05*** 
Cnr2 1.00 ± 0.12 1.34 ± 0.45 0.87 ± 0.09 
Others 
NMDAr1 1.00 ± 0.01 0.02 ± 0.01*** 0.24 ± 0.13*** 
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7. FIGURES 
Fig. 1. Relative abundance of the studied neurotransmitter receptors (mRNA) compared to 
the least expressed receptor in each analyzed tissue, in (a) rat brain cortex samples, (b) rat 
brain isolated microvessels isolated enzymatically, and (c) rat brain isolated microvessels 
isolated mechanically. All data have been normalized to TBP mRNA and are expressed as 
mRNA-fold expression to the least expressed gene in the analyzed tissue (expression level set as 
1). Results are means ± SEM of 3 independent samples.  
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Fig. 2. Overview of the mRNA relative expression of the studied neurotransmitter receptors 
between samples from rat brain cortex and rat brain isolated microvessels isolated 
enzymatically and mechanically. Transcript amounts for each target gene were normalized to 
TBP mRNA and are expressed as n-fold expression towards the smallest amount of one target 
gene mRNA detectable and quantifiable (Adora1 in rat brain microvessels isolated enzymatically, 
expression level set as 1). Results are means ± SD of 3 independent experiments. 
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General outcome: 
In this present work, we performed an original study concerning the development of BBB 
models, bringing new insights for the choice of a best approach to isolate brain capillaries 
for the study of the BBB. When the expression and relative abundance of several CNS 
cell markers, such as glut1 (BECs) ng2, pdgfrb (pericytes), gfap, s100b (astrocytes), 
cd11b (microglia), mbp (oligodendrocytes) and syp (neurons) was compared between 
samples, we conclude that there is an higher enrichment of BEC and pericyte cell markers 
with the enzymatic digestion approach, in comparison to the mechanical dissection 
method. In fact, glut1 is approximately 2-fold, ng-2 4.8-fold, and pdgfrb 1.2-fold higher in 
microvessels isolated enzymatically than in microvessels isolated mechanically. 
Furthermore, the expression of specific markers for astrocytes, oligodendrocytes and 
neurons was considerably reduced when microvessels were isolated with the enzymatic 
approach compared to the brain microvessels isolated mechanically. The resulting data 
point to a clear reduction on the contamination coming from other cell elements 
surrounding the brain capillaries in the microvessel isolates coming from the enzymatic 
digestion technique. Thus, microvessels isolated with an enzymatic approach yield a more 
pure fraction of brain capillaries than microvessels isolated with a mechanic approach, 
indicating that this technique should be preferentially adopted for studying the BBB 
properties in the rat. 
Among the 11 neurotransmitter receptor genes – adrenergic (Adra2a, Adrb1, Adrb2), 
adenosine (Adora1, Adora2a, Adora3), ATP (P2rx7, P2ry1), cannabinoid (Cnr1, Cnr2), 
and glutamate receptor NMDAr1, P2ry1 (788-fold of the least expressed gene, Adora1), 
Adora2a, P2rx7 and Adrb2 showed to assume an important expression level in rat brain 
microvessels. In addition, transcript levels found for Adora1, Cnr1 and NMDAr1 in rat 
brain microvessels were approximately 50-fold lower to those found in brain cortex 
samples, suggesting that such receptors are poorly expressed in rat brain capillaries, and 
likely come from neuronal contamination. On the other hand, Adrb2 and Adora2a are the 
only neurotransmitter receptors with an increased expression in rat brain microvessels in 
comparison to brain cortex, while Adra2a, Cnr2 and the ATP receptors P2rx7, P2ry1 do 
not register any considerable change of expression from brain cortex to brain microvessel 
samples. Furthermore, P2rx7 and P2ry1 showed to be among the most expressed genes 
in the rat brain cortex, and thus the microvessel expression of such genes is particularly 
important. These findings suggest that ATP receptors P2X7 and P2Y1, as well as the 
adenosine receptor A2A are present at the BBB, and so may play a central role in cell 
signaling at the NVU and in the normal function of the BBB. 
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Rationale and Objectives: 
In the objectives set for the present thesis dissertation, we primarily focused on a 
mechanism of modulation of P-gp and BCRP gene and protein expressions at the BBB. 
Still, it is difficult to estimate the impact of such P-gp and BCRP up-regulation on the 
activity of these drug efflux transporters, and thus, to predict the extent of this change on 
the pharmacokinetics and pharmacodynamics of drugs or other xenobiotics. On the other 
hand, the direct activation of ABC transporters, namely of P-gp, where an increase in its 
activity can be seen without any change in the gene or protein expression, is gaining 
increasing interest as a mechanism of modulation of transport across physiological 
barriers, since it directly affects the transport of its substrates and its impact can be easily 
estimated. Very recently, a set of thioxanthonic compounds has demonstrated to rapidly 
increase the transport activity of P-gp in Caco-2 cells (Silva et al. 2014c). Furthermore, the 
cytotoxicity induced by the toxic herbicide PQ was significantly reduced in the presence of 
most of these thioxanthonic derivatives, a protective effect that was reversed upon 
incubation with a specific P-gp inhibitor. These results encouraged us to investigate if 
such modulation could be attained in a BBB model, in order to use such compounds, 
named as P-gp activators, as antidotes to revert neuronal damage and its consequences 
in potential situations of acute intoxication with harmful P-gp substrates, in a fast and 
efficient manner.  
Therefore, the main objective of the following study is to uncover if six different 
thioxanthonic compounds can be used as P-gp activators at the BBB, and revert the 
mitoxantrone-induced cytotoxicity. For this purpose, RBE4 cells were used as in vitro BBB 
model, which were incubated for a short time with each thioxanthonic derivative and the 
efflux transport activity was evaluated, by measuring the intracellular accumulation of Rho 
123, a fluorescent P-gp substrate. Additionally, RBE4 cells were incubated with a broad 
range of concentrations of mitoxantrone, a toxic P-gp substrate, in the presence or 
absence of each tested thioxanthone. Cell death was then evaluated after 4h, 8h and 16h 
of incubation in order to estimate the protection conferred by each thioxanthonic 
compound against the mitoxantrone-induced toxicity. 
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Abstract: 
The activation of P-gp is a fast approach to increase the efflux of substrates, which could 
confer protection in an intoxication scenario. Some thioxanthonic derivatives were recently 
described to activate P-gp, protecting Caco-2 cells against paraquat toxicity. The aim of 
this study is to screen six thioxanthonic derivatives as potential P-gp activators and to 
evaluate whether they would afford protection against the cytotoxicity induced by 
mitoxantrone, a P-gp substrate,, in a blood-brain barrier (BBB) model, RBE4 cells. 
Thioxanthonic derivatives were synthesized and their cytotoxicity on RBE4 cells was 
assessed by the NR uptake and MTT reduction assays 24h after exposure. P-gp ATPase 
activity was determined in the presence of these derivatives to evaluate their potential as 
P-gp substrates. The effect of thioxanthones on the efflux of Rhodamine123 in RBE4 cells 
was evaluated by flow cytometry. Mitoxantrone-induced cytotoxicity was evaluated in the 
absence/presence of the thioxanthones. 
All thioxanthones showed no cytotoxicity at 10 μM, except TX129. None showed to be a 
clear P-gp substrate. TXA4, TXA3, TX105 and TX129 (10 μM) increased the efflux of 
Rhodamine123 up to 168%, reflecting an activation of P-gp transport in RBE4 cells. 
However, thioxanthones did not significantly reduce the cytotoxicity of mitoxantrone. 
In conclusion, this study demonstrates the potential of thioxanthonic compounds in the 
activation of P-gp at the BBB. However, the observed increase in P-gp activity did not 
protect cells against mitoxantrone cytotoxicity. Thus, the results highlight the absence of a 
mandatory correlation between higher P-gp activity and lower toxic effects of its 
substrates. 
 
Keywords: Blood-brain barrier, RBE4 cells, P-glycoprotein, Thioxanthones, P-
glycoprotein activation, Mitoxantrone 
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1. INTRODUCTION 
The blood-brain barrier (BBB) plays an important role in brain homeostasis and protection 
from potentially toxic substances, since it determines the bioavailability of a wide variety of 
compounds, including endogenous substances, drugs and xenobiotics in the brain 
(Chaves et al. 2014; DeGorter et al. 2012). ATP-binding cassette (ABC) transporters, in 
particular, are key elements present at the BBB implicated in the efflux of xenobiotics, 
which enable the extrusion of a large number of structurally unrelated substrates, and 
therefore regulate CNS drug efficacy and toxicity (Chaves et al. 2014; DeGorter et al. 
2012; Gottesman et al. 2002). A differential expression of ABC transporters contributes to 
the inter-individual vulnerability to xenobiotics and pharmacoresistance (Gottesman et al. 
2002). The induction of these drug efflux transporters can be understood as an antidote 
approach for limiting the toxicity of their substrates, through their augmented efflux and 
limited drug intracellular accumulation (Silva et al. 2014f).  
Our research group recently showed that newly synthesized (thio)xanthonic derivatives 
protected Caco-2 cells against the cytotoxicity of paraquat (Silva et al. 2014b; Silva et al. 
2014e). Protective effects of P-gp inducers are dependent on their ability to induce the 
synthesis of a functional protein, which may not be observed whenever an increased 
protein expression is registered. Interestingly, these newly synthesized compounds seem 
to be capable of rapidly increase P-gp activity with no need to increase its expression, 
representing a new class of drugs, known as P-gp activators. In silico studies showed 
interactions between (thio)xanthones and P-gp in the presence of paraquat, which 
suggested that a co-transport mechanism might be operating (Silva et al. 2014b; Silva et 
al. 2014e). 
In this way, we decided to test the thioxanthonic derivatives (Fig. 1) that showed to be 
promising P-gp activators in Caco-2 cells (TX87, TXA4, TXA3, TXOH), as well as new 
ones synthetized (TX105, TX129) and characterized in-house, on an in vitro BBB model – 
RBE4 cells – in order to understand if these compounds can also function as P-gp 
activators in such model, by conferring cytoprotection against a P-gp toxic substrate, 
mitoxantrone, and thus be used as a potential antidotal mechanism.  
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2. EXPERIMENTAL PROCEDURES 
2.1. Material 
Minimum essential medium, nutrient mixture F-10 Ham, sodium bicarbonate, 4-(2-
hydroxyethyl)-1- piperazineethanesulfonic acid (HEPES), neomycin sulfate, neutral red 
(NR) solution, methylthiazolyldiphenyl-tetrazolium bromide (MTT), rhodamine 123 (Rho 
123), cyclosporine A and zosuquidar were obtained from Sigma (St. Louis, MO, USA). 
Reagents used in cell culture, including fetal bovine serum (FBS), antibiotic solution (10 
000 U/mL penicillin G, 10 000 μg/mL streptomycin sulphate), rat tail collagen type I, 
Hanks’ balanced salt solution (HBSS) (either with or without Ca2+ and Mg2+ salts), 0.25% 
trypsin-EDTA solution, were obtained from Gibco Laboratories (Lenexa, KS). Basic 
fibroblast growth factor (bFGF) was from Invitrogen. 
Flow cytometry reagents and propidium iodide were obtained from Becton, Dickinson and 
Company (BD Biosciences, San Jose, California, USA). All other reagents used were of 
analytical grade or of the highest available grade.  
 
2.2. Synthesis of thioxanthones 
The synthesis of the thioxanthonic derivatives TX87, TXA4, TXA3 and TXOH was 
performed according to the described procedure (Palmeira et al. 2012) by Ullman cross-
coupling between 1-chloro-4-propoxy-9H-thioxanthen-9-one and an amine in alkaline 
medium using methanol as solvent and conventional heating (TX129) or N-
methylpirrrolidone (NMP) and microwave heating (TX87, TXA3, TX105 and TXA4), or by 
dealkylation of 1-chloro-4-propoxy-9H-thioxanthen-9-one with boron bromide, BBr3 
(TXOH). Thioxanthones were characterized by spectroscopic methods according to 
described procedures (Palmeira et al. 2012). Figure 1 shows the chemical structures of 
the six thioxanthones used in this study. The purity of each compound was determined by 
HPLC–DAD analysis using an isocratic elution of MeOH:H2O basified with TEA (1 %) 
(TX129, TX87, TXA3, TX105 and TXA4) or acidified with CH3COOH (1 %) (TXOH) at a 
constant flow rate of 1.0 mL/min (Palmeira et al. 2012). All tested compounds had a purity 
of at least 95 %. 
 
2.3. Cell culture  
Immortalized rat brain microvessel endothelial cells, RBE4 (Roux et al. 1994) were grown 
in minimum essential medium/Ham’s F10 (1:1) supplemented with 300 μg/mL neomycin, 
10% FBS, 1 ng/mL bFGF, 100 U/mL penicillin G, 100 μg/mL streptomycin, 25 mM sodium 
bicarbonate and 25 mM HEPES. This mixture will herein be referred to as cell culture 
medium. RBE4 cells were maintained in a humidified atmosphere of 5% CO2 at 37°C. The 
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cell culture medium was changed every 48 to 72 h. For sub-culturing, cells were 
dissociated with 0.25% trypsin-EDTA, which was neutralized with culture medium, and 
sub-cultured in 75 cm2 flasks. In all experiments, cells were seeded at a density of 25.000 
cells/cm2 and used 3 days after seeding, once confluence was reached.  
 
2.4. Cytotoxicity assays  
Cells were seeded in 96-well plates at a density of 10.000 cells per well, and the tested 
compounds cytotoxicity was evaluated three days after seeding. Thioxanthones (0–50 
μM) cytotoxicity was evaluated 24h after exposure by the MTT reduction and by the NR 
uptake assays.  
 
2.4.1. MTT reduction assay  
At the selected time point (24h), cell culture medium was removed, followed by the 
addition of fresh cell culture medium containing 0.5 mg/mL MTT and incubation at 37 °C 
in a humidified, 5% CO2 atmosphere for 1h. After this incubation period, the cell culture 
medium was removed and the formed formazan crystals dissolved in 100% DMSO. The 
absorbance was measured at 550 nm in a multi-well plate reader (PowerWaveX, BioTek 
Instruments, VT, USA). The percentage of MTT reduction relative to that of control cells 
was used as the cytotoxicity measure.  
 
2.4.2. NR uptake assay  
At the end of the incubation period, cells were incubated with NR (50 μg/mL in cell culture 
medium) at 37 °C, in a humidified, 5 % CO2 atmosphere, for 90 min. After this incubation 
period, cell culture medium was removed, and the dye absorbed by viable cells extracted 
with ethyl alcohol absolute/distilled water (1:1) with 5% acetic acid. The absorbance was 
measured at 540 nm in a multi-well plate reader (PowerWaveX, BioTek Instruments). The 
percentage of NR uptake relative to that of control cells was used as the cytotoxicity 
measure.  
 
2.5.  Mitoxantrone cytotoxicity assays  
Mitoxantrone cytotoxicity was evaluated in RBE4 cells by using the NR uptake assay, 
simultaneously incubated with the tested thioxanthones (10 μM) or with a well-known and 
potent P-gp inhibitor, zosuquidar (Shepard et al. 2003; Starling et al. 1997), at a non-
cytotoxic concentration (5 μM). Briefly, cells were seeded onto 96-well plates to obtain 
confluent monolayers at the day of the experiment. After reaching confluence, cells were 
Manuscript 4____________________________________________________________________	
212 
exposed to mitoxantrone (0.1-50 μM) in fresh cell culture medium in the presence or 
absence of the studied thioxanthones or with zosuquidar for 4h, 8h and 16h, and once the 
incubation period was finished it was replaced with fresh cell culture medium. Cytotoxicity 
was evaluated 24 h after the beginning of exposure by the NR uptake assay as described 
in section 2.4.2. Each experiment was performed in triplicate and repeated with at least 
three independent experiments. 
 
2.6.  Evaluation of P-glycoprotein transport activity  
The P-gp transport activity was evaluated by flow cytometry using 1 μM Rho 123 as a P-
gp fluorescent substrate, as previously described (Silva et al. 2014c). For that purpose, 
Rho 123 efflux was assessed in the presence of thioxanthones. RBE4 cells were seeded 
onto 75 cm2 flasks and, after reaching confluence, washed twice with HBSS (-/-) and 
harvested by trypsinization (0.25 % trypsin/1 mM EDTA) to obtain a cellular suspension. 
This cell suspension was then divided into aliquots of 500.000 cells/mL. The cells were 
centrifuged (300g, for 10 min, at 4°C), suspended in PBS buffer (pH 7.4) containing 10 % 
heat-inactivated FBS, 1 μM Rho 123 and the P-gp inhibitor cyclosporine A (10 μM), and 
incubated at 37°C for 30 min to allow maximum Rho 123 accumulation. After this inhibited 
accumulation (IA) phase, cells were submitted to an efflux phase, where the energy-
dependent P-gp function was re-established by removing the P-gp inhibitor (cyclosporine 
A) and by adding supplemented cell medium. For that purpose, cells were washed twice 
with ice-cold PBS buffer with 10% heat-inactivated FBS, centrifuged (300 g for 10 min, at 
4°C) and resuspended in cell culture medium, with or without the tested thioxanthones (10 
or 20 μM), and incubated for 45 min at 37 °C. Cells were then washed twice with ice-cold 
PBS buffer with 10 % heat-inactivated FBS and resuspended in ice-cold PBS buffer 
immediately before analysis. Fluorescence measurements of isolated cells were 
performed using a BD ACCURITM C6 flow cytometer. Green fluorescence of FITC-Rho 
123 was measured by a 530 ± 15 nm band-pass filter (FL1). Acquisition of data for 15.000 
cells was gated to include viable cells on the basis of their forward and side light scatters 
and the propidium iodide (2.5 μg/mL) incorporation (propidium iodide interlaces with a 
nucleic acid helix with a resultant increase in fluorescence intensity emission at 615 nm). 
Logarithmic fluorescence was recorded and displayed as a single parameter histogram. 
The mean of fluorescence intensity for 15.000 cells was the parameter used for 
comparison (calculated as percentage of control). Non-labeled cells (with or without 
thioxanthones) were also analyzed in each experiment by a 530 ± 15 nm band-pass filter 
(FL1) in order to detect a possible contribution from cells auto-fluorescence to the 
analyzed fluorescence signals. P-gp activity was expressed as percentage of control of 
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Rho 123 efflux ratio, which was in turn obtained by calculating the difference between 
mean fluorescence intensity values of intracellular Rho 123 before (in the presence of 
Cyclosporine A) and after the efflux phase. 
 
2.7.  Evaluation of P-glycoprotein ATPase activity 
P-gp ATPase activity was evaluated using the P-gp-Glo™ assay kit, according to the 
manufacturer’s instructions (Promega, USA). Briefly, P-gp enriched membrane vesicles 
(25 μg/well) were incubated with 5 mM MgATP and with either sodium orthovanadate 
(Na3VO4, 100 μM), verapamil (200 μM) or each of the tested thioxanthonic compounds 
(10 μM) for 120 min at 37 °C. Verapamil was used as a positive control for P-gp ATPase 
activity stimulation, while sodium orthovanadate acts as a P-gp ATPase activity inhibitor. 
Pgp ATPase reaction was stopped by adding 50 μL of developer solution to each well, 
and samples were incubated for an additional 20 min at room temperature, to allow signal 
developing. The remaining unmetabolized ATP was detected as a luciferase-generated 
luminescent signal, read in a multi-well plate reader (PowerWaveX, BioTek Instruments). 
Basal P-gp ATPase activity is a result of the difference of luminescence of untreated (NT) 
samples and sodium orthovanadate-treated controls (no P-gp ATPase activity), and are 
expressed as change in luminescence (ΔRLU). P-gp activity in the presence of the tested 
compounds (TC) is a result of the difference of luminescence of samples treated with 
either verapamil or thioxanthones and sodium orthovanadate-treated controls. Change in 
luminescence was calculated using the formula ΔRLU (TC) = RLU (Na3VO4) – RLU (TC), 
where TC stands for the verapamil-treated or thioxanthone-treated membranes. Two 
independent experiments in duplicate were performed for this assay. 
 
2.8. Docking of mitoxantrone and thioxanthones into a P-gp model 
For the structure-based study, the 3D structures of six thioxanthones and mitoxantrone 
were drawn using HyperChem 7.5 (Froimowitz 1993), and minimized by the semi-
empirical Polak-Ribiere conjugate gradient method (RMS<0.1 kcal.Å-1. mol-1) (Zhang et al. 
2006). Docking simulations between mouse P-gp (pdb code 4Q9H) and thioxanthones, or 
mitoxantrone, or thioxanthones together with mitoxantrone were undertaken in AutoDock 
Vina (Scripps Research Institute, USA) (Seeliger and de Groot 2010; Trott and Olson 
2009). Parallel docking simulations were performed using a previously built P-gp model 
based on sav1866 (Silva et al. 2014c; Silva et al. 2014d; Vilas-Boas et al. 2013b). 
AutoDock Vina considered the target conformation as a rigid unit, while the ligands were 
allowed to be flexible and adaptable to the target. Vina searched for the lowest binding 
affinity conformations and returned nine different conformations for each ligand. AutoDock 
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Vina was run using an exhaustiveness of eight and a grid box with the dimensions 37.0, 
30.0, 40.0, engulfing the channel formed by the transmembrane domains (TMDs). 
Conformations and interactions were visualized using PyMOL version 1.3 (Lill and 
Danielson 2010). 
 
2.9.  Statistical analysis 
Data were analyzed with GraphPad Prism® 6.0 software (San Diego, CA, USA). 
Normality of the data distribution was assessed by three different tests: KS normality test, 
D’Agostino & Pearson omnibus normality test and Shapiro–Wilk normality test. For data 
with parametric distribution, statistical comparisons were made using the parametric 
method of one-way ANOVA, followed by the Bonferroni’s multiple comparisons post hoc 
test. For data with nonparametric distribution, statistical comparisons were estimated 
using the nonparametric method of Kruskal–Wallis (one-way ANOVA on ranks), followed 
by the Dunn’s post hoc test. In experiments with two variables, statistical comparisons 
between groups were made using two-way ANOVA, followed by the Sidak’s multiple 
comparisons post hoc test.  In the mitoxantrone cytotoxicity assays, concentration–
response curves were fitted using least squares as the fitting method and the 
comparisons between curves (LOG EC50, TOP, BOTTOM, and Hill Slope) were made 
using the extra sum of squares F test. Details of the performed statistical analysis are 
described in each Figure legend. In all cases, p values lower than 0.05 were considered 
statistically significant.   
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3. RESULTS 
3.1.  Thioxanthones cytotoxicity assays  
Thioxanthones cytotoxicity was evaluated by the MTT reduction and the NR uptake 
assays, in order to select a noncytotoxic working concentration. According to the NR 
uptake assay, after 24h of incubation, no cytotoxicity was observed for TXA3 at any of the 
tested concentrations, while TX87, TXOH and TX105 only showed to be cytotoxic at 50 
μM, and TXA4 and TX129 for concentrations higher than 20 μM (Fig. 2, a). The MTT 
reduction assay demonstrates no cytotoxicity registered at any of the tested 
concentrations for the TX87, TXA3, TXOH and TX105 derivatives, and confirms TXA4 
cytotoxicity at 20 and 50 μM, and TX129 cytotoxicity from 10 μM (Fig. 2, b). 
For subsequent experiments, thioxanthones were tested at 10 μM, a noncytotoxic 
concentration for all the compounds, with the exception of TX129, which was the only 
compound that showed a slight cytotoxicity (89% cell viability) at this concentration on the 
MTT reduction assay. 
 
3.2.  P-glycoprotein transport activity  
Rho 123 is a P-gp fluorescent substrate widely used for the evaluation of P-gp activity 
(Silva et al. 2014c; Vilas-Boas et al. 2013b). In the present study, Rho 123 efflux was 
evaluated in the presence of the tested thioxanthones, at 10 μM and 20 μM, during an 
efflux step of 45 min, in order to evaluate their immediate effects on P-gp activity as a 
result of a direct activation of the transporter. The thioxanthonic derivatives TXA4, TXA3, 
TX105 and TX129 were able to produce a significant increase in the Rho 123 efflux from 
RBE4 ells (Fig. 3, a). At 20 μM, all the compounds provoked a significant increase in Rho 
123 efflux, with the exception of TXOH, when compared to control cells (Fig. 3, b). TXA4, 
TXA3, TX105 and TX129 revealed to be equally efficient as potential P-gp activators at 10 
μM, since they increased Rho 123 efflux by 159, 167, 161 and 168%, respectively. Rho 
123 efflux was only slightly increased to 170% when the compounds are used at 20 μM. 
The derivative TX87, although to a lower extent, also increased Rho 123 efflux to 126%, 
thus also indicating P-gp activation. 
 
3.3. P-glycoprotein ATPase activity in the presence of thioxanthones 
P-gp ATPase activity was assessed in order to determine if the tested thioxanthones in 
the present study are able to stimulate P-gp ATPase activity, and thus work as P-gp 
substrates. Basal P-gp ATPase activity was estimated based on the difference in 
luminescence of untreated samples towards sodium orthovanadate-treated samples, 
which inhibits P-gp ATPase activity. Verapamil was used as a positive control for 
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stimulation of P-gp ATPase activity, which rendered a change in luminescence of around 
31.000 RLU, representing an increase in luminescence of 4-fold in comparison to basal 
ATPase activity (p < 0.001) (Fig. 4). None of the thioxanthonic derivatives, at 10 μM, 
provoked a statistical significant increase on the P-gp ATPase activity in comparison to 
the untreated samples (p > 0.05). 
 
3.4. Docking Studies 
Since thioxanthones need to interact with the P-gp protein structure in order to promote its 
activation, it was hypothesized that these compounds could bind to the drug-binding 
pocket formed by the TMD interface, activating the drug efflux mechanism. Also, as we 
aim to test the role of thioxanthones against the cytotoxicity provoked by mitoxantrone, we 
performed docking simulations for mitoxantrone and thioxanthones in this binding pocket 
of P-gp (Table 1). A visual inspection of thioxanthones alone or complexed with 
mitoxantrone in the TMD interface of P-gp was performed (see Fig. 5). Mitoxantrone binds 
to a cavity formed by TMDs 2, 3, 10, and 11 (Fig. 5B), described as H-site for being the 
preferential binding site for Hoechst 33342 (Ferreira et al. 2013). Mitoxantrone has shape, 
size, and stereoelectronic complementarity to P-gp binding pocket forming a stable 
complex with P-gp with a negative energy of -5.3 kJ/mol and was predicted to establish 
hydrogen interactions with Arg-144, and Asn-179.  
When docked individually, all of the tested thioxanthones are predicted to have more 
affinity to P-gp than mitoxantrone (more negative docking scores, from -5.9 to -6.6 
kcal.mol-1) (Table 1). The TX129 is the top ranking thioxanthone, with a docking score of -
6.6 kcal.mol-1. Thioxanthones are predicted to dock to the same binding site as 
mitoxantrone (Fig 5C), but with higher affinity, suggesting a competitive mechanism of 
action. Thioxanthones and mitoxantrone, besides being able to bind individually to the 
same or to different binding pockets on P-gp, may bind simultaneously to the same cavity 
on the TMD by the establishment of stacking interactions between the two small 
molecules (Fig 5D). This non-covalent complex (Fig 4C) binds to P-gp with higher (TXA3, 
TXA4, TXOH, and TX129) or lower (TX105, TX87) affinity than the small molecules 
docked individually. The non-covalent complex occupies a larger volume in the substrate-
binding cavity, interacting with residues from several TMDs. The two-ligand complex 
establish polar interactions with residues such as Thr-941, Gln-343, and Gly-868, 
described as being part of the translocation pathway and/or involved in drug binding 
(Ferreira et al. 2013). 
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3.5.  Protective effects of thioxanthones against mitoxantrone-induced 
cytotoxicity  
Firstly, with the purpose of verifying the impact of P-gp on limiting the mitoxantrone-
induced toxicity in RBE4 cells, cells were exposed to a wide range of concentrations of 
mitoxantrone (0.1-50 μM) in the presence or absence of a P-gp specific inhibitor, 
zosuquidar (LY335979). Zosuquidar was used at a 5 μM concentration, since this 
concentration did not show to be cytotoxic in this cell line following 24h of incubation, 
according to the MTT and NR uptake assays (Sup. Fig. 2), and it was previously reported 
to be an efficient concentration to inhibit P-gp activity (Durmus et al. 2015; Liu et al. 2014). 
Mitoxantrone-induced cytotoxicity was evaluated after 4h, 8h and 16h of exposure in co-
incubation or not with zosuquidar by the NR uptake assay. For every time-point tested, the 
concentration-response (death) curves obtained show that the co-incubation with the P-gp 
inhibitor (MTX + ZQ) resulted in a leftwards shift of the curve (Fig. 6), which reflects an 
increase in the cytotoxicity of mitoxantrone when P-gp is inhibited. For all the fitted curves, 
no significant differences in the maximal cell death (TOP) and in the baseline (BOTTOM) 
were observed (Table 2). For that reason, the EC50 values, which represent the half-
maximum-effect concentrations from the fitted curves, were used for statistical 
comparison. As shown in Table 2, the EC50 values of the MTX + ZQ curves significantly 
decreased in comparison to the EC50 of the MTX curve after 4h, 8h and 16h incubation. 
After 4h of incubation the EC50 value in cells exposed to both mitoxantrone and 
zosuquidar decreased from 3.48 μM to 0.92 μM (p < 0.0001), and after 8h and 16h it 
decreased from 2.08 μM to 0.65 μM (p < 0.0001) and from 4.31 μM to 1.76 μM (p < 0.01), 
respectively. 
Afterwards, and in order to check whether the observed increases in P-gp activity could 
result in an effective protection of RBE4 cells against mitoxantrone-induced toxicity, cells 
were exposed to a wide range of concentrations of mitoxantrone (0.1–50 μM), and 
cytotoxicity was evaluated with or without simultaneous exposure to the tested 
thioxanthonic derivatives (10 μM) for 4h, 8h, and 16h. Mitoxantrone-induced cytotoxicity 
was evaluated 24h after the beginning of exposure by the NR uptake assay. Figure 4 
shows the concentration–response curves obtained with mitoxantrone alone and with 
simultaneous incubation with thioxanthones (MTX + TXs). For all the tested 
thioxanthones, any significant differences were observed in the mitoxantrone-induced cell 
death, and so a rightwards shift of the mitoxantrone concentration–response curves was 
not observed as it would if thioxanthone-protective effect was present (Fig. 7). For all the 
fitted curves, no significant differences in the maximal cell death (TOP) and in the baseline 
(BOTTOM) were observed (Table 3). EC50 values were then used for statistical 
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comparison. No significant differences were observed for the EC50 values of the fitted 
curves, when compared to the EC50 of the MTX curve, with the exception of TXA4 and 
TX105 for the 4h time point, where the EC50 value registered a decreased to 1.564 μM 
and 1.411 μM, respectively (Table 3B, 3C), in comparison to the EC50 of the MTX curve 
(2.455 μM) (p < 0.05).  
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4. DISCUSSION 
The data here presented show that, even though four of the tested thioxanthones – TXA4, 
TX105, TXA3 and TX129 – successfully increased P-gp activity, they failed to confer 
protection to RBE4 cells against mitoxantrone-induced cytotoxicity. 
The widely accepted in vitro BBB model used in the present study, the RBE4 cell line, is 
one of the best characterized brain endothelial cell lines, which retains many BBB 
characteristics, particularly the expression of P-gp (Regina et al. 1998; Roux et al. 1994). 
This cell line has been largely used for the study of the BBB physiology and modulation, 
namely in signaling studies (Fabian et al. 1998; Krizbai et al. 1995; Smith and Drewes 
2006; Zhang et al. 2009b), cell migration (Barakat et al. 2008), permeability studies (Pan 
et al. 2005), and regulation of P-gp expression and activity (Pilorget et al. 2007; Yu et al. 
2007). 
Thioxanthones (dibenzo-γ-thiopyrones) are a group of compounds that have risen 
increasing interest in the field of medicinal chemistry. These compounds have shown to 
have remarkable biological properties, such as antitumor activity and P-gp modulation 
(Paiva et al. 2013; Palmeira et al. 2012b; Silva et al. 2014c). Very recently, it was 
demonstrated that thioxanthonic derivatives were able to significantly increase both P-gp 
expression and activity in Caco-2 cells (Silva et al. 2014c). In addition, an important 
decrease on the Rho 123 intracellular accumulation, reflecting an increase on P-gp 
activity, could be seen only after a 45 min incubation period of Caco-2 cells with these 
thioxanthonic compounds (Silva et al. 2014c). This increase of P-gp activity does not 
reflect an effect from increased P-gp expression, since such a short time of Caco-2 cells 
incubation with thioxanthones is most probably not enough time to allow an induction on 
the protein expression to take place. 
In our present study, we tested four of the most promising thioxanthonic compounds 
according to the previous study performed in Caco-2 cells (Silva et al. 2014c), together 
with two newly synthetized thioxanthones, TX105 and TX129 in RBE4 cells. When the 
Rho 123 efflux was evaluated in the presence of the tested thioxanthones (10 μM) during 
an efflux step of 45 min, the thioxanthonic derivatives TXA4, TXA3, TX105 and TX129 
were able to produce a significant increase in the Rho 123 efflux from RBE4 cells, and 
thus inducing an activation of P-gp efflux transport. At 20 μM, all the compounds, except 
TXOH, provoked a significant increase in Rho 123 efflux. These four thioxanthonic 
compounds increased Rho 123 efflux by 160-170%, which means that the intracellular 
levels of the P-gp substrate were significantly reduced in the presence of these molecules. 
We further analyzed the impact of such compounds on the ATPase activity of recombinant 
human P-gp in a cell membrane fraction. Compounds that interact with P-gp can be 
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identified as stimulators or inhibitors of its ATPase activity. Stimulators of the ATPase 
activity are likely substrates for P-gp-mediated efflux, which will also competitively inhibit 
transport of other P-gp substrates (Ambudkar et al. 1999). Our results show that, at the 
concentration tested (10 μM), all the thioxanthones poorly increased the ATPase activity 
of human P-gp. These findings suggest that these compounds may work as poor P-gp 
substrates, and thus unlikely participate in competition phenomena and inhibit the 
transport of P-gp substrates. Docking studies explored the binding configurations of the 
tested thioxanthonic derivatives, using an X-ray P-gp structure based on the mouse P-gp 
(Szewczyk et al. 2015). Recent data shows that, unlike the symmetric Sav1866 template 
(already described in previous studies (Silva et al. 2014a; Silva et al. 2014d; Vilas-Boas et 
al. 2013a), mouse P-gp has a high degree of asymmetry, with only 44% similarity between 
the two halves of TMDs (Pan and Aller 2015), which likely may play a major role in the 
overall function and mechanism of the transporter. In fact, it is thought that mouse P-gp 
should favor closed TMDs and open nucleotide-binding domains, whereas Sav1866 
should favor the exact opposite configurations, as well as the hydrophobicity of mouse P-
gp in the drug-binding pocket is substantially larger than that of Sav1866 (Pan and Aller 
2015). Given that rat P-gp should have a closer homology to mouse P-gp than to the 
Sav1866 template, we decided to preferentially adopt the mouse P-gp model for docking 
studies. Indeed, when comparing the results retrieved with the Sav 1866 (see Sup. Data) 
and the mouse P-gp model, we can observe that all thioxanthones require a higher free 
energy to bind to P-gp in the mouse model than in the Sav1866, probably due to the 
higher hydrophobicity of its drug-binding pocket. Furthermore, thioxanthones are 
described to bind to different TMDs and with different affinities between models. Still, 
docking studies in both models allowed us to understand that thioxanthones bind to P-gp 
with a considerable high affinity, with a preferential binding pocket in P-gp, engulfed by 
TMD 2, 3, 10 and 11 according to the mouse model, further supporting that these 
compounds most probably interact with P-gp for its activation. According to the 
experimental results, thioxanthones activate P-gp efflux when simultaneously incubated 
with Rho 123, suggesting that, the former should bind at a different location, and increase 
the P-gp efflux of the later by allosteric modulation (Ghosh et al. 2006).  
Considering the observed effects of the tested thioxanthones on the P-gp activity and the 
unlikely scenario that they might competitively inhibit the P-gp substrate efflux, we 
evaluated the impact of these compounds on the mitoxantrone-induced cytotoxicity in 
RBE4 cells. Mitoxantrone is an antineoplastic agent, used in the treatment of several 
types of cancer, mostly metastatic breast cancer, acute myeloid leukemia, and non-
Hodgkin’s lymphoma (Parker et al. 2010). P-gp and BCRP have shown to team up at the 
BBB for the efflux transport of mitoxantrone (Agarwal et al. 2011a; Kodaira et al. 2010; 
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Lee et al. 2005). When RBE4 cells were co-incubated with mitoxantrone and the third 
generation P-gp inhibitor, zosuquidar, we observed a leftwards shift of the concentration-
response (cell death) curves, accompanied by a decrease in the EC50 values, in 
comparison to cells incubated with mitoxantrone alone. The results indicate that 
mitoxantrone successfully demonstrated to be a P-gp substrate in this cell line, since the 
P-gp inhibition resulted in a reduced efflux of mitoxantrone and thus an increase in the 
mitoxantrone-induced cytotoxicity. Therefore, RBE4 cells were further co-incubated with 
mitoxantrone and each test compound (10 μM) for 4h, 8h and 16h, and mitoxantrone-
induced cytotoxicity was evaluated 24h after the beginning of the exposure. Surprisingly, it 
was not observed a rightwards shift of the mitoxantrone concentration–response curves in 
the cell samples co-incubated with the thioxanthonic compounds, in comparison to cells 
incubated with mitoxantrone alone, as well as it was not observed a significant difference 
on the EC50 values of the fitted curves. These findings suggest that none of these 
compounds was able to confer additional protection against mitoxantrone-induced 
cytotoxicity in RBE4 cells, unlike what was observed in a previous study for paraquat in 
Caco-2 cells (Silva et al. 2014c). Docking results using the mouse P-gp model show that 
all thioxanthones bind with higher affinity to P-gp (lower docking scores) than 
mitoxantrone. This suggests that thioxanthones may compete with mitoxantrone for one of 
P-gp drug binding sites, even though thioxanthonic compounds showed to have 
alternative binding sites to that of mitoxantrone, nor should inhibit substrate transport by 
competition, since no increase on the P-gp ATPase activity was registered. Besides, since 
mitoxantrone is a common substrate of P-gp and BCRP, P-gp is not the only transporter 
implicated in the efflux of mitoxantrone in this experimental setting, which can explain the 
absence of a P-gp activation-mediated protection against its cytotoxicity. Several studies 
show that a double knockout or inhibition of P-gp and BCRP frequently results in an 
increase in a greater brain accumulation of common substrates than the additive effects of 
single knockout or inhibition, which suggests that when the function of one of the 
transporters is compromised it tends to compensated by the other with an increase in its 
expression and/or activity (Cisternino et al. 2004; de Vries et al. 2007). Also, there is 
evidence that BCRP expression can be down-regulated in cell models overexpressing P-
gp (Bark et al. 2008). Therefore, it cannot be put aside that an eventual change on Bcrp 
expression and/or activity may occur when P-gp is activated in the present experimental 
model, and thus that a P-gp/BCRP cooperation may imply that the activation of P-gp 
alone may not result in an appreciable decrease in cell accumulation of dual substrates. 
 On the other hand, it should also be considered that the likely reduction on the 
intracellular accumulation of mitoxantrone as a result of P-gp activation by thioxanthones 
may not be sufficient to see an actual reduction in its induced cytotoxicity. In fact, the P-gp 
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activation induced by thioxanthones might be a transient phenomenon, resulting in a 
reduction of mitoxantrone intracellular accumulation only for a short period of time, which 
may not be enough to confer cell protection over a period of exposure of 4h, 8h or 16h. 
Furthermore, in the previous study conducted by Silva et al (2014), thioxanthonic 
derivatives have shown to not only promote an immediate activation of P-gp but also to 
up-regulate the P-gp protein expression in Caco-2 cells (Silva et al. 2014c), which was not 
explored in the present study. An increase of the expression of P-gp at the cell membrane 
is more likely to produce long-lasting consequences in terms of the drug efflux of 
substrates over the course of the incubation period, which may explain the differences 
found between the present study and the previously conducted in Caco-2 cells. In fact, 
since the two models, Caco-2 and RBE4 cells, represent two different species, and 
considering the significant species differences of some of the P-gp regulatory pathways, 
particularly between ligand-binding and activation profiles for orphan nuclear receptors 
(Wang and LeCluyse 2003), we cannot guarantee that the mechanism by which 
thioxanthones up-regulate P-gp protein expression in the Caco-2 cell model is activated in 
the RBE4 cells. Besides, drug binding involves an induced fit (Loo et al. 2003c), and in 
order to produce a conformational change that induces ATP hydrolysis drug binding has 
to occur in certain sites, and in a certain orientation (Aller et al. 2009). As previously 
mentioned, the tested thioxanthonic compounds establish interactions with TMDs of the 
mouse P-gp model that are distinct from those established with the Sav1866 model. In 
addition, previous studies already evidenced different P-gp structure and activity 
depending on the animal model, indicating important interspecies differences (Pan and 
Aller 2015; Xia et al. 2006). In this way, thioxanthones may bind differently to the rat and 
to the human P-gp due to structural differences, which may explain the discrepant results 
regarding the protection against the cytotoxicity of P-gp substrates that these compounds 
produced in the present (rat) model and the previous one (Silva et al. 2014c) (Caco-2 
cells, human cell line). Furthermore, since P-gp has multiple and overlapping binding sites 
(Safa 2004), the mechanism of action of these thioxanthones may be inhibitory or 
activator, depending on the compounds that are co-incubated and their binding 
mechanisms (Litman et al. 1997).  
In conclusion, even though these compounds failed to demonstrate an increased 
protection against mitoxantrone-induced cytotoxicity in RBE4 cells, they remain as 
interesting drug candidates for an antidote strategy against the toxicity induced by P-gp 
substrates. Most of the thioxanthones showed to promptly activate P-gp efflux transport, 
achieved through a change in the protein conformation, which, in comparison with the 
induction phenomenon, results in a much faster manner to reduce the cytotoxicity of 
harmful P-gp substrates. However, as an increase in the protein expression of P-gp does 
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not always reflect an increase in its activity, an increase in the efflux of a P-gp substrate 
due to P-gp activation does not always translate into an overall increase in the efflux of all 
its substrates, and therefore it does not necessarily confer protection against the toxicity of 
any harmful P-gp substrate. 
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6. FIGURES 
 
 
 
 
 
Fig. 1. Chemical structures of the six thioxanthones (TXs) investigated in this study.  
(1) TX87 (1-{[2-(1,3-benzodioxol-5-yl)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one), 
(2) TXA4 (1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one), 
(3) TXA3 (1-[(2-methylpropyl)amino]-4-propoxy-9H-thioxanthen-9-one), 
(4) TXOH (1-chloro-4-hydroxy-9H-thioxanthen-9-one), 
(5) TX105 (1-{[2-(phenylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one, 
(6) TX129 (1-[(3,4-Dimethoxybenzyl)amino]- 4-propoxy-9H-thioxanthen-9-one. 
1 2 
3 4 
5 6 
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Fig. 2: Cytotoxicity profiles of all the tested thioxanthones, assessed by the NR 
uptake (A) and the MTT reduction (B) assays. Cytotoxic effect was evaluated 24h after 
exposure to the compound in concentrations ranging from 5 to 50 μM. Results are shown 
as mean ± SD of four independent experiments. Differences between control and treated 
cells were estimated using Kruskal-Wallis test (one-way ANOVA on ranks) followed by 
Dunn’s multiple comparison post hoc test (* p < 0.05; **p < 0.01; ***p < 0.001 vs control). 
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Fig. 3: P-glycoprotein activity evaluated through the Rho 123 efflux in the presence 
of thioxanthones, 10 μM (A) or 20 μM (B) during the Rho 123 efflux phase. Results 
are shown as mean ± SD from five independent experiments (performed in triplicate). 
Statistical comparisons were estimated using the nonparametric method of Kruskal-Wallis 
(one-way ANOVA), followed by Dunn’s post hoc test (** p < 0.01; *** p < 0.001 vs control). 
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Fig. 4. Effect of several thioxanthones on the ATPase activity in membrane vesicles 
enriched with human P-gp. Verapamil was used as a positive control of the stimulation 
of P-gp ATPase activity and P-gp substrate. Results are presented as change in 
luminescence (ΔRLU) and are expressed as mean ± SD from two independent 
experiments, performed in duplicate. Differences between basal, verapamil and 
thioxanthone-treated membranes were estimated using one-way ANOVA, followed by the 
Bonferroni’s multiple comparisons post hoc test (*** p < 0.001 vs basal P-gp ATPase 
activity).  
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Fig. 5. P-gp 3D structure with thioxanthones/mitoxantrone binding site surrounded 
by a red circle (A); Mitoxantrone (B) and TX129 (C) docked individually into P-gp 
TMDs; mitoxantrone and TX129 (C) docked simultaneously into P-gp TMDs. 
Mitoxantrone and TX129 are represented as blue and yellow sticks, respectively. Polar 
interactions are represented with yellow dashes. 
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7. TABLES 
Table 1. Docking scores (kcal.mol-1) of thioxanthones and mitoxantrone. 
Docking score 
(kcal.mol-1) 
Docking score 
(kcal.mol-1) 
TX105 -6.1 Mitoxantrone + TX105 -5.9 
TX129 -6.6 Mitoxantrone + TX129 -6.9 
TX87 -6.3 Mitoxantrone + TX87 -5.8 
TXA3 -5.8 Mitoxantrone + TXA3 -6.1 
TXA4 -6.2 Mitoxantrone + TXA4 -6.3 
TXOH -5.9 Mitoxantrone + TXOH -7.2 
Mitoxantrone -5.3 
 
 
Table 2. EC50 (half-maximum-effect concentrations), TOP (maximal effect), BOTTOM 
(baseline) and Hill Slope values of the MTX concentration-response curves, with 
(MTX + ZQ) or without (MTX) simultaneous exposure to a specific P-gp inhibitor, 
Zosuquidar (5 μM) for 4h, 8h and 16h. Concentration-response curves were fitted using 
the least squares as the fitting method and the comparisons between MTX and MTX + ZQ 
curves (EC50, TOP, BOTTOM, Hill Slope for 4h and 8h time points, and EC50, TOP, 
BOTTOM for 16h time point) were made using extra sum-of-squares F test. (** p < 0.01, 
*** p < 0.001, **** p < 0.0001 vs the MTX curve). 
Time of exposure 4h 8h 16h 
 MTX MTX + ZQ MTX MTX + ZQ MTX MTX + ZQ 
EC50 (μM) 3.48 0.92**** 2.08 0.65*** 4.31 1.76** 
TOP 55.84 56.34 60.27 66.52 67.51 63.77 
BOTTOM -3.01 8.36 -0.83 8.82 -6.88 -1.15 
Hill Slope 1.54 1.40 1.54 1.18 - - 
Curve p value (comparison 
between MTX and MTX + TXs 
curves) 
< 0.0001 < 0.0001 < 0.0001 
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Table 3. EC50 (half-maximum-effect concentrations), TOP (maximal effect), BOTTOM 
(baseline) and Hill Slope values of the mitoxantrone concentration-response 
curves, with (MTX + TXs) or without (MTX) simultaneous exposure to the tested 
thioxanthones (10 μM) for 4h, 8h and 16h. Concentration-response curves were fitted 
using the least squares as the fitting method and the comparisons between MTX and MTX 
+ TXs curves (EC50, TOP, BOTTOM, Hill Slope for 4h and 8h time points, and EC50, TOP, 
BOTTOM for 16h time point) were made using extra sum-of-squares F test. (* p < 0.05 vs 
the MTX curve). 
 
3A) TX87 
Time of exposure 4h 8h 16h 
 MTX MTX + TX87 MTX MTX + TX87 MTX MTX + TX87
EC50 (μM) 2.46 1.65 1.99 1.54 2.10 1.65 
TOP 54.04 47.42 60.38 53.45 64.36 62.48 
BOTTOM -1.00 0.34 0.20 -5.59 -2.07 -5.82 
Hill Slope 1.71 1.85 1.60 1.72 - - 
Curve p value (comparison between 
MTX and MTX + TXs curves) 0.24 0.42 0.97 
 
3B) TXA4 
Time of exposure 4h 8h 16h 
 MTX MTX + TXA4 MTX MTX + TXA4 MTX MTX + TXA4
EC50 (μM) 2.46 1.56* 1.99 1.58 2.10 1.34 
TOP 54.04 52.05 60.38 58.29 64.36 64.79 
BOTTOM -1.00 -1.21 0.20 -2.00 -2.07 -8.02 
Hill Slope 1.71 1.79 1.60 1.72 - - 
Curve p value (comparison between 
MTX and MTX + TXs curves) 0.06 0.90 0.65 
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3C) TX105 
Time of exposure 4h 8h 16h 
 MTX MTX + TX105 MTX MTX + TX105 MTX MTX + TX105
EC50 (μM) 2.46 1.41* 1.99 1.42 2.10 1.42 
TOP 54.04 51.54 60.38 59.28 64.36 64.24 
BOTTOM -1.00 -2.43 0.20 -5.54 -2.07 -2.61 
Hill Slope 1.71 1.72 1.60 1.49 - - 
Curve p value (comparison 
between MTX and MTX + TXs 
curves) 
0.06 0.76 0.61 
 
3D) TXA3 
Time of exposure 4h 8h 16h 
 MTX MTX + TXA3 MTX MTX + TXA3 MTX MTX + TXA3
EC50 (μM) 2.46 2.46 1.99 1.97 2.10 2.43 
TOP 54.04 54.66 60.38 60.19 64.36 63.43 
BOTTOM -1.00 -1.72 0.20 -7.05 -2.07 -6.37 
Hill Slope 1.71 1.80 1.60 1.59 - - 
Curve p value (comparison 
between MTX and MTX + TXs 
curves) 
0.98 0.30 0.43 
 
3E) TX129 
Time of exposure 4h 8h 16h 
 MTX MTX + TX129 MTX MTX + TX129 MTX MTX + TX129
EC50 (μM) 1.42 1.77 1.37 1.63 2.24 2.74 
TOP 78.61 77.46 78.93 83.06 90.59 93.61 
BOTTOM -1.27 -5.03 -6.44 -3.66 -5.06 -8.86 
Hill Slope 1.72 1.93 1.58 1.46 - - 
Curve p value (comparison 
between MTX and MTX + TXs 
curves) 
0.25 0.77 0.54 
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3F) TXOH 
Time of exposure 4h 8h 16h 
 MTX MTX + TXOH MTX MTX + TXOH MTX MTX + TXOH
EC50 (μM) 1.42 1.46 1.37 1.43 2.24 2.76 
TOP 78.61 75.02 78.93 81.60 90.59 91.21 
BOTTOM -1.27 -6.68 -6.44 -9.39 -5.06 -10.08 
Hill Slope 1.72 1.65 1.58 1.35 - - 
Curve p value (comparison 
between MTX and MTX + TXs 
curves) 
0.57 0.94 0.35 
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SUPPLEMENTARY DATA 
I. Experimental Section 
1.1. Docking of mitoxantrone and thioxanthones into a P-gp model built based 
on Sav1866 
For the structure-based study, the 3D structures of six thioxanthones and mitoxantrone 
were drawn using HyperChem 7.5 (Froimowitz 1993), and minimized by the semi-
empirical Polak-Ribiere conjugate gradient method (RMS<0.1 kcal.Å-1. mol-1) (Zhang et al. 
2006). Docking simulations between a previously built P-gp model [successfully used in 
the discovery of P-gp modulators in (Palmeira et al. 2012b)] and thioxanthones, or 
mitoxantrone, or thioxanthones together with mitoxantrone were undertaken in AutoDock 
Vina (Scripps Research Institute, USA) (Seeliger and de Groot 2010; Trott and Olson 
2009). AutoDock Vina considered the target conformation as a rigid unit while the ligands 
were allowed to be flexible and adaptable to the target. Vina searched for the lowest 
binding affinity conformations and returned nine different conformations for each ligand. 
AutoDock Vina was run using an exhaustiveness of 8 and a grid box with the dimensions 
37.0, 30.0, 40.0, engulfing the channel formed by the TMDS. Conformations and 
interactions were visualized using PyMOL version 1.3 (Lill and Danielson 2010). 
Validation of the docking of P-gp activators using known P-gp activators (Palmeira et al. 
2012b; Sousa et al. 2013; Sterz et al. 2009) has already been described (Silva et al. 
2014a; Silva et al. 2014d; Vilas-Boas et al. 2013a). 
 
II. Results 
 
2.1. Docking studies: results with a Sav P-gp model 
Mitoxantrone binds to a cavity formed by TMDs 4, 5, 8-10 and 12 (Sup. Fig 1A), and it has 
shape, size, and stereoelectronic complementarity to P-gp binding pocket forming a stable 
complex with P-gp with a negative energy of -7.5 kJ/mol and was predicted to establish 
hydrogen interactions with Gly-346, Asn-84, Ala-80, and Phe-79.  
When docked individually, five of the six thioxanthones are predicted to have more affinity 
to P-gp than mitoxantrone (more negative docking scores) (Sup. Table 1). The TX87 is 
the top ranking thioxanthone, with a docking score of -9.3 kcal.mol-1. Thioxanthones have 
two preferential binding pockets in P-gp, engulfed by TMDs 4, 5, 8-10 and 12, or by TM 1-
3, 6, 7, and 11. Thioxanthones and mitoxantrone, besides being able to bind individually 
to the same or to different binding pockets on P-gp, may bind simultaneously to the same 
cavity on the TMD by the establishment of stacking interactions between the two small 
molecules (Sup. Fig. 1C). This non-covalent complex (Sup. Fig. 1C) binds to P-gp with 
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higher (TXOH, TXA3, TX105, and TX129) or lower (TXA4, TX87) affinity than the small 
molecules docked individually. The non-covalent complex occupies a larger volume in the 
substrate-binding cavity, interacting with residues from several TMDs. The two-ligand 
complex establish polar interactions with residues such as Val-231, Ser-349, Pro-350, and 
Ala-871 residues, described as being part of the translocation pathway and/or involved in 
drug binding (Loo et al. 2009; Loo and Clarke 1999; Loo and Clarke 2000). 
Docking studies explored the binding configurations of the tested thioxanthonic derivatives 
using a model built based on Sav1866, an ABC transporter from S. aureus (Palmeira et al. 
2012b). These docking studies allowed us to understand that thioxanthones bind to P-gp 
with a considerable high affinity, with two preferential binding pockets in P-gp, engulfed by 
TMD 4, 5, 8-10 and 12, or by TM 1-3, 6, 7, and 11, further supporting that these 
compounds most probably interact with P-gp for its activation. 
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Supplementary Fig. 2. Cytotoxicity profiles of zosuquidar assessed by the MTT 
reduction (A) and NR uptake (B) assays. Cytotoxic effect was evaluated 24h after 
exposure to the compound in concentrations ranging from 0.05 to 50 μM. Results are 
shown as mean ± SD of 4 independent experiments. Differences between control and 
treated cells were estimated using Kruskal-Wallis test (one-way ANOVA on ranks) 
followed by Dunn’s multiple comparison post hoc test. **p<0.01; ****p<0.0001 
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Supplementary Table 1. Docking scores (kcal.mol-1) of thioxanthones and 
mitoxantrone. 
 Docking Score  Docking Score 
TX87 -9.3 Mitoxantrone + TX87 -8.7 
TXA4 -7.7 Mitoxantrone + TXA4 -7.4 
TX105 -8.6 Mitoxantrone + TX105 -8.9 
TXA3 -7.5 Mitoxantrone + TXA3 -7.8 
TX129 -8.8 Mitoxantrone + TX129 -9.2 
TXOH -7.4 Mitoxantrone + TXOH -7.8 
Mitoxantrone -7.5 - - 
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General outcome: 
The experimental work here presented explores, for the first time, the potential of six 
different thioxanthonic compounds as P-gp activators. The activation of P-gp drug efflux 
transport is of increasing interest as an approach to quickly increase the efflux of toxic 
compounds out of vital organs, such as the brain. Thus, these new class of compounds, 
which interact with the P-gp protein structure to induce a change in its conformation and 
promote the efflux of substrates, can confer an increased brain protection in acute 
intoxications or in potentially dangerous situations following an exposure to an harmful P-
gp substrate. 
In this study, we demonstrated that four of the six thioxanthones tested were able to 
increase the efflux of Rho 123 in the RBE4 cell line, following a very short period of 
incubation (45 min). Such increase could not be due to a protein up-regulation given the 
short time of exposure, thus evidencing an induction of P-gp activity. These compounds 
also show to have high affinities to the P-gp protein structure according to the findings 
obtained by docking studies based on a rat P-gp model. On the other hand, they did not 
show to stimulate ATPase activity of recombinant human P-gp, therefore suggesting that 
these thioxanthones are unlikely to be P-gp substrates and to inhibit the transport of P-gp 
substrates by competition. However, and contrary to what was expected, thioxanthones 
did not seem to confer additional protection against mitoxantrone-induced cytotoxicity in 
RBE4 cells, unlike what was observed in a previous study for paraquat in Caco-2 cells 
(Silva et al. 2014c). In fact, we did not observe a rightwards shift of the mitoxantrone 
concentration–cell death curves when cells were co-incubated with the thioxanthonic 
compounds, in comparison to cells incubated with mitoxantrone alone, nor a significant 
difference on the EC50 values of the fitted curves. Since mitoxantrone is a common 
substrate of P-gp and BCRP, and thus P-gp is not the only transporter implicated in the 
efflux of mitoxantrone in this experimental setting, mitoxantrone may not be the ideal drug 
candidate to perform this analysis. Therefore, we aim to reproduce this experiment with 
another drug that is preferentially, if not exclusively, transported by P-gp in order to 
exclude any potential interference by BCRP or another ABC transporter. 
Still, our results show that thioxanthonic compounds may be promising candidates for an 
antidote strategy against the toxicity induced by P-gp substrates through P-gp activation, 
resulting in a much faster manner to reduce the cytotoxicity of harmful P-gp substrates.
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Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug 
Penetration  
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Abstract: Since the discovery of P-glycoprotein (P-gp) in brain microvessels composing the human blood-brain barrier (BBB), ATP-
binding cassette (ABC) transporters have been recognized as bottlenecks in the development and delivery of neuropharmaceuticals. ABC 
transporters are expressed predominately at the plasma luminal membrane of brain capillary endothelial cells. These ABC transporters 
are responsible for the efflux of their substrates from the endothelial cells to the bloodstream against the concentration gradient and thus 
limit the entry of some drugs within the central nervous system (CNS). Advanced quantitative molecular biology tools allowed gene and 
protein quantification of the components of microvessels isolated from different species including human. Recently, positron emission 
tomography using radiolabelled probes that are substrates of ABC transporters allowed the determination of their functional activity at 
the human BBB. Here, we summarized new information regarding the relative expression, substrate recognition pattern for CNS drugs 
and functional activity of ABC transporters that are quantitatively expressed at the human BBB.  
Keywords: ATP-binding cassette transporters, blood-brain barrier, blood-cerebrospinal fluid barrier, P-glycoprotein, breast cancer resistance 
protein, multidrug resistance protein.
1. INTRODUCTION  
 Differential expression of transporters and metabolizing en-
zymes is one of the main factors that significantly contribute to the 
inter-individual variation in the bioavailability and vulnerability to 
drugs and xenobiotics. ATP-binding cassette (ABC) transporters, 
solute carrier (SLC) transporters and phase I and phase II metabo-
lizing enzymes play a prominent role in modulating the pharma-
cokinetics (i.e. absorption, distribution, metabolism and excretion) 
of a broad range of endogenous and exogenous compounds. ABC 
and SLC transporters are selectively expressed at interfaces in 
brain, intestine, kidney, liver, placenta and testis where they have 
an impact on drug absorption, disposition and elimination [1, 2]. 
 SLC transporter superfamily comprises more than 370 SLC
genes in the human genome. These transporters play a vital role in 
maintaining the homeostasis of the human body via selective and 
regulated transport of nutrients, hormones, electrolytes, metal ions, 
and metabolites [3, 4]. While SLC transporters essentially allow the 
entry of substrates into the cell down their gradient concentration, 
transporters of the ABC superfamily efflux substrates outside the 
cell and thus act as a key element in the pharmacokinetics of sev-
eral molecules. In the intestine, ABC transporters extrude substrates 
back into the lumen and hamper their absorption into the blood or 
lymph circulation [5, 6]. These transporters are determinants of the 
renal and biliary clearance since they are also responsible for excre-
tion of xenobiotics and metabolites via bile and urine [7, 8]. In pro-
tected tissues like brain, placenta and testis, ABC transporters are 
expressed at barriers where they limit substrate uptake and distribu-
tion by effluxing their substrates from the tissue into the blood-
stream [9]. 
 The primary interfaces between the peripheral circulation and 
the central nervous system are the blood-brain barrier (BBB) and 
the blood–cerebrospinal fluid barrier (BCSFB). Since the early 
concept of the BBB proposed by Ehrlich and Goldmann at the be-
ginning of the last century, the development of molecular biology 
and biochemistry tools including quantitative transcriptomic and 
*Address correspondence to this author at the INSERM U705 CNRS UMR 
8206, Faculté de Pharmacie, 4 avenue de l’Observatoire, 75006 Paris, 
France; Fax: (+33)-1-53 73 97 19;  
E-mail: xavier.decleves@parisdescartes.fr 
proteomic approaches considerably brought new insights into the 
phenotype of the human BBB. The BBB is a dynamic neurovascu-
lar unit with delicate cellular configuration. The brain capillary 
endothelial cells (BMECs) sealed by tight and adherent junctions 
are in dynamic interaction with the pericytes that share the basal 
membrane with the BMECs and the astrocyte end-foot processes 
with the neuron axonal projections that almost entirely surround the 
brain microvessels. These specific features make the endothelial 
cells of the brain microvessels very different from those of periph-
eral tissues. The tight junctions restricts paracellular diffusion and 
the presence of specific transport proteins make the BBB a physical 
and a biochemical barrier that controls the entry of endogenous and 
exogenous compounds into the brain. The BCSFB is composed of a 
tight monolayer of cuboidal epithelial cells known as choroid 
plexus epithelial cells, which function as a barrier in the choroid 
plexus (CP). The CP is a highly vascularized structure located in 
the four brain ventricles and its blood capillaries are relatively per-
meable due to the non-tight junction architecture [10]. Also, the 
arachnoid barrier, a brain membrane envelope formed by a multi-
layered epithelium with tight junctions between the cells, is a bar-
rier which only allows CSF movement out of the brain to blood; as 
it is non-vascularized, the arachnoid membrane is not an important 
route for the transport of molecules into the brain [11]. The ABC 
transporter superfamily is responsible for the efflux of xenobiotics 
from the brain into the bloodstream, making some ABC transport-
ers key elements in controlling the brain penetration of many drugs 
and thus their central nervous system (CNS) effects [11-13]. Typi-
cally, ABC transporters display low substrate specificities which 
enable them to extrude a large number of structurally unrelated 
substrates. Therefore, the BBB not only acts as a passive barrier, 
but also actively efflux a large number of molecules from the brain. 
In this review we will focus on recent data concerning the expres-
sion, relative abundance and activity of ABC transporters in the 
human BBB. 
2. HUMAN ABC TRANSPORTER GENES, PROTEINS AND 
ACTIVITIES IN THE BBB 
2.1. Classification, Nomenclature, Structure and General Func-
tions of Human ABC Transporters 
 ABC transporter superfamily members are grouped into sub-
families based on their amino acid sequence similarities and 
1873-4286/14 $58.00+.00  © 2014 Bentham Science Publishers
ABC Transporters in the Human BBB Current Pharmaceutical Design, 2014, Vol. 20, No. 10    1451
phylogeny. In human, there are 48 ABC members grouped into 7 
subfamilies A-G. The subfamilies are: ABCA (12 members; previ-
ously ABC1), ABCB (11 members; previously MDR/TAP), ABCC 
(13 members; previously MRP/CFTR), ABCD (4 members; previ-
ously ALD), ABCE (1 member; previously OABP), ABCF (3 
members; previously GCN20) and ABCG (5 members; previously 
White) [14, 15]. Investigations using topological models predicted 
the structure for most of the ABC family members. A common 
protein structure for the majority of ABC transporters can be de-
scribed as two hydrophobic transmembrane domains (TMDs), each 
consisting of multiple membrane-spanning -helices involved in the 
recognition of substrates, and two hydrophilic cytoplasmic nucleo-
tide-binding domains (NBDs) which couple conformational 
changes induced by ATP binding, ATP hydrolysis and ADP release 
to the transport process [16, 17]. Some members deviate from this 
common structure by deficiency or additional TMDs and/or NBDs. 
For example ABCG2 is a half transporter consisting of 1 TMD and 
1 NBD that dimerize or multimerize to form functional units. How-
ever, ABCC1-3, ABCC6, and ABCC10 have an additional amino 
terminal TMD, a total of three TMDs [18, 19]. 
 ABC transporters are membrane proteins that use the energy 
release by hydrolysis of ATP to transport various substrates across 
the cell membrane. The TMDs form an internal cavity that binds 
substrates through multiple interactions. Within the membrane, the 
TMDs are organized to build an inverted “V” pocket capable of 
accepting substrates from either the cytoplasmic side or extracellu-
lar space. Substrate binding to this pocket increases the affinity of 
the NBDs to ATP [20, 21]. Binding and hydrolysis of ATP by the 
NBDs induces a conformational change in the TMDs, leading to the 
opening of the inverted “V” to the opposite side, allowing substrate 
release into the extracellular space. Upon ATP hydrolysis, the 
transporter is then restored to its original inward facing orientation, 
able to initiate a new cycle of transport ([22]; reviewed in [23]). 
However, the exact mechanism of unidirectional substrate translo-
cation through ATP hydrolysis coupling is not completely clear so 
far. 
 This review is focused on ABC transporters expressed in nor-
mal tissues and that are implicated in the efflux transport of drug 
and toxic molecules either into the main bloodstream or in excre-
tion organs like liver, kidney and gut, depending on the tissue-
interface where these transporters are expressed [24, 25]. ABC 
transporters are major players in the multidrug resistance (MDR) 
phenotype that has been described in multidrug resistance cancer 
cells [26] and contribute actively to the pharmacoresistance ob-
served in CNS diseases like epilepsy, depression and brain cancers 
[27-29]. Researchers in academia and industry have been putting 
effort to determine the role of ABC transporters in the transport of 
neuropharmaceuticals across the BBB. These efforts have been 
facilitated by the concomitant development of sophisticated mo-
lecular biology techniques like quantification of mRNA (qRT-PCR) 
and proteins (quantitative proteomics using mass spectrometry), 
confocal immunofluorescence, isolation of brain microvessels from 
human tissues and positron emission tomography (PET) using ra-
diolabelled substrates. These studies enabled regional and cellular 
localization, relative abundance and activity of some ABC trans-
porters in human, and provided new insight into the respective role 
of ABC transporters in controlling the CNS distribution of drugs. 
2.2. ABC transporters in the human blood-brain interfaces 
2.2.1. Expression and Localization of ABC Transporters at Hu-
man Blood-brain Interfaces 
 The functions of ABC transporters at the human BBB are of 
major concern for researchers in academia and industry. Neverthe-
less, ABC transporters are particularly implicated in physiopathol-
ogy and pharmacoresistance. Many studies have examined the gene 
and protein expressions of ABC transporters at the BBB in many 
species. These studies brought new insights into the abundance of 
ABC transporters at the human BBB, which will be discussed with 
other studies in the following paragraphs. 
a. P-glycoprotein (ABCB1/MDR1)
 P-glycoprotein (ABCB1, MDR1, P-gp) was discovered in 1976 
[30] and it was the first ABC transporter detected in the endothelial 
cells of the human BBB by immunochemistry [31]. The human 
ABCB1 involved in the efflux of xenobiotics at the BBB is encoded 
by the ABCB1 (MDR1) gene. Using different techniques, the genes 
encoding P-glycoprotein have been identified in the cerebral endo-
thelial cells of most living species, including rodents, rabbits, pigs, 
dogfish, cattle and monkeys [25, 32-35]. The immunolocalization 
of ABCB1 in the human endothelial cells of the BBB has been 
extensively reported using brain sections, isolated brain microves-
sels and primary cultures of human brain endothelial cells. Tanaka 
et al. showed by immunoelectron microscopy studies that the local-
ization of ABCB1 in the walls of capillary blood vessels in human 
brain tissue was specifically on the luminal surface of the endothe-
lium [36] (Fig. 1). However, no staining for ABCB1 was observed 
in neurons and glial cells. In the human cerebral microvascular 
endothelial cell line hCMEC/D3 the expression and functional ac-
tivity of ABCB1 was demonstrated [37-39]. Similarly, expression 
was shown in primary cultures of human brain microvessel endo-
thelial cells (HBEC) co-cultured or not with astrocytes [40, 41]. No 
ABCB1 expression was found in primary human astrocytes cul-
tured alone [41]. Supporting these data, studies performed using 
human isolated microvessels and human brain sections showed a 
strong immunocytochemical staining for ABCB1, but no staining 
was seen in neurons and glial cells [42, 43]. In line with these re-
sults, two studies using isolated human brain microvessels showed 
the high expression of ABCB1 [44, 45]. However, the isolation 
procedure did not ensure astrocyte foot-processes removal which 
remain attached to the microvessels. Therefore, it is difficult to 
conclude that the expression of ABCB1 occurs only in the brain 
endothelial cells and to exclude its expression in astrocytes. Using 
microscopic immunogold cytochemistry Bendayan et al identified 
ABCB1 at both luminal and abluminal membranes of capillary 
endothelial cells, but also in adjacent pericytes and astrocytes of 
human BBB [46]. In accordance with this study, there is additional 
data suggesting that ABCB1 is present on the abluminal side of 
the human brain microvasculature, more specifically on. astrocyte 
foot processes [47, 48]. Also, a cause-relationship may exist be-
tween brain pathologies as epilepsy, glioma and cortical dysplasia 
and the up-regulation of the expression of ABCB1 in astrocytes 
[49-52]. Using human brain sections, immunodetection of ABCB1 
was also possible in the microvascular pericytes that closely en-
velop the brain capillary endothelial cells [43]. In other study using 
healthy human brains, ABCB1 and ABCC1 were not detectable in 
neurons [51, 53]. Rao et al found functionally active ABCB1 ex-
pression in the epithelia of choroid plexus in the human brain. It has 
been suggested that ABCB1 paradoxically prevents trafficking of 
substrates out of the cerebrospinal fluid (CSF) in choroid plexus 
epithelia [54]. Still, the presence and function of P-gp in the human 
CP remains questionable since Abcb1a/P-gp is much less expressed 
than Abcc1/Mrp1 in rat CP while Abcb1a/P-gp expression is higher 
than Abcc1/Mrp1 at the rat BBB [55] (Fig. 2). Further studies are 
needed to clearly demonstrate the role of ABCB1 in the human CP.  
b. Breast Cancer Resistance Protein (ABCG2/BCRP)
 ABCG2 (BCRP) has been identified for the first time in a breast 
cancer cell line exhibiting pharmacoresistance to cytotoxic drugs 
[56]. ABCG2 differs from common ABC transporters as it is a half-
transporter composed of a single nucleotide-binding domain with 
six transmembrane domains. ABCG2 may also function as ho-
modimers, homo-oligomer or hetero-oligomer held together by 
disulfide bonds [57]. Several studies showed the abundance of 
ABCG2 in the endothelium cells of capillaries and veins of many 
normal tissues and organs, particularly those expressing ABCB1 
[58, 59]. ABCG2 was first identified at the BBB by Hans-Joachim 
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Galla’s group [60] and is now a well-recognized BBB component. 
Abcg2 is much more abundant in the luminal membrane of cerebral 
endothelial cells than in the total cortex in mouse [61], rats [40], 
pigs [60] and humans [62]. 
 Aronica et al showed the presence of ABCG2 protein in human 
brain tissue, which is consistently expressed in lysates of human 
temporal cortex and hippocampus [63]. ABCG2 gene transcripts 
were detected in several regions of the human brain [64]. Expres-
sion and immunolocalization of ABCG2 was observed in human 
frozen brain sections, which strongly suggested that the fluorescent 
signals were limited to the microvessel endothelium [62]. Support-
ing evidence was obtained from human brain isolated microvessels, 
suggesting that ABCG2 is the major ABC transporter expressed at 
the BBB [44, 65]. Interestingly, ABCG2 expression was about 
twice that of ABCB1 in isolated human brain microvessels, sug-
gesting that it may be of interest to study its functional role at the 
human BBB in limiting CNS drug delivery. The expression at 
mRNA and protein level and functional activity of ABCG2 have 
been confirmed in primary cultures of human brain endothelial cells 
[40], in the immortalized human brain endothelial cell line BB19 
[66], and in hCMEC/D3 cells [37]. Regarding the membrane local-
ization within the endothelial cells, there is considerable proof that 
ABCG2 displays localization in the luminal side of the endothelium 
from normal human brain [59, 62, 63] (Fig. 1). According to 
Aronica et al, ABCG2 expression in the brain is limited to the 
blood brain vessels, as no neuronal or glial ABCG2 expression was 
detected [63]. However, Zhang et al detected the expression of 
ABCG2 protein in both human brain microvessel endothelial cells 
and fetal human astrocytes, although in the latter at levels consid-
ered low [67]. A very limited expression of ABCG2 was demon-
strated in the choroid plexus epithelial cells of the porcine and rat 
BCSFB, which may mean a similar but less significant function of 
this transporter in this brain barrier [60, 68]. However, ABCG2 
expression in the human BCSFB is currently unknown. 
c. Multidrug Resistance-associated Proteins (ABCCs/MRPs)
 The multidrug resistance-associated proteins, MRP (ABCC) are 
a group of 13 efflux transporters belonging to the C subfamily. 
Some ABCCs are able to transport drugs [18]. The ABCCs are 
presently divided into two groups depending on their structure. The 
“long” ABCCs are ABCC1-3, ABCC6 and ABCC7. They contain 
three transmembrane domains, TMD0, TMD1 and TMD2. The 
“short” ABCCs include ABCC4, ABCC5, ABCC8, and possibly 
ABCC9, which do not contain TMD0. The ABCC isoforms differ 
in their tissue distribution, substrate specificity, and proposed 
physiological functions [69]. The ABCCs are involved in a wide 
range of specific and essential physiological activities, particularly 
in the transport of organic anions either unconjugated or conjugated 
with glutathione, glucuronate, sulphate, or phosphate [70, 71]. 
Moreover, it is now clear that these proteins are involved in the 
transport of drugs across lipid membranes from inside to outside the 
cell contributing to multidrug resistance. In contrast to the distribu-
tion profiles of ABCB1 and ABCG2 in the BBB, ABCCs distribu-
tion is still controversial because of the large interspecies differ-
ences. This may explain the conflicting recently published results 
regarding their abundance and/or function at the BBB. 
Fig. (1). Schematic representation of the blood-brain barrier and the ABC transporters expressed in the human brain capillary endothelial cells. The 
ABC transporters are expressed at the luminal side of the membrane of endothelial cells, and ABCG2/BCRP seems to be the highly expressed transporter, 
followed by ABCB1/P-glycoprotein and ABCC4/MRP4. 
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 ABCC1 was the first identified member of the ABCC/MRP 
subfamily. Like other family members, it is involved in the efflux 
of many organic anionic substrates [71]. ABCC1 is usually present 
in cells of blood-tissue barriers protecting different body organs and 
limiting tissue distribution of certain substrates. In the brain, the 
localization of ABCC1 in the human BBB and thus its contribution 
in drug efflux are still controversial. ABCC1 mRNA has been de-
tected in human BMECs [65, 72, 73], but the expression of ABCC1 
protein remains unclear. ABCC1 couldn’t be detected in the human 
BBB in most studies [44, 53, 62, 72, 74]. However, Dauchy et al. 
found that ABCC1 gene expression was well demonstrated in 
hCMEC/D3 cells as compared to the rest of ABCCs [37], suggest-
ing culturing conditions of human brain endothelial cells may in-
crease in vitro the expression of ABCC1 that is probably not ex-
pressed in vivo in human. Nies et al detected a weak immunostain-
ing for ABCC1 in the luminal membrane of human brain endothe-
lial cells [37, 75]. ABCC1 immunocytochemical expression and 
activity was found in human epithelial cells of the choroid plexus, 
and it is located in the basolateral membrane of choroid plexus 
epithelial cells [53, 54] (Fig. 2). These findings indicate that 
ABCC1 contributes to the basolateral broad-specificity drug-
permeation barrier in choroid plexus, preventing the accumulation 
of several organic anions in the CSF. Studies reported that normal 
human astrocytes cultured in vitro expressed high amounts of 
ABCC1. The expression was shown mainly in foot-processes as 
observed by immunofluorescence when using astrocytes grown in 
chamber slides. This expression might indicate a physiological 
transport function of ABCC1 in normal astrocytes [76]. In contrast, 
ABCC1 protein was hardly detected in normal human astrocytes in 
situ [75]. However, ABCC1 has not been detected in isolated hu-
man brain microvessels showing that its expression is weak in brain 
endothelial cells and astrocyte foot processes of human origin. Con-
sidering the inconsistent and low-level expression of ABCC1, the 
function of ABCC1 at the human BBB may be limited. 
 hCMEC/D3 cells expressed ABCC2 and ABCC3 [37], in accor-
dance with those reported by Carl et al where they have shown that 
hCMEC/D3 cells expressed these ABCCs [77]. In contrast, qRT-
PCR studies showed that ABCC2 and ABCC3 are not expressed at 
the human BBB [44]. These results are consistent with the immu-
nolocalization studies using human brain and cultured human brain 
capillary endothelial cells, in which neither ABCC2, ABCC3 nor 
ABCC6 were detected. These observations substantiate the conclu-
sion on the absence of these ABCCs at the human BBB [75, 78, 
79]. However, rodent data showed Abcc2 expression in isolated 
brain microvessels, suggesting interspecies differences and ques-
tioning the reliability of using animal models in the study of brain 
uptake of ABCC2 substrates [80]. Nevertheless the most probable 
absence of these ABCCs at the human BBB, ABCC1 and ABCC2 
may gain importance in restricting the entry of organic anions into 
the brain under certain pathophysiological conditions like in epi-
lepsy. 
Fig. (2). Schematic representation of the blood-cerebrospinal fluid barrier and the ABC transporters present in the human choroid plexus epithelial 
cells. ABCC1/MRP1 and ABCC4/MRP4 are expressed in the basolateral membrane of the choroid epithelium, contributing to the prevention of the accumula-
tion of several organic anions, drugs and metabolites in the CSF. Paradoxically, ABCB1/P-gp evidenced an apical localization, which prevents trafficking of 
substrates out of the cerebrospinal fluid. 
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 Gene and protein studies using human brain freshly isolated 
microvessels showed the expression of ABCC4/ABCC4, and it was 
shown by absolute quantitative proteomics that only ABCC4 pro-
tein quantity was above the limit of quantification (LOQ), whereas 
the rest of ABCCs were below the LOQ [44, 65]. In accordance, 
hCMEC/D3 cells expressed significant amounts of ABCC4 gene 
transcripts [37]. ABCC4 was demonstrated in situ at the human 
BBB and BCSFB, where it was localized in the luminal side of 
capillary endothelial cells [75, 81], and in the basolateral membrane 
of choroid plexus epithelial cells [75, 81]. These observations indi-
cate an important function of ABCC4 in limiting drug brain pene-
tration and in the efflux of organic anions from brain to blood. 
ABCC4 was also immunolocalized in astrocytes of human brain 
slices [75]. 
 ABCC5 is involved in the efflux of cyclic nucleotides. ABCC5
gene transcripts were detected, in human brain freshly isolated mi-
crovessels and in hCMEC/D3 cells [37, 65]. A recent study cor-
roborated these data, and also established that ABCC5 is the most 
abundant ABCC family member expressed in human BMECs [73]. 
Nevertheless in the quantitative proteomic study of Shawahna et al.
the amount of ABCC5 was below the limit of quantification [44], 
human brain in situ studies reported its localization in the luminal 
membrane of capillary endothelial cells [75]. Human pyramidal 
neurons and human astrocytes showed detectable ABCC5 amounts 
[75]. 
 Few studies investigated ABCC6, ABCC10-ABCC12 expres-
sion in human BBB. A major problem is the lack of selective anti-
bodies against these ABCC. Two independent studies have reported 
mRNAs levels of ABCC10 and ABCC11 in homogenates of human 
brain [82, 83]. ABCC6, ABCC11 and ABCC12 mRNAs have been 
detected in the human brain cortex and in the isolated microvessels 
of the corresponding human brains [65]. However, any of the corre-
sponding proteins have been detected by quantitative proteomics 
[44, 45] and no mRNAs coding for these transporters was detected 
by RT-PCR in hCMEC/D3 immortalized human cerebral micro-
vascular endothelial cells [37]. Nevertheless, the high limit of 
quantification of quantitative proteomics did not allow excluding 
protein expression of ABCC6, ABCC10 and ABCC11 at the human 
BBB. ABCC11 was localized in axonal membrane of neurons in 
human cerebral cortex, but it was not detected in tumor cells and 
gliomas [84]. 
d. Other ABC Transporters Expressed at the Blood-CNS Inter-
faces
 In addition to the expression of the above mentioned ABC 
transporters, it was also shown that microvessels also express some 
transporters belonging to the ABCA subfamily in the human BBB, 
namely ABCA2 and ABCA8 [44, 174]. It is known that ABCA 
transporters are responsible for the transport of steroids, such as 
cholesterol and derivatives, which are important components of the 
CNS. However, in addition to the role that ABCA transporters play 
in maintaining the steroid homeostasis in the brain, it is yet to be 
discovered if they may also be involved in the efflux of drugs and 
xenobiotics whose structure is essentially similar to steroid or lipid 
structure, and thus contribute to the transport from the brain to the 
bloodstream. 
2.2.2. Relative Abundance of ABC Transporter Proteins and their 
Activities in the BBB 
 While the abundance of some ABC transporters in the BBB is 
still a matter of debate, ABCB1, ABCC4-5 and ABCG2 proteins 
are believed to be the main ABC transporters in human and mouse 
BMECs so far [65, 85] (Fig. 1). ABCB1 is also functional in the 
human BBB, as indicated by PET-imaging studies using 11C-
verapamil [86, 87], and 11C-desmethyl-loperamide [88]. ABCB1 
activity is quite uniform in all brain regions protected by the BBB 
and, consequently, ABCB1 inhibition results in strong increase in 
substrate accumulation throughout the healthy human brain [87]. 
The ABCB1 also plays in concert with the ABCG2 at the BBB to 
restrict the passage of their common substrates into the brain. Thus 
the deficiency or inhibition of one of the two transporters is not 
accompanied by an increase of the brain penetration of a common 
substrate: in Abcg2 deficient mice (but in which Abcb1 is present), 
the Abcb1 alone is sufficient to prevent the brain penetration of the 
substrate. Similarly, mice deficient in Abcb1 (but in which the 
Abcg2 is present), the Abcg2 alone is sufficient to limit the brain 
entry of the substrate [89]. These data clearly show that these two 
ABC transporters compensate for each other and act together to 
reduce the in vivo brain penetration of their common substrates. 
This synergistic effect of Abcb1 and Abcg2 at the BBB has been 
clearly established in mouse for anticancer drugs that are substrates 
of both ABC transporters [90] but remains to be demonstrated in 
human. 
 Unfortunately, no similar PET studies are presently available on 
the functions of ABCG2 and ABCC4-5 at the human BBB. So we 
still do not know whether ABCG2 and ABCC4 are functional in the 
human BBB. Since ABCG2 is believed to be more abundant than 
ABCB1 at the human BBB, PET studies should focus on the func-
tion of ABCG2 at the human BBB. However, no PET radiolabelled 
probes that are selective for ABCG2 function evaluation have been 
described, partly because of its recent discovery and due to the high 
overlapping substrate specificities of ABCG2 and ABCB1 [91]. 
11C-desmethyl-loperamide is a case of a radiolabelled PET probe 
that is highly selective for ABCB1, but not for ABCG2 or ABCC1 
[92]. Recently, 11C-gefitinib and 11C-tariquidar showed to be prom-
ising PET radiotracers suitable to evaluate the function of ABCG2 
by either genetic or chemical knockout of ABCB1 in the study 
model [93, 94]. Also, Tournier et al. validated an in vitro model 
using MDCKII cells transfected with human ABCB1 or ABCG2
genes to assess the transport of selected PET ligands by the concen-
tration equilibrium technique [95]. The model showed that the 
monoamine oxidase A antagonist befloxatone was exclusively 
transported by ABCG2, and not by ABCB1 [95], suggesting that it 
may be useful to study the activity of ABCG2 at the human BBB. 
 The identification of gene polymorphisms involving ABC 
transporters is gaining considerable importance regarding their 
relative expression and functional activity at the BBB. To the pre-
sent date, more than 50 single nucleotide polymorphisms (SNPs) 
have been identified for the ABCB1 gene, and particularly the func-
tional C3435T, G2677T and C1236T SNPs have been associated to 
an altered expression and function of ABCB1 in human tissues [96, 
97]. Kato et al found that the haplotype combination 3435C–
2677G–1236T within the ABCB1 gene was associated with a more 
severe depressive symptomatology, related to a poor response to 
antidepressants, and this may be due to a higher expression of 
ABCB1 or to more active protein forms [98]. Similarly, it was 
shown that the attention-deficit/hyperactivity disorder (ADHD) 
improvement caused by treatment with guanfacine was less evident 
in children with the T/T ABCB1 C3435T genotype, compared to 
either C/T or C/C genotypes [99]. Thus, a higher activation of 
ABCB1 would result in lower brain levels of CNS drugs that are 
ABCB1 substrates, and consequently in resistance to pharma-
cotherapy. In a study conducted in Japan by Fujii et al the C3435T 
SNP, and the TT genotype (TT3435) linked to this SNP, were 
shown to be significantly more common in patients with major 
depressive disorder than in the controls, suggesting that polymor-
phisms of ABCB1 may give susceptibility to this disorder [100]. In 
addition, it was reported that a higher frequency of the 1236C–
2677G is evident among individuals with Parkinson’s disease. 
Here, altered ABCB1 expression might result in accumulation of 
drugs and/or toxins in harmful amounts, and therefore contributing 
to the development of disease [101]. 
 Nevertheless, we still need to know the relative amounts of 
each ABC transporter at the BBB in order to better understand how 
they influence brain drug distribution. ABCB1 and ABCG2 are the 
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most extensively reported ABC transporters at the BBB. For a long 
time, it was believed that ABCB1 was the major ABC transporter at 
the BBB. This belief was substantiated by the findings that Abcb1 
was 3-fold more expressed than Abcg2 in isolated mouse brain 
capillaries [85]. However, human brain tissues showed that the 
expression of ABCG2 seemed higher compared to other ABC 
transporters, such as ABCB1 and ABCCs [62, 63]. The expression 
profiles of the genes encoding the main ABC transporters at the 
human BBB were recently established by studies on human cerebral 
microvessels isolated from the brains of patients undergoing neuro-
surgery (glioma or epileptic patients). It has to be noted that biop-
sies were as far as possible from the brain lesions suggesting that 
this part of the brain could be considered as healthy. In contrast to 
previous studies in rodents, Dauchy et al showed that ABCB1 was 
about 7-fold less expressed than ABCG2 in human brain microves-
sels, whereas ABCC4 and ABCC5 were much less expressed [65]. 
Also, ABCG2 is higher expressed than ABCB1 in total human 
brain homogenates [67]. At the human BBB, these data were re-
cently confirmed by quantitative proteomic analyses of isolated 
human cerebral capillaries, in collaboration with the group led by 
Drs. S. Ohtsuki and T. Terasaki (Tohoku University, Sendai, Ja-
pan), where the ABCG2 expression was also higher than that of 
ABCB1 in human brain microvessels [44, 45]. The ABCG2 expres-
sion was shown to be 1.6 times superior than ABCB1 expression 
and to be 12.8 times inferior than GLUT-1 expression, where 
ABCG2 absolute protein amount was found to be about 6.15 ± 1.41 
fmol/g of protein while ABCB1 protein was about 3.98 ± 0.88 
fmol/g of protein [44]. This is indicative of the substantial inter-
species differences and questions the use of rodents as representa-
tive models in studying drug efflux at the BBB. In the Uchida et al 
study, they investigated the proteomics of ABC transporters in mi-
crovessels isolated from frozen human brain samples [45], where it 
was compared to the protein amounts of transporter homologues in 
mouse. Interestingly, their results showed that the human ABCG2 
was 2-fold of the mouse Abcg2, whereas the human ABCB1 and 
ABCC4 were almost 2 and 8 times less than the mouse Abcb1a and 
Abcc4, respectively [45]. Thus, it is essential to keep in mind that 
the expression of different ABC transporters at the BBB is highly 
variable among different species. 
3. CNS DRUG SUBSTRATES OF ABC TRANSPORTERS 
EXPRESSED AT THE HUMAN BBB 
 The BBB, as a protecting mechanism built to hamper endoge-
nous and exogenous threatening molecules from entering and dam-
aging the brain, also prevents therapeutic drugs to reach the CNS, 
thus potentially reducing their efficacy. Of the 48 human ABC 
transporters that have been described, there are three particularly 
predominant at the human BBB, and which thus have been linked 
to a potential role in narrowing CNS drug penetration, these are 
ABCB1, ABCG2 and ABCC4. In this review we simply analyze 
the impact of these three ABC transporters, as they are believed to 
be the major ABC transporters involved in the regulation of brain 
uptake and extrusion of drugs at the human BBB. A list of some 
substrates of ABCB1, ABCG2 and ABCC4 are represented in Ta-
ble 1, together with some of their inducers, inhibitors and physio-
logical substrates, which is a representative list of the chemical 
diversity of molecules recognized and transported by these ABC 
transporters. 
a. P-glycoprotein 
 As ABCB1 was the first ABC transporter to be described, it is 
also by far the best characterized. ABCB1 limits the brain penetra-
tion of a broad range of chemically diverse substrate drugs. Its sub-
strates vary greatly in size, structure, and function. Substrates in-
clude chemotherapeutic agents as anthracyclines, vinca alkaloids, 
tyrosine kinase inhibitors, HIV protease inhibitors and HMG-CoA 
reductase inhibitors. Several chemotherapeutic agents have been 
shown to be substrates of ABCB1, namely anthracyclines such as 
doxorubicine and daunorubicine [102], etoposide [103], the tyrosine 
kinase inhibitors imatinib and gefitinib [93, 104] and vinca alka-
loids (vinblastine, vincristine) [105, 106]. ABCB1 over-expression 
is now considered a major player in the development of resistance 
to anticancer treatment, particularly in brain tumors. The majority 
of human immunodeficiency virus (HIV) protease inhibitors (indi-
navir, saquinavir, nelfinavir), which brought considerable progress 
in the treatment of HIV infection, are also important ABCB1 sub-
strates. Studies show that these drugs reach significantly higher 
brain levels in Abcb1a knockout mice when compared to wild-type 
mice [107, 108]. The remarkable increase in abacavir brain distribu-
tion showed in Abcb1-deficient mutant mice over wild-type mice 
by Shaik et al suggests that ABCB1 may also play a significant role 
in restricting the nucleoside analog reverse transcriptase inhibitor 
abacavir distribution to the CNS [109]. Thus, ABCB1 is also in-
volved in the brain resistance to HIV pharmacotherapy. There is 
also considerable evidence that a large number of antiepileptic 
drugs are transported by this ABC transporter. Cell lines transfected 
with the human ABCB1 gene confirmed that ABCB1 transported 
the active metabolite of carbamazepine (carbamazepine-10,11-
epoxide) as well as eslicarbazepine acetate and oxcarbazepine. 
Their transport was blocked by the ABCB1 inhibitors tariquidar and 
verapamil [110]. A similar study was conducted to show that 
phenytoin and phenobarbital are as well ABCB1 substrates [111]. 
Results indicated the possible role of ABCB1 in drug resistance in 
refractory epilepsy, especially if epilepsy patients exhibit over-
expression of ABCB1 at the BBB. Other xenobiotics recognized 
and transported by ABCB1 include opioid analgesics [112-114], 
antidepressants [115, 116] and anti-emetics [8]. Interestingly, a 
significant clinical drug-drug interaction exists between loperamide, 
a well-known substrate of ABCB1, and quinidine, a well-known 
inhibitor of ABCB1. The co-ingestion of these two drugs has pro-
duced significant CNS adverse effect due to the increase in brain 
uptake of loperamide [117]. Recently, we evidenced that norbu-
prenorphine, the main metabolite of buprenorphine (an opioid used 
in heroin addiction and pain), was a strong substrate of human 
ABCB1 [118] and that brain uptake of norbuprenorphine was sig-
nificantly decreased by Abcb1a at the mouse BBB, thus controlling 
its respiratory adverse effect [119]. A summary of ABCB1 sub-
strates is displayed in Table 1.  
b. ABCG2/BCRP 
 Since ABCG2 was first identified as a drug efflux protein con-
tributing to the multidrug resistance phenotype of cancer cell lines, 
a large number of chemotherapeutic and non-chemotherapeutic 
molecules have been shown to be substrates of this transporter. The 
ABCG2 substrate spectrum includes physiological compounds, 
nutrients, and several cancer and non-cancer drugs. Particularly in 
the case of non-cancer drugs, ABCG2 covers a spectrum of several 
structurally unrelated classes of anti-cancer agents, increasing the 
importance of ABCG2 as multidrug resistance protein. 
 Resistance to mitoxantrone is the hallmark of cells expressing 
ABCG2, as well as resistance to camptothecin derivatives (9-
aminocamptothecin, topotecan, irinotecan and SN-38, its active 
metabolite) [120-122]. Other chemotherapeutic substrates have 
been shown to be transported by ABCG2 as the tyrosine kinase 
inhibitors imatinib, gefitinib and nilotinib [123-125], indolocarba-
zoles and antifolates such as methotrexate [126]. Cells with a gly-
cine or threonine instead of an arginine at the amino acid 482 of the 
ABCG2, considered to be a “hotspot” for mutation, readily trans-
port doxorubicin and rhodamine 123 in addition to mitoxantrone 
[127-129]. Several other substrate classes have been described in-
cluding antivirals [130-132], HMG-CoA reductase inhibitors [133-
135], carcinogens [136-138] and antibiotics [139-141]. A summary 
of some of the cancer and non-cancer drugs transported by ABCG2 
is given in Table 1. The expanding list of ABCG2 substrates high-
lights the fact that this transporter may play a significant role in 
brain pharmacology and protection. 
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c. ABCC4/MRP4 
 ABCC4/MRP4 is known to participate in the extrusion of or-
ganic anions, the transport of diverse antiviral and has also been 
implicated in multidrug resistance during chemotherapy. Among 
the anticancer drugs known to be substrates of this ABC transporter 
are 6-mercaptopurine, methotrexate, 6-thioguanine [142-144] and 
topotecan [81], emphasizing the importance that this transporter 
may have in determining the CNS distribution of these drugs and 
contributing to cancer pharmacoresistance. ABCC4 confers resis-
tance to purine-based antiretroviral agents as ganciclovir [145], 
adefovir and tenofovir [146], and thus may influence the efficacy of 
antiviral therapy. Other drugs that are apparently transported by 
ABCC4 are the pharmacologically active form of oseltamivir [147], 
furosemide and hydrochlorothiazide [148]. 
4. ABC TRANSPORTERS AS DETERMINANTS OF CNS 
DRUG PENETRATION 
 Considering the previously discussed and largely documented 
expression of ABC transporters at the blood-CNS interfaces, 
namely the BBB and the BCSFB, allied to the wide list of drugs 
which correspond to their substrates, it is clear the significant im-
pact of ABC transporters on the CNS penetration of drugs used for 
the treatment of several diseases such as epilepsy, HIV, humour 
disorders, and brain tumors. Moreover, the occurrence of changes 
in the expression of ABC transporters at the human brain is an evi-
dent event in several pathologies, including ischemia, glioma and 
epilepsy. These changes may result in an increased or decreased 
expression of the usually present ABC transporters and may even 
induce the expression of an efflux transporter that is not normally 
expressed in the healthy brain. Tishler et al were the first to de-
scribe an up-regulation of ABCB1/ABCB1 gene and protein expres-
Table 1. List of some endogenous compounds and xenobiotics that are substrates, inducers and inhibitors of ABC transporters 
expressed at the human BBB. 
   
ABC Trans-
porter Xenobiotic substrates 
Endogenous com-
pounds 
Inducers Inhibitors 
ABCB1 Anticancer drugs: doxorubicine, daunorubicine, vinblastine, vincristine, 
etoposide, teniposide, paclitaxel, methotrexate, irinotecan, imatinib, 
gefitinib 
Anti-emetics: domperidone, ondansetron 
Corticoids: dexamethasone, hydrocortisone, corticosterone 
Anti-retroviral drugs: amprenavir, indinavir, saquinavir, abacavir, nelfi-
navir 
Opioids: morphine, methadone, oxycodone, fentanyl, loperamide 
Antidepressants: amitriptyline, nortryptiline, venlafaxine, fluoxetine, 
paroxetine, sertraline 
Antipsychotics: amisulpride, risperidone 
Antiepileptic drugs: phenytoin, carbamazepine, lamotrigine, phenobarbi-
tal, felbamate, gabapentin, topiramate 
Antibiotics: erythromycin, valinomycin, tetracyclines, fluoroquinolines 
Anthelminthic agents: ivermectin, abamectin 
Others: verapamil, colchicines, cimetidine, digoxine, fexofenadine 
-Amyloid peptide, 
bilirubin, cytokines, 
cortisol, aldosterone 
Rifampin, dex-
amethasone, Pheno-
barbital, 
TCDD 
Verapamil, cy-
closporine A, 
amlodipine, 
quinidine 
ABCG2 Anticancer drugs: considerable overlap with P-gp, anthracylines;  
camptothecins, indolocarbazoles, mitoxantrone, methotrexate, imatinib, 
gefitinib, erlotinib 
Anti-retroviral drugs: zidovudine, lamivudine, abacavir 
HMG-CoA reductase inhibitors: rosuvastatin, pitavastatin, cerivastatin 
Antibiotics: ciprofloxacin, ofloxacin, norfloxacin, erythromycin, rifam-
picin, nitrofurantoin 
Glucoronide, glutathione and sulphate conjugates 
Others: sulfasalazine, cimetidine, riboflavin, dipyridamole 
Estrone-3-sulfate,  
17-oestradiol, 
DHEA sulfate 
TCDD Fumitremorgin 
C, TKIs,  
flavonoids 
ABCC4 Anti-retroviral drugs: Adefovir, tenofovir 
Anticancer drugs: methotrexate, topotecan, 6-mercaptopurine, thiogua-
nine 
Others: dehydroepiandrosterone sulphate, furosemide 
DHEA sulfate, 
cyclic nucleotides, 
bile acids + GSH, 
Prostaglandin E2, 
Thromboxane B2 
Rifampin, clofi-
brate, cyclophos-
phamide 
Celecoxib, di-
clofenac 
For reference see [19, 28, 175, 176]; DHEA, dehydroepiandrosterone; GSH, reduced glutathione; TCDD, tetrachlorodibenzodioxin; TKI, tyrosine; kinase inhibtor 
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sions in epileptogenic brain regions, either in the capillary endothe-
lium or in astrocytes [51]. Following reports demonstrated that not 
only ABCB1 but also several ABCCs, such as ABCC1, ABCC2 
and ABCC5 are over-expressed in brain capillary endothelial cells 
and/or astrocytes of CNS-pharmacoresistant patients [50, 53, 74, 
149, 150]. Additionally, Lazarowski et al observed in the epilepto-
genic regions increased levels of ABCG2, in refractory epilepsy 
patients [151]. According to some studies, the expression of ABC 
transporters can also be up-regulated upon ischemia [152, 153], 
despite the fact that Patak et al didn’t find any changes of ABCB1 
and ABCC1 expressions immediately after hypoxia, in hCMEC/D3 
cells [154]. The efficacy of chemotherapy for malignant brain tu-
mors is very limited, since many anticancer drugs are substrates for 
multidrug transporters (see Table 1), and due to the presence of 
ABC transporters at the BBB. The expression of drug efflux trans-
porters as Abcb1b, Abcc1, Abcc4 and Abcc5 in glioma cells are a 
true evidence of the limitations of the anticancer drug therapy 
nowadays [155]. Therefore, the over-expression of ABC transport-
ers has logical consequences on the permeability of drugs across the 
BBB, leading to pharmacoresistance phenomena to the CNS-acting 
drugs. 
 Considering the anatomical and molecular characteristics of the 
BBB and BCSFB, there is a pressing need to develop strategies to 
circumvent the efflux capacity of ABC transporters, and thus en-
hance the permeability of CNS-acting drugs into the brain and im-
prove their brain distribution and bioavailability. Thus, designing of 
effective drugs that are not substrates, ABC transporter inhibitors, 
increase of BBB permeability through pharmacological or physical 
disruption of the BBB are imperative strategies to develop by the 
pharmaceutical industry to increase brain distribution of drugs [156, 
157]. Some studies showed the potential of the use of nanocarriers 
such as nanoparticles, liposomes and solid lipid nanoparticles 
(SLN) as promising vehicles facilitating the transport and delivery 
of CNS-acting drugs into the brain through endocytic pathways or 
inhibition of ABC transporters expressed at the BBB and BCSFB 
[74, 158-162]. The use of different types of ABC transporter inhibi-
tors in several studies also revealed a good correlation in terms of 
improving the brain delivery and bioavailability of CNS-acting 
agents that are substrates of ABC transporters [163-167]. Neverthe-
less, we have to consider the ubiquitous presence of ABC transport-
ers in the human body and once these inhibitors are not CNS-spe-
cific, their use may lead to undesirable alteration of pharmacokinet-
ics, and consequently to a high risk of drug toxicity and unpredict-
able drug-drug interactions. Likewise, the development of prodrugs 
formed by molecular conjugates of suitable functional groups with 
more favourable lipophilicity has arisen as a strategy to improve 
BBB passage by passive diffusion [163, 168, 169]. Once these pro-
drugs cross the endothelial cells of the BBB, they would subse-
quently be hydrolyzed to the active drug form within the brain. 
 On the contrary, an inverse strategy may also be to increase the 
function of ABC transporters to limit CNS drug distribution and/or 
to efflux toxic compounds, thus limiting CNS drug adverse effects. 
Interestingly, ABC transporters are also known to be transcrip-
tionally regulated by several transcription factors like pregnane-
X-receptor, constitutive androstane receptor and aryl hydrocarbon 
receptor that are expressed at the BBB [37, 170-172]. Therefore, 
up-regulating ABC transporters may be a strategy to limit CNS 
distribution of drugs with CNS adverse effects or to efflux toxic 
endogenous compounds as it has been postulated for -amyloid 
peptide by ABCB1 [173]. Regulation of ABC transporters at the 
blood-brain interfaces may also occur under pathophysiological 
conditions that were described elsewhere in this special issue. 
5. CONCLUSION 
 ABC transporters are key elements at the BBB, where they help 
to maintain the homeostasis and physiological functions of the 
CNS. The presence of these ABC transporters at the BBB has im-
plications not only for protection from toxin-induced damage but 
also for hampering brain penetration of pharmacological agents 
used for the treatment of several brain diseases. Due to the differ-
ences between animal and human transporter profiles, and even due 
to recurrent disparities in transporter expression between different 
human study models, there is an increasing need of a specific hu-
man model to clarify the ABC transporters’ substrate status of the 
drugs, as well as to predict the variability in the brain distribution. 
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IV. GENERAL DISCUSSION 
 
The experimental work conducted under the present dissertation has as a common thread 
the study of the mechanisms of regulation of ABC transporters present at the BBB, in 
particular P-gp and BCRP.  It includes methodological approaches as well as expression 
and modulatory studies, which enroll for a better understanding of the BBB. We adopted 
several BBB study models, being the isolation of brain microvessels the predominantly 
used model, but some studies were also complemented with in vitro models, such as the 
human hCMEC/D3 cell line and the rat RBE4 cell line. 
As previously presented in the literature review in a dedicated section, there are currently 
several animal and human models available to characterize and study BBB maintenance 
and regulation. Since the BBB is a dynamic system, which is regulated and modified by 
different signaling factors released by different surrounding cell types, it is ideal to choose 
an experimental model that closely preserves the brain microenvironment and its 
biological processes. 
The use of freshly isolated rat brain microvessels, a technique that was largely resorted to 
in the course of the experiments conducted for the present dissertation, represents a 
valuable tool for studying the BBB physiology, and particularly the characterization of 
gene and protein expression at the BBB. In vivo treatments can be carried out in a rat 
animal model, and their consequences on the BBB physiology and features can be 
studied while preserving brain biological processes and signaling pathways fully 
functional. Thus, given that this model preserves the high degree of complexity of the 
CNS and NVU cellular interaction, it closely mimics the human BBB, providing reliable 
data for the BBB study. However, this model has some limitations, since several studies 
already demonstrated some important interspecies differences between rodent and 
human BBB models (Cutler et al. 2006; Syvanen et al. 2009; Uchida et al. 2011), which 
render difficult the extrapolation of the obtained results to the human reality. Still, due to 
ethical considerations and the difficulty to have access to samples from human origin, the 
nature of the work conducted for the present dissertation would be impracticable in 
humans, and so was conducted in an accessible rat model. 
For this purpose, we used a mechanical isolation technique, which involves the 
homogenization of samples from rat brain cortical gray matter, and subsequent 
successive centrifugations and filtrations. This technique was previously validated in our 
laboratory (Yousif et al. 2007). The isolation of microvessels from the cortical gray matter 
of the brain tissue allows a considerable elimination of cell debris and contamination from 
other associated cell types in the NVU, in an expensive and fast manner. However, it does 
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not render a pure fraction of brain capillary endothelial cells since pericytes, which are 
embedded in the basement membrane and closely in contact with endothelial cells, and 
also some astrocytic end-feet processes, remain attached to the endothelium. The 
immediate use of the rat brain for microvessel isolation ensured limited mRNA and protein 
degradation. 
 
1. Consequences of a subchronic morphine treatment in the expression of P-gp and 
Bcrp at the rat BBB: a kinetic study 
The regulation of ABC transporters present at the BBB by drugs and xenobiotics is 
currently a subject of study of growing importance. This regulation is often associated with 
a change in the expression or functional activity of these transporters, which may 
therefore change the BBB features. In the experimental works performed for the present 
dissertation, we particularly focused on the effects of morphine exposure on the 
expression of P-gp and BCRP at the BBB. This subject is of particular interest since some 
data suggest that there is a possible correlation between the induction of P-gp by 
morphine and the development of tolerance to this substance. Furthermore, morphine is 
often co-administered with anticancer drugs, which are, in a great number, substrates for 
P-gp, and thus P-gp up-regulation by morphine may alter the distribution and efficacy of 
these anticancer agents. Previous studies conducted in mice and rats registered an 
increase of P-gp expression following a subchronic administration of morphine, with 
reduced antinociceptive response (Aquilante et al. 2000; Zong and Pollack 2003). A 
previous study, conducted by our research group, evidenced an induction of the gene 
expression of several ABC efflux transporters, such as Abcb1a, Abcg2, and Abcc1, in rat 
brain microvessels, following a subchronic treatment with morphine for 5 days (Yousif et 
al. 2008). Additionally, it induced the expression of P-gp in the rat brain cortex and 
hippocampus at both mRNA and protein level (Yousif et al. 2008), in morphine-treated 
rats that were sacrificed 12h after the last dose of morphine. Furthermore, little was known 
about the effect of exposure to morphine on the expression levels of BCRP at the BBB. 
In sequence with the previous studies conducted by our team, we had interest in 
analyzing the kinetics of the modulation of P-gp, but also, of Bcrp in the rat BBB following 
a subchronic morphine treatment, of 5 days, in an escalating dose regimen. For this 
purpose, rats were sacrificed at different times after the last dose of morphine: 6h, 9h, 
12h, 24h and 36h, and both large and microvessels from rat brain cortex were isolated. β-
actin was chosen as housekeeping gene or protein in the qRT-PCR and WB analyses, 
since it is greatly expressed in these samples, and does not suffer any modification in its 
expression with the applied protocols. At the 6h-time point, the Mdr1a and Bcrp mRNA 
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levels did not suffer any change with morphine treatment in comparison to control. An up-
regulation of the Mdr1a and Bcrp mRNA levels was registered from the 9h-time point 
onwards. Mdr1a mRNA expression registered a significant increase 12h and 24h after the 
last dose of morphine, in both large and microvessels, and returned to baseline 
expression at the 36h-time point. Similarly, Bcrp transcript levels registered an up-
regulation in rat brain microvessels as early as 9h after the last dose of morphine, and 
such up-regulation was verified until the last time-point tested (36h). The greatest increase 
observed in rat brain microvessels was at 24h after the last dose of morphine, where 
Mdr1a and Bcrp transcript levels increased 40% and 140%, respectively. These results 
were corroborated at protein level, where P-gp and Bcrp protein expression remained 
unchanged 6h after the last dose of morphine, and both registered an increase of 
approximately 1.5-fold, in both large and microvessels, at the 24h-time point. To date, this 
is the first time it is demonstrated that morphine exposure is capable of inducing the 
expression of Bcrp, in addition to P-gp, at the BBB. Also, these results suggest that 
tolerance to morphine may be increased following a subchronic exposure to morphine 
also due to the observed up-regulation of P-gp. 
 
2. Regulatory signaling pathways behind P-gp and Bcrp up-regulation following a 
subchronic treatment: the involvement of a glutamate-NMDA receptor-COX-2 
cascade 
On the other hand, there are three major results obtained in our study that point to a non-
direct involvement of morphine in the regulation of P-gp and Bcrp: 1) the expression of 
Mdr1a or Bcrp was not altered when rats were subjected to a single dose administration of 
morphine, 2) nor immediately after the treatment suspension in the subchronic morphine 
regimen, since P-gp and Bcrp expression were never seen to be altered at the 6h time-
point of sacrifice; 3) in addition, when hCMEC/D3 were exposed to several concentrations 
of morphine (0.01, 0.1, 1 and 10 μM) for 24h, no change in the MDR1 and BCRP 
transcript level was registered, indicating that morphine has no direct effect on the brain 
capillary endothelial cells. 
Indeed, every previously conducted study that showed an up-regulation of P-gp by 
morphine followed a subchronic morphine exposure protocol. Since the subchronic or 
chronic use of morphine is associated with the development of phenomena such as 
dependence, craving, and withdrawal syndrome, it is likely that some of these 
phenomena, and the underlying brain molecular changes, might be implicated in the 
registered up-regulation. In fact, the exact same morphine protocol applied in this study 
showed to trigger withdrawal symptoms as early as 9h after the last dose of morphine 
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(Desjardins et al. 2008), meaning that such phenomenon is already present by the time an 
induction on P-gp and Bcrp expressions is registered. In addition, its development seems 
to coincide with the onset of the regulation of the mRNA levels of these ABC transporters. 
Therefore, cellular mechanisms triggered during the development of morphine withdrawal 
may subsequently induce both P-gp and Bcrp at the rat BBB. 
Increasing evidence demonstrates that opioids significantly alter the function of the 
glutamatergic system. Morphine-dependent rats showed a 2-fold increase of the 
extracellular fluid levels of glutamate in the locus coeruleus when morphine withdrawal 
was precipitated by the administration of naloxone (Zhang et al. 1994a). In a second 
study, glutamate concentration in the extracellular fluid of the hippocampus was 
decreased following either an acute or chronic treatment of morphine in mice (Guo et al. 
2005). In turn, when morphine withdrawal was precipitated by naloxone in dependent 
mice, extracellular glutamate concentrations increased significantly in the hippocampus 
while no significant change was observed in saline-treated mice (Guo et al. 2005). In line 
with these results, the administration of naloxone or the cessation of morphine 
administration resulted in increased concentrations of glutamate in the nucleus 
accumbens of rats (Sepulveda et al. 2004). Naloxone-precipitated morphine withdrawal 
yielded such increase in just a few minutes after naloxone administration. Spontaneous 
morphine withdrawal also increased concentrations of glutamate in this brain region. 
When single doses of morphine were administered to rats previously withdrawn from 
chronic morphine treatment, the glutamate concentrations in the nucleus accumbens were 
restored to normal levels (Sepulveda et al. 2004). In addition, the glutamatergic NMDA 
receptor seems to be necessary for the development of physical withdrawal symptoms in 
several opioid-dependent animal models (Glass 2010; Higgins et al. 1992; McLemore et 
al. 1997; Trujillo and Akil 1991), and humans (Bisaga et al. 2001).  
In turn, glutamate, an excitatory neurotransmitter, has shown to be in high extracellular 
levels in the epileptic brain, since it is massively released from neurons and glial cells 
(Bankstahl et al. 2008). Likewise, it has been shown that epileptic seizures induce P-gp 
up-regulation at the brain capillary endothelial cells through glutamate by an NMDA 
receptor and COX-2-dependent mechanism (Bauer et al. 2008). In this study, isolated rat 
or mouse brain capillaries exposed to glutamate for 15 to 30 min showed an increased P-
gp expression and transport activity hours later. These increases were blocked by 
dizocilpine maleate (MK-801), an NMDA receptor antagonist, and by celecoxib, a 
selective COX-2 inhibitor. Furthermore, the intracerebral microinjection of glutamate 
provoked a local increase on P-gp expression in rat brain capillaries (Bauer et al. 2008). 
Considering that glutamate has been shown to increase P-gp expression in rodent brain 
microvessels (Bauer et al. 2008; Zhu and Liu 2004), together with the previous described 
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findings pointing to a considerable link between morphine withdrawal and increased 
extracellular glutamate levels in the brain, we built the hypothesis that the development of 
morphine withdrawal, and the consequent increase of glutamate levels, lead to the 
observed up-regulation of both P-gp and Bcrp at the rat brain microvessels. In order to 
test if a similar signalling pathway is involved in the morphine-dependent up-regulation of 
P-gp and Bcrp, we subjected the animals to a similar morphine treatment regimen as we 
used before (5 days, twice daily, in an escalating dose regimen), and at the end of this 
treatment protocol, rats were treated either with or without an NMDA receptor antagonist, 
MK-801, or a COX-2 inhibitor, meloxicam. Animals were sacrificed 24h after the last dose 
of morphine, since it was the time-point that gave the highest up-regulation levels for both 
ABC transporters among the previously tested. Morphine-dependent rats to which the 
NMDA receptor antagonist was given had P-gp and Bcrp protein levels comparable to 
those of saline-treated rats. Rats subchronically treated with morphine but not with MK-
801 registered a P-gp and Bcrp overexpression in both large and microvessels 24h after 
the last dose of morphine, confirming the previously obtained results. These data show 
that MK-801 blocked the morphine-dependent up-regulation of P-gp and Bcrp in large 
vessels and microvessels, indicating that the NMDA receptor, and thus its ligand, 
glutamate, are implicated in the subchronic morphine up-regulation of P-gp and Bcrp at 
the rat BBB. Similarly, the COX-2 inhibitor, meloxicam, also blocked the observed 
morphine-dependent up-regulation of P-gp and Bcrp in large and microvessels, which 
together indicate that, like in epilepsy, a glutamate-NMDA receptor-COX-2 pathway must 
be implicated in the regulation of the expression of P-gp and Bcrp at the rat BBB following 
a subchronic morphine exposure. 
As previously discussed in the introductory section, in this cascade of regulation, 
glutamate acts on the NMDA receptors to presumably increase the intracellular Ca2+, 
activating cPLA2 with increased production of arachidonic acid, which is then converted to 
PGE2 by COX-2, which subsequently signals through four different G protein-coupled 
receptors, EP1, EP2, EP3, and EP4 (Hata and Breyer 2004). Therefore, we decided to 
test the effect of two PGE2 analogs, iloprost and misoprostol, on the expression P-gp and 
BCRP on the hCMEC/D3 cell line, and further support the involvement of COX-2 in this 
cascade of regulation.  Iloprost is a structural analog of prostacyclin whose affinity for EP1 
receptors is similar to that of PGE2, while misoprostol is a PGE1 analog whose activity is 
mainly mediated by EP2, EP3, and EP4 receptors (Abramovitz et al. 2000). The use of 
PGE2 analogs, which have different affinities for the several EP receptors, served the 
purpose of uncovering the EP receptor(s) that should be preferentially implicated in this 
signaling cascade.  Iloprost increased both MDR1 and BCRP transcript levels, whereas 
misoprostol increased MDR1 mRNA levels but had little effect on BCRP expression. 
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These findings also point to COX-2 activity mediated by PGE2, which should preferentially 
act via EP1 receptor. EP1 receptor expression has already been evidenced in isolated rat 
brain capillaries (Pekcec et al. 2009). Further studies are in support of the involvement of 
such signaling pathway in the regulation of P-gp: in status epilepticus animal models, 
seizure-induced P-gp up-regulation in brain capillaries was blocked when rats were 
treated with the COX-2 inhibitor celecoxib (van Vliet et al. 2010; Zibell et al. 2009), and 
with SC-51089 (Fischborn et al. 2010; Pekcec et al. 2009), a specific EP1 receptor 
antagonist. In contrast to the amount of data concerning the effect of glutamate on P-gp 
expression, little data is available concerning its role on BCRP expression at the BBB. 
However, and contrary to the results hereby presented, a recent study reported a down-
regulation on BCRP expression and activity in isolated porcine and human brain 
capillaries exposed to glutamate, the latter obtained from surgical specimens of epileptic 
patients (Salvamoser et al. 2015). The mechanism underlying this down-regulation also 
seems to involve the NMDA receptor and COX-2 (Salvamoser et al. 2015). The down-
regulation of BCRP expression and activity observed in this study, and thus contrasting 
with our study, might be a result from the high glutamate concentrations (100 μM) to 
which brain capillaries were exposed (Salvamoser et al. 2015), which may be cytotoxic 
and accelerate the decline in the capillary cell viability in these animal models. 
 
3. Opioid withdrawal syndrome on the regulation of P-gp and Bcrp expressions at 
the rat BBB: what role? 
We therefore postulated that repeated exposure to morphine might not affect P-gp and 
BCRP expression at the BBB unless a subsequent withdrawal syndrome takes place. In 
the latter case, the glutamate released during spontaneous morphine withdrawal 
syndrome should in turn up-regulate P-gp and BCRP expressions, and may be part of the 
mechanism underlying morphine tolerance, even though it cannot be the major cause of 
tolerance since morphine is a poor substrate of P-gp (Schinkel et al. 1995). 
The pursuit of a better understanding of what drives the modulation of P-gp and Bcrp at 
the BBB by morphine motivated the second publication of the present PhD dissertation. 
This publication particularly focused on uncovering whether such modulation is a direct 
consequence of continued exposure to morphine, or rather a result of the morphine 
withdrawal that is further developed after discontinuation of treatment. Sprague-Dawley 
rats were treated according to different protocols of exposure to morphine and the 
expression of P-gp and Bcrp at the rat BBB was evaluated once rat brain microvessels 
were freshly isolated: 
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 In study 1, animals were subjected to a continuous i.v. infusion of morphine for 120h, 
at a constant infusion rate. This protocol was implemented in order to evaluate if 
morphine itself, following a prolonged, uninterrupted exposure, could be responsible 
for an up-regulation of P-gp and Bcrp expression at the rat BBB. The infusion flow rate 
(1 mL/kg/h) and the daily dose of morphine (15.6 mg/kg/day) were chosen to attain a 
theoretical plasmatic concentration of morphine of 100 ng/mL, based on the plasma 
clearance of morphine in the rat found in the literature (Ekblom et al. 1993; South et al. 
2001). The target morphine plasma concentration was chosen based on the 
correspondent plasma concentrations reached in patients who are continuously 
infused with morphine for pain control (Wolff et al. 1996). Animals were sacrificed 
immediately once morphine infusion was interrupted, to avoid the development of 
withdrawal symptoms. The results obtained with this study demonstrated that, even 
though animals were continuously exposed to morphine and had attained significant 
plasmatic concentrations of morphine throughout the treatment, P-gp and Bcrp protein 
expressions remain unaltered in rat brain microvessels. This suggests that the 
observed up-regulation of both ABC transporters in the previous study (Manuscript no. 
1) was not a direct consequence of morphine on the cascade of regulation of P-gp and 
Bcrp at the BBB. 
 In study 2, rats were subjected to an escalating morphine dosing regimen (10-40 
mg/kg, i.p., twice daily for 5 days) followed by an injection of a single dose of naloxone 
(1 mg/kg, s.c.), a strong μ-opioid receptor antagonist, 1h after in order to precipitate 
withdrawal. The peak and trough of morphine plasmatic concentrations, which is 
produced with this type of intermittent protocol, favours the installation of physical 
dependence and withdrawal once morphine treatment is suspended (Desjardins et al. 
2008). Opioid withdrawal signs were visible as soon as naloxone was injected, and 
animals showed typical opioid withdrawal behavioral signs, such as diarrhea, 
mastication, wet-dog shakes, ptosis, salivation and jumping. The global withdrawal 
score was significantly higher in morphine-pretreated rats than in saline-pretreated 
rats, confirming the success of the present protocol in the development of dependence 
to morphine and of the precipitated withdrawal. Rats were sacrificed 12h after 
naloxone administration. Since the onset of the opioid withdrawal immediately follows 
the injection of naloxone in this study, the time of sacrifice was chosen given the 
difference between the onset of a spontaneous morphine withdrawal syndrome (i.e. 
approximately 12h after the last dose of morphine) and the time-point at which it was 
registered the highest increase in P-gp and Bcrp expression in our previous study 
(24h after the last dose of morphine, and therefore 12h after the theoretical onset of 
the spontaneous morphine withdrawal) (Manuscript no.1). Morphine-treated rats 
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exhibited an increase in Mdr1a and Bcrp transcript levels of 1.4-fold and 2.5-fold, 
respectively, which are of similar magnitude to the previously obtained 24h after the 
cessation of a 5-day subchronic treatment with morphine (Manuscript no. 1). However, 
proteomic and WB analyses did not evidence the expected up-regulation of P-gp and 
Bcrp proteins in brain microvessels of morphine-pretreated animals. 
 In study 3, animals were submitted to a chronic morphine regimen (10 mg/kg s.c., 
twice daily for 5 days), followed by a withdrawal period (2 days), and treatment was 
resumed for 3 additional days. Similarly to study 2, a single administration of naloxone 
(1 mg/kg, s.c.) was given in order to trigger an intense opioid withdrawal. This protocol 
contrasts with the previous one since it has a first spontaneous withdrawal over a 2-
day period, which increases the naloxone-precipitated withdrawal syndrome. At the 
end of the treatment protocol (day 10), animals showed similar behavior and 
withdrawal signs to those observed in study 2 once the withdrawal was precipitated. 
Naloxone-precipitated withdrawal clearly induced a much stronger abnormal behavior 
than the spontaneous withdrawal. Rats were sacrificed at two different time points: 4h 
and 24h after naloxone administration. As in the study 2, Mdr1a and Bcrp transcript 
levels registered similar increasing rates 4h after the naloxone injection, but once 
more UHPLC-MS/MS and WB analyses evidenced that P-gp and Bcrp protein 
contents remained unchanged in the morphine-treated group compared to the control 
animals. Furthermore, when the brain transport of [3H]-verapamil, a P-gp substrate, or 
of [3H]-mitoxantrone, a preferential Bcrp substrate, were assessed by in situ brain 
perfusion, there were no significant differences in their transport across the BBB 
between saline- and morphine-treated rats, 18h after naloxone was administered. 
These results show that P-gp and Bcrp activities in brain microvessels did not suffer 
any change by the implemented treatment, corroborating the findings obtained at 
protein level. 
Contrary to what was expected, the present set of studies (Manuscript no. 2) did not allow 
us to establish a direct relationship between the up-regulation of P-gp and Bcrp at the 
BBB and the development of an opioid withdrawal in the rat. On one hand, P-gp and Bcrp 
modulation discrepancy found at mRNA and protein levels following naloxone-precipitated 
withdrawal could be explained by the occurring posttranslational regulation, as it has been 
previously suggested (Vogel and Marcotte 2012). Also, and even though naloxone is a 
selective antagonist of the µ-opioid receptors, the absence of P-gp and Bcrp up-regulation 
in brain microvessels following the naloxone-precipitated opioid withdrawal may be due to 
its effect on other non-opioid receptors (Liu et al. 2000a; Liu et al. 2000b), which may also 
be involved in the regulation of these ABC transporters following a morphine chronic 
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treatment, and thereby hamper P-gp and Bcrp up-regulation. In fact, naloxone has proved 
to inhibit TLR4 signaling (Hutchinson et al. 2008), even though it was produced with doses 
100-fold superior to the ones used in the present study (Manuscript no. 2). Activation of 
TLR4 leads to downstream production and release of pro-inflammatory cytokines like 
TNF-α and IL-1β. As reviewed in the introductory section, these pro-inflammatory 
cytokines are implicated in the regulation of P-gp and BCRP at the BBB in both 
inflammatory and oxidative stress cases (Hartz et al. 2008; Hartz et al. 2006; Miller 2015; 
Poller et al. 2010).  
In addition, our premise is based on the fact that during morphine withdrawal there is a 
massive increase in extracellular levels of glutamate in the brain parenchyma, as 
suggested by previous studies (Guo et al. 2005; Sepulveda et al. 2004; Zhang et al. 
1994a), and that this excitatory amino acid is able to up-regulate the expression of P-gp at 
the BBB (Bankstahl et al. 2008; Bauer et al. 2008; Zhu and Liu 2004), and presumably 
that of BCRP. However, even though such studies demonstrate that glutamate 
concentrations are excessively high in the hippocampus, locus coeruleus or nucleus 
accumbens during an opioid withdrawal, none comprises an analysis of the glutamate 
levels in the brain cortex, which is the brain region we used for the study of the modulation 
of the expression of these ABC transporters at the BBB. Therefore, it would be of interest 
to perform a kinetics study of the concentrations of glutamate in the parenchymal 
extracellular fluid in the rat brain cortex during the subchronic morphine protocols we 
applied and following the development of both spontaneous and precipitated morphine 
withdrawal. This study could be performed by brain microdialysis. The microdialysis 
technique is widely used in neuroscience, and enables sampling and quantification of 
small molecular weight substances, such as neurotransmitters, peptides, and hormones in 
the brain ISF (Chefer et al. 2009). However, this is an invasive technique, which may alter 
tissue morphology including the BBB integrity (Morgan et al. 1996), with some practical 
limitations, and requires a high expertise in the implementation of the method. 
Furthermore, brain extracellular levels of glutamate produced during opioid withdrawal 
(approximately 20 μM) (Guo et al. 2005; Sepulveda et al. 2004; Zhang et al. 1994a) are 
relatively inferior to those that have shown to increase P-gp expression in brain capillary 
isolates (50-100 μM) (Bauer et al. 2008; Zhu and Liu 2004; Zibell et al. 2009), suggesting 
that this mechanistic pathway should contribute, but in parallel with other activated 
signaling pathways, to the up-regulation of P-gp and Bcrp. Thus, P-gp and Bcrp up-
regulation following a subchronic morphine treatment (Yousif et al. 2012) (Manuscript no. 
1) might result of a sum of multiple mechanisms and signaling pathways implicated in the 
modulation of both transporters at the BBB, and naloxone may act at non-opioid 
receptors, such as TLR4 or even neurotransmitter receptors, linked for instance to an 
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inflammatory component of morphine withdrawal, to partially hamper P-gp and Bcrp up-
regulation. 
 
4. Characterization of isolated brain microvessels as a BBB study model: a 
comparison between techniques, and neurotransmitter receptor expression by 
qRT-PCR 
In the work developed for the elaboration of the present dissertation, we had also exposed 
the hCMEC/D3 cell line to several glutamate concentrations, in order to test the effect of 
glutamate on the expression of P-gp and BCRP in this BBB in vitro model (Manuscript no. 
1), and further support the involvement of this neurotransmitter in the regulatory 
mechanism of these transporters. Cells were exposed to 10 and 100 μM of glutamate for 
40 min, and then incubated in glutamate-free medium for 5h30min before the amounts of 
MDR1 and BCRP transcripts were analyzed by qRT-PCR. Yet, glutamate did not 
significantly alter the mRNA expression of any of these transporters in comparison to non-
treated cells. Considering this result, we questioned the expression of the glutamate 
receptor NMDA in this cell line. To clarify this, we checked the mRNA expression of the 
gene encoding for the NR1 subunit of the NMDA receptor in hCMEC/D3 cells. The NR1 
transcript levels found were very low and unquantifiable, which might explain the absence 
of effect of glutamate on MDR1 and BCRP mRNA levels in the hCMEC/D3 cell line. Still, 
the presence of the NMDA receptor in brain endothelium has been a matter of study over 
the past decade, with general controversy and little consensus regarding its actual 
expression and role at the BBB. The gene expression of several subunits of the NMDA 
receptor was demonstrated in cultured rat BECs for the first time in the late nineties 
(Krizbai et al. 1998). At the same time, in another study, gene expression and functional 
activity of the main NMDA receptor subunits was not demonstrated in either rat or human 
cortical microvessels and in cultured cerebrovascular endothelial cells (Morley et al. 
1998). The NR1 subunit protein expression was also not detected in a rat brain 
microvascular endothelial cell primary culture (Domoki et al. 2008). In turn, in 2003, the 
expression of the NR1 subunit was found in an immortalized human endothelial cell line 
using RT-PCR, WB and immunoprecipitation approaches (Sharp et al. 2003). Later on, 
the NR1 and NR2 subunits of the NMDA receptor were also showed to be expressed in 
primary cultures of rat brain endothelial cells (Andras et al. 2007); similarly, the expression 
of NR1 subunit was evidenced by qRT-PCR, immunostaining, and WB in mouse brain 
microvessel endothelial cells and in the hCMEC/D3 cell line (Legros et al. 2009; 
Reijerkerk et al. 2010). This later study clearly contrasts with our results, since they report 
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the expression of the NMDA receptor subunit using a similar technical approach and the 
same human cell line we used. 
The third study conducted under the preparation of this dissertation (Manuscript no. 3) 
comprehended a large screening of several receptors for their expression at the rat BBB, 
including the NMDA receptor subunit NR1 and many other neurotransmitter receptors 
implicated in the inflammatory cell-cell signaling, and which may have a role in the 
modulation of P-gp and BCRP efflux transporters. This study was performed in order to 
bring further insight into some of the already known mechanisms of regulation of ABC 
transporters, such as the one that morphine is implicated in. Many of these receptors may 
also have a general role in the regulation and maintenance of the BBB structure and 
properties, if present in the NVU cells, particularly in the BECs, astrocytes, pericytes, and 
microglia. 
In this study we first compared two different techniques of isolation of rat brain 
microvessels – mechanical dissection and enzymatic digestion – to determine which 
yielded the purest microvessel fraction for the study of the BBB. Hence, the relative 
expression, evaluated by qRT-PCR, of several specific cell markers for the different cell 
types that are part of the NVU – glut1 (BECs) ng2, pdgfrb (pericytes), gfap, s100b 
(astrocytes), cd11b (microglia), mbp (oligodendrocytes) and syp (neurons) – was 
compared between samples obtained by either mechanical dissection or enzymatic 
digestion. The expression of such markers in isolated microvessels was also compared 
against the expression in rat brain cortex as a measure of enrichment on the BBB cell 
markers. The results led us to conclude that there is a higher enrichment of BEC and 
pericyte cell markers with the enzymatic digestion approach, in comparison to the 
mechanical dissection method. In fact, glut1, ng-2, and pdgfrb registered higher 
expressions in microvessels isolated enzymatically than in microvessels isolated 
mechanically. Furthermore, the enzymatic technique results in a higher reduction on the 
contamination coming from other cell elements surrounding the brain capillaries as the 
expression of specific markers for astrocytes, oligodendrocytes and neurons was 
considerably reduced when microvessels were isolated with the enzymatic approach 
compared to the brain microvessels isolated mechanically. These results indicate that, 
since microvessels isolated with an enzymatic approach yield a more pure fraction of 
brain capillaries than microvessels isolated with a mechanical approach, this technique 
should be preferentially adopted for studying the BBB properties in the rat. Our previously 
presented studies used isolated microvessels obtained by mechanic disruption, which 
would not be the ideal approach, given these comparative results. However, we mainly 
focused on the study of the expression of ABC transporters in the brain microvessels, 
whose expression is essentially limited to the brain capillary endothelial cells. Data from 
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previous studies reported an induction of P-gp by other xenobiotics in parenchymal cells, 
such as astrocytes and neurons (van Vliet et al. 2004; Volk et al. 2005; Volk et al. 2004). 
However, previous observations obtained by our research group using 
immunohistochemistry on brain sections of animals following a subchronic morphine 
treatment, exclude this occurrence as no presence of P-gp was detected neither in 
astrocytes nor in neurons (Yousif et al. 2008). Hence, even though rat brain microvessels 
isolated by mechanic disruption might have some cell contamination from other elements 
surrounding the capillaries, it does not have an important impact on the yielded results 
concerning the expression of P-gp and Bcrp. 
The expression of 11 neurotransmitter receptors in both rat brain cortex samples and in 
isolated rat brain microvessels was then assessed: adrenergic receptors α2A, β1 and β2 
(Adra2a, Adrb1, Adrb2), adenosine receptors A1, A2A and A3 (Adora1, Adora2a, Adora3), 
ATP receptors P2X7 and P2Y1 (P2rx7, P2ry1), cannabinoid receptors CB1 and CB2 (Cnr1, 
Cnr2), and the glutamate receptor subunit NMDAr1. 
Among these neurotransmitter receptors, P2ry1 (788-fold of the least expressed gene, 
Adora1), Adora2a, P2rx7 and Adrb2 showed to assume an important expression level in 
rat brain microvessels, while Adora1, followed by Cnr1, Adrb1, Cnr2 and Adra2a are 
among the least expressed receptors. The comparisons of expressions between samples 
from brain cortex and from brain microvessels took into account the expression found in 
rat brain microvessels isolated using the enzymatic approach, since this was the 
technique that yielded the purest capillary fraction, and thus should best reflect the 
expression of neurotransmitter receptors at the BBB. In rat brain microvessels, the 
Adora1, Cnr1 and NMDAr1 transcript levels showed to be approximately 50-fold lower 
than those found in brain cortex samples, suggesting that these receptors are poorly 
expressed in rat brain capillaries, and are likely derived from neuronal contamination. 
Adrb2 and Adora2a are the only neurotransmitter receptors with an increased expression 
in rat brain microvessels in comparison to brain cortex, while Adra2a, Cnr2 and the ATP 
receptors P2rx7, P2ry1 do not register any considerable change of expression from brain 
cortex to brain microvessel samples. Yet, it is important to note that while Adra2a and 
Cnr2 are among the least expressed genes in the brain cortex, P2rx7 and P2ry1 are 
among the most expressed, meaning that the expression of these latter genes in the 
microvessels is very significant. Thus, the ATP receptors P2X7 and P2Y1, as well as the 
adenosine receptor A2A are highly expressed at the BBB, and so may play a central role in 
the cell signaling at the NVU and in the normal function of the BBB. Concordant with our 
findings, the expression of A2A receptors in the brain vasculature was already 
demonstrated in a few studies (Koehler et al. 2006; Ngai et al. 2001). This is further 
supported by studies performed on a primary culture of mice brain endothelial cells and in 
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hCMEC/D3 cells, where the protein expression of A2A adenosine receptors was evidenced 
(Carman et al. 2011; Mills et al. 2011). Our results, which are supported by the literature, 
indicate that the BBB is able to directly respond to extracellular adenosine, either coming 
from astrocytes and other neighboring cells, or from the bloodstream. However, to 
present, any connection between the activation of this adenosine receptor and the 
regulation of the expression of P-gp and BCRP is unknown. 
Regarding the ATP receptors, it is known that P2X7 receptors are predominantly 
expressed in the microglia (Harry 2013), and promote the release of pro-inflammatory 
cytokines, such as IL-1α, IL-1β and TNF-α (Bernardino et al. 2008; Ferrari et al. 1997; 
Hide et al. 2000; Mingam et al. 2008), and the ROS superoxide (Parvathenani et al. 
2003). In fact, pro-inflammatory factors, such as TNF-α, and ROS have been suggested 
as central elements implicated in the up-regulation of P-gp at the BBB during 
inflammation/oxidative stress phenomena (Felix and Barrand 2002; Nwaozuzu et al. 2003) 
(Bauer et al. 2007; Rigor et al. 2010), as extensively reviewed in the introductory section. 
Hence, the activation of this receptor in the microglia or in the endothelium may favor the 
installation of inflammatory and/or oxidative stress cascades, which may in turn interfere 
with the regulation of P-gp and BCRP at the BBB. In opposition to P2X7, the ATP receptor 
P2Y1 activation in microglia has shown to promote the down-regulation of the pro-
inflammatory response, since its activation increases the release of the anti-inflammatory 
cytokine, IL-10 (Seo et al. 2008). In this way, by limiting the inflammatory signaling 
propagation at the NVU, and by providing neuroprotection against oxidative stress, P2Y1 
may also play a role in the control of P-gp and BCRP levels at the BBB. Recent studies 
also indicate that activation of P2Y2 receptors in the brain vascular endothelium can 
increase the transendothelial permeability of leukocytes (Kukulski et al. 2010; Seye et al. 
2002; Seye et al. 2003). This suggests that the activation of P2Y2 receptors in brain 
microvessels, and possibly of P2Y1, may function as a novel target for increasing drug 
delivery into the brain. 
Similarly to P2Y1 receptors, CB2 receptors, predominantly expressed in microglia, are 
implicated in the reduction of oxidative stress and neuroinflammation by attenuating 
microglial activation and production of proinflammatory mediators (Campbell and Gowran 
2007; Horvath et al. 2012). In our study (Manuscript no. 3), we demonstrated very little 
expression of this receptor in rat brain microvessels, which likely comes from small 
contamination from microglia. This is in agreement with the literature, as little CB2 receptor 
immunorreactivity has been detected in the healthy brain microvasculature (Ramirez et al. 
2012). However, the expression of CB2 receptors seems to be up-regulated in pathologies 
and in response to inﬂammation and stress (Schley et al. 2009; Zhang et al. 2011b). 
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According to our study, the NR1 subunit expression is relatively poor in comparison to the 
other tested genes in rat brain microvessels isolated enzymatically. Considering that, 
among the tested receptors, the NMDA receptor was the receptor that registered, by far, 
the highest transcript levels in the rat cortex, it is likely that the expression of NR1 found in 
microvessels might represent a small contamination from the brain parenchyma. This poor 
NR1 expression in brain microvessels is in line with the absence of this NMDA receptor 
subunit found in the hCMEC/D3 cell line in one of our previous studies (Manuscript no. 1). 
Despite recent studies have indicated the presence of the NMDA receptor in the brain 
microvasculature as an element in the regulation of the expression of ABC transporters 
(Bauer et al. 2008; Salvamoser et al. 2015; Zibell et al. 2009), the expression of this 
receptor at the brain endothelium is controversial among the scientific community. Thus, it 
is more likely that the NMDA receptor takes part of a mechanism that involves the 
complete NVU, and not only the BECs, concerning the regulation of P-gp and BCRP at 
the BBB. 
 
 
5. P-gp activation at the BBB: thioxanthonic derivatives as P-gp activators and 
evaluation of their antidote properties against the substrate-induced neurotoxicity 
Several studies focusing on the regulation of ABC transporters at the BBB analyze their 
modulation in terms of gene and protein expression, but lack to confirm their correlation 
with an increased or decreased transport function, which is what ultimately may contribute 
to an altered brain distribution and therapeutic effect/toxicity of their substrates. However, 
it is generally accepted nowadays that a registered increase in protein expression may not 
necessarily result in a proportional increase in the protein function (Kosztyu et al. 2014). 
This is particularly true for P-gp, where several studies showed that an induction of the 
transporter did not always translate into an increase in its efflux activity (Silva et al. 2011; 
Silva et al. 2014a; Takara et al. 2009). On the other hand, there is rising evidence that 
several compounds are able to increase P-gp transport activity without increasing its 
protein expression (Silva et al. 2014c; Silva et al. 2014d; Sterz et al. 2009; Vilas-Boas et 
al. 2013b). These studies gave rise to a new emerging class of compounds, known as P-
gp activators. In fact, the activation of ABC transporters, a phenomenon that reflects the 
increased efflux of their substrates, has been recently brought to discussion and is 
gathering attention, given the important impact it may have in the rapid modulation of the 
transport of substrates of P-gp and other ABC transporters, and their therapeutic 
effectiveness/organ toxicity. The study and development of novel P-gp activators is a 
complex approach involving the establishment of quantitative structure-activity 
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relationships, since these molecules will act through a direct interaction with the ABC 
transporter to induce a change in its conformational position, and favor the transport of 
substrates. 
It was long known that several compounds could bind to P-gp and stimulate the transport 
of substrates on another binding site. As was reviewed in the introductory section, P-gp is 
suggested to have at least three drug binding sites, comprising an allosteric binding site 
which may exhibit a regulatory function (Shapiro et al. 1999). A fourth binding site was 
also proposed, with three transport sites and a regulatory one, which allows a change in 
the conformation of the transporter altering the affinity for substrates and increasing the 
rate of translocation (Martin et al. 2000). In addition, recent crystallography studies on the 
structure of the mouse P-gp evidenced a large drug-binding cavity, where at least two 
substrate molecules may bind simultaneously (Aller et al. 2009). The exposure of Caco-2 
cells to several NSAIDs, such as mefenamic acid, sulindac, naproxen, and meloxicam, 
significantly reduced intracellular accumulation of Rho 123, with no change in the MDR1 
mRNA levels (Takara et al. 2009). Some catechins were also reported to increase the P-
gp mediated transport of LDS, a fluorescent P-gp marker substrate, without affecting the 
daunorubicin or Rho 123 transport (Wang et al. 2002). In addition, several compounds 
primarily synthetized to act as p53 inhibitors and derivatives, generated different effects 
on the intracellular accumulation of P-gp substrates: these molecules stimulated the efflux 
transport of anthracyclines and Rho 123 by P-gp, whereas the P-gp mediated efflux of 
vinblastine and colchicine was inhibited (Kondratov et al. 2001; Sterz et al. 2009). It was 
therefore suggested that these modulating compounds should bind to the P-gp H site and 
stimulate the efflux of R site-binding substrates, while the transport of H site-binding 
substrates is competitively inhibited. 
Recently, it was shown in the RBE4 cell line that a synthetic derivative of rifampicin, 
RedRif, was able to increase both P-gp expression and activity (Vilas-Boas et al. 2013b). 
Yet, the increase on P-gp transport activity was registered at early points where no up-
regulation on P-gp expression had been observed: RedRif increased P-gp expression 
after 48h of exposure, while the efflux activity was increased after only 24h of exposure. 
The increased P-gp activity registered in RBE4 cells following a 24h pre-exposure or 
simultaneous exposure to RedRif resulted in higher cell protection against PQ-induced 
cytotoxicity (Vilas-Boas et al. 2013b). In fact, the simultaneous exposure to both the 
rifampicin derivative and PQ yielded the more efficient protection against PQ cytotoxicity. 
Recent studies performed in Caco-2 cells demonstrated that five newly synthetized 
thioxanthonic derivatives (Silva et al. 2014c) and five dihydroxylated xanthones (Silva et 
al. 2014d) significantly increased both P-gp expression and activity. Indeed, the 24-hour 
simultaneous incubation of Caco-2 cells with the (thio)xanthonic derivatives and PQ 
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resulted in a significant reduction in the PQ-induced cytotoxicity (Silva et al. 2014c; Silva 
et al. 2014d). The protection that these compounds conferred through P-gp activation 
against PQ cytotoxicity was further confirmed since this increased protection was 
abolished in the presence of a P-gp inhibitor, elacridar (Silva et al. 2014c; Silva et al. 
2014d). Importantly, it was also observed that these compounds rapidly increased the 
activity of this ABC transporter, assessed by the Rho 123 efflux assay, where Caco-2 cells 
are incubated with Rho 123 in the presence of (thio)xanthones during a short 45 min Rho 
123 efflux phase. These findings indicate an increased P-gp activity that is not a result of 
an increased P-gp protein expression, given the short time of exposure of cells to such 
compounds. Thus, these (thio)xanthonic derivatives showed to increase P-gp expression 
in Caco-2 cells, but also to produce an expression-independent increase in the activity of 
P-gp. 
Given their demonstrated ability to promptly activate P-gp efflux transport in Caco-2 cells, 
and considering their promising source of antidotes against the cytotoxicity of harmful P-
gp substrates, we decided to further evaluate if this mechanism of rapid activation could 
be triggered in a BBB model, using the RBE4 cell line (Manuscript no. 4). For this 
purpose, we selected some of the previously tested TXs in Caco-2 cells, such as TX87, 
TXA4, TXA3 and TXOH, and some new thioxanthonic derivatives, TX105 and TX129. The 
assays performed in RBE4 cells to evaluate the cytotoxicity profile of each thioxanthonic 
compound lead us to conclude that any compound showed to be toxic in a 10 μM 
concentration, with the exception of TX129, which according to the MTT reduction assay 
lowered the cell viability to 88%. When the P-gp transport activity was assessed by the 
Rho 123 efflux assay, where RBE4 cells were exposed to each thioxanthonic compound 
(10 μM) for a short period of 45 min during the Rho 123 efflux phase, most of the 
compounds – TXA4, TXA3, TX105 and TX129 – produced a significant reduction on the 
Rho 123 intracellular accumulation. TXA4, TXA3, TX105 and TX129 showed to be equally 
efficient as potential P-gp activators at this concentration, since they increased Rho 123 
efflux by 159, 167, 161 and 168%, respectively. When the concentration of such 
compounds was elevated to 20 μM, not only these compounds but also TX87 revealed to 
significantly activate P-gp. Once more, most of the thioxanthonic compounds showed to 
produce a significant increase in the P-gp-mediated efflux of a substrate, now in an in vitro 
BBB model upon a considerable short period of incubation (45 min), and where no 
increase on the P-gp protein expression is likely to occur. 
When the impact of thioxanthonic compounds on the ATPase activity of recombinant 
human P-gp was analyzed at the 10 μM concentration, all thioxanthones showed to poorly 
increase ATPase activity, suggesting that they may only work as poor P-gp substrates. 
Stimulators of ATPase activity are likely substrates for P-gp-mediated efflux, and thus also 
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competitively inhibit transport of other P-gp substrates (Ambudkar et al. 1999). Therefore, 
thioxanthones unlikely participate in competition phenomena and inhibit the transport of P-
gp substrates. Nevertheless, some of these thioxanthones have been previously tested for 
their capacity to stimulate or inhibit the P-gp ATPase activity, and at 20 μM concentration, 
TXA4, TXA3 and TXOH produced a significant increase (Silva et al. 2014c). This indicates 
that the concentration at which such molecules are used can be determinant in their role 
within the interaction with P-gp, namely in acting as potential substrates and in enrolling in 
competition phenomena. 
P-gp activators typically bind in the drug-binding pocket formed by the TMD interface. 
Since our aim was to test the effect of these compounds against the mitoxantrone-induced 
cytotoxicity, binding modes of the tested thioxanthonic derivatives, alone or with 
mitoxantrone, as well as of mitoxantrone alone, were further explored by a docking study, 
using an X-ray P-gp structure based on the mouse (Szewczyk et al. 2015). Recent data 
shows that, unlike the symmetric Sav1866 template (described and used in previous 
studies (Silva et al. 2014a; Silva et al. 2014d; Vilas-Boas et al. 2013a), mouse P-gp has a 
high degree of asymmetry, with only 44% similarity between the two halves of TMDs (Pan 
and Aller 2015), which likely play a major role in the overall function and mechanism of the 
transporter. In fact, it is thought that mouse P-gp should favor closed TMDs and open 
nucleotide-binding domains, whereas Sav1866 should favor the exact opposite 
configurations, as well as the hydrophobicity of mouse P-gp in the drug-binding pocket is 
substantially larger than that of Sav1866 (Pan and Aller 2015). Given that rat P-gp should 
have a closer homology to mouse P-gp than to the Sav1866 template, we decided to 
preferentially adopt the mouse P-gp model for docking studies.(Palmeira et al. 2012b) 
Even though they showed to be poor P-gp substrates, docking studies allowed us to 
understand that thioxanthones bind to P-gp with a considerable high affinity, with two 
preferential binding pockets in P-gp, and a preferential binding pocket engulfed by TMD 2, 
3, 10 and 11, further supporting that these compounds most probably interact with P-gp 
for its activation. 
Considering the observed effects of the tested thioxanthones on P-gp activity in RBE4 
cells, we further aimed to elucidate if they could confer additional protection to this cell line 
against the cytotoxicity of a P-gp substrate, mitoxantrone, as it was demonstrated in 
Caco-2 cells. In fact, in the previous study where these thioxanthonic compounds showed 
to efficiently activate P-gp in Caco-2 cells according to the Rho 123 efflux assay, cell 
simultaneous incubation with these thioxanthonic derivatives and PQ, a toxic P-gp 
substrate, resulted in a significant reduction in PQ cytotoxicity (Silva et al. 2014c). 
Mitoxantrone was chosen as the substrate of study, since it is transported by both P-gp 
and BCRP (Agarwal et al. 2011a; Kodaira et al. 2010; Lee et al. 2005). Given our interest 
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in studying the modulation of P-gp activity by these compounds, but it is also in 
perspective to study that of BCRP, mitoxantrone would thus allow us to understand, in a 
single assay, if Bcrp activity in RBE4 cell could be also modulated upon incubation with 
thioxanthones. Therefore, the cytotoxicity of mitoxantrone was assessed by the neutral 
red uptake assay, in the presence or absence of each test compound for 4h, 8h and 16h, 
and evaluated 24h after the beginning of the exposure. However, and surprisingly, no 
significant differences were observed in the overall comparison of the fitted curves (TOP, 
BOTTOM and EC50 value), meaning that none of these compounds was able to confer 
additional protection against mitoxantrone-induced cytotoxicity in RBE4 cells, unlike what 
was observed for PQ in Caco-2 cells. These results indicate that thioxanthones did not 
promote a biologically important increase in the activity of P-gp, and most likely neither in 
that of Bcrp, so that a protection against the cytotoxicity of mitoxantrone could be 
observed. 
Different biological scenarios can be at the origin of the observed results. In fact, it was 
already observed that the PQ-induced cytotoxicity was not reduced with all thioxanthones 
that showed to produce an increase in the P-gp activity in the Rho 123 assay, in Caco-2 
cells (Silva et al. 2014c). The different affinities between P-gp activators and P-gp 
substrates for the drug-binding pocket of P-gp may determine if P-gp activators can confer 
protection or not the cell models. Still, other scenarios can be pointed to justify the results 
obtained in this manuscript. 
Firstly, mitoxantrone may not have been a good drug candidate in this study, since it is a 
common substrate of P-gp and BCRP, and thereby P-gp is not the only transporter 
implicated in the efflux of mitoxantrone in this experimental setting. Previous studies 
demonstrated the important contribute of P-gp in the efflux transport of this molecule. The 
Cbrain/Cplasma mitoxantrone markedly increased in double knockout Mdr1a/1b(-/-)/Bcrp(-/-) 
mice compared with wild-type mice, or even to Mdr1a/1b(-/-), and/or Bcrp(-/-) mice, as 
well as in Mdr1a/1b (-/-) in comparison to wild-type mice (Kodaira et al. 2010). We also 
successfully demonstrated the impact of P-gp inhibition on the increase of mitoxantrone-
induced cytotoxicity in the RBE4 cell line (Manuscript no. 4), further confirming that 
mitoxantrone is a substrate of P-gp, and that this transporter is implicated in its efflux in 
this BBB in vitro model. Still, it is suggested that when the activity of either P-gp or BCRP 
is primarily compromised, the other transporter can compensate through an increase in its 
expression and/or activity. For example, double knockout studies or inhibition of both 
transporters frequently results in a greater increase in the brain accumulation of common 
substrates than the additive effects of single knockout or inhibition (Cisternino et al. 2004; 
de Vries et al. 2007). In addition, there is evidence that BCRP expression can be down-
regulated in cell models overexpressing P-gp (Bark et al. 2008). Thus, if P-gp activation 
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has been met in the performed study, we cannot put aside that an eventual change, and 
in the present case, down-regulation, in Bcrp expression and/or activity could have 
occurred. As a result, due to the P-gp/BCRP cooperation, an increase in P-gp activity 
alone may not translate into an appreciable decrease in cell accumulation of dual 
substrates, as it is the case of mitoxantrone. 
Secondly, the P-gp activation induced by thioxanthones in our study might be a transient 
phenomenon, resulting in a reduction of mitoxantrone intracellular accumulation only for a 
short period of time, which may not be enough to confer cell protection against 
mitoxantrone-induced cytotoxicity over a period of exposure of 4h, 8h or 16h. 
Furthermore, our study differs from the previous one conducted by Silva et al (2014), as in 
the latter thioxanthonic derivatives have shown to promote an immediate activation of P-
gp but also to induce an up-regulation on the P-gp protein expression in Caco-2 cells 
(Silva et al. 2014c), which was not explored in ours. In fact, an increase of the expression 
of P-gp at the cell membrane is more likely to produce long-lasting consequences on the 
drug efflux of substrates over the course of the incubation period, which may explain the 
different thioxanthones-mediated effects found between the study conducted on RBE4 
cells and the previously conducted in Caco-2 cells. 
Thirdly, important interspecies differences may contribute to these differential results 
among studies. Given that there are significant species differences of some of the 
pathways implicated in the regulation of P-gp expression, such as the ligand-binding and 
activation profiles for orphan nuclear receptors like PXR and CAR (Wang and LeCluyse 
2003), we cannot guarantee that the mechanism by which thioxanthones up-regulate P-gp 
protein expression in the Caco-2 cell model is activated in the RBE4 cells. Also, previous 
studies show that the P-gp structure and activity is different depending on the animal 
model (Pan and Aller 2015; Xia et al. 2006). Since Caco-2 cells express human P-gp and 
RBE4 cells express rat P-gp, thioxanthones and P-gp substrates may bind to the rat and 
to the human P-gp in a different arrangement due to structural differences. Indeed, there 
are interspecies differences in the affinities of P-gp activators and P-gp substrates for the 
drug-binding pockets of P-gp. This may explain the distinct results given by thioxanthones 
regarding the protection against the cytotoxicity of P-gp substrates in the rat model used 
in our study and in the previous one (Silva et al. 2014c). 
Still, even though thioxanthones failed to demonstrate an increased protection against the 
mitoxantrone-induced cytotoxicity in RBE4 cells, they remain as interesting drug 
candidates for an antidote strategy against the toxicity induced by P-gp substrates. Most 
of the thioxanthones showed to promptly activate P-gp efflux transport, achieved through 
a change in the protein conformation, which, in comparison with the induction 
phenomenon, results in a much faster manner to reduce the cytotoxicity of harmful P-gp 
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substrates. P-gp activators are able to immediately increase P-gp activity with no increase 
in its expression, since they act by binding to a specific ligand-binding site in the P-gp 
structure, which induces a conformational change in the P-gp structure. This stimulates 
the efflux of substrates bound onto another ligand-binding site (Vilas-Boas et al. 2013b). 
Indeed, it is believed that adaptation and survival mechanisms in living beings has 
permitted the establishment of multiple binding sites for xenobiotics in P-gp, thus favoring 
the co-transport of substrates by activating the transportation cycle (Safa 2004). 
Noteworthy, we can say that an increase in the protein expression of P-gp does not 
always reflect into an increase in its activity, and in the same way an increase in the efflux 
of a P-gp substrate due to P-gp activation does not always translate into an overall 
reduction of cytotoxicity of its substrates. Therefore, the P-gp activation phenomenon 
should be interpreted carefully, and studied case by case, since it does not necessarily 
mean that it may confer protection against the toxicity of any harmful P-gp substrate. 
 
 
 
______________________________________________________________General Conclusions 
289 
GENERAL CONCLUSIONS 
 
The work conducted in the present thesis dissertation resulted in some useful further 
insight regarding the use of different approaches for the study of the BBB, and especially 
into the mechanisms of modulation of drug efflux transporters present in this barrier. The 
further understanding of the molecular mechanisms that regulate P-gp and BCRP 
provided by these studies represents an interesting tool for the development of strategies 
to manipulate their expression and activity, depending on the main therapeutic goal: 
transporter expression and/or activity can be up-regulated to achieve a selective 
tightening of the barrier and reduce the brain accumulation of harmful neurotoxicants, or, 
on the other hand, transcriptional activation of ABC transporter genes can be controlled in 
order to increase drug delivery into the brain, and prevent pharmacoresistance 
phenomena, and CNS disorder-induced P-gp and/or BCRP up-regulation. The major 
conclusions of these studies can be summarized as follows: 
 A subchronic morphine treatment transiently up-regulates the expression of both P-gp 
and Bcrp at the rat BBB, observed at mRNA and protein level. However, the increased 
levels of both ABC transporters are not immediately observed once treatment is 
suspended, but only 9h-12h, and lasting for 24h-36h after the last dose of morphine 
was given, being timely-coincident with the development of a morphine withdrawal 
syndrome. 
 P-gp and Bcrp up-regulation following a subchronic morphine administration is 
dependent on the NMDA receptor activation by glutamate and the production of 
prostaglandins like PGE2 by COX-2, since the antagonism of the NMDA receptor and 
inhibition of COX-2 counteracted the increase of P-gp and Bcrp expressions at the rat 
BBB. Interestingly, these elements are also linked to the P-gp overexpression in 
epileptic patients. 
 A continuous infusion of morphine for 5 days, and thus morphine exposure by itself, 
does not modify the protein contents of P-gp and Bcrp in rat brain microvessels. 
 Naloxone-precipitated opioid withdrawal following subchronic morphine exposure 
protocols increased the mRNA expression of P-gp and Bcrp, but failed to produce an 
increase on their protein expression and activity. The glutamatergic pathway is 
probably not the only signalling mechanism activated upon morphine withdrawal 
driving the up-regulation of ABC transporters at the BBB, and naloxone may hamper 
other important pathways implicated in such regulation. 
 When the mRNA levels of specific cell markers for the different cells representing the 
NVU and the CNS were compared between brain microvessels obtained by two 
different techniques – a mechanic and an enzymatic approach – it lead us to conclude 
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that the enzymatic approach yielded the purest fraction of brain capillary endothelial 
cells. Indeed, brain microvessels isolated enzymatically are more highly enriched in 
pericyte and endothelial cell markers and with less other cell contaminants, and thus 
should be preferably used to the mechanic approach in the upcoming studies using 
brain microvessels for analysing BBB physiopathology and properties. 
 ATP receptors P2X7 and P2Y1, as well as the adenosine receptor A2A are highly 
specific receptors expressed at the rat BBB, suggesting they may have an important 
role in the signalling system for the normal function of the NVU. On the other hand, the 
adenosine receptor A1, as well as the cannabinoid receptor 1 and the NMDA receptor 
subunit NR1 expressions in rat brain microvessels were approximately 50-fold lower to 
those found in brain cortex samples, indicating that these receptors likely come from 
neuronal contamination. 
 Thioxanthonic compounds showed to promptly activate P-gp, and increase the efflux 
of P-gp substrates, like Rho 123, in the RBE4 brain endothelial cell line, even without 
any increase on the P-gp protein contents. However, when co-incubated with 
mitoxantrone, these compounds did not confer an increased protection against the 
mitoxantrone-induced cytotoxicity in RBE4 cells in culture for 24h. Still, thioxanthones 
remain as interesting drug candidates for an antidote strategy against the toxicity 
induced by harmful P-gp substrates, but P-gp activation phenomenon should be 
interpreted carefully, and studied case by case, since it does not necessarily mean 
that it may confer protection against the toxicity of every P-gp substrate. 
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FUTURE PERSPECTIVES 
 
In summary, the present work developed under this PhD dissertation explored important 
pathways of regulation of both the expression and activity of the two major ABC 
transporters present at the BBB, and thus can be valuable tools to either overcome 
pharmacoresistance in the treatment of neurological diseases or to revert the neurotoxicity 
of substrates. Nevertheless, our research has some shortcomings that need to be 
addressed, and that we intend to further investigate to better clarify the outcome of the 
here presented results: 
 Given that the isolation of brain microvessels using the enzymatic digestion has 
shown to yield a richer fraction of brain capillary endothelial cells than the mechanical 
dissection, and with less cell contaminants from other NVU and CNS cell-types, in the 
future, studies on the BBB properties and regulation of its transporters should be 
conducted with this technical approach; 
 Since the glutamatergic pathway is probably only one among other signalling 
pathways contributing to the up-regulation of P-gp and BCRP at the BBB during 
morphine withdrawal, the role and activation of other well-known regulatory pathways, 
such as the oxidative stress and inflammation-linked pathways, should be a matter of 
study following a subchronic morphine treatment; 
 Glutamate extracellular levels should be investigated in the rat brain cortex following a 
subchronic morphine treatment and during both spontaneous and precipitated-
morphine withdrawal. In fact, we systematically analysed the effect of drug treatment 
on the expression of ABC transporters from rat brain cortical microvessels, and to our 
knowledge it remains to be demonstrated that there is a glutamate overshoot in this 
brain region, even though it has been demonstrated in other brain regions like the 
hippocampus, locus coeruleus and nucleus accumbens, during opioid withdrawal; 
 To confirm that thioxanthones are able to successfully activate P-gp in RBE4 cells and 
increase the efflux of mitoxantrone, the intracellular accumulation of mitoxantrone 
should be analysed following its incubation in the presence and in the absence of the 
different thioxanthonic derivatives; 
 In parallel to the study of the activation of P-gp by these thioxanthonic derivatives, we 
should investigate if these compounds are also able to increase the P-gp protein 
expression in the RBE4 cell line, like it was demonstrated in the human Caco-2 cell 
line, and therefore verify if similar mechanisms of action are present in both models. 
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